VANILLOID RECEPTOR TRPV1 IN DRUG DISCOVERY
VANILLOID RECEPTOR TRPV1 IN DRUG DISCOVERY Targeting Pain and Other Pathological Disorders Edited by
ARTHUR GOMTSYAN CONNIE R. FALTYNEK Abbott Laboratories
A JOHN WILEY & SONS, INC., PUBLICATION
Copyright © 2010 by John Wiley & Sons, Inc. All rights reserved Published by John Wiley & Sons, Inc., Hoboken, New Jersey Published simultaneously in Canada No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at www.copyright.com. Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at http://www.wiley.com/go/permission. Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Neither the publisher nor author shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages. For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002. Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at www.wiley.com. Library of Congress Cataloging-in-Publication Data ISBN: 978-0-470-17557-6 Printed in the United States of America 10 9 8 7 6 5 4 3 2 1
Arthur wishes to dedicate this book to his wife Natalia, daughters Anahit, Lusine, Ani, and parents, especially father, with love and gratitude. Connie dedicates this book with love to her husband Robert, who is her lifelong dearest friend and soul mate.
CONTENTS PREFACE AND ACKNOWLEDGMENTS FOREWORD CONTRIBUTORS
PART I 1
INTRODUCTION TO THE TRP CHANNELS
TRP Channels and Human Diseases
ix xiii xv
1 3
Bernd Nilius and Rudi Vennekens
2
Role of TRP Channels in Pain: An Overview
68
Arpad Szallasi
3
Biochemical Pharmacology of TRPV1: Molecular Integrator of Pain Signals
101
Carol S. Surowy, Philip R. Kym, and Regina M. Reilly
4
TRPV1 Genetics
134
Ruslan Dorfman, Hubert Tsui, Michael W. Salter, and H.-Michael Dosch
PART II 5
ROLE FOR TRPV1 IN PAIN STATES
TRPV1 and Inflammatory Pain
151 153
Anindya Bhattacharya, Sonya G. Lehto, and Narender R. Gavva
6
Role of TRPV1 Receptors in Osteoarthritic Pain
175
Shailen K. Joshi and Prisca Honore
7
TRPV1 and Bone Cancer Pain
191
Juan Miguel Jimenez-Andrade and Patrick Mantyh
8
TRPV1 in Visceral Pain and Other Visceral Disorders
206
António Avelino and Francisco Cruz vii
viii
CONTENTS
9
TRPV1 Receptors and Migraine
239
Philip R. Holland and Peter J. Goadsby
10 TRPV1 in Neuropathic Pain and Neurological and Neuropsychiatric Disorders
260
Enza Palazzo, Katarzyna Starowicz, Sabatino Maione, and Vincenzo Di Marzo
PART III
TRPV1 ANTAGONISTS AND AGONISTS AS NOVEL ANALGESIC DRUGS
11 Aryl-Urea Class and Related TRPV1 Antagonists
293 295
Arthur Gomtsyan
12
2-Pyridinylpiperazine Carboxamide Class and Related TRPV1 Antagonists
311
Natalie A. Hawryluk and Nicholas I. Carruthers
13
TRPV1 Agonist Approaches for Pain Management
325
Keith R. Bley
PART IV
14
ROLE FOR TRPV1 IN OTHER PHYSIOLOGICAL PROCESSES BESIDES PAIN TRANSMISSION
The TRPV1 Channel in Normal Thermoregulation: What Have We Learned from Experiments Using Different Tools?
349
351
Andras Garami, Maria C. Almeida, Tatiane B. Nucci, Tamara Hew-Butler, Renato N. Soriano, Eszter Pakai, Kazuhiro Nakamura, Shaun F. Morrison, and Andrej A. Romanovsky
15
The Role of TRPV1 in Respiratory Diseases
403
Serena Materazzi, Alain Tchoimou, Romina Nassini, Marcello Trevisani, and Pierangelo Geppetti
16
The Role of TRPV1 in Diabetes
423
Hubert Tsui, Ruslan Dorfman, Michael W. Salter, and H.-Michael Dosch
AFTERWORD
449
INDEX
451
PREFACE AND ACKNOWLEDGMENTS
The intended purpose of this book is to summarize available data related to the therapeutic utility for transient receptor potential vanilloid 1 (TRPV1) ligands. Many of the world’s leading experts on TRPV1 contributed to this book, not only by reviewing the most relevant information on the subject but also by providing personal opinions on the critical issues. The history of the TRPV1 receptor is, for the most part, the history of chili pepper, a popular hot spice that has been cultivated in South America for over 6000 years and in the rest of the world since the sixteenth century. However, food flavoring has not been the only benefit chili peppers have offered. Chili preparations have been used as treatments for ulcers, backaches, and coughs, among other maladies. The ingredient that is responsible for the initial burning effect of chili pepper, as well as for its medicinal properties, is a compound called capsaicin, which constitutes approximately 0.14% w/w of chili peppers. Capsaicin was isolated in 1876, and its structure was determined shortly thereafter. The homovanillyl fragment in the structure of capsaicin was the basis for naming the putative cell surface receptor vanilloid receptor 1 (VR1). An amazing breakthrough occurred in 1997, when VR1 was molecularly cloned by David Julius’ team. VR1 later was renamed the TRPV1 to underscore its membership in a larger family of transient receptor potential (TRP) ion channels. The Foreword by Professor Julius presents an illuminating perspective on the entire field. The two introductory chapters in this volume (Nilius and Vennekens; Szallasi) are designed to familiarize the reader with the multifunctional TRP family of ion channels and, at the same time, to lay the foundation for the remaining chapters, which focus on one member of that family, TRPV1. Members of the TRP superfamily have been shown to be polymodal molecular ix
x
PREFACE AND ACKNOWLEDGMENTS
sensors, with the important roles of detecting a variety of thermal, mechanical, and chemical stimuli. These ion channels have been shown to contribute to sensory processes such as pain transmission, vision, taste, and hearing. The complex nature of TRPV1 modulation is described in the chapter by Surowy et al., which provides basic information about the structure of the receptor, numerous regulators (activators and sensitizers), and their modes and sites of action. The chapter on TRPV1 genetics (Dorfman et al.) reviews the impact of TRPV1 genetic variability on the pharmacological properties of TRPV1 in different species and summarizes available data on identification of the binding sites for biological substrates. Several key studies with TRPV1 knockout mice and with TRPV1 antagonists, support the conclusion that TRPV1 plays an important role in pain pathways. Indeed, most of the advances with TRPV1 as a new molecular target for novel medications have been in the development of new analgesics. The next chapters discuss in detail the connection between TRPV1 and various types of pain. Preclinical studies provide a strong case for the beneficial effects of TRPV1 blockade for the treatment of inflammatory, osteoarthritic, and bone cancer pain. The efficacy of TRPV1 antagonists in animal models of inflammatory pain is discussed in the chapter by Bhattacharya et al. Several preclinical studies have shown the benefit of TRPV1 antagonists in treating the pain associated with osteoarthritis (Joshi and Honore). It has also been shown that bone cancer pain, which is often poorly controlled by existing analgesics, can be successfully attenuated in mice by treatment with TRPV1 antagonists (Jimenez-Andrade and Mantyh). TRPV1 has been actively investigated as a potential target for conditions such as visceral pain and the treatment of lower urinary tract symptoms, including urinary frequency, urgency, and incontinence (Avelino and Cruz). Evidence for the role of TRPV1 in migraine (Holland and Goadsby) and in neuropathic pain (Palazzo et al.) is limited and inconclusive. To conclude the theme of TRPV1 antagonists and pain, two medicinal chemistry chapters summarize structural and structure–activity relationship information on the two major classes of TRPV1 antagonists: aryl-ureas (Gomtsyan) and pyridinylpiperazine carboxamides (Hawryluk and Carruthers). While the blockade of receptor activation by TRPV1 antagonists attenuates pain transmission, TRPV1 agonists have also been shown to be effective in pain management, especially for peripheral neuropathies (Bley). Antinociception induced by TRPV1 agonists is the result of receptor desensitization/defunctionalization after prolonged administration of the agonist. In fact, capsaicin cream has been used for many years to treat peripheral neuropathies, and new topical and injectable formulations of capsaicin with better safety margins are undergoing late-stage clinical trials. This volume also presents experts’ opinions on the links between TRPV1 and disease states other than pain. Some of these links are well established. For example, high expression of TRPV1 on sensory nerves in airways led
PREFACE AND ACKNOWLEDGMENTS
xi
scientists to explore the potential for TRPV1 antagonists in treating chronic cough, asthma, and other respiratory diseases (Materazzi et al.). A number of such compounds have shown potent antitussive activity in preclinical models of cough, and at least one compound (MK-2295) has entered clinical testing. The role of TRPV1 in some other diseases is less well validated. Expression of functional TRPV1 receptors in the brain suggests the possibility of novel strategies for the treatment of neurological and perhaps neuropsychiatric disorders (Palazzo et al.), while recent observations with non-obese diabetic mice suggest a potentially important role for TRPV1 in the development of diabetes (Tsui et al.). One of the properties of TRPV1 and other members of the TRP family is the ability to detect thermal stimuli within a specific intensity range. The chapter by Garami et al. discusses the role of TRPV1 in thermoregulation, presenting both a mechanistic point of view and the implications for the development of safe TRPV1 antagonist-based therapies. Recent setbacks in the clinical development of TRPV1 antagonists due to the induction of transient hyperthermia and a deficit in perception of potentially injurious heat make this chapter especially relevant. Our hope is that this book successfully highlights the role of TRPV1 as one of the best-known integrators of multiple painful stimuli and serves as a good reference regarding current and potential future applications of TRPV1 ligands in treating pain as well as other pathophysiological conditions. The editors are very grateful to the authors for their excellent contributions and their understanding of efforts to keep the delicate balance between appreciation of the busy schedules of the authors and the deadlines set by the publisher. We also express our indebtedness to Jonathan Rose at John Wiley & Sons for inviting us to serve as editors for this book and for patiently providing guidance throughout the process. Arthur Gomtsyan Connie R. Faltynek
FOREWORD
The use of plant extracts in folk medicine can be traced back thousands of years to geographically and ethnically diverse cultures. Such accumulated wisdom has served as the starting point for the development of important experimental and therapeutic drugs. This process is perhaps best exemplified by pain medications, so many of which—particularly those of the opiate and NSAID class—were inspired by the active ingredients in opium poppies and in willow bark, respectively. While some natural plant products (such as opiates) suppress pain, others produce it. This is certainly the case for capsaicin, the pungent agent in “hot” chili peppers that elicits that familiar and intense sensation of burning pain. Just as morphine and aspirin have served as chemical keys for unlocking cellular mechanisms of pain suppression, capsaicin and other pungent natural products have helped to define the neurons, molecules, and signaling pathways that initiate or enhance pain under normal (acute) and pathological (chronic) circumstances. The culinary and medicinal wonders of capsaicin and related vanilloid compounds can be traced to Central and South America, where Capsicum plants have their indigenous roots. Thousands of years later, Christopher Columbus and other explorers introduced chili peppers to European, Asian, and African continents, where they have been similarly and widely exploited for sensorial and medicinal applications ranging from food preservation to hypothermic cooling. In more recent times, seminal work from Jansco and colleagues in Hungary showed that capsaicin functions as a highly selective excitatory agent for a subset of primary afferent sensory neurons, making sensitivity to capsaicin a defining functional hallmark of the nociceptor. Consequently, the goal of delineating a mechanism of capsaicin action, and in particular, identifying a “vanilloid receptor,” became a holy grail of pain xiii
xiv FOREWORD
research, much in the same way that molecular identification of the T-cell receptor was seen as a watershed in the genetic and functional characterization of the lymphocyte. Leading up to this goal were the fundamental contributions of Rang, Bevan, Wood, and colleagues at the Sandoz Institute, as well as those of Blumberg and coworkers at the U.S. National Cancer Institute, whose early electrophysiological and pharmacological studies helped to better define and to validate a bona fide “vanilloid site.” Still, this putative receptor defied genetic identification for quite some time, and thus its existence and molecular nature remained enigmatic. The cloning and molecular characterization of TRPV1 (né VR1) by Michael Caterina and by other members of my group at once resolved these issues while providing a definitive molecular explanation for the highly selective nature of capsaicin action. In doing so, this accomplishment gave molecular validation to the so-called specificity theory of nociception first espoused by Sherrington over a century ago. From a more general perspective, cloning of the vanilloid receptor put a spotlight on TRP channels as important new players in vertebrate sensory systems. In retrospect, this should not have come as a great surprise given the well-established role of TRP channels in fly phototransduction, but for whatever reason, their relevance to sensory signaling in higher systems had not been fully appreciated. The study of TRPV1 has established several important new paradigms that are of general relevance to sensory signaling but also hold special significance for nociception and pain. Of course, one of these relates to the discovery that TRPV1 functions as a thermosensor, which has provided a molecular and cellular framework for understanding how ion channels sense heat or cold, and how primary afferent neurons detect changes in ambient temperature. Additionally, these studies set the stage for understanding how TRP channels function as polymodal signal detectors that can integrate information from both physical and chemical stimuli to modulate neuronal excitability in the face of changing environmental or physiological conditions. In the context of the primary afferent nociceptor, this has great significance for understanding how tissue injury and inflammation produce pain hypersensitivity. The molecular analysis of TRPV1 has opened up exciting new vistas in the study of somatosensation, nociception, and pain. Of course, the full therapeutic impact of this work will come with the development of analgesic agents that target TRP channels on primary afferent nociceptors. Should this come to pass—as I expect it will—then we can add capsaicin to the list of natural products that have inspired novel classes of pain medicines. David Julius San Francisco
CONTRIBUTORS
Maria C. Almeida, Systemic Inflammation Laboratory, Trauma Research, St. Joseph’s Hospital and Medical Center, Phoenix, AZ António Avelino, Institute of Histology and Embryology, Faculty of Medicine of Porto, Alameda Hernani Monteiro, Porto, Portugal; IBMC, University of Porto, R. Campo Alegre, Porto, Portugal; Email: aavelino@ med.up.pt Anindya Bhattacharya, Department of Pain and Related Disorders, Johnson & Johnson Pharmaceutical Research and Development, L.L.C., 3210 Merryfield Row, San Diego, CA 92121 Keith R. Bley, NeurogesX, Inc., 2201 Bridgepointe Parkway, San Mateo, CA 94404; Email:
[email protected] Nicholas I. Carruthers, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. San Diego, CA; Email:
[email protected] Francisco Cruz, Institute of Histology and Embryology, Faculty of Medicine of Porto, Alameda Hernani Monteiro, Porto, Portugal; IBMC, University of Porto, R. Campo Alegre, Porto, Portugal; Department of Urology, Hospital São João and Faculty of Medicine of Porto, Porto, Portugal; Email:
[email protected] Vincenzo Di Marzo, Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Naples, Italy; Email:
[email protected] xv
xvi CONTRIBUTORS
Ruslan Dorfman, University of Toronto, The Hospital For Sick Children, Research Institute, Genetics & Genome Biology Program, Toronto, Ontario, Canada H.-Michael Dosch, University of Toronto, The Hospital For Sick Children, Research Institute, Neurosciences & Mental Health Programs, Toronto, Ontario, Canada; Email:
[email protected] Connie R. Faltynek, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL; Email:
[email protected] Andras Garami, Systemic Inflammation Laboratory, Trauma Research, St. Joseph’s Hospital and Medical Center, Phoenix, AZ Narender R. Gavva, Department of Neuroscience Amgen Inc., Thousand Oaks, CA; Email:
[email protected] Pierangelo Geppetti, Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy; Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy; Email: pierangelo. geppetti@unifi.it Peter J. Goadsby, Headache Group Department of Neurology, University of California, San Francisco, CA; Email:
[email protected] Arthur Gomtsyan, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL; Email:
[email protected] Natalie A. Hawryluk, Johnson & Johnson Pharmaceutical Research & Development, L.L.C. San Diego, CA Tamara Hew-Butler, Systemic Inflammation Laboratory, Trauma Research, St. Joseph’s Hospital and Medical Center, Phoenix, AZ Philip R. Holland, Headache Group Department of Neurology University of California, San Francisco, CA Prisca Honore, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL; Email:
[email protected] Juan Miguel Jimenez-Andrade, Department of Pharmacology, University of Arizona, Tucson, AZ Shailen K. Joshi, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL; Email: shailen.
[email protected]
CONTRIBUTORS
xvii
David Julius, Department of Physiology and Department of Cellular and Molecular Pharmacology, University of California, San Francisco, CA Email:
[email protected] Philip R. Kym, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL Sonya G. Lehto, Department of Neuroscience Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA Sabatino Maione, Endocannabinoid Research Group, Department of Experimental Medicine, Section of Pharmacology “L. Donatelli,” Faculty of Medicine and Surgery, Second University of Naples, Naples, Italy; Email:
[email protected] Patrick Mantyh, Department of Pharmacology, University of Arizona, Tucson, AZ; Research Service, VA Medical Center, Minneapolis, MN Email:
[email protected] Serena Materazzi, Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy Shaun F. Morrison, Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR Kazuhiro Nakamura, Division of Neuroscience, Oregon National Primate Research Center, Oregon Health & Science University, Beaverton, OR Romina Nassini, Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy. Bernd Nilius, KU Leuven, Department of Molecular Cell Biology, Laboratory Ion Channel Research, Campus Gasthuisberg, Leuven, Belgium; Email:
[email protected] Tatiane B. Nucci, Systemic Inflammation Laboratory, Trauma Research, St. Joseph’s Hospital and Medical Center, Phoenix, AZ Eszter Pakai, Systemic Inflammation Laboratory, Trauma St. Joseph’s Hospital and Medical Center, Phoenix, AZ
Research,
Enza Palazzo, Endocannabinoid Research Group, Department of Experimental Medicine, Section of Pharmacology “L. Donatelli,” Faculty of Medicine and Surgery, Second University of Naples, Naples, Italy Regina M. Reilly, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL Andrej A. Romanovsky, Systemic Inflammation Laboratory, Trauma Research, St. Joseph’s Hospital and Medical Center, Phoenix, AZ; Email:
[email protected]
xviii
CONTRIBUTORS
Michael W. Salter, University of Toronto, The Hospital For Sick Children, Research Institute, Neurosciences & Mental Health Programs, Toronto, Ontario, Canada Renato N. Soriano, Systemic Inflammation Laboratory, Trauma Research, St. Joseph’s Hospital and Medical Center, Phoenix, AZ Katarzyna Starowicz, Department of Pain Pharmacology, Institute of Pharmacology PAS, 12 Smetna str 31343 Cracow Poland; Endocannabinoid Research Group, Institute of Biomolecular Chemistry, Consiglio Nazionale delle Ricerche, Naples, Italy Carol S. Surowy, Neuroscience Research, Global Pharmaceutical Research and Development, Abbott Laboratories, Abbott Park, IL; Email:
[email protected] Arpad Szallasi, Departments of Pathology and Laboratory Medicine, Monmouth Medical Center, Long Branch, NJ; Drexel University College of Medicine, Philadelphia, PA; Email:
[email protected] Alain Tchoimou, Department of Preclinical and Clinical Pharmacology, University of Florence, Florence, Italy Marcello Trevisani, Center of Excellence for the Study of Inflammation, University of Ferrara, Ferrara, Italy; present address: PharmEste srl, Ferrara, Italy Hubert Tsui, University of Toronto, The Hospital For Sick Children, Research Institute, Neurosciences & Mental Health Programs, Toronto, Ontario, Canada Rudi Vennekens, KU Leuven, Department of Molecular Cell Biology, Laboratory Ion Channel Research, Campus Gasthuisberg, Leuven, Belgium
PART I INTRODUCTION TO THE TRP CHANNELS
1 TRP CHANNELS AND HUMAN DISEASES Bernd Nilius and Rudi Vennekens
1.1
INTRODUCTION
Transient receptor potential (TRP) cation channels have been described in detail as polymodal cell sensors in many reviews (Nilius and Voets, 2005; Pedersen et al., 2005; Voets et al., 2005; Nilius and Mahieu, 2006; Ramsey et al., 2006; Nilius, 2007; Nilius et al., 2007; Venkatachalam and Montell, 2007). The mammalian TRP superfamily consists of 28 mammalian TRP cation channels, which can be subdivided into six main subfamilies: the TRPC (“Canonical”), TRPV (“Vanilloid”), TRPM (“Melastatin”), TRPP (“Polycystin”), TRPML (“MucoLipin”), and the TRPA (“Ankyrin”) groups. In the current review, we attempt to create an overview of the currently available data on the functional role of TRP channels and their possible significance for human disease. We will extend and complement the very comprehensive reviews on this topic published just recently (Jordt and Ehrlich, 2007; Kiselyov et al., 2007; Nilius, 2007; Nilius et al., 2007). For that reason, and due to space limitations, it is inevitable that some topics will not be covered at this occasion (Fig. 1.1). Several TRP channelopathies are known, that is, diseases with identified defects in the gene encoding the channels. Channel dysfunctions caused by regulatory proteins can also contribute to the genesis of several diseases and may result in changes in channel abundance, channel gating or modulation, and inadequate responses to various stimuli. Abnormal endogenous production of various agents during the development of a disease (e.g., in inflammation conditions) can affect channel function and may determine the progression Vanilloid Receptor TRPV1 in Drug Discovery, Edited by Arthur Gomtsyan & Connie R. Faltynek Copyright © 2010 John Wiley & Sons, Inc.
3
4
TRP CHANNELS AND HUMAN DISEASES TRPM3 TRPM6 “M, melastatin” TRPM7 TRPM1 TRPM2 TRPC7 TRPM8 TRPC3 TRPM4 TRPC6 TRPM5 TRPC5 “P, polycystin” TRPP3 TRPC4 (PKD2L1) TRPP2 TRPC1 (PKD2) TRPP5 TRPV6 (PKD2L2) TRPV5 TRPML1 TRPV2 TRPML2 “V, vanilloid” TRPV1 TRPV4 TRPV3TRPML3 “ML, mucolipin”
“C, canonical”
Figure 1.1
A phylogenetic tree of the mammalian members of the TRP family.
of the disease. This review will list all known mammalian TRP channels and will indicate links to possible diseases based on data from human patients, genetically manipulated organisms, and pharmacological studies. The increasing evidence that TRP channels are involved in human diseases has created a huge interest for these channels as novel drug targets. Comprehensive reviews have been published on the modulation of TRP channels by novel modulators and the general role of TRPs as pharmaceutical targets (see Okuhara et al., 2007; Szallasi et al., 2007; Landry and Gies, 2008). This topic will only sporadically be discussed.
1.2 THE “CANONICAL” TRPCS The mammalian TRPC (canonical) channels can be subdivided into four subclasses: TRPC1, TRPC2, TRPC3/6/7, and TRPC4/5 (Vazquez et al., 2004). All TRPC channels are nonselective Ca2+-permeable cation channels. TRPC1, TRPC4, and TRPC5 can form heteromers, and current properties are significantly different between TRPC5 and TRPC1/TRPC5-expressing cells. Similarly, TRPC3, TRPC6, and TRPC7 also can form heteromers (Strubing et al., 2001, 2003; Goel et al., 2002; Hofmann et al., 2002). TRPC activation occurs mainly via different isoforms of phospholipases (PLCs) (Venkatachalam et al., 2002). TRPC1, TRPC4, and TRPC5 are activated by receptor-induced PLC, but, in contrast to TRPC3, TRPC6, and TRPC7, are completely unresponsive to diacylglycerol (DAG) and show a quite complicated activation pattern including changes in membrane potential (voltage dependence), binding of multivalent cations to the pore region, and interaction with phosphatidylinositol phosphates (Hofmann et al., 1999; Venkatachalam et al., 2003;
5
THE “CANONICAL” TRPCS
Chromosomal location of Homo sapiens TRP channel genes 85.20
p q
(ML3) MCOLN3 MCOLN2 p (ML2) q
p q
p q p q
85.11
C1
135.58
C3
C7 137.26
Chr 2
Chr 3
Chr 4
Chr 5
p q
p q
A1 142.09
V6 V5
PKD2L2 (P5)
M8
Chr 1
p q
P2
Chr 6
Chr 7
142.13
Chr 8 P1
M5 p q
M3
p q
p q
M1
C4
p q
M7
M6 Mg
Chr 9
p q
p q
p q
p q
PKDL (P3)
C6
Chr 10 Chr 11
V3 36.67 V1 34.19 p V2 q
V4
Chr 12
Chr 13
MCOLN1 (ML1)
p q
p q
Chr 14
Chr 15
p q
p q
Chr 16 p q
p q
C5 M4
Chr 17
Chr 18
Chr 19
M2
Chr 20
Chr 21 Chr 22
PKDREJ (P4)
Chr X
Chr Y
Figure 1.2 Schematic overview of the chromosomal location of human TRP genes (reproduced from Abramowitz and Birnbaumer [2006] with the permission of SpringerVerlag and the authors). (See color insert.)
Otsuguro et al., 2008). TRPC channels have been linked to cardiovascular disease (Yao and Garland, 2005; Dietrich et al., 2007; Firth et al., 2007; Kwan et al., 2007; Ohba et al., 2007), pulmonary disease (Meng et al., 2008), inflammation (Brechard et al., 2008), cancer (Fraser and Pardo, 2008), skin disease (Pani and Singh, 2008), and proliferative diseases via dysregulation of the cell cycle (Quadid-Ahidouch and Ahidouch, 2007) (Fig. 1.2). 1.2.1 TRPC1 1.2.1.1 Cardiovascular Cardiac hypertrophy is coupled to an increased Ca2+ entry and a dysfunction of Ca2+ signaling (Bers and Guo, 2005) (for a review including the role of TRPs, see Watanabe et al. [2008]). Two lines of evidence suggest that TRPC1 may be involved in the development of cardiac hypertrophy. First, TRPC1 expression is significantly increased in the hearts of abdominal aortic-banded (AAB) rats, which develop pressure-induced hypertrophy, compared to sham-operated rats. It is also increased in cultured myocardial cells pretreated with hypertrophic factors such as endothelin-1 (ET-1), brain natriuretic peptide (BNP), and atrial natriuretic factor (ANF). Silencing of the TRPC1 gene via small interfering RNA (siRNA) prevents
6
TRP CHANNELS AND HUMAN DISEASES Hypertrophic agonists: ATII ET-1 PE
Gαq
TRPC1 TRPC3 Ca2+ TRPC6
DAG
L-type Ca2+ channel
Δϕ
Ca2+
PLC
Ca2+
Ca2+
IP3
ER Ca2+ store P
Calcineurin NFAT
Positive feedback system NFAT
MEF2
NFAT
GATA
TRPC
Cardiac growth and remodeling genes
Figure 1.3 Hypertrophic agents such as angiotensin II, endothelin-1, and phenylephrin promote hypertrophy of the cardiomyocyte by causing excess Ca influx, which stimulates NFAT-driven gene expression of specific genes. Ca influx either occurs directly through TRP channels or the membrane potential is set by these channels, influencing Ca influx through L-type Ca channels. Expression of several TRPC channels is stimulated by NFAT, generating a positive feedback loop. See text for more details and references. ER: endo/sarcoplasmic reticulum; GATA, MEF2, and NFAT: nuclear transcription factors; IP3: inositol-1,4,5-trisphosphate. (See color insert.)
ET-1-, angiotensin II (ATII)-, and phenylephrine (PE)-induced cardiac hypertrophy. Second, ATII also induces hypertrophy of vascular smooth muscle cells (VSMCs). TRPC1 is overexpressed in these cells, and TRPC1 siRNA prevents the development of ATII-induced hypertrophy (Takahashi et al., 2007). The induction of TRPC1 expression is probably mediated through the nuclear factor of activated T cell (NFAT). The general mechanism for hypertrophy development might be that proliferative stimuli activate TRPC1, inducing depolarization and activation of L-type Ca2+ channels, which subsequently increase cardiac [Ca2+]i, activate calcineurin, and trigger NFAT translocation to the nucleus, which in turn results in an increased transcription of TRPC1 channels (Bush et al., 2006) (Fig. 1.3). Occlusive vascular disease is often a lethal complication in myocardial infarction, stroke, atherosclerosis, and clinical procedures such as angioplasty and grafting in bypass surgery. It can be caused by a switch in smooth muscle cell phenotype to an invasive and proliferative mode, leading to neointimal
THE “CANONICAL” TRPCS
7
hyperplasia. TRPC1 might be involved in this switching of cell fate, which is associated with enhanced calcium entry and cell cycle activity. A specific E3targeted (pore blocking) antibody to TRPC1 reduced neointimal growth in human veins, indicating that this might be a new avenue in the treatment of occlusive vascular diseases (Kumar et al., 2006; van Breemen et al., 2006). 1.2.1.2 Skeletal Muscle A role for TRPC1 in Duchenne muscular dystrophy (DMD) has been suggested extensively (Gailly, 2002; Hopf et al., 2007). In dystrophic myocytes, an increased Ca2+ influx is apparent, which can be suppressed by antisense TRPC1, TRPC4, and TRPC6 oligonucleotides. Furthermore, a direct interaction between α1-syntrophin and TRPC1 was recently shown. Apparently, normal regulation of calcium influx in skeletal muscle depends on the association between TRPC1 channels and α1syntrophin that may anchor the store-operated channels (SOCs) to the dystrophin-associated protein complex (DAPC). The loss of this molecular association could contribute to the calcium alterations observed in DMD cells (Vandebrouck et al., 2007). A further indication for the role of TRPC1 in a myopathy comes from homer 1−/− mice. Mice lacking homer 1 show decreased muscle fiber crosssectional area and decreased skeletal muscle force generation. Homer 1−/− myotubes displayed altered cation influx, which can be blocked by TRPC1 downregulation. Diminished Homer 1 expression in mouse models of DMD suggests that loss of Homer 1 scaffolding of TRP channels may contribute to the increased stretch-activated channel activity observed in mdx (dystrophindeficient) myofibers (Stiber et al., 2008). Also, reactive oxygen species (ROS), which are increased in DMD, activate an src kinase, which in turn can activate TRPC1 (Gervasio et al., 2008). 1.2.1.3 Skin Darier’s disease (DD) is caused by mutations of SERCA2. Keratinocytes from DD patients show increased TRPC1 expression levels and increased Ca influx. The latter might be involved in reinforcement of NFkBmediated upregulation of antiapoptotic genes, for example, BclxL. TRPC1 therefore could increase cell proliferation, a hallmark of lesional keratinocytes (Beck et al., 2008; Pani and Singh, 2008). 1.2.1.4 Immunodefense TRPC1 is involved in antibody recognition in B lymphocytes. Suppression of TRPC1 results in reduced B-cell antigen receptor (BCR)-mediated oscillations in [Ca2+]i and consequently depressed activation of the NFAT (Mori et al., 2002). 1.2.1.5 Neurological Disorders TRPC channels seem to be crucially involved in the signaling via metabotropic glutamate receptors (Kim et al., 2003) and in the actions of brain-derived neurotrophic factor (BDNF) (Li et al., 1999) that include netrin-1 and BDNF-mediated growth cone guidance (Greka et al., 2003; Li et al., 2005c; Shim et al., 2005). Recent studies indicate
8
TRP CHANNELS AND HUMAN DISEASES
a potential link between TRPC1 and neurotoxicity induced by the exogenous agent 1-methyl-4-phenylpyridium (MPP). The latter causes selective nigral dopaminergic lesions and induces Parkinson’s disease-like syndromes. (Bollimuntha et al., 2005). Apparently, TRPC1 may execute a neuroprotective role in dopaminergic neurons. TRPC1 (and probably also TRPC3) are activated by the peptide hormone orexin A via the GPCR OX1 (Larsson et al., 2005). This activation mode may link TRP channels to important physiological functions, because orexin regulates sleep/wakefulness states, alertness, and food intake (appetite). In addition, the orexin knockout mouse is a very useful model of human narcolepsy, a disorder that is characterized primarily by rapid eye movement (REM) sleep dysregulation. 1.2.2 TRPC2 The TRPC2 gene trpc2 is a pseudogene in humans and will not be discussed further in this review. 1.2.3 TRPC3 1.2.3.1 Cardiovascular TRPC3 might be critically involved in heart hypertrophy. RNAi-mediated knockdown of TRPC3 decreases expression of hypertrophy-associated genes such as the A- and B-type natriuretic peptides (ANP and BNP) in response to numerous hypertrophic stimuli. Overexpression of TRPC3 increases BNP expression (Brenner and Dolmetsch, 2007). Increased Ca2+ causes cell death in response to ischemia–reperfusion (I/R). After I/R, apoptosis was significantly increased in TRPC3 overexpressing cardiomyocytes compared to control. TRPC3 overexpression increased not only apoptosis but also calpain-mediated proteolysis resulting from I/R injury, as well as sensitivity to Ca2+ overload in cardiomyocytes (Shan et al., 2008). It is noteworthy to mention that Epo activates TRPC3. TRPC3 is expressed in human erythroid progenitor cells and may regulate Ca2+ influx during erythroid differentiation (Tong et al., 2008). Importantly, Epo secretion is critically regulated by the hypoxia-induced factor HIF-1, which in turn upregulates two other TRPCs, TRPC1 and TRPC6 (Wang et al., 2006). 1.2.3.2 Immunodefense Interestingly, mutations in TRPC3 induce a reduction of T-cell receptor activation-induced Ca2+ entry in T lymphocytes, which may parallel the defective immune responses from patients with severe combined immunodeficiency (SCID) (Philipp et al., 2003). 1.2.3.3 Neurological Disorders TRPC3 seems to be critically involved in brain development. BDNF shapes synapses in hippocampal neurons. It also activates a nonselective cationic current (IBDNF) in CA1 pyramidal neurons. Activation requires phospholipase C, IP3 receptors, and the respective stores
THE “CANONICAL” TRPCS
9
and depends on extracellular Ca2+. CA1 neurons express TRPC3, and IBDNF is absent after silencing with TRPC3 siRNA. A sustained phase of IBDNF depends on phosphatidylinositol 3-kinase, which is required for plasma membrane insertion of TRPC3. TRPC3 channels are necessary for BDNF to increase dendritic spine density(Amaral and Pozzo-Miller, 2007). Furthermore, the Δ202 mouse line, which has defective TRPC3 expression, develops severe neurological problems, including paralysis and atrophy starting at week 4. Mice die around week 12. The neurologic syndrome of the Δ202 mice appears to be a monogenic recessive neuromotor disease caused by the interruption of the trpc3 gene, leading to a failure in the postnatal development of the central nervous system (CNS) (Rodriguez-Santiago et al., 2007). There may be a connection between TRPC3 and Parkinson’s disease: Parkinsonian movement disorders are often associated with abnormalities in the GABA neuron firing pattern in the substantia nigra pars reticulata. These neurons express TRPC3 channels, which are tonically active and mediate an inward Na+ current, leading to a substantial depolarization in these neurons. Inhibition of TRPC3 channels induces hyperpolarization, decreases firing frequency, and increases firing irregularity, all of which may contribute to movement disorders (Zhou et al., 2008a). Spinocerebellar ataxia type 14 (SCA14) is an autosomal dominant neurodegenerative disease caused by mutations in protein kinase PKCg. This kinase normally inhibits TRPC3. The mutant PKCγ cannot phosphorylate TRPC3, resulting in sustained Ca2+ entry. This alteration in Ca2+ homeostasis in Purkinje cells may contribute to neurodegeneration in SCA14 (Adachi et al., 2008). 1.2.4 TRPC4 1.2.4.1 Cardiovascular TRPC4 has been associated with regulation of vascular tone (Freichel et al., 2001) and endothelial permeability (Tiruppathi et al., 2002). Recently, TRPC4 has also been implicated in angiogenesis. The angiogenesis inhibitor thrombospondin-1 (TSP1) controls the switch in renal cell carcinoma (RCC) toward an angiogenic phenotype. This factor is highly secreted in normal kidney cells, whereas RCC cells secrete little TSP1. Ca2+ influx through TRPC4 may be critical for TSP1 secretion since expression of TRPC4 is very low in RCC cells, and TRPC4 silencing in normal kidney cells causes TSP1 retention and impaired secretion (Veliceasa et al., 2007). 1.2.4.2 Neurological Disorders Alzheimer’s disease has multiple genetic variants. A genome-wide screen of two extended pedigrees identified a gene related to TRPC4, TRPC4-associated protein (TRPC4AP), on chromosome 20q11.22, as relevant for the disease. Multiple significant single-nucleotide polymorphisms (SNPs) in this gene were found with an initial genome scan and were confirmed by haplotype analysis. TRPC4AP might be involved
10
TRP CHANNELS AND HUMAN DISEASES
with the disease in these late-onset Alzheimer’s families, but the mechanism is unclear (Poduslo et al., 2009). TRPC4 is also present in F2-synaptic terminals of the thalamic network. These terminals provide a GABAergic input into the dorsal lateral geniculate nucleus. GABA release from such F2 terminals depends on Ca2+ influx initiated by metabotropic receptors. In trpc4−/− mice, the 5-hydroxytryptamine (5-HT)-induced release of GABA from the thalamic interneurons is dramatically reduced (Munsch et al., 2003). This GABAergic component is critical for the control of the sleep/wake cycle, processing of visual information, and may also be important for the control of retinogeniculate transmission. 1.2.4.3 Skin Aberrant keratinocyte differentiation causes hyperproliferative skin diseases, including basal cell carcinoma (BCC). Ca2+ influx plays a crucial role in this differentiation process. Knocking down of both TRPC4 and TRPC1 expression prevents Ca2+-dependent differentiation of keratinocytes, and the expression of both channels is significantly decreased in BCC, suggesting a critical role for both channels in the process controlling normal keratinocyte differentiation (Beck et al., 2008). 1.2.5 TRPC5 1.2.5.1 Gastrointestinal Quite recently, TRPC5 and TRPC6 have been mentioned in infantile hypertrophic pyloric stenosis (IHPS) (OMIM #179010). This disease has an incidence of one to eight per 1000 live births and is inherited as a complex sex-modified multifactorial trait with a striking male preponderance. The disease is characterized by projectile vomiting due to gastric outlet obstruction caused by hypertrophy of the smooth muscle of the pylorus. In a genome-wide SNP-based high-density linkage scan, two genomic loci were identified, which harbor TRPC6 (11q21-22) and TRPC5 (Xq23) (Everett et al., 2008). 1.2.5.2 Joints The identification of endogenous agents interacting with TRP channels is a major priority in the field. Recently, it has been shown that activation of TRPC5 homomultimers and TRPC5–TRPC1 heteromultimers can be mediated by extracellular reduced thioredoxin (Xu et al., 2008). Thioredoxin is an endogenous redox protein, which has several intracellular functions in cancer, ischeamic reperfusion injury, inflammation, and aging. Also, thioredoxin is highly secreted in rheumatoid arthritis. TRPC5 and TRPC1 are expressed in secretory fibroblast-like synoviocytes (FLSs) (FLS cells). FLS cells secrete matrix metalloproteinases (MMPs), which promote the progression of arthritis. Thioredoxin decreases MMP secretion in these cells. (Q: is this OK?) Block of TRPC5-containing channels enhances secretion of MMPs and prevents suppression of MMP secretion by thioredoxin. Thus, TRPC5/TRPC1–TRPC5 activation could represent a novel strategy in the treatment of rheumatoid arthritis (Xu et al., 2008).
THE “CANONICAL” TRPCS
11
1.2.6 TRPC6 1.2.6.1 Cardiovascular Several lines of evidence point to a role for TRPC6 in multiple cardiovascular conditions. For instance, TRPC6 might play a role in idiopathic pulmonary arterial hypertension (IPAH), which can lead to right heart failure. The crucial event for IPAH is excessive pulmonary artery smooth muscle cell proliferation, which is connected to overexpression of TRPC3 and TRPC6 (Yu et al., 2004). TRPC6 is also involved in angiotensin-induced heart hypertrophy. ATII induces NFAT activation, and cardiac hypertrophic responses have been correlated with TRPC6 activity (Onohara et al., 2006). TRPC6 may contribute to the development of hypoxic pulmonary hypertension (Wang et al., 2006). Finally, transgenic overexpression of TRPC3 and TRPC6 induces heart hypertrophy (Kuwahara et al., 2006; Nakayama et al., 2006). Apparently, NFAT consensus sites in the promoter of the TRPC6 gene confer responsiveness to cardiac stress. TRPC6 has been found to mediate membrane depolarization in smooth muscle cells and subsequent vasoconstriction induced by elevated intravascular pressure, the important myogenic constriction response (Bayliss effect) in small arteries and arterioles (Welsh et al., 2002). However, somewhat paradoxically, trpc6−/− mice display elevated blood pressure, which may be explained by a compensatory increase in the expression of the constitutively active TRPC3 channel in smooth muscle cells obtained from trpc6−/− mice (Dietrich et al., 2005). TRPC6 is activated by DAG and its derivatives (Dietrich and Gudermann, 2007). Cellular DAG levels are controlled by DAG kinase (DGK), which catalyzes DAG phosphorylation and acts as a regulator of GPCR signaling. DGKε acts specifically on DAG produced by inositol cycling. Interestingly, a transgenic mouse with cardiac-specific overexpression of DGKε (DGK-TG) was resistant to cardiac hypertrophy and progression to heart failure under chronic pressure overload. Increases in heart weight after PE infusion and thoracic aortic vasoconstriction (TAC) were abolished in DGK-TG mice. Cardiac dysfunction after TAC was prevented in DGK-TG mice, and survival rate after TAC was higher in DGK-TG mice. Also, upregulation of TRPC6 expression after TAC was attenuated in DGK-TG mice (Niizeki et al., 2008). These data further underscore a role for TRPC6 activity in the development of cardiac hypertrophy. 1.2.6.2 Kidney TRPC6 is one of the few TRP channels to which a real channelopathy can be assigned. Six mutations of the trpc6 gene are linked to the human proteinuric kidney disease focal and segmental glomerulosclerosis (FSGS) of the late-onset type (Kriz, 2005; Reiser et al., 2005; Winn et al., 2005). TRPC6 is expressed in the podocytes in the kidney glomerular filter (Reiser et al., 2005; Winn et al., 2005). Podocyte foot processes and the glomerular slit diaphragm form the glomerular filter and are an essential part of the permeability barrier in the kidney, which is defective in FSGS (Kriz, 2005).
12
TRP CHANNELS AND HUMAN DISEASES
This results in proteinuria and progressive kidney failure, leading to end-stage renal failure (Kriz, 2005). However, it is currently unclear how mutant forms of TRPC6 contribute to disease development. Three of the TRPC6 mutations in FSGS patients are gain-of-function mutations of TRPC6. Thus, enhanced Ca2+ entry through TRPC6 may constitute the pathogenic trigger, initiating cell death or disregulation that compromises the integrity of the permeability barrier (Reiser et al., 2005). On the other hand, a lack of nephrin, a central component of the slit diaphragm, induces increased TRPC6 expression in podocytes and leads to an altered localization of TRPC6 (Reiser et al., 2005). Vice versa, TRPC6 may be important for guidance of proteins such as nephrin and podocin, which are required to maintain the filtration barrier (Winn et al., 2006). It is tempting to speculate that blocking TRPC6 channels could be of therapeutic benefit in idiopathic FSGS. Interestingly, in this regard, preliminary experiments reveal that the commonly used immunosuppressive agent FK-506 can inhibit TRPC6 activity in vivo (Winn, 2008). 1.2.6.3 Pulmonary During regional alveolar hypoxia, a local vasoconstriction shifts the blood flow from hypoxic to normoxic areas, a mechanism known as “hypoxic pulmonary vasoconstriction” (HPV) (Euler–Liljestrand mechanism). This mechanism excludes blood flow from poorly ventilated areas. For acute HPV, TRPC6 is apparently indispensable since it is absent in trpc6−/− mice. Hypoxia causes DAG production, which in turn activates TRPC6. This mechanism may be extremely important in pulmonary gas exchange disturbances (Weissmann et al., 2006). 1.2.6.4 Neurological Disorders An interesting connection between TRPC6 and depression has been suggested. TRPC6 is activated by hyperforin, a bicyclic polyprenylated acylphloroglucinol derivative, which is the main active principle of St. John’s wort extract. This extract is used as an antidepressant. Hyperforin inhibits the neuronal serotonin and norepinephrine reuptake similarly to synthetic antidepressants such as Prozac. However, hyperforin also increases synaptic serotonin and norepinephrine concentrations by an indirect mechanism, that is, increase in [Na+]i, which inhibits the neuronal Na–amino acid pump. Hyperforin thus has a dual effect on neurotransmitter regulation. TRPC6 channels could be a novel target for a new class of antidepressants (Leuner et al., 2007). Some data also suggest a role for TRPC6 in Alzheimer’s disease. Mutations in the presenilin (PS) genes are linked to the development of early-onset Alzheimer’s disease. Transient expression of PS mutants (N141I and M239V) with TRPC6 in HEK-293 cells results in a strong inhibition of agonist-induced Ca2+ entry (Lessard et al., 2005). Interestingly, TRPC6 is localized to excitatory synapses and promotes their formation via a CaMKIV-Kinase-CREB-dependent pathway. Overexpression of TRPC6 increases the number of spines in hippocampal neurons and TRPC6 gene silencing decreases their number. Transgenic mice overexpressing
THE TRPV SUBFAMILY
13
TRPC6 showed enhancement in spine formation and better spatial learning and memory in Morris water maze. These results reveal the role of TRPC6 in synaptic plasticity and the behavioral consequences (Zhou et al., 2008b). 1.2.7 TRPC7 To our knowledge, no data are available in the literature linking TRPC7 to human disaeses.
1.3 THE TRPV SUBFAMILY The TRPV family comprises six mammalian genes, TRPV1–TRPV6. Members of the TRPV family contain six ankyrin repeats in their cytosolic N-termini, which have now been crystallized (Jin et al., 2006; Lishko et al., 2007; Phelps and Gaudet, 2007). TRPV1–TRPV4 are polymodal thermo- and chemosensitive channels that are nonselective for cations and are modestly permeable to Ca2+. In contrast, TRPV5 and TRPV6 are the only highly Ca2+-selective channels in the TRP family, and both channels are tightly regulated by [Ca2+]i (Vennekens et al., 2000; Yue et al., 2001) (for more detailed reviews, see Liedtke [2005], Nijenhuis et al. [2005a], O’Neil and Heller [2005], and Vennekens et al. [2008]). 1.3.1 TRPV1 The involvement of TRPV1 in pain and other disorders is the topic of this book. For more details on this intriguing subject, we refer to the proceeding chapters in this volume. Apart from those topics, however, it might be interesting to coin a few other leads to a role for TRPV1 in human disease. For instance, one might consider a role for TRPV1 in obesity. TRPV1 is expressed in preadipocytes and in visceral adipose tissue from mice and humans. Oral administration of capsaicin for 120 days prevented obesity in male wild-type (WT) mice but not in trpv1−/− mice under high fat diet (Zhang et al., 2007a). Also, an important role of TRPV1 has been suggested in bladder diseases (Birder, 2005). In the urinary bladder, TRPV1 is expressed on sensory nerve terminals and in the epithelial cells (urothelium) lining the bladder lumen (Birder et al., 2001). Overactive bladder symptoms due to various etiologies have been successfully treated with capsaicin or resiniferatoxin (RTX) (Kim and Chancellor, 2000; Cannon and Chancellor, 2002). Mice lacking TRPV1 display a higher frequency of low-amplitude (spontaneous low-volume spotting) non-voiding bladder contractions in comparison to WT animals (Birder et al., 2002). This gain of function was accompanied by reduction in both spinal cord signaling and reflex voiding during bladder filling. TRPV1 might also be
14
TRP CHANNELS AND HUMAN DISEASES
required for bladder stretch detection, which involves stretch-evoked release of ATP and nitric oxide (NO). Release of both mediators is reduced in bladders from trpv1−/− mice. Moreover, the trpv1−/− mouse does not develop bladder overactivity during acute bladder inflammation, indicating that TRPV1 is involved in bladder hyperreflexia in inflammation (Daly et al., 2007). A role for TRPV1 in bladder overactivity is also supported by clinical observations. In patients suffering from neurogenic detrusor overactivity (NDO), TRPV1 immunoreactivity in the urothelium and the number of nerve fibers expressing TRPV1 are increased (Brady et al., 2004; Apostolidis et al., 2005). For those patients who benefited from intravesicle RTX therapy, TRPV1 urothelial immunoreactivity decreased following treatment. In addition, in biopsies from the same patients, suburothelial TRPV1-expressing nerve fibers were reduced in number following therapy with RTX. Apparently, successful therapy using RTX leads to reduced TRPV1 expression in both urothelial and neuronal cells (Apostolidis et al., 2005). TRPV1 is activated in patients with gastroesophageal reflux disease (GERD), which is characterized by heartburn and chest pain. TRPV1 is expressed in sensory nerves within the mucosa of the esophagus, and its expression is upregulated in esophagitis patients (Matthews et al., 2004). TRPV1 is activated by acid pH and its activation is sensitized by ethanol, which all trigger the burning pain characteristic of GERD (Bhat and Bielefeldt, 2006). Also, TRPV1 is a potential target for novel therapies for functional bowel disorders (FBDs) (Holzer, 2004; Schicho et al., 2004). TRPV1 seems to be important for several skin diseases. Importantly, TRPV1 is involved in the control of human hair growth. TRPV1 activation by capsaicin in native human hair follicle cells causes inhibition of hair shaft prolongation, suppression of hair follicle cell proliferation, induction of apoptosis, and premature hair follicle cell regression (Bodo et al., 2005). In parallel, intrafollicular transforming growth factor (TGFβ2) and other known endogenous hair growth inhibitors (e.g., interleukin 1β) were upregulated, and hair growth promoters (e.g., insulin-like growth factor 1, hepatocyte growth factor, stem cell factor) were downregulated (Bodo et al., 2005; Biro et al., 2006). TRPV1 may also be a target for modulating epithelial cell growth disorders. Cell layers in the skin are characterized by a Ca2+ gradient and [Ca2+]i is sensitively regulated in keratinocytes, which express TRPV1. Finally, TRPV1 might be linked to memory and synaptic plasticity and consequently to neuropsychiatric and cognitive disorders, for example, epilepsy and schizophrenia (Newson et al., 2005; Li et al., 2008). The TRPV1 channel is a potential target to facilitate long-term potentiation (LTP) and to suppress long-term synaptic depression (LTD) (Li et al., 2008). TRPV1 activation is necessary and sufficient to trigger LTD. Excitatory synapses onto hippocampal interneurons were depressed either by capsaicin or an endogenously released eicosanoid, 12-(S)-HPETE. TRPV1 receptor antagonists prevented interneuron LTD. In brain slices from TRPV1−/− mice, LTD was absent (Gibson et al., 2008).
THE TRPV SUBFAMILY
15
1.3.2 TRPV2 TRPV2 is involved in pain transmission. The channel is activated by very noxious temperatures and is expressed, among other locations, in dorsal root ganglia (DRGs), in medium-sized neurons. Intraplantar injection of complete Freund’s adjuvant in rat induces overexpression of TRPV2, which is connected to peripheral sensitization during inflammation and thermal hyperalgesia (Shimosato et al., 2005). Expression of either TRPV1 and/or TRPV2 influences heat sensitization to painful thermal stimuli in deep and superficial C- and Aδ-nociceptors in skin (Rau et al., 2007). 1.3.2.1 Muscle A mouse model with specific overexpression of TRPV2 in the heart displays cardiomyopathy, left ventricular dilation, decreased systolic performance, disorganized myocyte arrangement, and interstitial fibrosis. Thus TRPV2 may play a role in cardiac hypertrophy (Iwata et al., 2003). Furthermore, the expression of TRPV2 is increased in the sarcolemma of skeletal/cardiac muscle in dystrophic patients and in an animal model (the BIO14.6 strain of the Syrian hamster) that lacks functional δ-sarcoglycan and displays reduced abundance of dystrophin (Iwata et al., 2003). 1.3.2.2 Bladder Both the full-length TRPV2 (hTRPV2) and a short splice variant (s-TRPV2) are detected in normal human bladder, in normal human urothelial cells, and in urothelial carcinomas (UCs). Enhanced hTRPV2 expression was found in high-grade UC specimens and in UC cell lines. On the other hand, a progressive decline of s-TRPV2 was associated with progressive UC (Caprodossi et al., 2007). 1.3.3 TRPV3 TRPV3 is highly expressed in the skin, both in keratinocytes and in cells surrounding hair follicles (Chung et al., 2004; Moqrich et al., 2005; Asakawa et al., 2006). TRPV3 functions as a voltage-dependent thermoTRP channel. Trpv3−/− mice exhibit deficits in innoxious and noxious heat perception. Hair abnormalities have been reported in the TRPV3 knockout mouse (Moqrich et al., 2005). TRPV3 gain-of-function mutations cause an autosomal dominant hairless phenotype with dermatitis (Xiao et al., 2008). Interestingly, TRPV3 is also a target for antidepressants. Incensole acetate, a plant compound from Boswellia, has been used as an antidepressant and is now described as a strong activator of TRPV3 (Moussaieff et al., 2008). 1.3.4 TRPV4 TRPV4 is a polymodal channel activated by a variety of stimuli, including heat, cell swelling, shear stress, and ligands such as the non-PKC-activating phorbol 4αPDD. Several studies in the literature imply a role for TRPV4 in neuropathic pain. For instance, in several neuropathy models (vincristine
16
TRP CHANNELS AND HUMAN DISEASES
chemotherapy, alcoholism, diabetes, and human immunodeficiency virus/ acquired immunodeficiency syndrome), mechanical hyperalgesia was reduced by spinal intrathecal administration of antisense oligonucleotides to TRPV4 (Alessandri-Haber et al., 2004, 2006). Mechanical hyperalgesia induced by paclitaxel, vincristine, or diabetes was strongly reduced in the TRPV4 knockout mice (Alessandri-Haber et al., 2008). Taxol-induced painful peripheral neuropathy could be treated by gene silencing of TRPV4 (Alessandri-Haber et al., 2004), and the induction of osmotic and mechanical hyperalgesia was absent in trpv4−/− mice (Alessandri-Haber et al., 2006). TRPV4 might play a crucial role in chronic dorsal root compression (CCD)induced mechanical allodynia (Zhang et al., 2007b). TRPV4 is expressed in DRG. After CCD, TRPV4 expression is significantly increased, and administration of TRPV4 antisense oligonucleotides partly reversed the CCD-induced mechanical allodynia. TRPV4 is also involved in the development of inflammatory mechanical and thermal hyperalgesia induced by intraplantar injection of carrageenan, a powerful inflammogen, or a cocktail of inflammatory mediators (Todaka et al., 2004). During inflammation, the protease-activated receptor 2 (PAR2) is activated. PAR2 agonists sensitize activation of TRPV4 by 4α-phorbol 12,13-didecanoate (4αPDD) and hypotonic cell swelling. Development of mechanical hyperalgesia by PAR2 activation is absent in trpv4−/− mouse (Sipe et al., 2008). Ca2+ entry via TRPV4 causes release of substance P (SP) and calcitonin gene related peptide (CGRP), which may underlie, at least partially, the pathomechanism of inflammatory mechanical hyperalgesia (Grant et al., 2007). TRPV4 has also been linked to visceral pain. Mechanosensory responses of colonic serosal and mesenteric afferents were enhanced by a TRPV4 agonist and were dramatically reduced by targeted deletion of TRPV4. Behavioral responses to noxious colonic distention were also substantially reduced in mice lacking TRPV4 (Brierley et al., 2008). TRPV4 expression is increased in sinus mucosa from patients with a specific form of chronic rhinosinusitis (CRS), which may indicate a potential role for TRPV4 in mucus homeostasis and in CRS pathogenesis (Bhargave et al., 2008). 1.3.4.1 Cardiovascular The analysis of the functional effects of TRPV4 (and other TRP channels) has been hampered by the poor specificity of agonists or antagonists. Recently, GSK1016790A was reported to be a novel specific TRPV4 activator. Injection of this compound in mice induced a dosedependent reduction in blood pressure, followed by profound circulatory collapse. On the other hand, the compound had no effect in the trpv4−/− mouse. GSK1016790A had no effect on rate or contractility in the heart of normal mice. Instead, it produced a potent endothelium-dependent relaxation of rodent-isolated vascular ring segments in vitro that was abolished by NO synthase (NOS) inhibition (L-NAME), ruthenium red, and eNOS gene deletion. Nevertheless, the in vivo circulatory collapse caused by GSK1016790A
THE TRPV SUBFAMILY
17
was not altered by NOS inhibition (L-NAME) or eNOS gene deletion but rather was associated with (concentration and time dependent) profound vascular leakage and tissue hemorrhage in the lung, intestine, and kidney (Willette et al., 2008). Thus, GSK1016790A may help to determine the role of TRPV4 in disorders associated with edema and with microvascular congestion. Several other studies have suggested a role for TRPV4 in vascular disease. For instance, TRPV4 is indirectly activated by 5-HT in pulmonary arterial smooth muscle cells (Ducret et al., 2008). TRPV4 surface expression is downregulated by WNK kinases (Fu et al., 2006). Several WNK kinases, in particular WNK4, have been put forward as candidate genes for essential hypertension, familial hyperkalemia and hypertension (FHH or Gordon’s syndrome, or pseudohypoaldosteronism type II, PHA-II). The proposed causal link is the downregulation of the expression of the Na+/Cl− cotransporter (NCC) in the kidney by WNK kinases. However, this effect does not occur in some diseasecausing WNK mutants (Wilson et al., 2003; Yang et al., 2003). It is intriguing to hypothesize that the osmoregulatory channel TRPV4 might also be involved in the pathogenesis of hypertension (Cope et al., 2005). 1.3.4.2 Pulmonary TRPV4 is widely expressed in the airway system and seems to be involved in bronchial hyperresponsiveness, an asthma symptom (Liedtke and Simon, 2004). Asthma is accompanied by a denudation of the epithelial lining of the bronchi and bronchioli. Bronchial smooth muscle cells, as well as nerve endings, can become exposed to the hypotonic bronchial fluid, which could contribute to bronchial hyperresponsiveness through activation of TRPV4. Activation of TRPV4 might also be involved in cilia movement in bronchial epithelial cells, as shown for oviductal cells (Andrade et al., 2005). TRPV4 is important for regulation of the lung barrier. Elevation of lung microvascular pressure increases endothelial [Ca2+]i via activation of TRPV4. This increase elevates the filtration coefficient via activation of myosin lightchain kinases and simultaneously stimulates NO synthesis. In TRPV4-deficient mice, pressure-induced increases in endothelial [Ca2+]i, NO synthesis, and lung wet/dry weight ratio are greatly reduced. Endothelial NO formation limits the permeability increase by a cGMP-dependent attenuation of the pressureinduced [Ca2+]i, via inactivation of TRPV4 in pulmonary microvascular endothelial cells in a negative feedback loop (Yin et al., 2008). TRPV4 activation can disrupt the alveolar septal barrier. TRPV4 activators increase lung endothelial permeability and induce breaks in the epithelial layer of the alveolar septal wall. This disruption leads to acute lung injury, patchy alveolar flooding, and hypoxemia (Alvarez et al., 2006). Stretch-activated cation channels initiate the acute pulmonary vascular permeability increase in response to high peak inflation pressure (PIP) ventilation. This stretch-activated channel may be identical to TRPV4. Permeability was assessed by measuring the filtration coefficient (Kf) in isolated perfused lungs of WT mice. Pretreatment with the inhibitors of TRPV4 (ruthenium red), arachidonic acid production (meth-
18
TRP CHANNELS AND HUMAN DISEASES
anandamide), or P450 epoxygenases (miconazole) prevented the increases in Kf. In trpv4−/− knockout mice, the high PIP ventilation protocol did not increase Kf. Lung distention, which causes Ca2+ entry in isolated mouse lungs, did not occur in trpv4−/− and in ruthenium red-treated lungs. Alveolar and perivascular edema were also significantly reduced in trpv4−/− lungs. Rapid calcium entry through TRPV4 channels is a major determinant of the acute vascular permeability increase in lungs following high PIP ventilation (Hamanaka et al., 2007). Interestingly, aquaporin-5 (AQP5), a water-permeable channel expressed in the lung, in the cornea, and in various secretory glands, is downregulated in hypotonic media. In mouse lung epithelial cells, the downregulation of AQP5 can be blocked by pharmacological inhibitors of TRPV4, suggesting that TRPV4 is involved in the water and osmolyte homeostasis in various epithelial cells of the lung (Sidhaye et al., 2006). 1.3.4.3 Skin TRPV4 is highly expressed in the skin and influences the epidermal permeability barrier. Skin forms a water-impermeable barrier and prevents transcutaneous water loss. A defect in barrier function often accompanies human diseases. Damage of the stratum corneum (e.g., by “tape stripping”) can impair the barrier function.. At temperatures from 36 to 40 °C, barrier recovery is accelerated in a hairless mouse model and in human skin. 4αPDD accelerates barrier recovery, whereas ruthenium red, a nonselective blocker of TRPV4, delays barrier recovery. Capsaicin, an activator of TRPV1, delayed barrier recovery, whereas capsazepin, an antagonist of TRPV1, blocked this delay. TRPV4 might be activated by osmotic pressure to fulfill the role of a sensor to restore skin barrier function (Denda et al., 2007). 1.3.4.4 Bone TRPV4 is expressed in chondrocytes and in osteoblasts. It also has been implicated in mechanosensing in bone. Mechanical stress determines the levels of bone mass. Hind limb unloading induces osteopenia in WT but not in TRPV4-deficient mice. Unloading induces an increase in the number of osteoclasts in the primary trabecular bone, which is suppressed by TRPV4 knockout. Unloading-induced reduction in the longitudinal length of primary trabecular bone is also suppressed by TRPV4 deficiency (Mizoguchi et al., 2008). 1.3.4.5 Bladder TRPV4 as a putative mechanosensor may also be involved in the regulation of the normal bladder voiding, since trpv4−/− mice manifest an incontinent phenotype (Gevaert et al., 2007). Cystometric experiments revealed that trpv4−/− mice exhibit a lower frequency of voiding contractions as well as a higher frequency of non-voiding contractions. Decreased stretchevoked ATP release occurs in isolated whole bladders from trpv4−/− mice. Thus, TRPV4 appears to play a role in voiding behavior and in urotheliummediated transduction of intravesical mechanical pressure. (Gevaert et al., 2007).
THE TRPV SUBFAMILY
19
Additionally, infusion of the potent TRPV4 agonist GSK1016790A into the bladders of trpv4+/+ mice induces bladder overactivity (Thorneloe et al., 2008). These data suggest that TRPV4 antagonists may be beneficial against bladder overactivity and may increase the storage volume of the bladder (Thorneloe et al., 2008). Interestingly, several families have been identified with nocturnal enuresis/ incontinence. Four linkages to chromosomal regions were described, two of which refer to the location of TRP channel genes, namely, trpc4 (13q13) and trpv4 (12q) (Loeys et al., 2002). 1.3.4.6 Hearing TRPV4 is expressed in the cochlea within hair cells, the stria vascularis, and the spiral ganglion (Liedtke et al., 2000). It has been proposed that TRPV4 is involved in sensorineural hearing impairment. Indeed, trpv4−/− mice, older than 24 weeks, demonstrate a higher hearing threshold as evaluated by the auditory brainstem response. TRPV4 might thus be associated with a delayed-onset hearing loss and with an increased cochlea vulnerability to acoustic injury (Tabuchi et al., 2005). One of the gene loci for autosomal dominant nonsyndromic hearing loss (ADNSHL) has been mapped to a small region in chromosome 12q21-24 where the trpv4 gene is located (Greene et al., 2001). The TRPV4 gene locus has also been discussed as the human ortholog of the region affected in the bronx waltzer (bw) mutant mice, which are characterized by waltzing behavior, deafness, and the loss of cochlear inner hair cells during early development. 1.3.5 TRPV5 and TRPV6 The Ca2+-selective channels, TRPV5 and TRPV6, seem to play an essential role in the maintenance of a constant extracellular Ca2+ concentration. The important role of TRPV5 and TRPV6 in the processes of transcellular Ca2+ reabsorption in the kidney and intestine is well established. TRPV5 is mainly expressed in the apical membrane of kidney distal convoluted tubule (DCT) and of connecting tubule (CNT) cells in the bone and intestine, whereas TRPV6 is widely expressed in the brush border of the apical membrane in the intestine but also in the kidney. An excellent review on the molecular and functional aspects of these channels has been published recently (Hoenderop and Bindels, 2008). trpv5−/− mice exhibit a diminished Ca2+ reabsorption in the kidney, which causes severe hypercalciuria. However, compensatory hyperabsorption of dietary Ca2+ was measured in trpv5−/− mice (Hoenderop et al., 2003). The urine from trpv5−/− mice is much more acidic than from WT animals, which might be a defense mechanism against kidney stone formation. TRPV5 dysfunction could also be involved in diseases such as osteoporosis (Hoenderop et al., 2003). A possible TRPV5 channelopathy is autosomal dominant idiopathic hypercalciuria (IH) (Muller et al., 2002). Although the coding sequence of the TRPV5 gene is not altered in this disease, three SNPs were detected in the
20
TRP CHANNELS AND HUMAN DISEASES
5′-flanking region. Inactivation of the trpv6 gene causes decreased intestinal Ca2+ reabsorption (Bianco et al., 2004). Some Ca2+-related disorders are associated with alterations in TRPV5 and/ or TRPV6 (van Abel et al., 2005): (1) Vitamin D deficiency rickets type I (VDDR-I): This autosomal recessive disease is characterized by low 1,25(OH)2D3 levels, hypocalcemia, rickets, osteomalacia, growth retardation, and failure to thrive. Both Ca2+ reabsorption channels, TRPV5 and TRPV6, are downregulated, which is consistent with a pathogenic role in this disease. (2) Postmenopausal osteoporosis: Estrogen has stimulatory effects on TRPV5 and TRPV6 expression. This type of osteoporosis is coupled to estrogen deficiency and decreased Ca2+ reabsorption via both channels. (3) IH: This autosomal disease is caused by either excessive intestinal Ca2+ reabsorption or defective renal Ca2+ reabsorption. Both forms of IH increase the risk of kidney stone formation. It is currently unknown whether mutations in either TRPV5 or TRPV6 are involved in the pathogenesis of this disorder. (4) Parathyroid hormone (PTH)-related disorders: Reduced serum PTH levels downregulate TRPV5 expression, which contributes to hypocalcemia. (5) Tacrolism: Immunosuppressant drugs, like tacrolimus, induce increased bone turnover with hypercalciuria. Renal Ca2+ wasting may be due to decreased TRPV5 expression (Nijenhuis et al., 2004). (6) Thiazide diuretics: These diuretics increase Ca2+ reabsorption and cause hypocalciuria. A similar phenotype occurs in mutations of the NCC leading to Gitelman’s syndrome. An upregulation of TRPV5 has been excluded in this disease (Nijenhuis et al., 2005b). However, an increased paracellular reabsorption of Ca2+ has been measured (Nijenhuis et al., 2003) and a clear downregulation of TRPM6 has been observed. The trpv6 gene was completely sequenced in 170 renal calcium stone patients. The ancestral trpv6 haplotype consisting of three non-synonymous polymorphisms (C157R, M378V, and M681T) occurred in significantly more calcium stone-forming patients than in the general population, which does not have the ancestral genotype. Expression of the mutated protein (157R + 378V + 681T) in Xenopus oocytes showed enhanced calcium permeability. Thus, the gain of function of TRPV6 might play a role in calcium stone formation (see also Hughes et al., 2008; Suzuki et al., 2008b). 1.3.5.1 Cancer TRPV5 and TRPV6 are both expressed in the prostate. Expression of TRPV6 is significantly increased in prostate adenocarcinoma in comparison to benign prostate hyperplasia. Moreover, expression levels of TRPV6 correlate with tumor grade (Peng et al., 2001; Wissenbach et al., 2001). TRPV6 expression is decreased by dihydrotestosterone and is conversely increased by an androgen receptor antagonist (Peng et al., 2001). Prostate carcinoma is a hormone-sensitive malignancy, and nonsteroidal antiandrogens, such as flutamide, are frequently used in prostate cancer treatment. Furthermore, estrogens, which are also used in the therapy of prostate cancer, positively regulate TRPV5 and TRPV6 expression. Hence, TRPV6 might be
THE TRPV SUBFAMILY
21
a molecular mediator involved in the anticancer effects of these compounds. The channel is consistently overexpressed not only in prostate cancer but also in breast, thyroid, colon, and ovarian carcinomas (Zhuang et al., 2002; Bolanz et al., 2008). Ca2+ entry through TRPV6 may increase the rate of Ca2+dependent cell proliferation and thus may be directly linked to tumor growth (Schwarz et al., 2006). It has to be noted that hormonal effects are more widespread than just modulating TRPV6 expression, which might exlain complex interaction patterns with tumor growth. 1.3.5.2 Age TRPV5 knockout mice develop age-related osteoporosis and hyperparathyroidism much earlier than WT mice (van Abel et al., 2006). Aging is associated with changes in Ca2+ homeostasis, which contribute to age-dependent osteoporosis and hyperparathyroidism. It has been recently shown that the impaired Ca2+ reabsorption in the elderly is caused by a downregulation of TRPV5 and TRPV6. 1.3.5.3 Placenta Function Maternal-fetal Ca2+ transport is crucial for fetal Ca2+ homeostasis and bone mineralization. The Ca2+ concentrations in fetal blood and amniotic fluid are significantly lower in trpv6−/− fetuses than in WT fetuses (Suzuki et al., 2008a). The transport activity of radioactive Ca2+ (45Ca) from mother to fetuses was 40% lower in trpv6−/− mice than in WT mice. It was recently proposed that cyclophylin B (CypB) is a novel TRPV6 accessory protein, which apparently has a stimulatory effect on TRPV6 channel activity. In the human placenta, TRPV6 and CypB are mainly located intracellularly in the syncytiotrophoblast layer, but a small amount of TRPV6 and CypB is also expressed in microvilli apical membranes, the feto-maternal barrier (Stumpf et al., 2008). 1.3.5.4 Skin Silencing of TRPV6 impairs cell differentiation, as shown by decreased expression of differentiation markers such as involucrin, transglutaminase-1, and cytokeratin-10. TRPV6 silencing also affects keratinocyte morphology, the development of intercellular contacts, and the ability of cells to stratify. 1,25-Dihydroxyvitamin D3, which is a well-known cofactor of keratinocyte differentiation, upregulates TRPV6, thereby increasing [Ca2+]i and promoting cellular differentiation (Lehen’kyi et al., 2007). 1.3.5.5 Hearing TRPV5 and TRPV6 are expressed in the inner ear (Yamauchi et al., 2005). The channels are likely required for maintaining the endolymph Ca2+ concentration in the μM range. pH-dependent inhibition of TRPV5 and TRPV6 might be responsible for the vestibular dysfunction in Pendred Syndrome due to endolymph acidification, which occurs by knocking out of the Cl − HCO3− exchanger SLC26A4 (pendrin) (Nakaya et al., 2007; Wangemann et al., 2007). Pendred syndrome is an inherited disorder that accounts for as much as 10% of hereditary deafness.
22
TRP CHANNELS AND HUMAN DISEASES
1.4 THE TRPM SUBFAMILY Members of the TRPM family, on the basis of sequence homology, fall into three subgroups: TRPM1/3, TRPM4/5, and TRPM6/7. TRPM2 and TRPM8 represent structurally distinct channels. TRPM channels exhibit highly variable permeability to Ca2+ and Mg2+, ranging from Ca2+-impermeable (TRPM4 and TRPM5) to highly Ca2+ and Mg2+ permeable (TRPM6 and TRPM7). In contrast to TRPCs and TRPVs, TRPMs do not contain ankyrin repeats within their N-terminal domain. The following reviews summarize the key features of the members of the TRPM subfamily (Aarts and Tymianski, 2005; Chubanov et al., 2005; Kraft and Harteneck, 2005; Kuhn et al., 2005; McNulty and Fonfria, 2005; Reid, 2005; Scharenberg, 2005). 1.4.1 TRPM1 1.4.1.1 Cancer TRPM1 is possibly a tumor suppressor. The melanocytespecific gene trpm1 is exclusively expressed in melanoma cells and is downregulated during the development of metastasis in cutaneous malignant melanoma. Malignant melanoma is a tumor developing from moles or normallooking skin, as well as in eyes and the meninges, and constitutes the most aggressive skin tumor (Duncan et al., 2001). The inverse correlation between TRPM1 transcript expression and metastatic potential represents one of the most reliable differential diagnostic markers to discriminate between nonmetastatic and metastatic melanomas. TRPM1 has at least five splice variants. A potential, but disputed, mechanism of the regulation of TRPM1 may involve a short cytosolic variant (TRPM1-S) binding to, or interacting with, the fulllength variant (TRPM1-L) to suppress its translocation to the plasma membrane. Upon a specific yet unidentified stimulus, TRPM1-S might dissociate from TRPM1-L and might enable plasma membrane insertion of the latter where subunit proteins can associate and form functional Ca2+ influx channels (Xu et al., 2001). This model suggests that retention of TRPM1-L in an intracellular compartment is critical in regulating Ca2+ influx. 1.4.2 TRPM2 1.4.2.1 Cardiovascular Blocking TRPM2 may represent a novel therapeutic approach to protect against oxidant-induced endothelial barrier disruption (Dietrich and Gudermann, 2008; Hecquet et al., 2008). H2O2 stimulates ADPribose formation, which activates TRPM2. Expression of TRPM2 increases endothelial permeability and endothelial dysfunction by oxidative stress. siRNA depleting of TRPM2 or antibody blocking of TRPM2 attenuates the increased endothelial permeability induced by H2O2 (Hecquet et al., 2008). 1.4.2.2 Cell Death TRPM2 activation is implicated in β-cell death after application of radicals, such as H2O2 (Ishii et al., 2006). TRPM2 is activated
THE TRPM SUBFAMILY
23
by ROS, and its activation induces necrotic cell death. Insertion of TRPM2 into A172 human glioblastoma cells enhances cell death induced by H2O2. Proliferation, migration, and invasion activities were not affected by the expression of TRPM2 (Ishii et al., 2007). Death of hematopoietic cells through activation of caspases and poly (ADP-ribose) polymerase (PARP) cleavage might also be mediated by TRPM2 (Zhang et al., 2005). 1.4.2.3 Immunology and Inflammation TRPM2 is highly expressed in granulocytes and cells of the monocytic lineage, including macrophages (Perraud et al., 2004). When such cells are exposed to oxidative stress and become activated, they produce ROS in a process known as the respiratory burst. An involvement of ROS in the fight against invading pathogens has been postulated (Babior, 2000). Ca2+ signaling via TRPM2 could play an important role during this process: activation of TRPM2 by ROS induces Ca2+ entry, which in turn potentiates activation of this channel, leading to a positive feedback mechanism. Similar to the situation in lymphocytes, the oxidantinduced activation of the transcription factors NF-kB and AP-1 is thought to be of importance in the production of cytokines in macrophages (Iles and Forman, 2002). ROS induce chemokines responsible for the recruitment of inflammatory cells to sites of injury or infection. Recently, it has been shown that TRPM2 controls ROS-induced chemokine production in monocytes. ROS evoke Ca2+ influx through TRPM2, which subsequently activates the Ca2+-dependent tyrosine kinase Pyk2 and amplifies Erk signaling via Ras GTPase. This causes nuclear translocation of NFκB, which is essential for the production of the chemokine interleukin-8. This mechanism is impaired in TRPM2-deficient mice (Yamamoto et al., 2008). 1.4.2.4 Neurological Disorders The pathophysiology of bipolar disorder has been connected to a variety of TRP channels. TRPM2 is expressed in several human tissues, and abundantly so in the brain, lymphocytes, and hematopoietic cells (Nagamine et al., 1998; Sano et al., 2001; Heiner et al., 2003). A truncated variant of TRPM2 is expressed in the striatum (i.e., caudate nucleus and putamen) (Nagamine et al., 1998; Uemura et al., 2005). Both TRPM2 and TRPM7 have been directly implicated in neuronal cell death pathways and have been proposed as potential factors in neurodegenerative diseases including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, stroke, and diseases associated with oxidant-mediated neuronal damage (Li et al., 2004, 2005a; McNulty and Fonfria, 2005). For instance, inhibition of TRPM2 by the selective poly(ADP-ribose) polymerase inhibitor SB-750139 (GlaxoSmithKline) attenuates hydrogen peroxide and amyloid β-peptide-induced cell death in rat striatum neurons (Fonfria et al., 2005). This may suggest a direct involvement of TRPM2 in Alzheimer’s disease. The role of TRPM2 in neuronal cell death seems to be evident. TRPM2 expression is elevated in a rat stroke model. It is localized in microglial cells, which play a key role in pathology produced following ischemic injury in the CNS (Fonfria et al., 2006).
24
TRP CHANNELS AND HUMAN DISEASES
TRPM2 might be involved in bipolar disorder I (BD-I) and bipolar disorder II (BD-II). A putative susceptibility locus of BD-I is within the chromosomal regions 12q23–q24.1, which encodes the Ca2+-ATPase, SERCA, and 21q22.3, to which the TRPM2 gene has been mapped (Straub et al., 1994; Aita et al., 1999; Liu et al., 2001). In addition to these findings, it has been shown that SNPs in the promoter region of TRPM2 are significantly associated with BD-II, suggesting that TRPM2 polymorphisms contribute to the risk for BD-II (Xu et al., 2006). Recently, a very interesting pathology has been described in more detail, that is, Guamanian amyotrophic lateral sclerosis (ALS-G) and Parkinsonism dementia (PD-G or Parkinsonism dementia complex [PDC]). These are related neurodegenerative disorders that are found at a relatively high incidence on the Pacific Islands Guam and Rota (Plato et al., 2002). The hyperendemic ALS-G/PDC foci in the Western Pacific (including Guam) have been extensively studied over the years. Results of these studies suggest that a complex interaction between genetic predisposition and environmental factors is involved. However, the etiology of these disorders remains elusive (Plato et al., 2003). Recent work has proposed TRPM2 and TRPM7 as candidate susceptibility genes (Hermosura et al., 2005, 2008). The trpm2 gene is located on chromosome 21 (21q22.3), which has been associated with familial ALS (Rosen et al., 1993). Recently, a heterozygous variant of trpm2 in a subset of ALS-G and PDC cases has been identified. This variant, TRPM2P1018L, produces a missense mutation in the channel protein, changing proline 1018 (Pro1018) to leucine (Leu1018). Functional studies using a heterologous expression system revealed that, unlike WT TRPM2, P1018L channels rapidly inactivate and are unable to maintain sustained ion influx (Hermosura et al., 2008). 1.4.3 TRPM3 TRPM3 is expressed in the kidney, brain, pancreas, testis, and spinal cord. The gene is transcribed in at least 12 splice variants (Grimm et al., 2003; Lee et al., 2003; Oberwinkler et al., 2005), which have been shown to be functionally distinct (Oberwinkler et al., 2005). Importantly, TRPM3 has now been indentified as a steroid-modulated channel; for example, pregnenolone sulfate activates the channel. In addition, TRPM3 is highly expressed in the pancreas and may play an important role in insulin release (Nilius and Voets, 2008; Wagner et al., 2008). 1.4.4 TRPM4 and TRPM5 TRPM4 and TRPM5 represent the only known TRP channels that are directly gated by elevated [Ca2+]i. Both TRPM4 and TRPM5 are essentially impermeable to Ca2+ but form ion channels permeable to monovalent cations with single-channel conductances of approximately 20–25 pS. They are depolariz-
THE TRPM SUBFAMILY
25
ing channels that reduce the inward driving force for Ca2+. TRPM4 proteins are detected in the following: heart, pancreas, intestine, lung, thymus, uterus, vomeronasal organ, brain, fat tissue, adrenal gland, kidney, spleen, cultured aortic endothelial cells, and bone marrow-derived mast cells (Vennekens and Nilius, 2007). TRPM5, which is expressed in taste receptor cells, is a downstream depolarizing signal transducer of G protein-coupled receptors in taste buds. TRPM5 appears to be important, though not indispensible, for the transduction of sweet, amino acid, and bitter stimuli (Perez et al., 2002; Zhang et al., 2003; Damak et al., 2006). 1.4.4.1 TRPM4 in Immune Cells TRPM4 exerts control over [Ca2+]i in mast cells by maintaining a relatively depolarized membrane potential, which limits the driving force for Ca2+ entry (Vennekens and Nilius, 2007; Vennekens et al., 2007). trpm4−/− bone marrow-derived mast cells activate a larger Ca2+ entry after FcεI stimulation than trpm4+/+ mast cells and release more histamine, leukotrienes, and tumor necrosis factor. trpm4−/− mice also exhibit a more severe IgE-mediated acute passive cutaneous anaphylactic response. These results may suggest a new mechanism of allergic hypersensitivity and may provide a new therapeutic target (Vennekens and Nilius, 2007; Vennekens et al., 2007). A similar mechanism may regulate Ca2+ oscillations after T-lymphocyte activation, which is required for NFAT-dependent interleukin-2 (IL-2) production (Launay et al., 2004). However, it is unclear whether TRPM4 is actually expressed in T cells (Vennekens and Nilius, 2007; Vennekens et al., 2007). Nevertheless, it seems likely that defects in the function of TRPM4 will result in the inappropriate release of cytokines, triggering immunological hyperresponsiveness, proinflammatoty conditions, or allergy. 1.4.4.2 Cardiovascular TRPM4-like currents have been observed in many tissues, including cardiomyocytes (Guinamard et al., 2004a,b). TRPM4 is overexpressed in cardiomyocytes from spontaneously hypertensive rats, which also show cardiac hypertrophy, kidney sclerosis, and increased bone calcification and are characterized by cardiac arrhythmias caused by delayed afterdepolarization. TRPM4-like channels may be involved in the myogenic constriction response in small arteries (Bayliss effect) (Earley et al., 2004). Alteration of the arterial myogenic response associated with stroke causes cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) (Folgering et al., 2008). TRPM4 may also affect blood vessel tone indirectly by virtue of its expression in the endothelium. Agonist stimulation of endothelial cells activates a nonselective cation channel with characteristics similar to those of TRPM4 (Suh et al., 2002). This channel is regulated by NO and ATP. NO donors such as S-nitroso-N-acetylpenicillamine (SNAP) and 3-morpholinosydnonimine (SIN-1) inhibit TRPM4. Inhibitors of NO synthases potentiate the TRPM4like current, whereas superoxide dismutase (SOD), which inhibits the breakdown of NO, causes inhibition. This mechanism indicates a role for TRPM4
26
TRP CHANNELS AND HUMAN DISEASES
in sensing the metabolic state of the cell and NO in endothelial cells (Suh et al., 2002). 1.4.4.3 Neurological Disorders An intriguing function for TRPM4 can be proposed based on experiments in which the GABA receptor antagonist bicuculline was employed to initiate spontaneous epileptic activity in neocortical slices. TRPM4-like channels are activated during paroxysmal depolarization shift (PDS) discharges and appear to play a role in maintaining subsequent sustained after-depolarization waveforms. The latter effect depends on an increase in [Ca2+]i and can be blocked by maneuvers that inhibit TRPM4 (Schiller, 2004). Neuronal damage evoked by reduced blood supply to the brain (“vascular stroke”), which induces severe hypoxia and hypoglycemia, is very often accompanied by a phenomenon in which susceptible neurons slowly lose their membrane potential and then suddenly enter a transient state of complete depolarization, known as spreading depression (SD)-like hypoxic depolarization. SD is associated with an increase in [Ca2+]i. Intriguingly, TRPM4 (and TRPM5) could be a candidate for triggering this dramatic event, although there is at present no direct experimental evidence in support of this conjecture (Somjen, 2001; Anderson and Andrew, 2002). It is also worthwhile mentioning that activation of a current with features reminiscent of TRPM4 is involved in the generation of slow (<1 Hz) sleep oscillations (Crunelli et al., 2005). Another example that hints at a contribution of TRPM4 in the pathogenesis of brain swelling during stroke is the discovery in hypoxic gliotic tissue of a nonselective Ca2+-activated channel (NCCa-ATP) that also opens under conditions of [ATP]i depletion (Chen and Simard, 2001; Simard and Chen, 2004). This channel, which shares many properties with TRPM4 (i.e., single-channel conductance, concentration range of activation by [Ca2+]i, submicromolar block by ATP, and voltage-dependent open probability), is found in astrocytes in the adult brain and is regulated by sulfonylurea receptor 1 (SUR1), similar to the KATP channel (Chen et al., 2003). Activation of NCCa-ATP causes complete membrane depolarization and cell swelling in astrocytes from injured brains (Chen and Simard, 2001; Simard and Chen, 2004). Many diseases in the brain, including traumatic conditions, edema, ischemia, and stroke are exacerbated by cerebral edemas. Importantly, these events induce an upregulation of NCCa-ATP (Simard et al., 2006). Cerebral edema after occlusion of the middle cerebral artery (MCA) stroke is responsible for a high mortality of ∼80% of the patients (Ayata and Ropper, 2002). Edemas in MCA stroke are paralled by an increased expression of the SUR1 driven by an upregulation of the transcription factor Sp 1. Glibenclamide attenuates the development of cerebral edema by MCA stroke. It would be interesting to determine whether TRPM4 is indeed the channel regulated by SUR1 and involved in the pathogenesis of cerebral edemas. If so, TRPM4 might provide a new and promising therapeutic approach to stroke. The trpm5 gene maps to the chromosomal area 11p15.5 (Prawitt et al., 2000). A genetic disorder involving a loss of imprinting in this region is the
THE TRPM SUBFAMILY
27
Beckwith–Wiedemann syndrome (BWS), a disease that is mainly characterized by exomphalus, macroglossia, gigantism, and taste abnormalities. Moreover, BWS patients also demonstrate a strong predisposition for neoplasias, especially for Wilms tumor and the aggressive rhabdomyosarcomas. Therefore, it seems likely that this area contains at least one gene with oncogenic potential and/or a tumor suppressor gene, and impairment in their function, or regulation, will potentially result in disease development. A possible connection between gain-of-function TRPM5 and BWS is anticipated. So far, no mutations in the TRPM5 gene that relate to BWS are known. Interestingly, possibly affected genes are insulin-like growth factor 2 (IGF2), cyclin-dependent kinase inhibitor 1C (CDKN1C), cyclin-dependent kinase inhibitor p21 (p21CIP1), KCNQ1OT1 (potassium channel KCNQ1), and ZNF215 (putative transcription factor), which are located in the same chromosomal region. Such a complex situation might be expected also for other TRPs, which are involved in syndromic diseases. Interestingly, BWS patients have persistent hypoglycemia and hyperinsulinism, features that are similar to diseases caused by mutations in the SUR1 subunits of the KATP channel, which is crucial in glucose-regulated insulin release (Fournet et al., 2001; Munns and Batch, 2001). Because TRPM5 is highly expressed in pancreatic β cells (Prawitt et al., 2003), it is tempting to hypothesize that the TRPM5 channel plays a unique regulatory role in islet β-cell function. It can be assumed that the upregulation of insulin secretion has an oncogenic potential indicating a possible connection between functional TRPM5 and BWS that has not yet been discovered. It remains to be shown whether TRPM5 might play a role in dysfunction of insulin secretion. 1.4.5 TRPM6 TRPM6 and TRPM7 (see below) combine channel and enzymatic activities (“chanzymes”) and are involved in Mg2+ homeostasis. TRPM6 is highly expressed in the kidney and in the intestine, specifically in association with the apical membrane of the DCT and the brush border membrane, respectively (Voets et al., 2004). TRPM6 constitutes a cation channel with high permeability to Mg2+, and to a lesser extent Ca2+. TRPM6 functions as a homotetramer, but also as a heterotetramer in association with TRPM7 (Li et al., 2006). An atypical serine/threonine protein kinase (α-kinase family) is common to the C-terminal domains of TRPM6 and TRPM7 and is subject to autophosphorylation (Runnels et al., 2001; Schmitz et al., 2003). 1.4.5.1 TRPM6 in the Kidney and in the Intestine The trpm6 gene has been mapped to chromosome 9q21.13, an area identified as the “hypomagnesemia with secondary hypocalcemia (HSH)-critical region.” Defects in this chromosomal locus have been associated with the disease HSH (Schlingmann et al., 2002; Walder et al., 2002). HSH is an autosomal recessive disorder that is characterized by very low serum levels of Mg2+ and Ca2+. The primary defect
28
TRP CHANNELS AND HUMAN DISEASES
is an impaired intestinal Mg2+ absorption. The defect in intestinal transport distinguishes HSH from all other known forms of hereditary hypomagnesemia. Detailed analysis of the HSH-critical region revealed a variety of mutations in the trpm6 gene in all tested HSH patients. Most mutations resulted in a truncated protein through the introduction of stop codons, although single point mutations, frame shift mutations, exon deletions, and mutations affecting alternative splicing have also been described (Schlingmann et al., 2002, 2005; Walder et al., 2002). Recently, a new missense mutation was described, which is located in the pore region of TRPM6, P1017R. Because neither surface expression of TRPM6 nor hetereomerization with TRPM7 is affected, the disease-causing mechanism seems to be a defect in the channel pore (Chubanov et al., 2007). Intestinal Mg2+ uptake in the brush border epithelia occurs in a curvilinear manner and is regulated by two independent pathways: (1) passive paracellular absorption, which rises linearly with increasing luminal Mg2+ concentrations, and (2) transcellular transport, driven by secondary active transport, reaching saturation at high luminal Mg2+ levels (Konrad et al., 2004). TRPM6 represents an essential molecular component of the active transcellular Mg2+ uptake, being the Mg2+ influx channel at the apical membrane (Voets et al., 2004). Saturation at high luminal Mg2+ concentrations is necessary to prevent the cell from becoming overloaded with Mg2+. This feedback mechanism is provided by TRPM6 itself, which is highly regulated by the intracellular concentration of Mg2+ (Voets et al., 2004). On the basolateral aspect of the epithelial cell, a yet unidentified Na+/Mg2+ exchanger accounts for onward transport of Mg2+ into the interstitial space and blood. The situation in the distal convoluted tubule (DCT) cells of the nephron is different. Although most reabsorption of Mg2+ in the nephron occurs via a paracellular pathway in the thick ascending limb of the loop of Henle, it is the DCT that determines the final reabsorption of filtered Mg2+ from the lumen to the blood and thus the final urinary Mg2+ excretion. In the DCT, paracellular transport of Mg2+ does not occur, and TRPM6, located on the apical membrane of the epithelial cells, is the obligate pathway for the active reabsorption of Mg2+. If this pathway is defective, as in HSH, no further Mg2+ can be reabsorbed, resulting in the urinary Mg2+ leak that has often been observed in HSH patients. Apart from HSH, TRPM6 has also been shown to play a critical role in the etiology of isolated autosomal recessive renal hypomagnesemia. A homozygosity-based mapping strategy in affected patients led to the identification of a chromosomal area containing the EGF gene. Subsequent work showed that a single mutation in this gene (P1070L) is responsible for the development of this disease (and actually established for the first time EGF as a magnesiotropic hormone). The mutation causes mislocation of pro-EGF at the basolateral membrane of the DCT cell, resulting in reduced EGF production at the basolateral membrane, reduced activation of EGFR, and, through an unknown mechanism, reduced TRPM6 activity. This ultimately results in Mg2+ wasting through the urine (Groenestege et al., 2007; Muallem and Moe, 2007).
THE TRPM SUBFAMILY
29
1.4.6 TRPM7 The closest relative of TRPM6 is TRPM7 (Nadler et al., 2001; Runnels et al., 2001). In contrast to the rather restricted expression pattern of TRPM6, TRPM7 is ubiquitously distributed. TRPM7 provides an ion channel pathway for Mg2+ and Ca2+ entry into cells and is also responsible for trace metal ion uptake (Monteilh-Zoller et al., 2003). Mg2+ influx through TRPM7 is indispensable for cellular viability. Targeted deletion of TRPM7 in DT-40 chicken B lymphocytes causes rapid cell growth arrest followed by cell death within 2–3 days (Nadler et al., 2001). However, viability can be maintained and the arrest of cell proliferation reversed by supplementation of the culture medium with excess Mg2+ (>10 mM) or by reintroduction of WT, or functional mutants, of TRPM7 (Nadler et al., 2001; Schmitz et al., 2003). An intriguing potential mechanism is a downregulation of the G1-S transition in the cell cycle (Wolf and Cittadini, 1999). 1.4.6.1 Cardiovascular A novel role for TRPM6 and TRPM7 in vascular dysfunction has recently been proposed. It is well documented that increased [Mg2+]i in VSMCs causes vasodilation and reduces agonist-induced vasoconstriction. By contrast, low [Mg2+]i contributes significantly to increased vascular tone, enhanced responses to vasoconstrictors, defective vasodilation and vascular remodeling, and elevated blood pressure (Touyz, 2003). Increased [Mg2+]i is also involved in cell cycle activation and growth of VSMCs (Touyz and Yao, 2003). The influence of [Mg2+]i on VSMCs appears to be tightly connected to Mg2+ influx via TRPM7 (He et al., 2005). Both ATII and aldosterone increase TRPM7 expression (He et al., 2005; Sontia et al., 2008). Long-term ATII application results in an increase in [Mg2+]i and in the growth of VSMC, which are attenuated when TRPM7 is knocked down. Furthermore, [Mg2+]i is significantly reduced in VSMCs isolated from spontaneous hypertensive rats (SHR), in parallel with a significantly reduced TRPM7 expression, in comparison to normotensive Wistar Kyoto (WKY) rat controls (Touyz et al., 2005). These results suggest an important role for TRPM7 in blood pressure regulation and in VSMC growth. 1.4.6.2 Neurological Disorders TRPM7 has been put forward as a potential factor in neurodegenerative diseases including Alzheimer’s disease, ALS, Parkinson’s disease, and stroke (McNulty and Fonfria, 2005). Earlier, we mentioned ALS-G and PD-G (see under TRPM2) (Plato et al., 2002, 2003). A TRPM7 missense mutation, T1482I, which is located between the channel and the kinase domain, has been described in a subgroup of both ALS-G and PD-G patients (Hermosura et al., 2005). The T1482I mutant has no detectable alteration in α-kinase activity but has an increased sensitivity to inhibition by intracellular Mg2+ within a physiologically relevant range. It is known that the incidence of both ALS-G and PD-G is increased in environments, such as in the west Pacific, that are deficient in Ca2+ and Mg2+. Therefore, increased
30
TRP CHANNELS AND HUMAN DISEASES
sensitivity of TRPM7 to inhibition by Mg2+ could even worsen the Mg2+ homeostasis in a Mg2+-deficient environment, leading to a reduced intracellular Mg2+ concentration (Schmitz et al., 2003; Hermosura et al., 2005). Although both ALS-G and PD-G have a multifactorial etiology, the functional changes of the missense mutations may hint at a contribution of TRPM7 malfunction, that is, a channelopathy, to the pathogenesis of both neurodegenerative diseases (Hermosura et al., 2005). TRPM7 plays a universal role in Mg2+ homeostasis associated with basic cellular metabolism and activities such as cell viability and proliferation. Cases of anoxic neuronal death have been described that include the involvement of TRPM7 in cellular damage due to an imbalance of the normal physiological processes (Aarts et al., 2003; Wei et al., 2007). In situations of brain ischemia, oxygen–glucose deprivation (OGD) and excitotoxicity mediate neuronal death (Aarts and Tymianski, 2005). The key processes involve high Ca2+ influx as a consequence of the excitotoxicity. Subsequent production of ROS/reactive nitrogen species consecutively activates another Ca2+ conductance, named IOGD, which is mediated by TRPM7, and results in cellular Ca2+ overload and cell death. In models of ischemic stroke (oxygen and glucose deprivation, NaCN chemical anoxia), the activation of NMDA receptors (NMDA-R) provides a route for toxic Ca2+ influx, but TRPM7 probably provides an additional pathway (Macdonald et al., 2006). TRPM7 is activated by products of nNOS (free radicals, ROS) and by transient depletion of extracellular Ca2+ and Mg2+ (e.g., by a decrease in [Mg2+]i). In addition, depolarization by TRPM7 activation will relieve voltage-dependent block of NMDA-R by Mg2+, inducing a positive feedback on NMDA-R-mediated Ca2+ entry (for a detailed review, see Macdonald et al. [2006]). 1.4.6.3 Immunodefense Mg2+ is also essential for the normal functioning of the immune response, suggesting a potential role of TRPM7 (and TRPM6). Mg2+ deficiency affects the immune system, for example, by causing a decrease in serum IgA and IgG levels (Zimowska et al., 2002; Perraud et al., 2004) Under conditions of inflammation, Mg2+ deficiency leads to an exacerbated immune stress response and to a decrease of specific immune responses (Petrault et al., 2002). 1.4.7 TRPM8 TRPM8 is widely expressed with high levels in sensory neurons, but also in the bladder and in the prostate (Andersson et al., 2004; Bandell et al., 2004; Stein et al., 2004; Zhang and Barritt, 2004; Tsukimi et al., 2005). TRPM8 is activated by cooling (<22–26 °C) and by pharmacological agents evoking a “cool” sensation, such as (-)-menthol and the “supercooling” agent, icilin (McKemy et al., 2002; Peier et al., 2002; Xu et al., 2002). Structurally diverse agents that act as antagonists, or blockers, of TRPV1, namely, BCTC, CPTC,
THE TRPM SUBFAMILY
31
capsazepine, and ruthenium red, also suppress the activation of TRPM8 (Weil et al., 2005; Liu et al., 2006). 1.4.7.1 Pain TRPM8 has been implicated in cool sensation and cold pain by recent knockout mouse studies. TRPM8 appears to exert a novel analgesic gating control over noxious inputs in chronic pain states (Fleetwood-Walker et al., 2007). In vivo activation of TRPM8 with cutaneous or intrathecal application of menthol or icilin produces a profound analgesic effect in chronic pain models. Activation of TRPM8 causes the release of glutamate from a subpopulation of DRG neurons, which affects group II/III metabolic glutamate receptors in dorsal horn neurons or in presynapses of DRG neurons in an inhibitory fashion, and results in an analgesic effect (Proudfoot et al., 2006). L5 DRG sections from rats with chronic constrictive nerve injury (CCI) show increased expression of TRPM8. Ca2+ flux and ion currents induced by cold and menthol are increased in these studies. These changes occur in capsaicin-sensitive neurons, a subpopulation of nociceptive-like neurons. The gain of TRPM8-mediated cold sensitivity on nociceptive afferent neurons provides a mechanism of cold allodynia (Xing et al., 2007). In mice expressing a genetically encoded axonal tracer in TRPM8 neurons, it has been shown that TRPM8 neurons have the neurochemical hallmarks of both C- and Aδfibers (afferent markers IB4, NF200, peripherin), and presumptive nociceptors and non-nociceptors. TRPM8 axons diffusely innervate the skin and oral cavity, terminating in peripheral zones that contain nerve endings mediating distinct perceptions of innocuous cool, noxious cold, and first- and second-cold pain. Cold temperatures generate a variety of distinct sensations that range from pleasantly cool to painfully aching, prickling, and burning. Pulpal fibers perceive cold allodynia via TRPM8 sensitization. CCI is a neuropathic pain model, which is characterized by cold allodynia in the hind limbs. The cold allodynic response was significantly reduced by capsazepine, which is a blocker for both TRPM8 and TRPV1. Cold fibers, caused by the diverse neuronal context of TRPM8 expression, use a single molecular sensor to convey a wide range of cold sensations (Takashima et al., 2007). 1.4.7.2 Respiratory A functional, but truncated, TRPM8 variant is expressed in human bronchial epithelial cells. Activation of the TRPM8 variant in lung cells is coupled with enhanced expression of the inflammatory cytokines IL-6 and IL-8. This may partially explain the asthmatic respiratory hypersensitivity to cold air (Sabnis et al., 2008). Breathing cold air induces strong respiratory autonomic responses, including cough, airway constriction, and mucosal secretion. Such a situation can be dangerous in asthmatics and can directly trigger an asthma attack. This cold-induced respiratory response is caused through an autonomic nerve reflex via vagal afferent nerves expressing TRPM8. Thus, TRPM8 contributes to cold-induced exacerbation of asthma and other pulmonary disorders (Xing et al., 2008).
32
TRP CHANNELS AND HUMAN DISEASES
1.4.7.3 Bladder An intriguing example of the possible role of TRPM8 in bladder function has recently been postulated (Tsukimi et al., 2005; Jiang et al., 2008), although experimental observations suggesting such a role date back to the early 1990s (Lindstrom and Mazieres, 1991). Filling of the bladder with ice-cold water induces a rapid detrusor reflex and voiding in patients with supraspinal lesions, but these effects do not occur in patients with peripheral lesions or in normal subjects. Experimental studies have revealed that the bladder cooling reflex originates from TRPM8 receptors in the bladder wall (Mukerji et al., 2006). In cats (Lindstrom and Mazieres, 1991), guinea pigs (Tsukimi et al., 2005), and rats (Nomoto et al., 2008), inclusion of menthol within an intravesicular infusion of cold saline greatly facilitates the detrusor reflex, presumably by sensitization of TRPM8. Indeed, Lindstrom and Mazieres (1991) commented with great prescience that “[the effect of menthol] could be described as a shift of the temperature-response curve for the cooling reflex towards higher temperatures.” The bladder specimens from patients with painful bladder syndrome (PBS) and idiopathic detrusor overactivity (IDO), but not asymptotic microscopic hematuria, show marked increases in the number of TRPM8 immuoreactive sensory nerve fibers of small caliber, in the absence of any change in urothelial TRPM8 immunoreactivity. Thus, TRPM8 may provide a novel target for painful and overactive bladder diseases (Mukerji et al., 2006). 1.4.7.4 Cancer It has been convincingly shown that significant differences exist in the level of expression of TRPM8 between malignant and nonmalignant prostate. TRPM8 is a much more specific marker for prostate cancer than other markers (prostate-specific antigen [PSA], kallikrenin 2 [hK2], or prostate stem cell antigen [PSCA]) (Fuessel et al., 2003). In the androgenresponsive prostate epithelial cell line (LNCaP), TRPM8 localizes to the endoplasmic reticulum and the plasma membrane, and TRPM8 has been reported to form a Ca2+-permeable channel at both locations (Zhang and Barritt, 2004). However, in another study performed on LNCaP cells, TRPM8 was found to be largely restricted to the endoplasmic reticulum and to function as an SOC (Thebault et al., 2005). In any case, TRPM8 regulates Ca2+ homeostasis in prostate epithelial cells and is required for cell survival, thus defining a potential drug target in the management of prostate cancer. (Zhang and Barritt, 2004; Thebault et al., 2005). Sustained activation of TRPM8 by menthol, however, induces cell death in the LNCaP cell line (Zhang and Barritt, 2004). Moreover, expression of TRPM8 appears to be lost as prostate tumors progress to androgen independence and to more severe diseases (Henshall et al., 2003). TRPM8 is also expressed in human melanoma cells. The viability of melanoma cells is apparently decreased, in a dose-dependent fashion, by the TRPM8 activator menthol. TRPM8 may be involved in mechanisms underlying tumor progression and may represent a novel target of drug development for malignant melanoma. (Yamamura et al., 2008).
TRPA
33
Finally, the trpm8 gene may be a promising candidate for gene therapy for cancer. One extracellular region in TRPM8, GLMKYIGEV, has been identified as an activating domain for cytotoxic T lymphocytes (Kiessling et al., 2003). Thus, TRPM8 may provide an endogenous defense mechanism against cancer growth (for a detailed review, see Zhang and Barritt [2006]). It has been shown that TRPM8 is expressed in neuroendocrine tumors (NET). Ca2+ influx via TRPM8 regulates the secretion of neurotensins from such tumor cells. This regulation of neurotransmitter secretion in NETs by TRPM8 may have a potential clinical implication in the diagnosis or therapy of cancer (Mergler et al., 2007).
1.5 TRPA The TRPA family currently comprises one mammalian member, TRPA1, which is expressed among others in DRG and trigeminal neurons, in hair cells (Story et al., 2003; Corey et al., 2004; Nagata et al., 2005), and in vagal sensory nerves innervating the airways (Brooks, 2008; Nassenstein et al., 2008). TRPA1 exhibits 14 NH2 terminal ankyrin repeats (Story et al., 2003), an unusual structural feature that is relevant to a proposed mechanosensory role of the channel (Nagata et al., 2005). Initial reports (Story et al., 2003; Bandell et al., 2004) claimed TRPA1 to be activated by noxious cold (<17 °C), although such a mode of stimulation has subsequently been disputed (Jordt et al., 2004; Nagata et al., 2005; Bautista et al., 2006). Initially identified chemical activators of TRPA1 include isothiocyanates (the pungent compounds in mustard oil [MO], wasabi, and horseradish) (Bandell et al., 2004; Jordt et al., 2004), methyl salicylate (in winter green oil) (Bandell et al., 2004), cinnamaldehyde (CA) (in cinnamon) (Bandell et al., 2004), allicin and diallyl disulfide (in garlic) (Macpherson et al., 2005; Bautista et al., 2006), acrolein (an irritant in exhaust fumes and tear gas) (Bautista et al., 2006), and Δ9 tetrahydrocannabinol (Δ9THC, the psychoactive compound in marijuana (Jordt et al., 2004) (for a more detailed review, see McMahon and Wood [2006]). TRPA1 is now considered as a universal chemosensor. Electrophilic compounds activate TRPA1 through covalent modification of cysteine residues in the N-terminus of TRPA1 (Hinman et al., 2007; Macpherson et al., 2007; Andersson et al., 2008). In addition, formaldehyde, which is commonly used to induce experimental chemical pain, activates TRPA1 channels. The endogenous aldehyde 4-hydroxynonenal (4-HNE; an α,β-unsaturated aldehyde that accumulates in membranes during inflammatory or oxidative stress), 15dPGJ2, and other prostaglandins activate TRPA1 (Trevisani et al., 2007; Tai et al., 2008). 4-HNE is produced by lipid peroxidation in cells following inflammation or tissue injury. At higher concentrations, 4-HNE induces apoptosis and necrosis, and is involved in Alzheimer’s disease, cataracts, atherosclerosis, and cancer. Importantly, it has recently been established that menthol is also a TRPA1 activator, confounding conclusions
34
TRP CHANNELS AND HUMAN DISEASES
from previous studies that used menthol as a TRPM8-specific stimulus (Karashima et al., 2007). 1.5.1 TRPA1 1.5.1.1 Pain TRPA1 has been implicated in several forms of pain sensation, including inflammatory pain (thermal and mechanical hyperalgesia), neuropathic pain, mechanical pain (Bautista et al., 2006; Frederick et al., 2007), pungent pain caused by chemical agents, for example, MO and tear gas (Bautista et al., 2006; McMahon and Wood, 2006; Albin et al., 2008; Brône et al., 2008) and even hangover pain (Bang et al., 2007). Recent results obtained with two independent trpa1−/− mouse models (Bautista et al., 2006; Kwan et al., 2006) underscore an important role for TRPA1 in the pain response to endogenous inflammatory mediators and to diverse exogenous irritants, including MO, acreolin in tear gas (and a metabolite of cyclophosphamide and fosfamide, which are widely used chemotherapeutic agents), and allicin from garlic and onions. In WT mice, topical application of MO constitutes an acute noxious stimulus and evokes neurogenic inflammation causing thermal and mechanical hyperalgesia. By contrast, in trpa1−/− mice, the acute effects of MO (e.g., paw licking and flinching) are abolished (Bautista et al., 2006) or reduced (Kwan et al., 2006), and hypersensitivity is either absent (Bautista et al., 2006) or blunted (Kwan et al., 2006). Of considerable significance, the algesic peptide bradykinin activates TRPA1 in a G protein-dependent manner (Bandell et al., 2004), and in trpa1−/− mice, the development of hyperalgesia in response to injections of bradykinin is greatly reduced (Bautista et al., 2006; Kwan et al., 2006). TRPA1 has also been linked to cold hyperalgesia, a symptom of inflammatory and neuropathic pain. Inflammation and nerve injury both increase the expression of TRPA1 (and TRPV1) in DRG and in trigeminal neurons without affecting the abundance of TRPM8 (Katsura et al., 2006; Diogenes et al., 2007). Such overexpression appears to be driven by NGF engaging the p38 mitogen-activated protein kinase (MAPK) pathway (see Mizushima et al., 2006), and also involves ERK5 (Katsura et al., 2007). TRPA1 appears to contribute to injury-induced cold hyperalgesia since TRPA1 knockdown by siRNA strategies suppresses cold hyperalgesia in a rat nerve injury model (Obata et al., 2005). Therefore, TRPA1 may represent a new target for treatment of cold hyperalgesia caused by inflammation and by nerve damage. Some (allegedly) specific compounds have been shown to reduce pain behaviors in mice. For instance, a specific small-molecule TRPA1 inhibitor (AP18) can reduce CA-induced nociception in vivo. AP18 can also reverse complete Freund’s adjuvant (CFA)-induced mechanical hyperalgesia in mice. Although TRPA1-deficient mice develop normal CFA-induced hyperalgesia, AP18 is ineffective in the knockout mice, consistent with an on-target mechanism (Petrus et al., 2007). Probably, compensatory mechanisms may account for the normal hyperalgesia in TRPA1-deficient mice; for example, TRPV4 upregulation would be an intruiging candidate (Petrus et al., 2007). Also, the
TRPA
35
cannabinoid agonists R-(+)-(2,3-dihydro-5-methyl-3-[(4-morpholinyl)methyl] pyrol[1,2,3-de]-1,4-b enzoxazin-6-yl)-(1-naphthalenyl) methanone mesylate [WIN 55,212-2 (WIN)] and (R,S)-3-(2-iodo-5-nitrobenzoyl)-1-(1-methyl-2piperidinylmethyl)-1H-indole (AM1241) exert peripheral antihyperalgesia in inflammatory pain models. The mechanisms of action are not well understood, but both WIN and AM1241 activate TRPA1. It has been proposed that TRPA1 activation in sensory neurons and the subsequent Ca2+ influx desensitizes TRPV1 thereby exerting their antihyperalgesic effects. The knockdown of TRPA1 activity in neurons completely eliminates the desensitizing effects of WIN and AM1241 on TRPV1. Furthermore, the WIN- or AM1241-induced inhibition of capsaicin-evoked nocifensive behavior is reversed in trpa1−/− mice (Akopian et al., 2008). 1.5.1.2 Cardiovascular Raw garlic, with its active component, the TRPA1 activator allicin, protects against the development of right ventricular hypertrophy in monocrotaline-induced pulmonary hypertensive rats (Sun and Ku, 2006). This protective effect is due to an action on vascular endothelium, preventing endothelial cell dysfunction. Boiled or aged garlic, which lack the active component allicin, was without effect. Due to the remarkable activation of TRPA1 by garlic, it is intriguing to speculate that this channel might be involved in these beneficial effects. TRPA1 is expressed in the heart (Stokes et al., 2006). However, it has been shown recently that the cardiovascular active compound derived from garlic might be the gaseous messenger H2S, which induces vasorelaxation by KATP-induced hyperpolarization in smooth muscles, prevents leukocyte adhesion, reduces cardiac arrhythmias, and acts as a cardioprotective agent (see a concise review in Lefer [2007]). 1.5.1.3 Irritation Airways continously sense multiple stimuli. Nasal trigeminal nerve endings are particularly sensitive to oxidants formed in polluted air and during oxidative stress, as well as to chlorine, which is frequently released in industrial and domestic accidents. Oxidant activation of airway neurons induces respiratory depression, nasal obstruction, sneezing, cough, and pain. While normally protective, chemosensory airway reflexes can provoke severe complications in patients affected by inflammatory airway conditions like rhinitis and asthma. Hypochlorite, the oxidizing mediator of chlorine, and hydrogen peroxide, a ROS, activate Ca2+ influx and membrane currents in an oxidant-sensitive subpopulation of chemosensory neurons in WT mice, but not in trpa1−/− mice (Bessac et al., 2008). TRPA1 is found preferentially on nociceptive sensory neurons, including capsaicin-sensitive TRPV1-expressing vagal bronchopulmonary C-fibers. Oxidative stress, a pathological feature of many respiratory diseases, causes the endogenous formation of a number of reactive electrophilic alkenals via lipid peroxidation. 4-oxononenal (4-ONE), a very electrophilic compound, induced substantial action potential discharge and tachykinin release from bronchopulmonary C-fiber terminals. 4-ONE also caused a large TRPV1-dependent response. 4-ONE is a relevant endogenous activator of vagal C-fibers via an interaction
36
TRP CHANNELS AND HUMAN DISEASES
with both TRPA1 and TRPV1 to induce bronchopulmonary dysfunction (Taylor-Clark et al., 2008). Irritant-induced cough might be caused by TRPA1 activation and by repeated or severe irritant-induced airway epithelial injury (e.g., reactive airway dysfunction syndrome [RADS]) is probably induced by persistent TRPV1 and TRPA1 activation (Brooks, 2008). 1.5.1.4 Bladder Immunohistochemical studies revealed the expression of TRPA1 in sensory nerve fibers innervating the bladder, that is, in unmyelinated nerve fibers within the urothelium, the suburothelial space, and the muscle layer as well as around blood vessels throughout the bladder (Streng et al., 2008). A majority, but not all TRPA1 nerves also expressed immunoreactivity for CGRP or TRPV1. Low expression was reported in the bladder mucosa (Du et al., 2007). Interestingly, TRPA1 expression in human bladder mucosa might be correlated with bladder outlet obstruction (BOO) or benign prostatic hyperplasia (BPH) (Du et al., 2007). Recent reports also showed TRPA1 in the urothelium. Apparently TRPA1 was observed in basal urothelial cells, whereas TRPV1 was located to the outer layers (Gratzke et al., 2009; Streng et al., 2008). Several indications point to a functional role of TRPA1 in the bladder. Activation of TRPA1 with allyl isothiocyanate (MO) or CA causes a contraction of the rat urinary bladder in vitro, which shows desensitization after repeated application. This occurs most likely through sensory fiber stimulation. Ca2+ influx may induce release of tachykinins and may produce cyclooxygenase metabolites, probably prostaglandin E2 (Andrade et al., 2006). Intravesical perfusion of trans-CA and allyl isothiocyanate (MO) significantly decreased the intercontraction interval and pressure threshold in rat urinary bladder (Du et al., 2007). After precontraction with PE, MO, CA, and NaHS caused concentration-dependent relaxations of urethral strip preparations (Gratzke et al., 2009). A new TRPA1 agonist, H2S, increased micturition frequency and reduced the voiding volume in female rats (Streng et al., 2008). TRPA1 might also be involved in inflammation in the bladder. The action of acrolein to induce inflammation and bladder overactivity seems to be mediated via cooperation of α1-adrenoreceptor and TRPA1 (Geppetti et al., 2008). Finally, a short remark should be added to these results. It has been shown recently that some overlap exists between TRPA1 and TRPV1 agonists. In a high concentration range, “TRPA1-specific” compounds such as allicin also activate TRPV1 (Salazar et al., 2008). Thus, whether to assign a specific effect to TRPA1 or TRPV1 activity might be critically dependent on obtaining data from the respective knockout mice.
1.6 THE TRPML SUBFAMILY The TRPML family contains three mammalian members (TRPML1–TRPML3) that are relatively small proteins consisting of less than 600 amino acid resi-
THE TRPML SUBFAMILY
37
dues. TRPML1 is widely expressed and appears to reside in late endosomes/ lysosomes (Qian and Noben-Trauth, 2005). It contains a nuclear localization signal and a putative late endosomal/lysosomal targeting signal (Sun et al., 2000). The loop between TM1 and TM2 contains a lipase domain of unknown function, although it may be speculated that this region is enzymatically active or represents a binding site for lipids that could potentially exert a regulatory influence on TRPML1 (Bach, 2005). To date, TRPML2 and TRPML3 have not been adequately functionally characterized (for a more detailed review, see Qian and Noben-Trauth [2005]). 1.6.1 TRPML1 TRPML1 (or mucolipin 1 [MLN1]) is a transmembrane protein encoded by the gene mcoln1. TRPML1 is a high-conductance nonselective cation channel that is permeable to Ca2+ and is regulated by pH changes (Raychowdhury et al., 2004). TRPML1 probably assembles into complexes that demonstrate variable single-channel conductance. Channel activity is reduced at low pH probably due to an assembly defect (Cantiello et al., 2005). The protein contains a serine–lipase domain in the amino part of the protein between the first two transmembrane domains that might function either enzymatically as a lipase, or as a binding domain, or as a transporter of lipids that might act as channel regulators. TRPML1 would thus appear to be a Ca2+-permeable channel regulated by pH (Qian and Noben-Trauth, 2005). 1.6.1.1 Neurological Disorders Mutations in mcoln1 cause mucolipidosis type IV (MLIV), an autosomal recessive, neurodegenerative, lysosomal storage disorder. MLIV is clinically characterized by severe psychomotor retardation, ophthalmologic abnormalities including corneal opacity, retinal degeneration, strabismus, agenesis of the corpus callosum, blood iron deficiency, and achlorohydria (Bach, 2005). The disease normally presents itself within the first year of life and progresses slowly, with patients remaining in an apparent steady state for two to three decades (Bach, 2001). The pathological mechanisms underlying MLIV are incompletely understood. Abnormal storage of amphiphilic lipids (phospholipids, gangliosides, neutral lipids, and mucopolysaccharides) and membranous materials in multiconcentric lamella together with granulated, water-soluble substances in late endosomes and lysosomes has been visualized by electron microscopy (Bach, 2001). However, there is a considerable variability in the composition of the stored materials between different organs and tissues. Such abnormal storage has been hypothesized to be due to altered membrane fusion and fission events in the late endocytic pathway (Chen et al., 1998). Mutants of TRPML1 found in human patients (i.e., V446l and ΔF408) retain channel function, but unlike WT, TRPML1 are unaffected by pH changes, suggesting that these mutations somehow affect control of clustering and complexing of TRPML1 (Raychowdhury et al., 2004). There is no defec-
38
TRP CHANNELS AND HUMAN DISEASES
tive hydrolytic activity, but rather a defective endocytic process in MLIV. An elevation of approximately 1 pH unit was determined in the storage vacuoles of affected cells, which is typical of late endosomes and prelysosomal vacuoles (Luzio et al., 2003; Maxfield and McGraw, 2004). Defective TRPML1 channels induce changes in the endocytotic transport of membrane components, such as block of the endocytotic route to the final lysosome. In cells from MLIV patients, a disturbed Ca2+ signaling has been described. In addition, large acidic organelles appeared consisting of late endosomes and lysosomes. It would appear that the Ca2+-dependent fusion between late endosome/lysosome hybrid vesicles is defective. TRPML1 could play a key role in Ca2+ release from the endosome/lysosome hybrid, which triggers the fusion and trafficking of these organelles. Perhaps TRPML1 is important in decreasing the intravesicular concentration of Ca2+ (LaPlante et al., 2004). In addition to this mechanism, TRPML1 may constitute a H+ leak that limits lysosomal acidification. It has been recently suggested that with TRPML1 mutants, the lysosomes are chronically overacidified because of the dysfunctional TRPML1 (Kiselyov et al., 2005). 1.6.2 TRPML2 and TRPML3 TRPML1 and TRPML2 are lysosomal, homomeric channels, whereas TRPML3 is a heteromer localized in the endoplasmic reticulum. When coexpressed with TRPML1 or TRPML2, TRPML3 is translocated to lysosomes. Distribution of TRPML3 is impaired when lysosomal trafficking of TRPML1 and TRPML2 is disrupted (Venkatachalam et al., 2006). Thus, localization of TRPML3 is regulated by TRPML1 and TRPML2 and not vice versa. Possibly, traffic of TRPML3 to lysosomes is required for the normal function of the mucolipidosis inducing TRPML1. It is not currently clear whether mutants of TRPML1 causing MLIV disrupt TRPML translocation, resulting in a decreased number of TRPML1 channels in the patient’s lysosomes. Recently, the Scharenberg group showed that TRPML regulates the special lysosomal compartment in B lymphocytes. Lysosomes function normally in the absence of either TRPML1 or TRPML2. However, if the C-terminus of TRPML1 is fused to TRPML2 or vice versa, the function of these channels is antagonized, and large ventricular bodies appear together with enlarged lysosomes. TRPMLs are required for the normal regulation of specialized lysosomal compartments (multivesicular bodies [MVBs]) in B lymphocytes (Song et al., 2006). 1.6.2.1 Hearing Extensive work in recent years has elucidated that the long-known varitint-waddler phenotype in mice is caused by mutations in the TRPML3 gene (for a review, see Cuajungco and Samie [2008]). The varitintwaddler mouse is characterized by hearing loss, vestibular dysfunction (circling behavior, waddling), and coat color dilution. Two genetic variants
THE TRPP SUBFAMILY
39
exist: Va and VaJ. Va/Va homozygosity is lethal, Va/+ and VaJ/VaJ represent an intermediate form, and VaJ/+ represents the less severe form (normal vestibular function, partial hearing, and very little pigmentation deficiency). In the cochlea, Va and VaJ mice show progressive cytoplasmic abberation and highly distinctive disorganization of stereociliary bundle formation of the inner and the outer hair cells (Cuajungco and Samie, 2008) A decisive breakthrough was established when it was shown that the Va genotype represents a single amino acid substitution (A419P) in the TRPML3 protein, while the VaJ genotype carries an additional mutation in the trpml3 gene (I362T/A419P). TRPML3 is widely expressed in mouse tissues, and specific immunohistochemical staining was shown in hair cell bodies and stereocilia (DiPalma et al., 2002). Heterologous overexpression studies have shown that TRPML3 represents a cation channel, which is highly permeable to Ca but to a lesser extent also to Na, K, and Mg (Grimm et al., 2007; Kim et al., 2007, 2008; Xu et al., 2007; Nagata et al., 2008). The exact electrophysiological properties of the TRPML3 channel remain controversial in the literature. Apparently, TRPML3 is regulated both by Ca2+; that is, high Ca2+ levels inactivate the channel, and by extracystolic protons via three histidine residues (Kim et al., 2008). The Va and VaJ mutations lead to a gain of function of the TRPML3 channel (Grimm et al., 2007; Kim et al., 2007, 2008; Xu et al., 2007; Nagata et al., 2008). A419P, such as found in the Va mutant, lies within the predicted cytoplasmic face of the α-helical transmembrane segment 5, and its presence probably induces a “kink, hinge, or swivel,” locking the channel in a permanently open state. Additionally, this mutation also abolishes the regulation of the channel by extracellular protons (Kim et al., 2008). This is important because mutations in three His residues mimick the Va channel phenotype, indicating that the A419P mutation affects the gating mechanism of the channel. The additional I362T mutation apparently reduces membrane expression of the mutated protein (Grimm et al., 2007; Kim et al., 2007). Death of melanocytes in the inner ear (and other tissue), leading to the devastating Va phenotype, probably occurs through Ca2+ overloading of the cell and/or loss of the cation gradient in hair cells (Grimm et al., 2007). VaJ partly ameliorates this phenotype through limiting the number of channels at the plasma membrane. However, to our knowledge, similar mutations in hTRPML3, attributing to deafness and other inner ear-related disorders in humans, are unknown at the present time.
1.7 THE TRPP SUBFAMILY The TRPP family is very heterogeneous and can be divided, based on structural criteria, into PKD1 (TRPP1)- and PKD2 (TRPP2)-like proteins. PKD1like members comprise TRPP1 (previously termed PKD1), PKDREJ, PKD1L1, PKD1L2, and PKD1L3. TRPP1 consists of 11 transmembrane domains, a very long and complex ∼3000 amino acid extracellular domain
40
TRP CHANNELS AND HUMAN DISEASES
and an intracellular C-terminal domain that interacts with the C-terminus of TRPP2 through a coiled-coil domain (Qian and Noben-Trauth, 2005). The N-terminal domain of TRPP1 contains numerous structural motifs including several adhesive domains that are likely to participate in cell–cell and cell– matrix interactions. TRPP1-like proteins possess a large extracellular loop, containing conserved “polycystin motifs” of unknown function, between the sixth and seventh presumed transmembrane segments. The latter region is homologous to the loop interposed between the putative first and second transmembrane region in TRPP2-like family members (Qian and NobenTrauth, 2005). The PKD2-like members structurally resemble other TRP channels in that they are predicted to have intracellular N- and C-termini, six transmembrane-spanning domains, and a pore region. The members of this subgroup comprise PKD2 (TRPP2), PKD2L1 (TRPP3), and PKD2L2 (TRPP5). All PKD2-like members possess a coiled-coil structure in their C-terminus and form polymodal multiprotein/ion channel complexes (Delmas, 2005). TRPP2 and TRPP3 additionally feature a Ca2+-binding EF hand motif in the C-terminus (Koulen et al., 2002). In heterologous expression systems, TRPP2 and TRPP3 form constitutively active cation selective channels of relatively large conductance (Somlo and Markowitz, 2000; Delmas, 2004; Delmas et al., 2004). Both channels are permeable to Ca2+, with TRPP3 displaying modest selectivity toward divalent cations (Delmas, 2005) (for more detailed reviews, see Delmas [2005], Qian and Noben-Trauth [2005], and Köttgen et al. [2008]). 1.7.1 TRPP1 (PKD1) and TRPP2 1.7.1.1 Kidney Mutations in TRPP1 and TRPP2 lead to autosomal dominant polycystic kidney disease (ADPKD), which is the most prevalent inherited form of (PKD). PKD consists of a group of conditions with progressive development of large cysts in the kidney as their major common characteristic (for a more detailed review, see Köttgen et al. [2008]). In this condition, epithelial-lined cysts are formed, filled with fluid, and occupying much of the mass of the abnormally enlarged kidneys, thereby compressing and destroying normal renal tissue and impairing kidney function. Approximately 50% of patients with the primary form of PKD will progress to kidney failure, or endstage renal disease (ESRD) (Grantham, 1993). ADPKD is the result of a two-hit mechanism whereby somatic inactivation of the normal allele in individual polarized epithelial cells results in loss of heterozygosity and initiates cyst formation (Somlo and Markowitz, 2000). Early cyst formation, which can occur in any segment of the nephron, is associated with an increase in the number of cells in the circumference of already dilated renal tubules (Boletta and Germino, 2003). Also, lengthening of tubules, with a characteristic mitotic orientation of cells along the tubule axis, is lacking in epithelial cells from PKD models (Fischer et al., 2006). Cysts are initially contiguous with the
THE TRPP SUBFAMILY
41
nephron from which they pouch, but well-developed large cysts exist as independent sacs formed by epithelial cell proliferation. They are filled with fluid, perhaps via active secretion mediated by the cyst epithelium (Sutters and Germino, 2003). Although ADPKD is characterized by kidney cysts and renal failure, it should be regarded as a systemic disorder with cysts also occurring in other organs (pancreas, brain, and liver) and a range of cardiovascular abnormalities (Köttgen et al., 2008). Indeed, TRPP1 and TRPP2 are also expressed in smooth muscle cells and seem to be important for the integrity of the vessel wall. ADPKD patients with TRPP1 and/or TRPP2 mutations also suffer from aneurysms, vessel rupture, and internal bleeding (Dietrich et al., 2006). TRPP2 mutations are also related to structural defects in the heart, for example, defective septum formation (Wu et al., 2000). Intriguingly, cultured endothelial cells from pkd1−/− or Tg737(orpk/orpk) mutant mice are unable to respond to extracellular shear stress and do not mediate shear dependent nitric oxide synthesis, which might implicate TRPP1 in blood pressure regulation (Nauli et al., 2008). Disease-causing mutations have been identified in both the TRPP1 and the TRPP2 genes. Eighty to eighty-five percent of cases are caused by mutations in the TRPP1 gene; 56 disease-causing mutations are known. Forty-five disease-causing mutations in TRPP2 are also known, but they lead to less severe diseases. As mentioned above, it is unclear what the actual physiological role of TRPP1 and TRPP2 actually is. TRPP1 has been reported to participate in various signaling pathways, including PI3 kinase, JAK/STAT, Wnt, and NFAT pathways. Subcellular localization of TRPP2 is a matter of debate. The protein has been reported in the plasma membrane, in the ER membrane, and in the primary cilium, where it could serve distinct functions and where its localization could be dynamically regulated (Köttgen et al., 2008). It is therefore hard to speculate exactly how both proteins actually contribute to the development of the disease. Nevertheless, it has been shown recently that both basal and EGFstimulated kidney cell proliferation are upregulated in cells that lack TRPP2, indicating that TRPP2 might act as a negative regulator of cell growth. TRPP2 is also a regulator of tubulogenesis: TRPP2-lacking kidney cells form branching and multicellular tubules, suggesting a role in cyst formation (Grimm et al., 2005). TRPP2 overexpression in mice leads to anomalies in tubular function caused by defective tubule morphogenesis (Burtey et al., 2007). Another possible explanation includes TRPP1- and TRPP2-dependent transfer of the helix-loop-helix (HLH) protein Id2 (a crucial regulator of cell proliferation and differentiation) into the nucleus. Enhanced nuclear localization of Id2 in renal epithelial cells from AKPKD patients could be a mechanism for the hyperproliferative phenotype and may cause cyst formation (Benezra, 2005; Li et al., 2005b). The various mechanisms by which TPKD1 (TRPP1)/TRPP2 are involved in controlling [Ca2+]i and the transcription of genes controlling cell growth are summarized in Fig. 1.4.
42
TRP CHANNELS AND HUMAN DISEASES
Cilium
1 2
3 PKD1 NH2 Ca
PKD domain TRPP2 TRPC1 TRPV4
2+
TRPP2
NH2
COOH
+
Na
TRPP2 Ca
REJ domain
2+ Na+
GPS-cleaved NH2 PKD1
6
Plasma membrane NH2
G PLC
2+
Ca
Ca2+ PI3K NFAT
TRPP2 Ca
AC
InsP3 DAG cAMP
4 IP3R
2+
Ca
2+
PKC
PKD1 C-terminus
P COOH
COOH NH2
ER
Id2
NH2
NH2 Ankyrin repeats COOH
COOH
COOH
5
PKA
AP-1Ras/B-Raf Id2-E-protein dimer
MEK/ERK
AP-1
E protein Ca
2+
2+
Ca
Ca
2+ 2+
Ca
Nucleus Growth-suppressive genes
Figure 1.4 Compartment-specific functions of TRPP2. Various models for the localization-dependent functions of TRPP2 are depicted. (1,2,4) In the ER, TRPP2 may function as a Ca2+-regulated Ca2+ release channel. TRPP2 channel activity in the ER might be regulated by interaction with polycystin-1 (PC-1) in the plasma membrane or by interaction with the inositol 1,4,5-trisphosphate receptor (IP3-R) in the ER. (B) In the basolateral plasma membrane TRPP2 is thought to function in a complex with polycystin-1. This complex resides either at the basal cell–matrix interface or at cell–cell junctions in the lateral membrane. (3) In the primary cilium TRPP2 may function as a sensor for mechanical or chemical cues. Flow-mediated bending of the cilium was shown to trigger cytosolic Ca2+ signals, in a process that was proposed to require the TRPP2–polycystin-1 complex. Other members of the TRP family (TRPV4 and TRPC1) may also be involved in ciliary mechanosensation. (5,6) PKD1 can undergo a proteolytic cleavage. The carboxy-terminal tail is released and is translocated to the nucleus where the transcription factor AP1 is activated. Phosphorylated TRPP2 sequesters Id2 in the cytoplasm and prevents it from entering the nucleus. Id2 binds to a helix-loop-helix protein E-protein, which normally activated growth suppression genes. This decreased transcription of growth suppressors may induce cyst forming. (ERK, extracellular signal-regulated kinase; Id2, inhibitor of DNA binding 2; MEK, mitogen-activated protein kinase/ERK kinase; REJ, receptor for egg jelly). Reprinted by permission from Macmillan Publishers Ltd: Giamarchi, A., Padilla, F., Coste, B., Raoux, M., Crest, M., Honoré, E. and Delmas, P. EMBO Reports 7, 787–793 (2006). (See color insert.)
REFERENCES
43
Due to the complexity of the pathogenesis of PKD, a strategy for treating this disease is not obvious. However, a recent study has shown that a TRPP2 activating compound might be interesting in this regard. Triptolide is the active diterpene in the traditional Chinese medicine Lei Gong Teng. This natural product can be isolated from the medical vine Tripterygium wilfordii Hook F (the Thunder God Vine). It is used in Chinese medicine for the treatment of fever, chills, edema, and carbuncle. Triptolide induces Ca2+ release via a TRPP2-dependent mechanism. In a murine model of ADPKD (a trpp1−/− kidney), triptolide arrests cellular proliferation and attenuates overall cyst formation. This rescue is due to reactivation of Ca2+ signaling in the tubular epithelial cells. Small-molecule activation of TRPP2 causing Ca2+ release may become a valid therapeutic strategy for ADPKD (Leuenroth et al., 2007). 1.8
CONCLUSIONS
We have shown that TRP channels are connected to fundamental cell functions in a variety of tissues. A plethora of links and possible links to diseases has been listed. It is obvious that in most of the cases, the mechanism by which TRP dysfunction induces and modifies the progression of diseases is poorly understood, and the connection is occasionally tentative. Nevertheless, we are convinced that TRP channels are and will remain in the focus of fundamental scientists, physicians, and medical pharmacists in search of innovative therapeutic strategies for dreadful diseases. Other diseases that can be directly linked to TRP channel dysfunction will likely be identified when more molecular biological and functional information becomes available. The lack of selective pharmacological agents, as well as specific antibodies for detection of TRP channels in the native cells, however, still hampers progress in this field. Nonetheless, considering the large amount of information already available from different approaches, TRP channels are without any doubt important tools to identify new pathomechanisms and will remain very promising targets for new pharmacological developments. REFERENCES Aarts M, Iihara K, Wei WL, Xiong ZG, Arundine M, Cerwinski W, MacDonald JF, and Tymianski M (2003) A key role for TRPM7 channels in anoxic neuronal death. Cell 115:863–877. Aarts MM and Tymianski M (2005) TRPMs and neuronal cell death. Pflugers Arch 451:243–249. Abramowitz J and Birnbaumer L (2006) Know thy neighbors: a survey of diseases and complex syndromes that map to chromosomal regions encoding TRP channels. In TRP Channels (Flockerzi V and Nilius B, eds.), pp. 377–406. Springer-Verlag, Berlin.
44
TRP CHANNELS AND HUMAN DISEASES
Adachi N, Kobayashi T, Takahashi H, Kawasaki T, Shirai Y, Ueyama T, Matsuda T, Seki T, Sakai N, and Saito N (2008) Enzymological analysis of mutant protein kinase Cgamma causing spinocerebellar ataxia type 14 and dysfunction in Ca2+ homeostasis. J Biol Chem 283:19854–19864. Aita VM, Liu J, Knowles JA, Terwilliger JD, Baltazar R, Grunn A, Loth JE, Kanyas K, Lerer B, Endicott J, Wang Z, Penchaszadeh G, Gilliam TC, and Baron M (1999) A comprehensive linkage analysis of chromosome 21q22 supports prior evidence for a putative bipolar affective disorder locus. Am J Hum Genet 64:210–217. Akopian AN, Ruparel NB, Patwardhan A, and Hargreaves KM (2008) Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci 28:1064–1075. Albin KC, Carstens MI, and Carstens E (2008) Modulation of oral heat and cold pain by irritant chemicals. Chem Senses 33:3–15. Alessandri-Haber N, Dina OA, Joseph EK, Reichling D, and Levine JD (2006) A transient receptor potential vanilloid 4-dependent mechanism of hyperalgesia is engaged by concerted action of inflammatory mediators. J Neurosci 26:3864–3874. Alessandri-Haber N, Dina OA, Joseph EK, Reichling DB, and Levine JD (2008) Interaction of transient receptor potential vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia. J Neurosci 28:1046–1057. Alessandri-Haber N, Dina OA, Yeh JJ, Parada CA, Reichling DB, and Levine JD (2004) Transient receptor potential vanilloid 4 is essential in chemotherapy-induced neuropathic pain in the rat. J Neurosci 24:4444–4452. Alvarez DF, King JA, Weber D, Addison E, Liedtke W, and Townsley MI (2006) Transient receptor potential vanilloid 4-mediated disruption of the alveolar septal barrier. A novel mechanism of acute lung injury. Circ Res 99:988–995. Amaral MD and Pozzo-Miller L (2007) TRPC3 channels are necessary for brainderived neurotrophic factor to activate a nonselective cationic current and to induce dendritic spine formation. J Neurosci 27:5179–5189. Anderson TR and Andrew RDJ (2002) Spreading depression: imaging and blockade in the rat neocortical brain slice. Neurophysiology 88:2713–2725. Andersson DA, Chase HW, and Bevan S (2004) TRPM8 activation by menthol, icilin, and cold is differentially modulated by intracellular pH. J Neurosci 24:5364–5369. Andersson DA, Gentry C, Moss S, and Bevan S (2008) Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci 28: 2485–2494. Andrade EL, Ferreira J, Andre E, and Calixto JB (2006) Contractile mechanisms coupled to TRPA1 receptor activation in rat urinary bladder. Biochem Pharmacol 72:104–114. Andrade YN, Fernandes J, Vazques E, Fernandez-Fernandez JM, Arniges M, Sanchez TM, Villalon M, and Valverde MA (2005) TRPV4 channel is involved in the coupling of the fluid viscosity changes to epithelail ciliary activity. J Cell Biol 168: 869–874. Apostolidis A, Brady CM, Yiangou Y, Davis J, Fowler CJ, and Anand P (2005) Capsaicin receptor TRPV1 in urothelium of neurogenic human bladders and effect of intravesical resiniferatoxin. Urology 65:400–405. Asakawa M, Yoshioka T, Matsutani T, Hikita I, Suzuki M, Oshima I, Tsukahara K, Arimura A, Horikawa T, Hirasawa T, and Sakata T (2006) Association of a Mutation
REFERENCES
45
in TRPV3 with defective hair growth in rodents. J Invest Dermatol 126:2664– 2672. Ayata C and Ropper AH (2002) Ischaemic brain oedema. J Clin Neurosci 9:113–124. Babior BM (2000) Phagocytes and oxidative stress. Am J Med 109:33–44. Bach G (2001) Mucolipidosis type IV. Mol Genet Metab 73:197–203. Bach G (2005) Mucolipin 1: endocytosis and cation channel-a review. Pflugers Arch 451:313–317. Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, Earley TJ, and Patapoutian A (2004) Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 41:849–857. Bang S, Kim KY, Yoo S, Kim YG, and Hwang SW (2007) Transient receptor potential A1 mediates acetaldehyde-evoked pain sensation. Eur J Neurosci 26:2516–2523. Bautista DM, Jordt SE, Nikai T, Tsuruda PR, Read AJ, Poblete J, Yamoah EN, Basbaum AI, and Julius D (2006) TRPA1 mediates the inflammatory actions of environmental irritants and proalgesic agents. Cell 124:1269–1282. Beck B, Lehen’kyi V, Roudbaraki M, Flourakis M, Charveron M, Bordat P, Polakowska R, Prevarskaya N, and Skryma R (2008) TRPC channels determine human keratinocyte differentiation: new insight into basal cell carcinoma. Cell Calcium 43:492– 505. Benezra R (2005) Polycystins: inhibiting the inhibitors. Nat Cell Biol 7:1064–1065. Bers DM and Guo T (2005) Calcium signaling in cardiac ventricular myocytes. Ann N Y Acad Sci 1047:86–98. Bessac BF, Sivula M, von Hehn CA, Escalera J, Cohn L, and Jordt SE (2008) TRPA1 is a major oxidant sensor in murine airway sensory neurons. J Clin Invest 118: 1899–1910. Bhargave G, Woodworth BA, Xiong G, Wolfe SG, Antunes MB, and Cohen NA (2008) Transient receptor potential vanilloid type 4 channel expression in chronic rhinosinusitis. Am J Rhinol 22:7–12. Bhat YM and Bielefeldt K (2006) Capsaicin receptor (TRPV1) and non-erosive reflux disease. Eur J Gastroenterol Hepatol 18:263–270. Bianco S, Peng JB, Takanaga H, Kos CH, Crescenzi A, Brown EM, and Hediger MA (2004) Mice lacking the epithelial calcium channel CaT1 (TRPV6) show a deficiency in intestinal calcium reabsorption despite high plasma levels of 1,25-dihydroxy vitamin D. FASEB Journal 18:A706. Birder LA (2005) More than just a barrier: urothelium as a drug target for urinary bladder pain. Am J Physiol Renal Physiol 289:F489–495. Birder LA, Kanai AJ, de Groat WC, Kiss S, Nealen ML, Burke NE, Dineley KE, Watkins S, Reynolds IJ, and Caterina MJ (2001) Vanilloid receptor expression suggests a sensory role for urinary bladder epithelial cells. Proc Natl Acad Sci U S A 98:13396–13401. Birder LA, Nakamura Y, Kiss S, Nealen ML, Barrick S, Kanai AJ, Wang E, Ruiz G, De Groat WC, Apodaca G, Watkins S, and Caterina MJ (2002) Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci 5: 856–860. Biro T, Bodo E, Telek A, Geczy T, Tychsen B, Kovacs L, and Paus R (2006) Hair cycle control by vanilloid receptor-1 (TRPV1): evidence from TRPV1 knockout mice. J Invest Dermatol 126:1909–1912.
46
TRP CHANNELS AND HUMAN DISEASES
Bodo E, Biro T, Telek A, Czifra G, Griger Z, Toth BI, Mescalchin A, Ito T, Bettermann A, Kovacs L, and Paus R (2005) A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am J Pathol 166:985–998. Bolanz KA, Hediger MA, and Landowski CP (2008) The role of TRPV6 in breast carcinogenesis. Mol Cancer Ther 7:271–279. Boletta A and Germino GG (2003) Role of polycystins in renal tubulogenesis. Trends Cell Biol 13:484–492. Bollimuntha S, Singh BB, Shavali S, Sharma SK, and Ebadi M (2005) TRPC1-mediated inhibition of MPP+ neurotoxicity in human SH-SY5Y neuroblastoma cells. J Biol Chem 280:2132–2140. Brady CM, Apostolidis AN, Harper M, Yiangou Y, Beckett A, Jacques TS, Freeman A, Scaravilli F, Fowler CJ, and Anand P (2004) Parallel changes in bladder suburothelial vanilloid receptor TRPV1 and pan-neuronal marker PGP9.5 immunoreactivity in patients with neurogenic detrusor overactivity after intravesical resiniferatoxin treatment. BJU Int 93:770–776. Brechard S, Melchior C, Plancon S, Schenten V, and Tschirhart EJ (2008) Storeoperated Ca(2+) channels formed by TRPC1, TRPC6 and Orai1 and non-storeoperated channels formed by TRPC3 are involved in the regulation of NADPH oxidase in HL-60 granulocytes. Cell Calcium 44:492–506. Brenner JS and Dolmetsch RE (2007) TrpC3 regulates hypertrophy-associated gene expression without affecting myocyte beating or cell size. PLoS ONE 2:e802. Brierley SM, Page AJ, Hughes PA, Adam B, Liebregts T, Cooper NJ, Holtmann G, Liedtke W, and Blackshaw LA (2008) Selective role for TRPV4 ion channels in visceral sensory pathways. Gastroenterology 134:2059–2069. Brône B, Peeters PJ, Marrannes R, Mercken M, Nuydens R, Meert T, and Gijsen HJM (2008) Tear gasses CN, CR, and CS are potent activators of the human TRPA1 receptor. Toxicol Appl Pharmacol 231:150–156. Brooks SM (2008) Irritant-induced chronic cough: irritant-induced TRPpathy. Lung 186(Suppl 1):S88–S93. Burtey S, Riera M, Ribe E, Pennekamp P, Passage E, Rance R, Dworniczak B, and Fontes M (2007) Overexpression of PKD2 in the mouse is associated with renal tubulopathy. Nephrol Dial Transplant 23:1157–1165. Bush EW, Hood DB, Papst PJ, Chapo JA, Minobe W, Bristow MR, Olson EN, and McKinsey TA (2006) TRPC channels promote cardiomyocyte hypertrophy through activation of calcineurin signaling. J Biol Chem 281:33487–33496. Cannon TW and Chancellor MB (2002) Pharmacotherapy of the overactive bladder and advances in drug delivery. Clin Obstet Gynecol 45:205–217. Cantiello HF, Montalbetti N, Goldmann WH, Raychowdhury MK, Gonzalez-Perrett S, Timpanaro GA, and Chasan B (2005) Cation channel activity of mucolipin-1: the effect of calcium. Pflugers Arch 451:304–312. Caprodossi S, Lucciarini R, Amantini C, Nabissi M, Canesin G, Ballarini P, Di Spilimbergo A, Cardarelli MA, Servi L, Mammana G, and Santoni G (2007) Transient receptor potential vanilloid type 2 (TRPV2) expression in normal urothelium and in urothelial carcinoma of human bladder: correlation with the pathologic stage. Eur Urol 54:612–620.
REFERENCES
47
Chen CS, Bach G, and Pagano RE (1998) Abnormal transport along the lysosomal pathway in mucolipidosis, type IV disease. Proc Natl Acad Sci U S A 95:6373– 6378. Chen M, Dong Y, and Simard JM (2003) Functional coupling between sulfonylurea receptor type 1 and a nonselective cation channel in reactive astrocytes from adult rat brain. J Neurosci 23:8568–8577. Chen M and Simard JM (2001) Cell swelling and a nonselective cation channel regulated by internal Ca2+ and ATP in native reactive astrocytes from adult rat brain. J Neurosci 21:6512–6521. Chubanov V, Gudermann T, and Schlingmann KP (2005) Essential role for TRPM6 in epithelial magnesium transport and body magnesium homeostasis. Pflugers Arch 451:228–234. Chubanov V, Schlingmann KP, Waring J, Heinzinger J, Kaske S, Waldegger S, Schnitzler MM, and Gudermann T (2007) Hypomagnesemia with secondary hypocalcemia due to a missense mutation in the putative pore-forming region of TRPM6. J Biol Chem 282:7656–7667. Chung MK, Lee H, Mizuno A, Suzuki M, and Caterina MJ (2004) 2-Aminoethoxydiphenyl borate activates and sensitizes the heat-gated ion channel TRPV3. J Neurosci 24:5177–5182. Cope G, Golbang A, and O’Shaughnessy KM (2005) WNK kinases and the control of blood pressure. Pharmacol Ther 106:221–231. Corey DP, Garcia-Anoveros J, Holt JR, Kwan KY, Lin SY, Vollrath MA, Amalfitano A, Cheung EL, Derfler BH, Duggan A, Geleoc GS, Gray PA, Hoffman MP, Rehm HL, Tamasauskas D, and Zhang DS (2004) TRPA1 is a candidate for the mechanosensitive transduction channel of vertebrate hair cells. Nature 432:723–730. Crunelli V, Toth TI, Cope DW, Blethyn K, and Hughes SW (2005) The “window” T-type calcium current in brain dynamics of different behavioural states. J Physiol 562:121–129. Cuajungco MP and Samie MA (2008) The varitint-waddler mouse phenotypes and the TRPML3 ion channel mutation: cause and consequence. Pflugers Arch 457:463–473. Daly DM, Rong W, Chess-Williams R, Chapple C, and Grundy D (2007) Bladder afferent sensitivity in wildtype and TRPV1 knockout mice. J Physiol 583:663–674. Damak S, Rong M, Yasumatsu K, Kokrashvili Z, Perez CA, Shigemura N, Yoshida R, Mosinger B Jr., Glendinning JI, Ninomiya Y, and Margolskee RF (2006) Trpm5 null mice respond to bitter, sweet, and umami compounds. Chem Senses 31:253–264. Delmas P (2004) Polycystins: from mechanosensation to gene regulation. Cell 118:145–148. Delmas P (2005) Polycystins: polymodal receptor/ion-channel cellular sensors. Pflugers Arch 451:264–276. Delmas P, Padilla F, Osorio N, Coste B, Raoux M, and Crest M (2004) Polycystins, calcium signaling, and human diseases. Biochem Biophys Res Commun. 322:1374–1383. Denda M, Sokabe T, Fukumi-Tominaga T, and Tominaga M (2007) Effects of skin surface temperature on epidermal permeability barrier homeostasis. J Invest Dermatol 127:654–659.
48
TRP CHANNELS AND HUMAN DISEASES
Dietrich A, Chubanov V, Kalwa H, Rost BR, and Gudermann T (2006) Cation channels of the transient receptor potential superfamily: their role in physiological and pathophysiological processes of smooth muscle cells. Pharmacol Ther 112: 744–760. Dietrich A and Gudermann T (2007) Trpc6. Handb Exp Pharmacol:125–141. Dietrich A and Gudermann T (2008) Another TRP to endothelial dysfunction: TRPM2 and endothelial permeability. Circ Res 102:275–277. Dietrich A, Kalwa H, Fuchs B, Grimminger F, Weissmann N, and Gudermann T (2007) In vivo TRPC functions in the cardiopulmonary vasculature. Cell Calcium 455: 465–477. Dietrich A, Mederos YSM, Gollasch M, Gross V, Storch U, Dubrovska G, Obst M, Yildirim E, Salanova B, Kalwa H, Essin K, Pinkenburg O, Luft FC, Gudermann T, and Birnbaumer L (2005) Increased vascular smooth muscle contractility in TRPC6-/- mice. Mol Cell Biol 25:6980–6989. Diogenes A, Akopian AN, and Hargreaves KM (2007) NGF up-regulates TRPA1: implications for orofacial pain. J Dent Res 86:550–555. Di Palma F, Belyantseva I, Kim H, Vogt T, Kachar B, and Noben-Trauth K (2002) Mutations in Mcoln3 associated with deafness and pigmentation defects in varitintwaddler (Va) mice. Proc Natl Acad Sci USA 99:14994–14999. Du S, Araki I, Yoshiyama M, Nomura T, and Takeda M (2002) Transient receptor potential channel A1 involved in sensory transduction of rat urinary bladder through C-fiber pathway. Urology 70:826–831. Ducret T, Guibert C, Marthan R, and Savineau J (2008) Serotonin-induced activation of TRPV-like current in rat intrapulmonary arterial smooth muscle cells. Cell Calcium 43:315–323. Duncan LM, Deeds J, Cronin FE, Donovan M, Sober AJ, Kauffman M, and McCarthy JJ (2001) Melastatin expression and prognosis in cutaneous malignant melanoma. J Clin Oncol 19:568–576. Earley S, Waldron BJ, and Brayden JE (2004) Critical role for transient receptor potential channel TRPM4 in myogenic constriction of cerebral arteries. Circ Res 95:922–929. Everett KV, Chioza BA, Georgoula C, Reece A, Capon F, Parker KA, Cord-Udy C, McKeigue P, Mitton S, Pierro A, Puri P, Mitchison HM, Chung EM, and Gardiner RM (2008) Genome-wide high-density SNP-based linkage analysis of infantile hypertrophic pyloric stenosis identifies loci on chromosomes 11q14-q22 and Xq23. Am J Hum Genet 82:756–762. Firth AL, Remillard CV, and Yuan JX (2007) TRP channels in hypertension. Biochim Biophys Acta 1772:895–906. Fischer E, Legue E, Doyen A, Nato F, Nicolas JF, Torres V, Yaniv M, and Pontoglio M (2006) Defective planar cell polarity in polycystic kidney disease. Nat Genet 38:21–23. Fleetwood-Walker SM, Proudfoot CW, Garry EM, Allchorne A, Vinuela-Fernandez I, and Mitchell R (2007) Cold comfort pharm. Trends Pharmacol Sci 28:621– 628. Folgering JH, Sharif-Naeini R, Dedman A, Patel A, Delmas P, and Honore E (2008) Molecular basis of the mammalian pressure-sensitive ion channels: focus on vascular mechanotransduction. Prog Biophys Mol Biol 97:180–195.
REFERENCES
49
Fonfria E, Marshall IC, Boyfield I, Skaper SD, Hughes JP, Owen DE, Zhang W, Miller BA, Benham CD, and McNulty S (2005) Amyloid beta-peptide(1–42) and hydrogen peroxide-induced toxicity are mediated by TRPM2 in rat primary striatal cultures. J Neurochem 95:715–723. Fonfria E, Mattei C, Hill K, Brown JT, Randall A, Benham CD, Skaper SD, Campbell CA, Crook B, Murdock PR, Wilson JM, Maurio FP, Owen DE, Tilling PL, and McNulty S (2006) TRPM2 is elevated in the tMCAO stroke model, transcriptionally regulated, and functionally expressed in C13 microglia. J Recept Signal Transduct Res 26:179–198. Fournet JC, Mayaud C, de Lonlay P, Gross-Morand MS, Verkarre V, Castanet M, Devillers M, Rahier J, Brunelle F, Robert JJ, Nihoul-Fekete C, Saudubray JM, and Junien C (2001) Unbalanced expression of 11p15 imprinted genes in focal forms of congenital hyperinsulinism: association with a reduction to homozygosity of a mutation in ABCC8 or KCNJ11. Am J Pathol 158:2177–2184. Fraser SP and Pardo LA (2008) Ion channels: functional expression and therapeutic potential in cancer. Colloquium on Ion Channels and Cancer. EMBO Rep 9:512– 515. Frederick J, Buck ME, Matson DJ, and Cortright DN (2007) Increased TRPA1, TRPM8, and TRPV2 expression in dorsal root ganglia by nerve injury. Biochem Biophys Res Commun 358:1058–1064. Freichel M, Suh SH, Pfeifer A, Schweig U, Trost C, Weissgerber P, Biel M, Philipp S, Freise D, Droogmans G, Hofmann F, Flockerzi V, and Nilius B (2001) Lack of an endothelial store-operated Ca2+ current impairs agonist-dependent vasorelaxation in TRP4-/- mice. Nat Cell Biol 3:121–127. Fu Y, Subramanya A, Rozansky D, and Cohen DM (2006) WNK kinases influence TRPV4 channel function and localization. Am J Physiol Renal Physiol 290:F1305– F1314. Fuessel S, Sickert D, Meye A, Klenk U, Schmidt U, Schmitz M, Rost AK, Weigle B, Kiessling A, and Wirth MP (2003) Multiple tumor marker analyses (PSA, hK2, PSCA, trp-p8) in primary prostate cancers using quantitative RT-PCR. Int J Oncol 23:221–228. Gailly P (2002) New aspects of calcium signaling in skeletal muscle cells: implications in Duchenne muscular dystrophy. Biochim Biophys Acta 1600:38–44. Geppetti P, Nassini R, Materazzi S, and Benemei S (2008) The concept of neurogenic inflammation. BJU Int 101:2–6. Gervasio OL, Whitehead NP, Yeung EW, Phillips WD, and Allen DG (2008) TRPC1 binds to caveolin-3 and is regulated by Src kinase—role in Duchenne muscular dystrophy. J Cell Sci 121:2246–2255. Gevaert T, Vriens J, Segal A, Everaerts W, Roskams T, Talavera K, Owsianik G, Liedtke W, Daelemans D, Dewachter I, Van Leuven F, Voets T, De Ridder D, and Nilius B (2007) Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest 117:3453–3462. Gibson HE, Edwards JG, Page RS, Van Hook MJ, and Kauer JA (2008) TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron 57:746–759. Goel M, Sinkins WG, and Schilling WP (2002) Selective association of TRPC channel subunits in rat brain synaptosomes. J Biol Chem 277:48303–48310.
50
TRP CHANNELS AND HUMAN DISEASES
Grant AD, Cottrell GS, Amadesi S, Trevisani M, Nicoletti P, Materazzi S, Altier C, Cenac N, Zamponi GW, Bautista-Cruz F, Barajjas Lopez C, Joseph E, Levine JD, Liedtke W, Vanner S, Vergnolle N, Geppetti P, and Bunnett NW (2007) Proteaseactivated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia. J Physiol 578:715–733. Grantham JJ (1993) Polycystic kidney disease: hereditary and acquired. Adv Intern Med 38:409–420. Gratzke C, Streng T, Waldkirch E, Sigl K, Stief C, Andersson KE, and Hedlund P (2009) Transient receptor potential A1 (TRPA1) activity in the human urethraevidence for a functional role for TRPA1 in the outflow region. Eur Urol 55:696– 704. Greene CC, McMillan PM, Barker SE, Kurnool P, Lomax MI, Burmeister M, and Lesperance MM (2001) DFNA25, a novel locus for dominant nonsyndromic hereditary hearing impairment, maps to 12q21-24. Am J Hum Genet 68:254–260. Greka A, Navarro B, Oancea E, Duggan A, and Clapham DE (2003) TRPC5 is a regulator of hippocampal neurite length and growth cone morphology. Nat Neurosci 6:837–845. Grimm C, Cuajungco MP, van Aken AFJ, Schnee M, Jörs M, Kros CJ, Ricci AJ, and Heller S (2007) A helix-breaking mutation in TRPML3 leads to constitutive activity underlying deafness in the varitint-waddler mouse. Proc Natl Acad Sci U S A 104:19583–19588. Grimm C, Kraft R, Sauerbruch S, Schultz G, and Harteneck C (2003) Molecular and functional characterization of the melastatin-related cation channel TRPM3. J Biol Chem 278:21493–21501. Grimm DH, Karihaloo A, Cai Y, Somlo S, Cantley LG, and Caplan MJ (2005) Polycystin-2 regulates proliferation and branching morphogenesis in kidney epithelial cells. J Biol Chem 281:137–144. Groenestege WM, Thebault S, van der Wijst J, van den Berg D, Janssen R, Tejpar S, van den Heuvel LP, van Cutsem E, Hoenderop JG, Knoers NV, and Bindels RJ (2007) Impaired basolateral sorting of pro-EGF causes isolated recessive renal hypomagnesemia. J Clin Invest 117:2260–2267. Guinamard R, Chatelier A, Demion M, Potreau D, Patri S, Rahmati M, and Bois P (2004a) Functional characterization of a Ca(2+)-activated non-selective cation channel in human atrial cardiomyocytes. J Physiol 558:75–83. Guinamard R, Chatelier A, Lenfant J, and Bois P (2004b) Activation of the Ca(2+)activated nonselective cation channel by diacylglycerol analogues in rat cardiomyocytes. J Cardiovasc Electrophysiol 15:342–348. Hamanaka K, Jian MJ, Weber DS, Alvarez DF, Townsley MI, Al-Mehdi AB, King JA, Liedtke W, and Parker JC (2007) TRPV4 initiates the acute calcium-dependent permeability increase during ventilator-induced lung injury in isolated mouse lungs. Am J Physiol Lung Cell Mol Physiol 293:L923–L932. He Y, Yao G, Savoia C, and Touyz RM (2005) Transient receptor potential melastatin 7 ion channels regulate magnesium homeostasis in vascular smooth muscle cells: role of angiotensin II. Circ Res 96:207–215. Hecquet CM, Ahmmed GU, Vogel SM, and Malik AB (2008) Role of TRPM2 channel in mediating H2O2-induced Ca2+ entry and endothelial hyperpermeability. Circ Res 102:347–355.
REFERENCES
51
Heiner I, Eisfeld J, Halaszovich CR, Wehage E, Jungling E, Zitt C, and Luckhoff A (2003) Expression profile of the transient receptor potential (TRP) family in neutrophil granulocytes: evidence for currents through long TRP channel 2 induced by ADP-ribose and NAD. Biochem J 371:1045–1053. Henshall SM, Afar DE, Hiller J, Horvath LG, Quinn DI, Rasiah KK, Gish K, Willhite D, Kench JG, Gardiner-Garden M, Stricker PD, Scher HI, Grygiel JJ, Agus DB, Mack DH, and Sutherland RL (2003) Survival analysis of genome-wide gene expression profiles of prostate cancers identifies new prognostic targets of disease relapse. Cancer Res 63:4196–4203. Hermosura MC, Go RCV, Davenport B, Shetler CM, Cui AM, Mocz G, Schmitz C, Garruto RM, and Perraud A-L (2008) Altered functional properties of a TRPM2 variant in Guamanian ALS and PDC. Proc Natl Acad Sci U S A 105:18029– 18034. Hermosura MC, Nayakanti H, Dorovkov MV, Calderon FR, Ryazanov AG, Haymer DS, and Garruto RM (2005) A TRPM7 variant shows altered sensitivity to magnesium that may contribute to the pathogenesis of two Guamanian neurodegenerative disorders. Proc Natl Acad Sci U S A 102:11510–11515. Hinman A, Chuang H-H, Bautista DM, and Julius D (2007) TRP channel activation by reversible covalent modification. Proc Natl Acad Sci U S A 103:19564–19568. Hoenderop JG and Bindels RJ (2008) Calciotropic and magnesiotropic TRP channels. Physiology (Bethesda) 23:32–40. Hoenderop JG, van Leeuwen JP, van der Eerden BC, Kersten FF, van der Kemp AW, Merillat AM, Waarsing JH, Rossier BC, Vallon V, Hummler E, and Bindels RJ (2003) Renal Ca2+ wasting, hyperabsorption, and reduced bone thickness in mice lacking TRPV5. J Clin Invest 112:1906–1914. Hofmann T, Obukhov AG, Schaefer M, Harteneck C, Gudermann T, and Schultz G (1999) Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol. Nature 397:259–263. Hofmann T, Schaefer M, Schultz G, and Gudermann T (2002) Subunit composition of mammalian transient receptor potential channels in living cells. Proc Natl Acad Sci U S A 99:7461–7466. Holzer P (2004) TRPV1 and the gut: from a tasty receptor for a painful vanilloid to a key player in hyperalgesia. Eur J Pharmacol 500:231–241. Hopf FW, Turner PR, and Steinhardt RA (2007) Calcium misregulation and the pathogenesis of muscular dystrophy. Subcell Biochem 45:429–464. Hughes DA, Tang K, Strotmann R, Schoneberg T, Prenen J, Nilius B, and Stoneking M (2008) Parallel selection on TRPV6 in human populations. PLoS ONE 3:e1686. Iles KE and Forman HJ (2002) Macrophage signaling and respiratory burst. Immunol Res 26:95–105. Ishii M, Oyama A, Hagiwara T, Miyazaki A, Mori Y, Kiuchi Y, and Shimizu S (2007) Facilitation of H2O2-induced A172 human glioblastoma cell death by insertion of oxidative stress-sensitive TRPM2 channels. Anticancer Res 27:3987–3992. Ishii M, Shimizu S, Hara Y, Hagiwara T, Miyazaki A, Mori Y and Kiuchi Y (2006) Intracellular-produced hydroxyl radical mediates H(2)O(2)-induced Ca(2+) influx and cell death in rat beta-cell line RIN-5F. Cell Calcium 39:487–494.
52
TRP CHANNELS AND HUMAN DISEASES
Iwata Y, Katanosaka Y, Arai Y, Komamura K, Miyatake K, and Shigekawa M (2003) A novel mechanism of myocyte degeneration involving the Ca2+-permeable growth factor-regulated channel. J Cell Biol 161:957–967. Jiang C, Yang H, Fu X, Qu S, and Lindstroem S (2008) Bladder cooling reflex and external urethral sphincter activity in the anesthetized and awake guinea pig. Pflugers Arch 457:61–66. Jin X, Touhey J, and Gaudet R (2006) Structure of the N-terminal ankyrin repeat domain of the TRPV2 ion channel. J Biol Chem 281:25006–25010. Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Hogestatt ED, Meng ID, and Julius D (2004) Mustard oils and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427:260–265. Jordt SE and Ehrlich BE (2007) TRP channels in disease. Subcell Biochem 45:253–271. Karashima Y, Damann N, Prenen J, Talavera K, Segal A, Voets T, and Nilius B (2007) Bimodal action of menthol on the transient receptor potential channel TRPA1. J Neurosci 27:9874–9884. Katsura H, Obata K, Mizushima T, Sakurai J, Kobayashi K, Yamanaka H, Dai Y, Fukuoka T, Sakagami M, and Noguchi K (2007) Activation of extracellular signalregulated protein kinases 5 in primary afferent neurons contributes to heat and cold hyperalgesia after inflammation. J Neurochem 102:1614–1624. Katsura H, Obata K, Mizushima T, Yamanaka H, Kobayashi K, Dai Y, Fukuoka T, Tokunaga A, Sakagami M, and Noguchi K (2006) Antisense knockdown of TRPA1, but not TRPM8, alleviates cold hyperalgesia after spinal nerve ligation in rats. Exp Neurol 200:112–123. Kiessling A, Fussel S, Schmitz M, Stevanovic S, Meye A, Weigle B, Klenk U, Wirth MP, and Rieber EP (2003) Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein trp-p8. Prostate 56:270–279. Kim DY and Chancellor MB (2000) Intravesical neuromodulatory drugs: capsaicin and resiniferatoxin to treat the overactive bladder. J Endourol 14:97–103. Kim HJ, Li Q, Tjon-Kon-Sang S, So I, Kiselyov K, and Muallem S (2007) Gainof-function mutation in TRPML3 causes the mouse varitint-waddler phenotype. J Biol Chem 282:36138–36142. Kim HJ, Li Q, Tjon-Kon-Sang S, So I, Kiselyov K, Soyombo AA, and Muallem S (2008) A novel mode of TRPML3 regulation by extracytosolic pH absent in the varitint-waddler phenotype. Embo J 27:1197–1205. Kim SJ, Kim YS, Yuan JP, Petralia RS, Worley PF, and Linden DJ (2003) Activation of the TRPC1 cation channel by metabotropic glutamate receptor mGluR1. Nature 426:285–291. Kiselyov K, Chen J, Rbaibi Y, Oberdick D, Tjon-Kon-Sang S, Shcheynikov N, Muallem S, and Soyombo A (2005) TRP-ML1 is a lysosomal monovalent cation channel that undergoes proteolytic cleavage. J Biol Chem 280:43218–43223. Kiselyov K, Soyombo A, and Muallem S (2007) TRPpathias. J Physiol 578:641–653. Konrad M, Schlingmann KP, and Gudermann T (2004) Insights into the molecular nature of magnesium homeostasis. Am J Physiol Renal Physiol 286:F599–F605. Köttgen M, Buchholz B, Garcia-Gonzalez M, Fu X, Kotsis F, Steffl D, Tauber R, Kuehn W, Wegierski T, Suzuki M, Kramer-Zucker A, Germino GG, Watnick T,
REFERENCES
53
Prenen J, Nilius B, and Walz G (2008) TRPP2 forms a channel complex with TRPV4 to exert tissue-specific functions. J Biol Chem 182:437–447. Koulen P, Cai Y, Geng L, Maeda Y, Nishimura S, Witzgall R, Ehrlich BE, and Somlo S (2002) Polycystin-2 is an intracellular calcium release channel. Nat Cell Biol 4:191–197. Kraft R and Harteneck C (2005) The mammalian melastatin-related transient receptor potential cation channels: an overview. Pflugers Arch 451:204–211. Kriz W (2005) TRPC6—a new podocyte gene involved in focal segmental glomerulosclerosis. Trends Mol Med 11:527–530. Kuhn FJ, Heiner I, and Luckhoff A (2005) TRPM2: a calcium influx pathway regulated by oxidative stress and the novel second messenger ADP-ribose. Pflugers Arch 451:212–219. Kumar B, Dreja K, Shah SS, Cheong A, Xu SZ, Sukumar P, Naylor J, Forte A, Cipollaro M, McHugh D, Kingston PA, Heagerty AM, Munsch CM, Bergdahl A, Hultgardh-Nilsson A, Gomez MF, Porter KE, Hellstrand P, and Beech DJ (2006) Upregulated TRPC1 channel in vascular injury in vivo and its role in human neointimal hyperplasia. Circ Res 98:557–563. Kuwahara K, Wang Y, McAnally J, Richardson JA, Bassel-Duby R, Hill JA, and Olson EN (2006) TRPC6 fulfills a calcineurin signaling circuit during pathologic cardiac remodeling. J Clin Invest 116:3114–3126. Kwan HY, Huang Y, and Yao X (2007) TRP channels in endothelial function and dysfunction. Biochim Biophys Acta 1772:907–914. Kwan KY, Allchorne AJ, Vollrath MA, Christensen AP, Zhang DS, Woolf CJ, and Corey DP (2006) TRPA1 Contributes to cold, mechanical, and chemical nociception but is not essential for hair-cell transduction. Neuron 50:277–289. Landry Y and Gies JP (2008) Drugs and their molecular targets: an updated overview. Fundam Clin Pharmacol 22:1–18. LaPlante JM, Ye CP, Quinn SJ, Goldin E, Brown EM, Slaugenhaupt SA, and Vassilev PM (2004) Functional links between mucolipin-1 and Ca2+-dependent membrane trafficking in mucolipidosis IV. Biochem Biophys Res Commun 322:1384–1391. Larsson KP, Peltonen HM, Bart G, Louhivuori LM, Penttonen A, Antikainen M, Kukkonen JP, and Akerman KE (2005) Orexin-A induced Ca2+ entry: evidence for involvement of TRPc channels and protein kinase C regulation. J Biol Chem 280:1771–1781. Launay P, Cheng H, Srivatsan S, Penner R, Fleig A, and Kinet JP (2004) TRPM4 regulates calcium oscillations after T cell activation. Science 306:1374–1377. Lee N, Chen J, Sun L, Wu S, Gray KR, Rich A, Huang M, Lin JH, Feder JN, Janovitz EB, Levesque PC, and Blanar MA (2003) Expression and characterization of human transient receptor potential melastatin 3 (hTRPM3). J Biol Chem 278:20890– 20897. Lefer DJ (2007) A new gaseous signaling molecule emerges: cardioprotective role of hydrogen sulfide. Proc Natl Acad Sci U S A 104:17907–17908. Lehen’kyi V, Beck B, Polakowska R, Charveron M, Bordat P, Skryma R, and Prevarskaya N (2007) TRPV6 is a Ca2+ entry channel essential for Ca2+-induced differentiation of human keratinocytes. J Biol Chem 282:22582–22591. Lessard CB, Lussier MP, Cayouette S, Bourque G, and Boulay G (2005) The overexpression of presenilin2 and Alzheimer’s-disease-linked presenilin-2 variants influences TRPC6-enhanced Ca2+ entry into HEK293 cells. Cell Signal 17:437–445.
54
TRP CHANNELS AND HUMAN DISEASES
Leuenroth SJ, Okuhara D, Shotwell JD, Markowitz GS, Yu Z, Somlo S, and Crews CM (2007) Triptolide is a traditional Chinese medicine-derived inhibitor of polycystic kidney disease. Proc Natl Acad Sci U S A 104:4389–4394. Leuner K, Kazanski V, Muller M, Essin K, Henke B, Gollasch M, Harteneck C, and Muller WE (2007) Hyperforin–a key constituent of St. John’s wort specifically activates TRPC6 channels. FASEB J 21:4101–4111. Li HB, Mao RR, Zhang JC, Yang Y, Cao J, and Xu L (2008) Antistress effect of TRPV1 channel on synaptic plasticity and spatial memory. Biol Psychiatry 64:286–292. Li HS, Xu XZ, and Montell C (1999) Activation of a TRPC3-dependent cation current through the neurotrophin BDNF. Neuron 24:261–273. Li M, Jiang J, and Yue L (2006) Functional characterization of homo- and heteromeric channel kinases TRPM6 and TRPM7. J Gen Physiol 127:525–537. Li S, Gosling M, Poll CT, Westwick J, and Cox B (2005a) Therapeutic scope of modulation of non-voltage-gated cation channels. Drug Discov Today 10:129–137. Li X, Luo Y, Starremans PG, McNamara CA, Pei Y, and Zhou J (2005b) Polycystin-1 and polycystin-2 regulate the cell cycle through the helix-loop-helix inhibitor Id2. Nat Cell Biol 7:1102–1112. Li Y, Jia YC, Cui K, Li N, Zheng ZY, Wang YZ, and Yuan XB (2005c) Essential role of TRPC channels in the guidance of nerve growth cones by brain-derived neurotrophic factor. Nature 434:894–898. Li S, Westwick J, Cox B, and Poll CT (2004) TRP channels as drug targets. Novartis Found Symp 258:204–213; discussion 213–221, 263–206. Liedtke W (2005) TRPV4 as osmosensor: a transgenic approach. Pflugers Arch 451: 176–180. Liedtke W, Choe Y, Marti-Renom MA, Bell AM, Denis CS, Sali A, Hudspeth AJ, Friedman JM, and Heller S (2000) Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor. Cell 103:525– 535. Liedtke W and Simon SA (2004) A possible role for TRPV4 receptors in asthma. Am J Physiol Lung Cell Mol Physiol 287:L269–L271. Lindstrom S and Mazieres L (1991) Effect of menthol on the bladder cooling reflex in the cat. Acta Physiol Scand 141:1–10. Lishko PV, Procko E, Jin X, Phelps CB, and Gaudet R (2007) The ankyrin repeats of TRPV1 bind multiple ligands and modulate channel sensitivity. Neuron 54: 905–918. Liu J, Juo SH, Terwilliger JD, Grunn A, Tong X, Brito M, Loth JE, Kanyas K, Lerer B, Endicott J, Penchaszadeh G, Gilliam TC, and Baron M (2001) A follow-up linkage study supports evidence for a bipolar affective disorder locus on chromosome 21q22. Am J Med Genet 105:189–194. Liu Y, Lubin ML, Reitz TL, Wang Y, Colburn RW, Flores CM, and Qin N (2006) Molecular identification and functional characterization of a temperature-sensitive transient receptor potential channel (TRPM8) from canine. Eur J Pharmacol 530: 23–32. Loeys B, Hoebeke P, Raes A, Messiaen L, De Paepe A, and Vande Walle J (2002) Does monosymptomatic enuresis exist? A molecular genetic exploration of 32 families with enuresis/incontinence. BJU Int 90:76–83.
REFERENCES
55
Luzio JP, Poupon V, Lindsay MR, Mullock BM, Piper RC, and Pryor PR (2003) Membrane dynamics and the biogenesis of lysosomes. Mol Membr Biol 20:141– 154. Macdonald JF, Xiong ZG, and Jackson MF (2006) Paradox of Ca(2+) signaling, cell death and stroke. Trends Neurosci 29:75–81. Macpherson L, Geierstanger BH, Viswanath V, Bandell M, Eid SR, and Patapoutian A (2005) The pungency of garlic: activation of TRPA1 and TRPV1 in response to allicin. Curr Biol 15:929–934. Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, and Patapoutian A (2007) Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature 445:541–545. Matthews PJ, Aziz Q, Facer P, Davis JB, Thompson DG, and Anand P (2004) Increased capsaicin receptor TRPV1 nerve fibres in the inflamed human oesophagus. Eur J Gastroenterol Hepatol 16:897–902. Maxfield FR and McGraw TE (2004) Endocytic recycling. Nat Rev Mol Cell Biol 5: 121–132. McKemy DD, Neuhausser WM, and Julius D (2002) Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416:52– 58. McMahon SB and Wood JN (2006) Increasingly irritable and close to tears: TRPA1 in inflammatory pain. Cell 124:1123–1125. McNulty S and Fonfria E (2005) The role of TRPM channels in cell death. Pflugers Arch Eur J Physiol 451:235–242. Meng F, To WK, and Gu Y (2008) Inhibition effect of arachidonic acid on hypoxiainduced [Ca(2+)](i) elevation in PC12 cells and human pulmonary artery smooth muscle cells. Respir Physiol Neurobiol 162:18–23. Mergler S, Strowski MZ, Kaiser S, Plath T, Giesecke Y, Neumann M, Hosokawa H, Kobayashi S, Langrehr J, Neuhaus P, Plockinger U, Wiedenmann B, and Grotzinger C (2007) Transient receptor potential channel TRPM8 agonists stimulate calcium influx and neurotensin secretion in neuroendocrine tumor cells. Neuroendocrinology 85:81–92. Mizoguchi F, Mizuno A, Hayata T, Nakashima K, Heller S, Ushida T, Sokabe M, Miyasaka N, Suzuki M, Ezura Y, and Noda M (2008) Transient receptor potential vanilloid 4 deficiency suppresses unloading-induced bone loss. J Cell Physiol 216: 47–53. Mizushima T, Obata K, Katsura H, Yamanaka H, Kobayashi K, Dai Y, Fukuoka T, Tokunaga A, Mashimo T, and Noguchi K (2006) Noxious cold stimulation induces mitogen-activated protein kinase activation in transient receptor potential (TRP) channels TRPA1- and TRPM8-containing small sensory neurons. Neuroscience 140:1337–1348. Monteilh-Zoller MK, Hermosura MC, Nadler MJ, Scharenberg AM, Penner R, and Fleig A (2003) TRPM7 provides an ion channel mechanism for cellular entry of trace metal ions. J Gen Physiol 121:49–60. Moqrich A, Hwang SW, Earley TJ, Petrus MJ, Murray AN, Spencer KS, Andahazy M, Story GM, and Patapoutian A (2005) Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin. Science 307:1468–1472.
56
TRP CHANNELS AND HUMAN DISEASES
Mori Y, Wakamori M, Miyakawa T, Hermosura M, Hara Y, Nishida M, Hirose K, Mizushima A, Kurosaki M, Mori E, Gotoh K, Okada T, Fleig A, Penner R, Iino M, and Kurosaki T (2002) Transient receptor potential 1 regulates capacitative Ca(2+) entry and Ca(2+) release from endoplasmic reticulum in B lymphocytes. J Exp Med 195:673–681. Moussaieff A, Rimmerman N, Bregman T, Straiker A, Felder CC, Shoham S, Kashman Y, Huang SM, Lee H, Shohami E, Mackie K, Caterina MJ, Walker JM, Fride E, and Mechoulam R (2008) Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB J 22:3024–3034. Muallem S and Moe OW (2007) When EGF is offside, magnesium is wasted. J Clin Invest 117:2086–2089. Mukerji G, Yiangou Y, Corcoran SL, Selmer IS, Smith GD, Benham CD, Bountra C, Agarwal SK, and Anand P (2006) Cool and menthol receptor TRPM8 in human urinary bladder disorders and clinical correlations. BMC Urol 6:6. Muller D, Hoenderop JG, Vennekens R, Eggert P, Harangi F, Mehes K, Garcia-Nieto V, Claverie-Martin F, Os CH, Nilius B, and R JMB (2002) Epithelial Ca(2+) channel (ECAC1) in autosomal dominant idiopathic hypercalciuria. Nephrol Dial Transplant 17:1614–1620. Munns CF and Batch JA (2001) Hyperinsulinism and Beckwith-Wiedemann syndrome. Arch Dis Child Fetal Neonatal Ed 84:F67–F69. Munsch T, Freichel M, Flockerzi V, and Pape HC (2003) Contribution of transient receptor potential channels to the control of GABA release from dendrites. Proc Natl Acad Sci U S A 100:16065–16070. Nadler MJ, Hermosura MC, Inabe K, Perraud AL, Zhu Q, Stokes AJ, Kurosaki T, Kinet JP, Penner R, Scharenberg AM, and Fleig A (2001) LTRPC7 is a Mg.ATPregulated divalent cation channel required for cell viability. Nature 411:590–595. Nagamine K, Kudoh J, Minoshima S, Kawasaki K, Asakawa S, Ito F, and Shimizu N (1998) Molecular cloning of a novel putative Ca2+ channel protein (TRPC7) highly expressed in brain. Genomics 54:124–131. Nagata K, Duggan A, Kumar G, and Garcia-Anoveros J (2005) Nociceptor and hair cell transducer properties of TRPA1, a channel for pain and hearing. J Neurosci 25: 4052–4061. Nagata K, Zheng L, Madathany T, Castiglioni AJ, Bartles JR, and Garcia-Anoveros J (2008) The varitint-waddler (Va) deafness mutation in TRPML3 generates constitutive, inward rectifying currents and causes cell degeneration. Proc Natl Acad Sci U S A 105:353–358. Nakaya K, Harbidge DG, Wangemann P, Schultz BD, Green E, Wall SM, and Marcus DC (2007) Lack of pendrin HCO3- transport elevates vestibular endolymphatic [Ca2+] by inhibition of acid-sensitive TRPV5 and TRPV6 channels. Am J Physiol Renal Physiol 292:F1314–F1321. Nakayama H, Wilkin BJ, Bodi I, and Molkentin JD (2006) Calcineurin-dependent cardiomyopathy is activated by TRPC in the adult mouse heart. FASEB J 20: 1660–1670. Nassenstein C, Kwong KK, Taylor-Clark TE, Kollarik M, Macglashan DW, Braun A, and Undem BJ (2008) TRPA1 expression and function in vagal afferent nerves innervating mouse lungs. J Physiol 586:1595–1604.
REFERENCES
57
Nauli SM, Kawanabe Y, Kaminski JJ, Pearce WJ, Ingber DE, and Zhou J (2008) Endothelial cilia are fluid shear sensors that regulate calcium signaling and nitric oxide production through polycystin-1. Circulation 117:1161–1171. Newson P, Lynch-Frame A, Roach R, Bennett S, Carr V, and Chahl LA (2005) Intrinsic sensory deprivation induced by neonatal capsaicin treatment induces changes in rat brain and behaviour of possible relevance to schizophrenia. Br J Pharmacol 146:408–418. Niizeki T, Takeishi Y, Kitahara T, Arimoto T, Ishino M, Bilim O, Suzuki S, Sasaki T, Nakajima O, Walsh RA, Goto K, and Kubota I (2008) Diacylglycerol kinase{varepsilon} restores cardiac dysfunction under chronic pressure overload: a new specific regulator of G{alpha}q signaling cascade. Am J Physiol Heart Circ Physiol 295:H245–H255. Nijenhuis T, Hoenderop JG, and Bindels RJ (2004) Downregulation of Ca(2+) and Mg(2+) transport proteins in the kidney explains tacrolimus (FK506)-induced hypercalciuria and hypomagnesemia. J Am Soc Nephrol 15:549–557. Nijenhuis T, Hoenderop JG, and Bindels JM (2005a) TRPV5 and TRPV6 in Caz2+ (re) absorption: regulating calcium entry at the gate. Pflugers Arch Eur J Physiol 451: 181–192. Nijenhuis T, Vallon V, van der Kemp AW, Loffing J, Hoenderop JG, and Bindels RJ (2005b) Enhanced passive Ca2+ reabsorption and reduced Mg2+ channel abundance explains thiazide-induced hypocalciuria and hypomagnesemia. J Clin Invest 115: 1651–1658. Nijenhuis T, Hoenderop JG, Loffing J, van der Kemp AW, van Os CH, and Bindels RJ (2003) Thiazide-induced hypocalciuria is accompanied by a decreased expression of Ca2+ transport proteins in kidney. Kidney Int 64:555–564. Nilius B (2007) TRP channels in disease. Biochim Biophys Acta 1772:805–812. Nilius B and Mahieu F (2006) A road map for TRP(I)Ps. Mol Cell 22:297–307. Nilius B, Owsianik G, Voets T, and Peters JA (2007) Transient receptor potential channels in disease. Physiol Rev 87:165–217. Nilius B and Voets T (2005) Trp channels: a TR(I)P through a world of multifunctional cation channels. Pflugers Arch Eur J Physiol 451:1–10. Nilius B and Voets T (2008) A TRP channel-steroid marriage. Nat Cell Biol 10:1383– 1384. Nomoto Y, Yoshida A, Ikeda S, Kamikawa Y, Harada K, Ohwatashi A, and Kawahira K (2008) Effect of menthol on detrusor smooth-muscle contraction and the micturition reflex in rats. Urology. 72:701–705. Obata K, Katsura H, Mizushima T, Yamanaka H, Kobayashi K, Dai Y, Fukuoka T, Tokunaga A, Tominaga M, and Noguchi K (2005) TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. J Clin Invest 115:2393–2401. Oberwinkler J, Lis A, Giehl KM, Flockerzi V, and Philipp SE (2005) Alternative splicing switches the divalent cation selectivity of TRPM3 channels. J Biol Chem 280: 22540–22548. Ohba T, Watanabe H, Murakami M, Takahashi Y, Iino K, Kuromitsu S, Mori Y, Ono K, Iijima T, and Ito H (2007) Upregulation of TRPC1 in the development of cardiac hypertrophy. J Mol Cell Cardiol 42:498–507.
58
TRP CHANNELS AND HUMAN DISEASES
Okuhara DY, Hsia AY, and Xie M (2007) Transient receptor potential channels as drug targets. Expert Opin Ther Targets 11:391–401. O’Neil RG and Heller S (2005) Mechanosensitive nature of TRPV channels. Pflugers Arch Eur J Physiol 451:193–203. Onohara N, Nishida M, Inoue R, Kobayashi H, Sumimoto H, Sato Y, Mori Y, Nagao T, and Kurose H (2006) TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy. EMBO J 25:5305–5316. Otsuguro KI, Tang J, Tang Y, Xiao R, Freichel M, Tsvilovskyy V, Ito S, Flockerzi V, Zhu MX, and Zholos AV (2008) Isoform-specific inhibition of TRPC4 channel by phosphatidylinositol 4,5-bisphosphate. J Biol Chem 283:10026–10036. Pani B and Singh BB (2008) Darier’s disease: a calcium-signaling perspective. Cell Mol Life Sci 65:205–211. Pedersen SF, Owsianik G, and Nilius B (2005) TRP channels: an overview. Cell Calcium 38:233–252. Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, Earley TJ, Dragoni I, McIntyre P, Bevan S, and Patapoutian A (2002) A TRP channel that senses cold stimuli and menthol. Cell 108:705–715. Peng JB, Zhuang L, Berger UV, Adam RM, Williams BJ, Brown EM, Hediger MA, and Freeman MR (2001) CaT1 expression correlates with tumor grade in prostate cancer. Biochem Biophys Res Commun 282:729–734. Perez CA, Huang L, Rong M, Kozak JA, Preuss AK, Zhang H, Max M, and Margolskee RF (2002) A transient receptor potential channel expressed in taste receptor cells. Nat Neurosci 5:1169–1176. Perraud AL, Knowles HM, and Schmitz C (2004) Novel aspects of signaling and ion-homeostasis regulation in immunocytes. The TRPM ion channels and their potential role in modulating the immune response. Mol Immunol 41:657– 673. Petrault I, Zimowska W, Mathieu J, Bayle D, Rock E, Favier A, Rayssiguier Y, and Mazur A (2002) Changes in gene expression in rat thymocytes identified by cDNA array support the occurrence of oxidative stress in early magnesium deficiency. Biochim Biophys Acta 1586:92–98. Petrus M, Peier AM, Bandell M, Hwang SW, Huynh T, Olney N, Jegla T, and Patapoutian A (2007) A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol Pain 3:40. Phelps CB and Gaudet R (2007) The role of the N terminus and transmembrane domain of TRPM8 in channel localization and tetramerization. J Biol Chem 282: 36474–36480. Philipp S, Strauss B, Hirnet D, Wissenbach U, Mery L, Flockerzi V, and Hoth M (2003) TRPC3 mediates T-cell receptor-dependent calcium entry in human T-lymphocytes. J Biol Chem 278:26629–26638. Plato CC, Galasko D, Garruto RM, Plato M, Gamst A, Craig UK, Torres JM, and Wiederholt W (2002) ALS and PDC of Guam: forty-year follow-up. Neurology 58: 765–773. Plato CC, Garruto RM, Galasko D, Craig UK, Plato M, Gamst A, Torres JM, and Wiederholt W (2003) Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: changing incidence rates during the past 60 years. Am J Epidemiol 157:149–157.
REFERENCES
59
Poduslo SE, Huang R, Huang J, and Smith S (2009) Genome screen of late-onset Alzheimer’s extended pedigrees identifies TRPC4AP by haplotype analysis. Am J Med Genet B Neuropsychiatr Genet 150B:50–55. Prawitt D, Enklaar T, Klemm G, Gartner B, Spangenberg C, Winterpacht A, Higgins M, Pelletier J, and Zabel B (2000) Identification and characterization of MTR1, a novel gene with homology to melastatin (MLSN1) and the trp gene family located in the BWS-WT2 critical region on chromosome 11p15.5 and showing allele-specific expression. Hum Mol Genet 9:203–216. Prawitt D, Monteilh-Zoller MK, Brixel L, Spangenberg C, Zabel B, Fleig A, and Penner R (2003) TRPM5 is a transient Ca2+-activated cation channel responding to rapid changes in [Ca2+]i. Proc Natl Acad Sci U S A 100:15166–15171. Proudfoot CJ, Garry EM, Cottrell DF, Rosie R, Anderson H, Robertson DC, Fleetwood-Walker SM, and Mitchell R (2006) Analgesia mediated by the TRPM8 cold receptor in chronic neuropathic pain. Curr Biol 16:1591–1605. Qian F and Noben-Trauth K (2005) Cellular and molecular function of mucolipins (TRPML) and polycystin 2 (TRPP2). Pflugers Arch 451:277–285. Quadid-Ahidouch H and Ahidouch A (2007) K+ channel expression in human breast cancer cells: involvement in cell cycle regulation and carcinogenesis. J Membrane Biol 221:1–6. Ramsey IS, Delling M, and Clapham DE (2006) An introduction to TRP channels. Annu Rev Physiol 68:619–647. Rau KK, Jiang N, Johnson R, and Cooper BY (2007) Heat sensitization in skin and muscle nociceptors expressing distinct combinations of TRPV1 and TRPV2 protein. J Neurophysiol 97:2651–2662. Raychowdhury MK, Gonzalez-Perrett S, Montalbetti N, Timpanaro GA, Chasan B, Goldmann WH, Stahl S, Cooney A, Goldin E, and Cantiello HF (2004) Molecular pathophysiology of mucolipidosis type IV: pH dysregulation of the mucolipin-1 cation channel. Hum Mol Genet 13:617–627. Reid G (2005) ThermoTRP channels and cold sensing: what are they really up to? Pflugers Arch Eur J Physiol 451:250–263. Reiser J, Polu KR, Moller CC, Kenlan P, Altintas MM, Wei C, Faul C, Herbert S, Villegas I, Avila-Casado C, McGee M, Sugimoto H, Brown D, Kalluri R, Mundel P, Smith PL, Clapham DE, and Pollak MR (2005) TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function. Nat Genet 37:739–744. Rodriguez-Santiago M, Mendoza-Torres M, Jimenez-Bremont JF, and Lopez-Revilla R (2007) Knockout of the trcp3 gene causes a recessive neuromotor disease in mice. Biochem Biophys Res Commun 360:874–879. Rosen DR, Siddique T, Patterson D, Figlewicz DA, Sapp P, Hentati A, Donaldson D, Goto J, O’Regan JP, Deng HX, Rahmani Z, Krizus A, McKenna-Yasek D, Cayabyab A, Gaston SM, Berger R, Tanzi RE, Halperin JJ, Herzfeldt B, Van den Bergh R, Hung W-H, Bird T, Deng G, Mulder DW, Smyth C, Laing NG, Soriano E, Pericak-Vance MA, Haines J, Rouleau GA, Gusella JS, Horvitz HR, and Brown RH (1993) Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362:59–62. Runnels LW, Yue L, and Clapham DE (2001) TRP-PLIK, a bifunctional protein with kinase and ion channel activities. Science 291:1043–1047.
60
TRP CHANNELS AND HUMAN DISEASES
Sabnis AS, Shadid M, Yost GS, and Reilly CA (2008) Human lung epithelial cells express a functional cold-sensing TRPM8 variant. Am J Respir Cell Mol Biol 39: 466–474. Salazar H, Llorente I, Jara-Oseguera A, Garcia-Villegas R, Munari M, Gordon SE, Islas LD, and Rosenbaum T (2008) A single N-terminal cysteine in TRPV1 determines activation by pungent compounds from onion and garlic. Nat Neurosci 11: 255–261. Sano Y, Inamura K, Miyake A, Mochizuki S, Yokoi H, Matsushime H, and Furuichi K (2001) Immunocyte Ca2+ influx system mediated by LTRPC2. Science 293: 1327–1330. Scharenberg AM (2005) TRPM2 and TRPM7: channel/enzyme fusions to generate novel intracellular sensors. Pflugers Arch 451:220–227. Schicho R, Florian W, Liebmann I, Holzer P, and Lippe IT (2004) Increased expression of TRPV1 receptor in dorsal root ganglia by acid insult of the rat gastric mucosa. Eur J Neurosci 19:1811–1818. Schiller Y (2004) Activation of a calcium-activated cation current during epileptiform discharges and its possible role in sustaining seizure-like events in neocortical slices. J Neurophysiol 92:862–872. Schlingmann KP, Sassen MC, Weber S, Pechmann U, Kusch K, Pelken L, Lotan D, Syrrou M, Prebble JJ, Cole DE, Metzger DL, Rahman S, Tajima T, Shu SG, Waldegger S, Seyberth HW, and Konrad M (2005) Novel TRPM6 mutations in 21 families with primary hypomagnesemia and secondary hypocalcemia. J Am Soc Nephrol 16:3061–3069. Schlingmann KP, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, Kratz M, Haddad E, Ristoff E, Dinour D, Syrrou M, Nielsen S, Sassen M, Waldegger S, Seyberth HW, and Konrad M (2002) Hypomagnesemia with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. Nat Genet 31:166–170. Schmitz C, Perraud AL, Johnson CO, Inabe K, Smith MK, Penner R, Kurosaki T, Fleig A, and Scharenberg AM (2003) Regulation of vertebrate cellular Mg2+ homeostasis by TRPM7. Cell 114:191–200. Schwarz EC, Wissenbach U, Niemeyer BA, Strauss B, Philipp SE, Flockerzi V, and Hoth M (2006) TRPV6 potentiates calcium-dependent cell proliferation. Cell Calcium 39:163–173. Shan D, Marchase RB, and Chatham JC (2008) Overexpression of TRPC3 increases apoptosis but not necrosis in response to ischemia-reperfusion in adult mouse cardiomyocytes. Am J Physiol Cell Physiol 294:C833–C841. Shim S, Goh EL, Ge S, Sailor K, Yuan JP, Roderick HL, Bootman MD, Worley PF, Song H, and Ming GL (2005) XTRPC1-dependent chemotropic guidance of neuronal growth cones. Nat Neurosci 8:730–735. Shimosato G, Amaya F, Ueda M, Tanaka Y, Decosterd I, and Tanaka M (2005) Peripheral inflammation induces up-regulation of TRPV2 expression in rat DRG. Pain 119:225–232. Sidhaye VK, Guler AD, Schweitzer KS, D’Alessio F, Caterina MJ, and King LS (2006) Transient receptor potential vanilloid 4 regulates aquaporin-5 abundance under hypotonic conditions. Proc Natl Acad Sci U S A 103:4747–4752.
REFERENCES
61
Simard JM and Chen M (2004) Regulation by sulfanylurea receptor type 1 of a nonselective cation channel involved in cytotoxic edema of reactive astrocytes. J Neurosurg Anesthesiol 16:98–99. Simard JM, Chen M, Tarasov KV, Bhatta S, Ivanova S, Melnitchenko L, Tsymbalyuk N, West GA, and Gerzanich V (2006) Newly expressed SUR1-regulated NC(CaATP) channel mediates cerebral edema after ischemic stroke. Nat Med 12:433– 440. Sipe W, Brierley SM, Martin CM, Phillis BD, Bautista Cruz F, Grady EF, Liedtke W, Cohen DM, Vanner SJ, Blackshaw L, and Bunnett NW (2008) Transient receptor potential vanilloid 4 mediates protease activated receptor 2-induced sensitization of colonic afferent nerves and visceral hyperalgesia. Am J Physiol Gastrointest Liver Physiol 294:G1288–G1298. Somjen GG (2001) Mechanisms of spreading depression and hypoxic SD-like depolarization. Physiol Rev 81:1065–1096. Somlo S and Markowitz GS (2000) The pathogenesis of autosomal dominant polycystic kidney disease: an update. Curr Opin Nephrol Hypertens 9:385–394. Song Y, Dayalu R, Matthews SA, and Scharenberg AM (2006) TRPML cation channels regulate the specialized lysosomal compartment of vertebrate B-lymphocytes. Eur J Cell Biol 85:1253–1264. Sontia B, Montezano AC, Paravicini T, Tabet F, and Touyz RM (2008) Downregulation of renal TRPM7 and increased inflammation and fibrosis in aldosterone-infused mice: effects of magnesium. Hypertension 51:915–921. Stein RJ, Santos S, Nagatomi J, Hayashi Y, Minnery BS, Xavier M, Patel AS, Nelson JB, Futrell WJ, Yoshimura N, Chancellor MB, and De Miguel F (2004) Cool (TRPM8) and hot (TRPV1) receptors in the bladder and male genital tract. J Urol 172:1175–1178. Stiber JA, Zhang ZS, Burch J, Eu JP, Zhang S, Truskey GA, Seth M, Yamaguchi N, Meissner G, Shah R, Worley PF, Williams RS, and Rosenberg PB (2008) Mice lacking Homer 1 exhibit a skeletal myopathy characterized by abnormal TRP channel activity. Mol Cell Biol 28:2637–2647. Stokes A, Wakano C, Koblan-Huberson M, Adra CN, Fleig A, and Turner H (2006) TRPA1 is a substrate for de-ubiquitination by the tumor suppressor CYLD. Cell Signal 18:1584–1594. Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacher J, Hricik TR, Earley TJ, Hergarden AC, Andersson DA, Hwang SW, McIntyre P, Jegla T, Bevan S, and Patapoutian A (2003) ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112:819–829. Straub RE, Lehner T, Luo Y, Loth JE, Shao W, Sharpe L, Alexander JR, Das K, Simon R, Fieve RR, Lerer B, Endicott J, Ott J, Gilliam TC, and Baron M (1994) A possible vulnerability locus for bipolar affective disorder on chromosome 21q22.3. Nat Genet 8:291–296. Streng T, Axelsson HE, Hedlund P, Andersson DA, Jordt SE, Bevan S, Andersson KE, Hogestatt ED, and Zygmunt PM (2008) Distribution and function of the hydrogen sulfide-sensitive TRPA1 ion channel in rat urinary bladder. Eur Urol 53:391–399. Strubing C, Krapivinsky G, Krapivinsky L, and Clapham DE (2001) TRPC1 and TRPC5 form a novel cation channel in mammalian brain. Neuron 29:645–655.
62
TRP CHANNELS AND HUMAN DISEASES
Strubing C, Krapivinsky G, Krapivinsky L, and Clapham DE (2003) Formation of novel TRPC channels by complex subunit interactions in embryonic brain. J Biol Chem 278:39014–39019. Stumpf T, Zhang Q, Hirnet D, Lewandrowski U, Sickmann A, Wissenbach U, Dörr J, Lohr C, Deitmer JW, and Fecher-Trost C (2008) The human TRPV6 channel protein is associated with cyclophilin B in human placenta. J Biol Chem 283: 18086–18098. Suh SH, Watanabe H, Droogmans G, and Nilius B (2002) ATP and nitric oxide modulate a Ca2+-activated non-selective cation current in macrovascular endothelial cells. Pflugers Arch Eur J Physiol 444:438–445. Sun M, Goldin E, Stahl S, Falardeau JL, Kennedy JC, Acierno JS Jr., Bove C, Kaneski CR, Nagle J, Bromley MC, Colman M, Schiffmann R, and Slaugenhaupt SA (2000) Mucolipidosis type IV is caused by mutations in a gene encoding a novel transient receptor potential channel. Hum Mol Genet 9:2471–2478. Sun X and Ku DD (2006) Allicin in garlic protects against coronary endothelial dysfunction and right heart hypertrophy in pulmonary hypertensive rats. Am J Physiol Heart Circ Physiol 291:H2431–2438. Sutters M and Germino GG (2003) Autosomal dominant polycystic kidney disease: molecular genetics and pathophysiology. J Lab Clin Med 141:91–101. Suzuki Y, Kovacs CS, Takanaga H, Peng JB, Landowski CP, and Hediger MA (2008a) The calcium channel TRPV6 is involved in murine maternal-fetal calcium transport. J Bone Miner Res 23:1249–1256. Suzuki Y, Pasch A, Bonny O, Mohaupt MG, Hediger MA, and Frey FJ (2008b) Gain of function haplotype in the epithelial calcium channel TRPV6 is a risk factor for renal calcium stone formation. Hum Mol Genet 17:1613–1618. Szallasi A, Cortright DN, Blum CA, and Eid SR (2007) The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 6:357–372. Tabuchi K, Suzuki M, Mizuno A, and Hara A (2005) Hearing impairment in TRPV4 knockout mice. Neurosci Lett 382:304–308. Tai C, Zhu SJ, and Zhou N (2008) TRPA1: the central moleculae for chemical sensing in pain pathway? J Neurosciences 28:1019–1021. Takahashi Y, Watanabe H, Murakami M, Ohba T, Radovanovic M, Ono K, Iijima T, and Ito H (2007) Involvement of transient receptor potential canonical 1 (TRPC1) in angiotensin II-induced vascular smooth muscle cell hypertrophy. Atherosclerosis 195:287–296. Takashima Y, Daniels RL, Knowlton W, Teng J, Liman ER, and McKemy DD (2007) Diversity in the neural circuitry of cold sensing revealed by genetic axonal labeling of transient receptor potential melastatin 8 neurons. J Neurosci 27: 14147–14157. Taylor-Clark TE, McAlexander MA, Nassenstein C, Sheardown SA, Wilson S, Thornton J, Carr MJ, and Undem BJ (2008) Relative contributions of TRPA1 and TRPV1 channels in the activation of vagal bronchopulmonary C-fibres by the endogenous autocoid 4-oxononenal. J Physiol 586:3447–3459. Thebault S, Lemonnier L, Bidaux G, Flourakis M, Bavencoffe A, Gordienko D, Roudbaraki M, Delcourt P, Panchin Y, Shuba Y, Skryma R, and Prevarskaya N
REFERENCES
63
(2005) Novel role of cold/menthol-sensitive transient receptor potential melastatine family member 8 (TRPM8) in the activation of store-operated channels in LNCaP human prostate cancer epithelial cells. J Biol Chem 280:39423–39435. Thorneloe KS, Sulpizio AC, Lin Z, Figueroa DJ, Clouse AK, McCafferty GP, Chendrimada TP, Lashinger ES, Gordon EA, Evans L, Misajet BA, Demarini DJ, Nation JH, Casillas LN, Marquis RW, Votta BJ, Sheardown SA, Xu X, Brooks DP, Laping N, and Westfall TD (2008) GSK1016790A, a novel and potent TRPV4 channel agonist induces urinary bladder contraction and hyperactivity: part I. J Pharmacol Exp Ther 326:432–442. Tiruppathi C, Freichel M, Vogel SM, Paria BC, Mehta D, Flockerzi V, and Malik AB (2002) Impairment of store-operated Ca2+ entry in TRPC4(-/-) mice interferes with increase in lung microvascular permeability. Circ Res 91:70–76. Todaka H, Taniguchi J, Satoh J, Mizuno A, and Suzuki M (2004) Warm temperaturesensitive transient receptor potential vanilloid 4 (TRPV4) plays an essential role in thermal hyperalgesia. J Biol Chem 279:35133–35138. Tong Q, Hirschler-Laszkiewicz I, Zhang W, Conrad K, Neagley DW, Barber DL, Cheung JY, and Miller BA (2008) TRPC3 is the epo-regulated calcium channel in human erythroid cells. J Biol Chem 283:10385–10395. Touyz RM (2003) Role of magnesium in the pathogenesis of hypertension. Mol Aspects Med 24:107–136. Touyz RM, He Y, Montezano AC, Yao G, Chubanov V, Gudermann T, and Callera GE (2005) Differential regulation of TRPM6/7 cation channels by Ang II in vascular smooth muscle cells from spontaneously hypertensive rats. Am J Physiol Regul Integr Comp Physiol 290:R73–R78. Touyz RM and Yao G (2003) Modulation of vascular smooth muscle cell growth by magnesium-role of mitogen-activated protein kinases. J Cell Physiol 197:326– 335. Trevisani M, Siemens J, Materazzi S, Bautista DM, Nassini R, Campi B, Imamachi N, Andre E, Patacchini R, Cottrell GS, Gatti R, Basbaum AI, Bunnett NW, Julius D, and Geppetti P (2007) 4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenic inflammation through activation of the irritant receptor TRPA1. Proc Natl Acad Sci U S A 104:13519–13524. Tsukimi Y, Mizuyachi K, Yamasaki T, Niki T, and Hayashi F (2005) Cold response of the bladder in guinea pig: involvement of transient receptor potential channel, TRPM8. Urology 65:406–410. Uemura T, Kudoh J, Noda S, Kanba S, and Shimizu N (2005) Characterization of human and mouse TRPM2 genes: identification of a novel N-terminal truncated protein specifically expressed in human striatum. Biochem Biophys Res Commun 328:1232–1243. van Abel M, Hoenderop JG, and Bindels RJ (2005) The epithelial calcium channels TRPV5 and TRPV6: regulation and implications for disease. Naunyn Schmiedebergs Arch Pharmacol 371:295–306. van Abel M, Huybers S, Hoenderop JG, van der Kemp AW, van Leeuwen JP, and Bindels RJ (2006) Age-dependent alterations in Ca2+ homeostasis: role of TRPV5 and TRPV6. Am J Physiol Renal Physiol 291:F1177–F1183.
64
TRP CHANNELS AND HUMAN DISEASES
van Breemen C, Poburko D, and Okon EB (2006) TRP proteins: a new dimension in the treatment of occlusive vascular disease. Circ Res 98:446–447. Vandebrouck A, Sabourin J, Rivet J, Balghi H, Sebille S, Kitzis A, Raymond G, Cognard C, Bourmeyster N, and Constantin B (2007) Regulation of capacitative calcium entries by {alpha}1-syntrophin: association of TRPC1 with dystrophin complex and the PDZ domain of {alpha}1-syntrophin. FASEB J 21:608–617. Vazquez G, Wedel BJ, Aziz O, Trebak M, and Putney JW Jr. (2004) The mammalian TRPC cation channels. Biochim Biophys Acta 1742:21–36. Veliceasa D, Ivanovic M, Hoepfner FT, Thumbikat P, Volpert OV, and Smith ND (2007) Transient potential receptor channel 4 controls thrombospondin-1 secretion and angiogenesis in renal cell carcinoma. FEBS J 274:6365–6377. Venkatachalam K, Hofmann T, and Montell C (2006) Lysosomal localization of TRPML3 depends on TRPML2 and the mucolipidosis-associated protein TRPML1. J Biol Chem 281:17517–17527. Venkatachalam K and Montell C (2007) TRP channels. Annu Rev Biochem 76:387–417. Venkatachalam K, van Rossum DB, Patterson RL, Ma HT, and Gill DL (2002) The cellular and molecular basis of store-operated calcium entry. Nat Cell Biol 4: E263–E272. Venkatachalam K, Zheng F, and Gill DL (2003) Regulation of canonical transient receptor potential (TRPC) channel function by diacylglycerol and protein kinase C. J Biol Chem 278:29031–29040. Vennekens R, Hoenderop JG, Prenen J, Stuiver M, Willems PH, Droogmans G, Nilius B, and Bindels RJ (2000) Permeation and gating properties of the novel epithelial Ca2+ channel. J Biol Chem 275:3963–3969. Vennekens R and Nilius B (2007) Insight into TRPM4 function, regulation and physiological role. In Transient Receptor Potentail (TRP) Channels (Flockerzi V and Nilius B, eds.), pp. 269–285. Springer-Verlag, Berlin/Heidelberg/New York. Vennekens R, Olausson J, Meissner M, Bloch W, Mathar I, Philipp S, Schmitz F, Weissgerber P, Nilius B, Flockerzi V, and Freichel M (2007) Increased IgEdependent mast cell activation and anaphylactic responses in mice lacking the Ca2+activated non-selective cation channel TRPM4. Nat Immunol 8:312–320. Vennekens R, Owsianik G, and Nilius B (2008) Vanilloid transient receptor potential cation channels: an overview. Curr Pharm Des 14:18–31. Voets T, Nilius B, Hoefs S, van der Kemp AW, Droogmans G, Bindels RJ, and Hoenderop JG (2004) TRPM6 forms the Mg2+ influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem 279:19–25. Voets T, Talavera K, Owsianik G, and Nilius B (2005) Sensing with TRP channels. Nat Biol Chem 1:85–92. Wagner TF, Loch S, Lambert S, Straub I, Mannebach S, Mathar I, Dufer M, Lis A, Flockerzi V, Philipp SE, and Oberwinkler J (2008) Transient receptor potential M3 channels are ionotropic steroid receptors in pancreatic beta cells. Nat Cell Biol 10: 1421–1430. Walder RY, Landau D, Meyer P, Shalev H, Tsolia M, Borochowitz Z, Boettger MB, Beck GE, Englehardt RK, Carmi R, and Sheffield VC (2002) Mutation of TRPM6
REFERENCES
65
causes familial hypomagnesemia with secondary hypocalcemia. Nat Genet 31: 171–174. Wang J, Weigand L, Lu W, Sylvester JT, Semenza GL, and Shimoda LA (2006) Hypoxia inducible factor 1 mediates hypoxia-induced TRPC expression and elevated intracellular Ca2+ in pulmonary smooth muscle cells. Circ Res 98:1528–1537. Wangemann P, Nakaya K, Wu T, Maganti RJ, Itza EM, Sanneman JD, Harbidge DG, Billings S, and Marcus DC (2007) Loss of cochlear HCO3- secretion causes deafness via endolymphatic acidification and inhibition of Ca2+ reabsorption in a Pendred syndrome mouse model. Am J Physiol Renal Physiol 292:F1345– 1353. Watanabe H, Murakami M, Ohba T, Takahashi Y, and Ito H (2008) TRP channel and cardiovascular disease. Pharmacol Ther 118:337–351. Wei WL, Sun HS, Olah ME, Sun X, Czerwinska E, Czerwinski W, Mori Y, Orser BA, Xiong ZG, Jackson MF, Tymianski M, and Macdonald JF (2007) TRPM7 channels in hippocampal neurons detect levels of extracellular divalent cations. Proc Natl Acad Sci U S A 104:16232–16328. Weil A, Moore SE, Waite NJ, Randall A, and Gunthorpe MJ (2005) Conservation of functional and pharmacological properties in the distantly related temperature sensors TRPV1 and TRPM8. Mol Pharmacol 68:518–527. Weissmann N, Dietrich A, Fuchs B, Kalwa H, Ay M, Dumitrascu R, Olschewski A, Storch U, Mederos YSM, Ghofrani HA, Schermuly RT, Pinkenburg O, Seeger W, Grimminger F, and Gudermann T (2006) Classical transient receptor potential channel 6 (TRPC6) is essential for hypoxic pulmonary vasoconstriction and alveolar gas exchange. Proc Natl Acad Sci U S A 103:19093–19098. Welsh D, Morielli A, Nelson M, and Brayden J (2002) Transient receptor potential channels regulate myogenic tone of resistance arteries. Circ Res 90:248–250. Willette R, Bao W, Nerurkar S, Yue TL, Doe CP, Stankus G, Turner GH, Ju H, Thomas H, Fishman C, Sulpizio A, Behm D, Hoffman S, Lin Z, Lozinskaya I, Casillas L, Lin M, Trout RE, T, Thorneloe K, Lashinger ES, Figueroa DJ, Votta B, Marquis R, and Xu X (2008) Systemic activation of the transient receptor potential V4 channel causes endothelial failure and circulatory collapse: part 2. J Pharmacol Exp Ther 326:443–452. Wilson FH, Kahle KT, Sabath E, Lalioti MD, Rapson AK, Hoover RS, Hebert SC, Gamba G, and Lifton RP (2003) Molecular pathogenesis of inherited hypertension with hyperkalemia: the Na-Cl cotransporter is inhibited by wild-type but not mutant WNK4. Proc Natl Acad Sci U S A 100:680–684. Winn MP (2008) 2007 Young Investigator Award: TRP’ing into a new era for glomerular disease. J Am Soc Nephrol 19:1071–1075. Winn MP, Conlon PJ, Lynn KL, Farrington MK, Creazzo T, Hawkins AF, Daskalakis N, Kwan SY, Eversviller S, Burchette JL, Pericak-Vance MA, Howell DN, Vance JM, and Rosenberg PB (2005) A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis. Science 308:1801–1804. Winn MP, Daskalakis N, Spurney RF, and Middleton JP (2006) Unexpected role of TRPC6 channel in familial nephrotic syndrome: does it have clinical implications? J Am Soc Nephrol 17:378–387. Wissenbach U, Niemeyer BA, Fixemer T, Schneidewind A, Trost C, Cavalie A, Reus K, Meese E, Bonkhoff H, and Flockerzi V (2001) Expression of CaT-like, a novel
66
TRP CHANNELS AND HUMAN DISEASES
calcium-selective channel, correlates with the malignancy of prostate cancer. J Biol Chem 276:19461–19468. Wolf FI and Cittadini A (1999) Magnesium in cell proliferation and differentiation. Front Biosci 4:D607–D617. Wu G, Markowitz GS, Li L, D’Agati VD, Factor SM, Geng L, Tibara S, Tuchman J, Cai Y, Park JH, van Adelsberg J, Hou H Jr., Kucherlapati R, Edelmann W, and Somlo S (2000) Cardiac defects and renal failure in mice with targeted mutations in Pkd2. Nat Genet 24:75–78. Xiao R, Tian J, Tang J, and Zhu MX (2008) The TRPV3 mutation associated with the hairless phenotype in rodents is constititively active. Cell Calcium 43:334–343. Xing H, Chen M, Ling J, Tan W, and Gu JG (2007) TRPM8 mechanism of cold allodynia after chronic nerve injury. J Neurosci 27:13680–13690. Xing H, Ling JX, Chen M, Johnson RD, Tominaga M, Wang CY, and Gu J (2008) TRPM8 mechanism of autonomic nerve response to cold in respiratory airway. Mol Pain 4:22. Xu C, Macciardi F, Li PP, Yoon IS, Cooke RG, Hughes B, Parikh SV, McIntyre RS, Kennedy JL, and Warsh JJ (2006) Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 141:36–43. Xu H, Delling M, Li L, Dong X, and Clapham DE (2007) Activating mutation in a mucolipin transient receptor potential channle leads to melanocyte loss in varitintwaddler mice. Proc Natl Acad Sci U S A 104:18321–18326. Xu HX, Ramsey IS, Kotecha SA, Moran MM, Chong JHA, Lawson D, Ge P, Lilly J, Silos Santiago I, Xie Y, DiStefano PS, Curtis R, and Clapham DE (2002) TRPV3 is a calcium-permeable temperature-sensitive cation channel. Nature 418:181– 186. Xu SZ, Sukumar P, Zeng F, Li J, Jairaman A, English A, Naylor J, Ciurtin C, Majeed Y, Milligan CJ, Bahnasi YM, Al-Shawaf E, Porter KE, Jiang LH, Emery P, Sivaprasadarao A, and Beech DJ (2008) TRPC channel activation by extracellular thioredoxin. Nature 451:69–72. Xu XZ, Moebius F, Gill DL, and Montell C (2001) Regulation of melastatin, a TRPrelated protein, through interaction with a cytoplasmic isoform. Proc Natl Acad Sci U S A 98:10692–10697. Yamamoto S, Shimizu S, Kiyonaka S, Takahashi N, Wajima T, Hara Y, Negoro T, Hiroi T, Kiuchi Y, Okada T, Kaneko S, Lange I, Fleig A, Penner R, Nishi M, Takeshima H, and Mori Y (2008) TRPM2-mediated Ca(2+) influx induces chemokine production in monocytes that aggravates inflammatory neutrophil infiltration. Nat Med 14:738–747. Yamamura H, Ugawa S, Ueda T, Morita A and Shoichi S (2008) TRPM8 activation suppresses cellular viability in human melanoma. Am J Physiol Cell Physiol. 295: C296-C301. Yamauchi D, Raveendran NN, Pondugula SR, Kampalli SB, Sanneman JD, Harbidge DG, and Marcus DC (2005) Vitamin D upregulates expression of ECaC1 mRNA in semicircular canal. Biochem Biophys Res Commun 331:1353–1357. Yang CL, Angell J, Mitchell R, and Ellison DH (2003) WNK kinases regulate thiazidesensitive Na-Cl cotransport. J Clin Invest 111:1039–1045.
REFERENCES
67
Yao X and Garland CJ (2005) Recent developments in vascular endothelial cell transient receptor potential channels. Circ Res 97:853–863. Yin J, Hoffmann J, Kaestle SM, Neye N, Wang L, Baeurle J, Liedtke W, Wu S, Kuppe H, Pries AR, and Kueble rWM (2008) Negative-feedback loop attenuates hydrostatic lung edema via a cGMP-dependent regulation of transient receptor potential vanilloid 4. Circ Res 102:966–974. Yu Y, Fantozzi I, Remillard CV, Landsberg JW, Kunichika N, Platoshyn O, Tigno DD, Thistlethwaite PA, Rubin LJ, and Yuan JX (2004) Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension. Proc Natl Acad Sci U S A 101:13861–13866. Yue L, Peng JB, Hediger MA, and Clapham DE (2001) CaT1 manifests the pore properties of the calcium-release-activated calcium channel. Nature 410:705–709. Zhang L and Barritt GJ (2004) Evidence that TRPM8 is an androgen-dependent Ca2+ channel required for the survival of prostate cancer cells. Cancer Res 64: 8365–8373. Zhang L and Barritt GJ (2006) TRPM8 in prostate cancer cells: a potential diagnostic and prognostic marker with a secretory function? Endocr Relat Cancer 13:27–38. Zhang LL, Yan Liu D, Ma LQ, Luo ZD, Cao TB, Zhong J, Yan ZC, Wang LJ, Zhao ZG, Zhu SJ, Schrader M, Thilo F, Zhu ZM, and Tepel M (2007a) Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity. Circ Res 100:1063–1070. Zhang Y, Wang YH, Ge HY, Arendt-Nielsen L, Wang R, and Yue SW (2007b) A transient receptor potential vanilloid 4 contributes to mechanical allodynia following chronic compression of dorsal root ganglion in rats. Neurosci Lett 432: 222–227. Zhang W, Hirschler-Laszkiewicz I, Tong Q, Conrad K, Sun SC, Penn L, Barber DL, Stahl R, Carey DJ, Cheung JY, and Miller BA (2005) TRPM2 is an ion channel which modulates hematopoietic cell death through activation of caspases and PARP cleavage. Am J Physiol Cell Physiol 290:C1146–C1159. Zhang Y, Hoon MA, Chandrashekar J, Mueller KL, Cook B, Wu D, Zuker CS, and Ryba NJ (2003) Coding of sweet, bitter, and umami tastes: different receptor cells sharing similar signaling pathways. Cell 112:293–301. Zhou FW, Matta SG, and Zhou FM (2008a) Constitutively active TRPC3 channels regulate basal ganglia output neurons. J Neurosci 28:473–482. Zhou J, Du W, Zhou K, Tai Y, Yao H, Jia Y, Ding Y, and Wang Y (2008b) Critical role of TRPC6 channels in the formation of excitatory synapses. Nat Neurosci 11: 741–743. Zhuang L, Peng JB, Tou L, Takanaga H, Adam RM, Hediger MA, and Freeman MR (2002) Calcium-selective ion channel, CaT1, is apically localized in gastrointestinal tract epithelia and is aberrantly expressed in human malignancies. Lab Invest 82: 1755–1764. Zimowska W, Girardeau JP, Kuryszko J, Bayle D, Rayssiguier Y, and Mazur A (2002) Morphological and immune response alterations in the intestinal mucosa of the mouse after short periods on a low-magnesium diet. Br J Nutr 88:515–522.
2 ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW Arpad Szallasi
2.1
INTRODUCTION
Despite the investment of significant resources by the pharmaceutical industry to identify novel analgesic drugs, chronic pain, which is most commonly defined as pain lasting longer than 3 months (i.e., outlasting the usual healing process), still represents a difficult treatment challenge in a large sector of the population, consisting of an estimated 50 million Americans (http:// www.painfoundation.org). Patients suffering from disabling painful conditions often need complex and aggressive treatment that combines medical and surgical approaches (Campbell et al., 2006; Gidal and Billington, 2006; Katz and Berkin, 2008). The mainstay of medical pain therapy remains drugs that have been around for decades, like nonsteroidal anti-inflammatory drugs (NSAIDs), or drugs that have been around even for centuries, such as opiates (Katz and Berkin, 2008). Many patients, however, find that overthe-counter NSAID medications are ineffective for pain relief. Opiates are very powerful painkillers, but their clinical use is limited by adverse effects (Gallagher and Rosenthal, 2008). Also, many clinicians are concerned about the abuse of opiates (http://www.opiates.com/prescription-painkillersaddiction.html). Of the newer agents, the COX-2 inhibitor rofecoxib (sold by Merck under the brand name Vioxx) was withdrawn from the market over concerns of its cardiovascular side effects (Brophy, 2007), casting a large cloud over the Vanilloid Receptor TRPV1 in Drug Discovery, Edited by Arthur Gomtsyan & Connie R. Faltynek Copyright © 2010 John Wiley & Sons, Inc.
68
THE CENTRAL ROLE OF TRP CHANNELS
69
future of this class of drugs (Scanzello et al., 2008). Adverse effects also appear to plague the use of other recent additions to the market. For example, pregabalin (marketed as Lyrica), which is an α2δ calcium channel blocker, is poorly tolerated by some patients due to its central nervous system (CNS) adverse effects, especially somnolence and dizziness (Owen, 2007).The clinical use of ziconotide (brand named Prialt), which is a conopeptide N-type calcium channel blocker, is restricted to intractable (opiate-refractory) pain due to a combination of side effects and the need for intrathecal delivery (Wallace, 2006). Consequently, chronic pain is often undertreated and remains a significant unmet medical need (http://www.aarp.org/health/brain/diseases/chronic_ pain.html) (Dray, 2008; Katz and Berkin, 2008). In late 2000, the U.S. Congress declared the 10-year period that began January 1, 2001 as the Decade of Pain Control and Research (http://www. ampainsoc.org/decadeofpain). Furthermore, the Joint Commission of Accreditation of Healthcare Organizations (JCAHO) has mandated pain as the “fifth vital sign” (the other four being blood pressure, respiration, pulse, and temperature). Over the past few years, significant scientific progress has been made in our understanding of the mechanisms that underlie inflammatory and neuropathic pain. Preclinical research has identified new factors and mechanisms that are involved in the development and maintenance of chronic pain, many of which represent potential therapeutic targets (Stucky et al., 2001; Cortright et al., 2007; Cheng and Ji, 2008; Oertel and Lötsch, 2008; Zhuo, 2008). A key discovery was the molecular cloning of the vanilloid (capsaicin) receptor transient receptor potential vanilloid subfamily member 1 (TRPV1), a polymodal nociceptor on primary sensory neurons (Caterina et al., 1997). Targeting TRPV1 represents a new strategy in pain relief (Malmberg and Bley, 2005; Roberts and Connor, 2006; Szallasi et al., 2007; Knotkova et al., 2008). In contrast to traditional analgesic agents that either suppress inflammation (e.g., NSAIDs) or inhibit pain transmission (e.g., opiates), TRPV1 antagonists aim to prevent pain by blocking a receptor where pain is generated (Fig. 2.1). As discussed in subsequent chapters, small-molecule TRPV1 antagonists are being evaluated in proof-of-concept pain clinical trials. Other transient receptor potential (TRP) channels on sensory neurons represent emerging therapeutic targets (Cortright et al., 2007; Dray, 2008; Eid and Cortright, 2009; Cortright and Szallasi, 2009b; Patapoutian et al., 2009). The clinical value of TRPV1 antagonists might be the litmus test for the feasibility of this novel approach.
2.2 THE CENTRAL ROLE OF TRP CHANNELS IN NOCICEPTION AND INFLAMMATORY PAIN Nociceptors were first described by Charles Scott Sherrington more than a century ago. A nociceptor (from the Latin nocere or “to hurt”) is defined as a “pain cell” that is capable of sensing noxious stimuli and transmitting the
70
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
TRPV1
Blood vessel
Neurogenic inflammation
TRPV4
Mast cell
Histamine
SP CGRP
Neuropeptide release
TRPV1 TRPV3 TRPV4 Transducer potential
TRPA1
PAR-2
Dorsal horn of the spinal cord
Protons, NGF, and “inflammatory soup”
TRPV1
[TRPM8]
Action potential
TRPV1 TRPV3 TRPV4
TRPV1
DRG
TRPA1
TRPA1 [TRPM8]
Second-order neuron
Action potential
Interleukin-1 TRPV1, TRPV3, TRPV4
Keratinocyte
Skin Skin irritants
Noxious heat or cold
Figure 2.1 Simplified, schematic representation of the complex participation of neuronal and non-neuronal TRP channels in nociception, neurogenic inflammation, and inflammatory pain. Temperature (heat- and cold)-sensitive TRP channels, so-called “thermoTRPs,” are expressed both in nociceptive neurons and in cells that are in contact with these neurons (e.g., keratinocytes and immune cells in the skin). When nociceptive neurons are activated by noxious environmental stimuli, an action potential is generated (afferent function), which is transmitted to the central nervous system where it is perceived as painful, and, at the same time, proinflammatory neuropeptides (e.g., SP and CGRP) are released in the periphery, initiating the biochemical cascade collectively known as neurogenic inflammation. Epithelial cells (e.g., keratinocytes) are believed to generate interleukins when their TRP channels are stimulated by skin irritants; these interleukins, in turn, sensitize sensory nerve endings. Agents in “inflammatory soup” sensitize or activate nociceptive neurons via both direct and indirect effects on TRP channels (e.g., receptor protein phosphorylation). A third route of nociceptor sensitization is by protease-activated receptor-2 (PAR-2). Vascular endothelial cells also express TRPV1 and TRPV4; these channels may enhance or block the neurogenic inflammatory response. TRP channels, in particular TRPV1, expressed on central terminals of primary sensory neurons, are believed to play a role in the process of central sensitization, also known as the “wind-up” phenomenon. Of note, following injury, DRG neurons undergo a “phenotypic change” (also known as “injuryinduced messenger plasticity”) when the expression of some TRP channels is increased, whereas others are downregulated. SP, substance P; CGRP, calcitonin gene-related peptide; NGF, nerve growth factor; PAR-2, protease-activated receptor 2; DRG, dorsal root ganglion.
THE CENTRAL ROLE OF TRP CHANNELS
71
pain signal (Belmonte and Cervero, 1996). In mammals, primary sensory (nociceptive) neurons form an anatomic connection between potentially harmful external and internal agents and the CNS (Fig. 2.1) (Moller, 2002). Many non-neuronal cells, for example, urothelial cells and keratinocytes, also express nociceptor TRP channels (Fig. 2.1), in particular TRPV1 (Denda et al., 2001; Birder et al., 2002; Southall et al., 2003; Wilder-Smith et al., 2007), TRPV3 (Facer et al., 2007), and TRPV4 (Chung et al., 2003; Gevaert et al., 2007), and it has been suggested that these cells may also function as pain sensors (Southall et al., 2003; Birder 2005, 2006). Generally speaking, primary sensory neurons are bipolar cells with somata in the dorsal root ganglion (DRG) and in the trigeminal ganglion (TG). The central axons of these neurons enter the CNS where they form synapses with second-order neurons in the dorsal horn of the spinal cord (DRG neurons) or in the spinal nucleus of the trigeminal tract (TG neurons) (Fig. 2.1). Many neurons innervating the viscera are located in the nodose ganglia. Their peripheral fibers travel with the vagus nerve, whereas their central axons project to the area postrema (Holzer, 1991). Most primary sensory neurons possess unmyelinated axons (C-fibers) and are capsaicin sensitive (Holzer, 1991). A small subset of neurons with thin myelinated axons (Aδ-fibers) also expresses TRPV1 receptors. Interestingly, it has been shown that Aδ-fibers that do not normally express TRPV1 do so under inflammatory conditions or following injury (Ma, 2002; Rashid et al., 2003). This abnormal, TRPV1positive Aδ-fiber population has been suggested to contribute to neuropathic pain in patients with diabetic polyneuropathy (Rashid et al., 2003). Indeed, desensitization by TRPV1 agonists (e.g., capsaicin and its ultrapotent natural analogue, resiniferatoxin) relieves chronic pain in these patients (Knotkova et al., 2008) despite the degeneration of C-fibers (Lauria et al., 2006; Facer et al., 2007). A unifying feature of TRP channels relevant to pain is their sensitivity to temperature, hence the term “thermoTRPs” (Dhaka et al., 2006; Bandell et al., 2007; Talavera et al., 2008). Of the currently known 28 TRP channels, seven sense hot and warm temperatures (TRPV1 to TRPV4, TRPM2, TRPM4, and TRPM5), whereas two (TRPA1 and TRPM8) are activated by cold (Levine and Alessandri-Haber, 2007). Combined, these channels cover a wide temperature range, with extremes falling between 10 °C (TRPA1) and 53 °C (TRPV2). Another shared feature of these channels is their sensitivity to a variety of natural products (Table 2.1) (Appendino et al., 2008). In fact, the TRPV1 channel was originally termed the capsaicin receptor (capsaicin is responsible for the piquancy of hot chili peppers) or the vanilloid receptor VR1, based on the vanillyl fragment present in capsaicin and resiniferatoxin (a diterpene ester isolated from the latex of the perennial Euphorbia resinifera) (Szallasi and Blumberg, 1999). In addition to capsaicin, TRPV1 is also a receptor for pungent compounds in jellyfish (Cuypers et al., 2006) and for some spider toxins (Siemens et al., 2006). TRPA1 is activated by both cinnamaldehyde (from cinnamon) (Bandell et al., 2004; Namer et al., 2005) and
72
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
allicin (an active ingredient in garlic) (Macpherson et al., 2005). TRPM8 is also referred to as the menthol receptor (Peier et al., 2002a), and TRPV3 represents a target for camphor (Moqrich et al., 2005). TRPV4 is thought to mediate the actions of bisandrographolide, the bioactive ingredient in the Chinese medicinal plant Andrographis paniculata (Smith et al., 2006). While some natural products from plants show selectivity for particular TRP channels (such as resiniferatoxin for TRPV1), others are not as “picky.” For example, citral, a bioactive component in lemongrass, which is used both as a taste enhancer and as an insect repellant, functions as a partial agonist for all TRPs in sensory neurons (TRPV1, TRPV3, TRPA1, and TRPM8), with a lasting blockage of TRPV1, TRPV3, and TRPM8 and a transient inhibition of TRPV4 and TRPA1 (Stotz et al., 2008). Menthol is an even more interesting compound in that it activates TRPM8 (hence its well-known cooling effect), but, paradoxically, it also stimulates TRPV3, causing a warm sensation, and blocks TRPA1 (Macpherson et al., 2006). Furthermore, there is significant “cross talk” between the TRP channels that modifies the bioactivity of natural TRP channel agonists. An interesting example of this phenomenon is camphor, which acts as a direct agonist for TRPV3 and then strongly desensitizes both TRPA1 and TRPV1 (Xu et al., 2005). Cannabinoids constitute another example since they desensitize capsaicin responses, not via cannabinoid CB1 or CB2 receptors, but rather via TRPA1 activation (Akopian et al., 2008). Apparently, the antinociceptive and antihyperalgesic actions of cannabinoids are mediated by distinct biological targets, consistent with the observation that these cannabinoid effects occur at different concentrations (Johanek et al., 2001). TRP channels play a central role in thermal nociception and also in detecting noxious chemicals (Fig. 2.1) (Liedtke and Heller, 2007; Nilius et al., 2007). This is interesting biology, but, per se, it would not make these channels potential targets for analgesic drugs. Importantly, TRPV1 is also activated and/or sensitized by agents in “inflammatory soup,” ranging from tissue acidosis (protons) through cytokines (e.g., nerve growth factor [NGF], bradykinin, 12- and 15-hydroxyperoxyeicosatetraenoic acid [HPETE], and other arachidonic acid metabolites [Table 2.1]) (Caterina and Julius, 2001; Pingle et al., 2007; Szallasi et al., 2007). These agents act in concert to lower the heat activation threshold of TRPV1 (Di Marzo et al., 2002; Szallasi et al., 2007). These findings have identified TRPV1 as a promising target to relieve inflammatory pain (Fig. 2.1). Indeed, both genetic deletion (Caterina et al., 2000; Davis et al., 2000) and pharmacological blockade of TRPV1 ameliorate heat hyperalgesia in rodent models of inflammatory pain (Malmberg and Bley, 2005; Szallasi et al., 2007; Gunthorpe and Szallasi, 2008). Of relevance is the finding that TRPV1 expression is increased in reflux esophagitis (where “heartburn” is due to exposure to acidic gastric contents) and in inflammatory bowel disease (IBD) (Yiangou et al., 2001; Matthews et al., 2004; Bhat and Bielefeldt, 2006). TRPV1 is also elevated in irritable bowel syndrome (also known as colon irritable), a fairly common condition of unknown etiology
THE CENTRAL ROLE OF TRP CHANNELS
73
TABLE 2.1 ThermoTRP Channels: Selected Activators and Relevance to Pain Selected Activators TRPV1
TRPV3
Heat (>43 °C) Protons Capsaicin, resiniferatoxin, piperine Anandamide, NADA, 12-HPETE Jellyfish and spider venoms Warm temperature (>33 °C) Camphor, thymol, eugenol Incensole acetate
TRPV4
Warm temperature (>25 °C) Change in osmolality Candidate mechanosensor
TRPA1
Cold (<17 °C) Hypertonicity Mustard oil, allicin Reactive oxidants (cigarette smoke, exhaust fumes, tear gases, etc.)
TRPM8
Cold (<23 °C) Menthol, icilin
Relevance to Pain Noxious heat detection Thermal hyperalgesia during inflammation
Candidate sensor for noxious stimuli in keratinocytes Proposed role in neuropathic pain (upregulated after nerve injury) Key role in mechanical hyperalgesia under inflammatory conditions Important role in colic pain Major player in chemotherapyinduced neuropathy Major chemosensor in airways Candidate mechanosensor: mechanical hyperalgesia in colitis and overactive bladder Mediator of cold hyperalgesia (pathological cold pain) Target for paradoxical pain by anesthetic drugs Role in cold allodynia Possible contribution to genitourinary hyperalgesia and pain Possible role in colic pain
NADA: N-arachidonoyldopamine.
characterized by frequent bowel movements and tenesmus (painful straining at stool) (Chan et al., 2003). Because there is no effective medical therapy, irritable bowel syndrome is frustrating for both patients and their physicians. Therefore, it is an exciting possibility that per os TRPV1 antagonists may provide symptomatic relief. Indeed, there is anecdotal evidence that eating hot, spicy food exacerbates symptoms in patients with irritable bowel syndrome. Moreover, TRPV1 is emerging as an indirect, downstream target for various endogenous agents, such as endothelin-1, that evoke pain (Plant et al., 2007). A shared (and controversial) feature of thermoTRP channels, in particular TRPV1 (Prescott and Julius, 2003) and TRPM8 (Liu and Qin, 2005), is their regulation by phosphatidylinositol 4,5-biphosphate (PIP2) (Brauchi et al.,
74
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
2007; Qin, 2007). TRPV1 possesses PIP2 recognition sites (Lishko et al., 2007; Kim et al., 2008). It was postulated that TRPV1 is under the inhibitory control of PIP2 (Prescott and Julius, 2003), implying a pivotal role for phospholipase C, the enzyme that cleaves PIP2, in TRPV1 activation. However, PIP2 may be either inhibitory or activating, depending on the context (Lukacs et al., 2007). Of note, recently it was suggested that ethanol potentiates TRPV1-mediated responses via the PIP2–TRPV1 interaction (Vetter et al., 2008).
2.3 THE EMERGING ROLE OF TRP CHANNELS IN VISCERAL PAIN As reviewed elsewhere, the majority of sensory fibers that project into the viscera possess TRPV1 (Holzer, 2004). TRPV1-positive nerves appear to mediate visceral pain in response to noxious rectal distension (Spencer et al., 2008). This is somewhat surprising since TRPV1 is not supposed to have mechanosensitive properties. Although surprising, it is not unprecedented, since TRPV1(–/–) mice exhibit decreased mechanical hyperreactivity of the bladder during cystitis (Wang et al., 2008). Moreover, silencing by RNA interference of TRPV1 has been reported to ameliorate visceral pain in rats (Christoph et al., 2006), implying a role for TRPV1 in visceral pain during colitis. Indeed, the first generation TRPV1 antagonist capsazepine diminishes discomfort to colorectal distension in mice (Sugiura et al., 2007), similar to the decrease seen in TRPV1 (–/–) animals (Jones et al., 2005). Increased TRPV1 immunoreactivity was observed in colonic sensory afferents in patients with IBD (both Crohn’s disease and ulcerative colitis [Yiangou et al., 2001]) and in rectal sensory fibers with rectal hypersensitivity and fecal urgency (Chan et al., 2003). Currently, it is unclear whether these changes in TRPV1 expression are pathogenic or adaptive. In a rat model of irritable bowel syndrome, TRPV1 antagonists prevent the development of visceral hypersensitivity initiated by acetic acid treatment during the neonatal period (Winston et al., 2007). These findings imply a pathogenic role for the dysfunction of TRPV1-positive colonic fibers in irritable bowel syndrome. In accord, a correlation has been described between the number of TRPV1-immunoreactive fibers in the rectosigmoid colon and the abdominal pain score in patients with irritable bowel syndrome (Akbar et al., 2008). Taken together, these observations suggest that TRPV1 is a relevant therapeutic target for the treatment of visceral pain. In a rat model of IBD, topical capsaicin treatment reduces bowel ulceration in response to trinitrobenzene sulfonic acid (TNBS) (Goso et al., 1993). In this model, the small-molecule TRPV1 antagonist JYL1421 suppresses microscopic colitis and significantly reduces (but does not completely abolish) visceromotor response to colorectal distension (Miranda et al., 2007). TRPV1 also appears to be involved in the post-inflammatory hyperalgesia that occurs
THE EMERGING ROLE OF TRP CHANNELS IN VISCERAL PAIN
75
after resolution of dextran sodium sulfate (DSS)-induced experimental colitis (Eijkelkamp et al., 2007). Nonetheless, it may be a premature conclusion that TRPV1 is exclusively responsible for the beneficial effect of capsaicin in preclinical models of colitis. In a murine model of visceral pain, TRPV1 (–/–) mice show a 60% reduction in pain response magnitude compared to wild-type controls (Jones et al., 2005). So, what is responsible for the remaining 40% of the pain behavior? The amiloride-sensitive acid-sensing ion channels (ASICs) may be a major contributor (Sugiura et al., 2007). Indeed, ASIC (–/–) mice display a reduction in pain behavior, which is similar in magnitude to that observed in the TRPV1 knockouts (Jones et al., 2005). Furthermore, new evidence shows that TRPA1 (presumably present on TRPV1-positive fibers, Fig. 2.1) is markedly upregulated during TNBS-evoked colitis (Yang et al., 2008). Consistent with a pathogenic role of the increased TRPA1, intrathecal administration of TRPA1 antisense oligodeoxynucleotide reverses hyperalgesia to colonic distension (Yang et al., 2008). It has been known for decades that capsaicin desensitization prevents neurogenic inflammation by cigarette smoke (Lundberg and Saria, 1983; Lundberg et al., 1983), although it is now known that these responses are initiated by TRPA1 rather than TRPV1 (André et al., 2008; Simon and Liedtke, 2008). One cannot help but wonder if a similar phenomenon may also play at least a partial role in the beneficial effect of capsaicin desensitization in the TNBS colitis model (Goso et al., 1993). In man, capsaicin exerts a protective effect against gastric mucosal damage by ethanol (Mózsik et al., 2007), suggesting that functional TRPV1 is protective in the gastrointestinal tract during inflammation or chemical damage (Eysselein et al., 1991). If this hypothesis holds true, a potential side effect for TRPV1 antagonists given per os could be exacerbation of gastric ulcer formation. Confusingly, genetic deletion of TRPV1 has a protective action against gastric ulcers (P. Reeh, pers. comm.). Clearly, more research is needed in this area. In summary, the exact contribution of TRPV1 to visceral pain is still being debated (Hicks, 2006). As discussed above, ASIC and other acid-sensitive ion channels may also be involved in visceral pain (Holzer, 2003). Recently, TRPA1 (Mitrovic and Holzer, 2008; Yang et al., 2008) and TRPV4 (Brierley et al., 2008) have emerged as molecular mechanotransducers on visceral afferents, suggesting these TRP channels may also play an important role in visceral pain. TRPV4 appears to be preferentially expressed in high levels in colonic sensory neurons (Brierley et al., 2008). Behavioral responses to painful colonic distension are significantly reduced in TRPV4 (–/–) mice (Brierley et al., 2008), as is the mechanical hyperalgesia that occurs in response to protease-activated receptor 2, (PAR-2) (Grant et al., 2007). Of note, PAR-2 also sensitizes TRPV1 (Amadesi et al., 2004). Thus, PAR-2 appears to function as a regulator of TRP channels (Surprenant, 2007). Since gut bacteria produce high amounts of PAR-2, TRPV4 is an attractive pharmacological target to relieve visceral pain. Unfortunately, as discussed below, pharmacological blockade of TRPV4 may have severe adverse effects.
76
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
2.4 CONTRIBUTION OF TRP CHANNELS TO NEUROPATHIC PAIN, CANCER PAIN, AND MIGRAINE There is good experimental evidence that sensory neurons expressing TRP channels, in particular TRPV1, are important mediators of pathological pain (Fig. 2.1). For instance, rats desensitized to resiniferatoxin are devoid of the thermal hyperalgesia and guarding behavior that develops following mechanical damage of the sciatic nerve (Bennett model) (A. Szallasi, M. Tal, and G. Bennett, unpublished data). Strikingly, resiniferatoxin also abolishes pain behavior when given to rats in a “therapeutic fashion,” that is, to animals already in discomfort following the operation. As detailed in the chapter by Jimenes-Andrade and Mantyh in this volume, cancer pain is a promising indication for TRPV1 blockade. Here it suffices to mention that TRPV1 expression is enhanced in DRG neurons ipsilateral to bone cancer (osteosarcoma) in the mouse (Niiyama et al., 2007). In mice and dogs, treatment with resiniferatoxin to desensitize TRPV1-containing neurons ameliorates bone cancer pain (Brown et al., 2005; Menendez et al., 2006). In mice, this effect was mimicked by both genetic disruption of the TRPV1 gene and pharmacological TRPV1 blockade by the selective antagonist JNJ17203212 (Ghilardi et al., 2005). In man, capsaicin-containing topical patches (e.g., NGX-4010 by NeurogesX) and injectable capsaicin preparations (e.g., Adlea by Anesiva) were reported to provide relief from pain associated with diabetic neuropathy, AIDS-related neuropathy, and post-herpetic neuralgia (Knotkova et al., 2008). Other indications for topical capsaicin treatment include migraine, cluster headache, osteoarthritis, lateral epicondylitis (e.g., “tennis elbow”), Morton’s neuroma, and postsurgical pain (e.g., bunionectomy and hernia repair) (Knotkova et al., 2008). The therapeutic value of capsaicin and other TRPV1 agonists is discussed in the chapter by Bley in this volume. The rationale for using potent, selective small-molecule TRPV1 antagonists to relieve inflammatory pain is the recognition that TRPV1 is directly activated by agents in the “inflammatory soup,” including the so-called “endovanilloids” (Fig. 2.1 and Table 2.1) (Di Marzo et al., 2002; Szallasi et al., 2007; see also the chapter by Bhattacharya et al. in this volume). In other words, TRPV1 antagonists prevent the binding of endovanilloids to TRPV1. No such straightforward explanation exists for the mechanism of capsaicin desensitization. It is well established that capsaicin “silences” TRPV1-expressing neurons via ill-defined molecular processes (Szallasi and Blumberg, 1999). Indeed, neurons desensitized to capsaicin are also unresponsive to mustard oil (Jancsó et al., 1985; Patacchini et al., 1990), although this chemical agent acts on TRPA1 rather than TRPV1 (Jordt et al., 2004). Since TRPV1 agonists like capsaicin and resiniferatoxin block neuropathic pain whereas TRPV1 antagonists apparently do not, it is a reasonable assumption that other receptors present on capsaicin-sensitive neurons besides TRPV1 are directly involved in neuropathic pain. In accord, evidence was presented at the 2008 World
CONTRIBUTION OF TRP CHANNELS
77
Pharmaceutical Congress by investigators at Glenmark that the TRPV3 antagonist GRC15133 is capable of inhibiting neuropathic pain (Gullapalli et al., 2008). A second mechanism of capsaicin desensitization was described as “vanilloid-induced messenger plasticity” (Szallasi and Blumberg, 1999). This reversible and long-lasting process was suggested to involve downregulation of TRPV1 and of neuropeptides that are proalgesic (e.g., substance P [SP] and calcitonin gene-related peptide [CGRP]) as well as upregulation of peptides (e.g., galanin), enzymes (e.g., nitric oxide synthase [NOS]), and receptors (e.g., cholecystokinin [CCK-1] receptors) that are analgesic (Szallasi and Blumberg, 1999). TRPV1 is now well established as a major mediator of thermal hyperalgesia. The link between TRPV1 and mechanical hyperalgesia is much weaker. In the skin, the expression of TRPV1 appears to be restricted to mechanically insensitive nerve fibers (Lawson et al., 2008). In accord, perineural resiniferatoxin administration blocks thermal, but not mechanical, hyperalgesia during inflammation (Neubert et al., 2008). Resiniferatoxin was previously reported to cause some decrease in mechanical hyperalgesia, presumably mediated by a spinal site, but this effect was very transient compared to the lasting blockade of thermal hyperalgesia (Xu et al., 1997). This is a problem for TRPV1 antagonists because many pain clinicians consider mechanical allodynia and hyperalgesia more significant than thermal hyperalgesia. Recently, a specific small-molecule TRPA1 antagonist was reported to reverse complete Freund’s adjuvant (CFA)-induced mechanical hyperalgesia in wild-type, but not in TRPA1-deficient, mice (Petrus et al., 2007). As discussed in the chapter by Holland and Goadsby in this volume, the relationship between migraine and TRPV1 remains controversial. There is anecdotal evidence that capsaicin applied to the nasal mucosa is beneficial in patients with cluster headache (Sicuteri et al., 1989). Moreover, ethanol is known to worsen migraine symptoms (Szallasi et al., 2006), and it has been suggested that ethanol sensitizes TRPV1 via PIP2 (Vetter et al., 2008). CGRP released from sensory neurons has been postulated to play an important role in migraine (Geppetti et al., 2005). Indeed, CGRP antagonists prevent migraine attacks, although these compounds are much less effective when given during the attacks (Goadsby, 2005, 2008). These findings imply a therapeutic value for TRPV1 antagonists in migraine patients (Szallasi et al., 2006). The clinical trials, however, have proved very disappointing. In fact, GSK terminated its migraine clinical trials with TRPV1 antagonists due to lack of clinical efficacy (Gunthorpe and Szallasi, 2008). With the benefit of hindsight, the negative clinical trial is not unexpected. It is unclear what endovanilloid could be generated during migraine. Moreover, in the trigeminal system, the colocalization of TRPV1 and CGRP is limited. In contrast, CGRP is highly coexpressed with TRPV4. Based on this observation, some neurologists advocate the local injection of TRPV4 antagonists directly into TG for migraine refractory to conventional medical therapy (Liedtke, 2008).
78
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
2.5 DIFFERENTIAL TRP CHANNEL EXPRESSION DEFINES FUNCTIONAL SENSORY NEURON SUBTYPES: IMPLICATIONS FOR DRUG DEVELOPMENT Primary sensory neurons are heterogenous in several aspects, including their anatomy, neurochemistry, and function. For example, these neurons differ in the myelin sheet that protects their axons (myelinated Aβ-fibers, thin myelinated Aδ-fibers, and unmyelinated C-fibers); they use different mediators (e.g., peptidergic and non-peptidergic); and they convey different somatosensory information to the CNS (e.g., touch, pain, itch, and temperature). One way to subclassify primary sensory neurons is by the TRP channels that they express. A major population of neurons with C-fibers, as well as a minor subset of Aδ neurons, coexpresses TRPV1 with the related channels TRPV3 and TRPV4 and also with TRPA1 (Kobayashi et al., 2005). TRPV1, TRPV3, and TRPV4 are heat-activated channels so their presence on the same neurons is not unexpected. It is more difficult to explain why these heat receptors are coexpressed with the cold receptor TRPA1. Adding to the complexity, TRPA1 seems to be present on both peptidergic and non-peptidergic neurons (Hjerling-Leffler et al., 2007). A second major subset of primary sensory neurons, encompassing both A- and C-fiber neurons, is characterized by their TRPM8 expression (Kobayashi et al., 2005). The minimal overlap between TRPV1 and TRPM8 expression suggests that TRPV1-positive neurons and TRPM8-expressing neurons are fundamentally different, although TRPA1 appears to be present on both TRPV1- and TRPM8-expressing populations (Kobayashi et al., 2005). In keeping with this concept, TRPV1-like immunoreactivity is elevated, whereas TRPM8 is, by contrast, reduced in injured human brachial plexus nerves (Facer et al., 2007). Based on these findings, it has been postulated that TRPV1 may be a more relevant therapeutic target than other thermoTRPs for pain related to posttraumatic neuropathy (Facer et al., 2007). Intriguingly and in contrast to expression in DRG, TRPM8 is coexpressed with TRPV1 in vagal sensory neurons innervating the mouse lung (Nassenstein et al., 2008). It has been suggested that TRPV1 forms heteromultimers with other TRP channels (Liapi and Wood, 2005; Szallasi et al., 2007). If this hypothesis holds true, antagonists that do not distinguish between thermoTRPs may have a therapeutic value by targeting TRP heteromultimers. The shared TRP domain in these channels may represent a target for such inhibitors (Garcia-Sanz et al., 2007). Of note, N-(4-tertiarybutylphenyl)-4-(3-chloropyridin-2-yl)tetrahydropyrazine-1(2H)-carboxamide (BCTC), originally described as a TRPV1 antagonist, also functions as a potent inhibitor of TRPM8 (Weil et al., 2005). Of note, thermoTRP channels are also colocalized with other receptors involved in pain transmission. In an innovative study, capsaicin has been used to deliver sodium channel blockers into neurons expressing TRPV1. QX-314 is a quaternary derivative of lidocaine that is ineffective when administered alone because it is not capable of crossing the membrane. However, when
TAKING A SHORT TR(i)P BEYOND PAIN
79
coadministered with capsaicin, QX-314 enters the sensory neuron through the open TRPV1 pore and gains access to its binding site on the sodium channel (Binshtok et al., 2007). This elegant approach affords selective targeting of TRPV1-expressing sensory neurons (Binshtok et al., 2007). The peripheral terminals of TRPV1-expressing primary sensory neurons are sites of release for a variety of proinflammatory neuropeptides (e.g., SP and CGRP) that initiate the biochemical cascade collectively known as neurogenic inflammation (Fig. 2.1) (Geppetti and Holzer, 1996). Neurogenic inflammation is thought to play a central role in the pathogenesis of various disease states that range from migraine (chapter by Holland and Goadsby in this volume) through asthma (chapter by Materazzi et al. in this volume) to IBD and cystitis (chapter by Avelino and Cruz in this volume). Obviously, diseases with a prominent neurogenic inflammatory component are potential therapeutic indications for TRP channel blockers.
2.6 TAKING A SHORT TR(i)P BEYOND PAIN Neuropeptides released from sensory neurons have been linked to various conditions encompassing pruritus, cough, emesis, neuroimmune regulation (e.g., type-1 diabetes), glucose control (metabolic syndrome and type-2 diabetes), obesity, and sepsis. The participation of TRP channels in these disorders has been exhaustively reviewed elsewhere (Birder, 2007; Jordt and Ehrlich, 2007; Kim and Baraniuk, 2007; Nilius, 2007; Nilius et al., 2007; Venkatachalam and Montell, 2007; Cortright and Szallasi, 2009a; see also the chapter by Nilius and Vennekens and chapter by Tsui et al. in this volume). Clearly, these topics go beyond the scope of this chapter, namely, pain, but a brief recapitulation of these observations might be useful to the degree the findings imply novel innovative uses for drugs targeting TRP channels. For example, the TRPV1 agonist resiniferatoxin is a powerful antiemetic agent in ferrets (Andrews and Bhandari, 1993), implying a potential for this class of compounds to inhibit intractable nausea and vomiting secondary to radiation and/or chemotherapy (Sharkey et al., 2007). Inhaled capsaicin is a standard agent to evoke cough response in human studies, and potent small-molecule TRPV1 antagonists are being tested in the clinics as promising antitussive drugs (McLeod et al., 2008; see also the chapter by Mazeratti et al. in this volume). TRP channels other than TRPV1, in particular TRPA1, are also potential targets for antitussive drugs (Kim and Baraniuk, 2007; Brooks, 2008). Pruritus is another promising indication for drugs acting on TRP channels (Paus et al., 2006; Bíró et al., 2007). On an empirical basis, both capsaicin and menthol have been in clinical use to relieve itch for decades, identifying TRPV1 and TRPM8 as relevant pharmacological targets for novel antipruritic agents (reviewed in Bíró et al. [2007]). The “supercooling” agent icilin, which is several hundredfold more potent than menthol, reduces the degree of excoriations by scratching at least 50% in rats on a Mg2+-deficient diet (Bíró et al., 2007). It can
80
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
be also argued that TRPV3 and TRPV4 in keratinocytes participate in the pathomechanism of pruritus. In fact, TRPV3 is a known target for skin sensitizers, and activation of TRPV3 in murine keratinocytes by eugenol was reported to release the proinflammatory substance interleukin-1 (IL-1) (Xu et al., 2006). The emerging role of TRPV1 in neuroimmune regulation in general (Cortright and Szallasi, 2009a) and in type-1 diabetes in particular (Suri and Szallasi, 2008) was recently reviewed elsewhere and is also the subject of the chapter by Tsui et al. in this volume. Of note, TRPV1 has also been linked to obesity, metabolic syndrome, and type-2 diabetes (Gram, 2003; Suri and Szallasi, 2008). TRPV1 (–/–) mice on high fat diet are protected from visceral obesity, the type of “pear-shaped” obesity that has been linked to metabolic syndrome in man (Motter and Ahern, 2008). Type-2 diabetes has been suggested to have a significant low-grade inflammatory component mediated by capsaicin-sensitive nerves (Gram, 2003). Indeed, the small-molecule TRPV1 antagonist BCTC has been reported to improve glucose tolerance in a mouse model of type-2 diabetes (Gram and Hansen, 2007).
2.7 DISEASE-RELATED CHANGES IN TRP CHANNEL EXPRESSION: A NEW SPIN COMPLICATING DRUG DEVELOPMENT TRP channels not only show bidirectional changes during disease states (up- or downregulation) but can be also expressed in cells that do not normally express such channels (Szallasi et al., 2007). Representative examples are discussed below. These observations have important practical implications for drug development. For example, animal experiments suggest that TRPM8 may be a relevant target to ameliorate cold hyperalgesia that develops following nerve injury (Katsura et al., 2006; Ji et al., 2007; Xing et al., 2007). In support of this hypothesis, mRNA encoding TRPM8 is increased in the rat DRG following chronic constriction injury (Frederick et al., 2007). However, in man, TRPM8 appears to be downregulated after nerve injury (Facer et al., 2007) and in painful dental pulp (Alvarado et al., 2007). Indeed, no evidence for the involvement of TRPM8 in cold allodynia has been found in neuropathic pain patients (Namer et al., 2008). This is a worrisome example of the species-related differences in TRP channel biology that hinder extrapolation of animal experiments to patients. In contrast, TRPA1 appears to be upregulated in human DRG after nerve injury (Anand et al., 2008). In rats, antisense knockdown of TRPA1 alleviates cold hyperalgesia after spinal nerve ligation (Katsura et al., 2006). However, the relevance of these observations is unclear, since cold allodynia appears to be independent of TRPA1 in neuropathic pain patients (Namer et al., 2008). In rodents, the expression of TRPV4 is increased at both the mRNA and protein levels following mechanical nerve injury, induced by CCD (chronic compression of dorsal root ganglia [DRG]) (Zhang et al., 2008). TRPV4 has
TRPS ON NOCICEPTIVE NEURONS AS TARGETS
81
also been linked to chemotherapy (e.g., taxol- or vincristine)-induced neuropathy (Alessandri-Haber et al., 2004, 2008). When given intrathecally, TRPV4 oligodeoxynucleotide antisense reverses mechanical allodynia induced by CCD (Zhang et al., 2008) and ameliorates mechanical hyperalgesia in animal models of neuropathy of various etiologies, such as diabetes, alcoholism, and chemotherapy (Alessandri-Haber et al., 2008). TRPV4 appears to be also involved in inflammatory pain, as implied by the reduced response to “inflammatory soup” in TRPV4 (–/–) mice (Chen et al., 2007). This finding is consistent with the role of TRPV4 as an osmosensor and with the hypotonic nature of the inflammatory soup. TRPV1 shows bidirectional expression changes in various disease states. During inflammation and in bone cancer, TRPV1 levels increase substantially (Niiyama et al., 2007). Conversely, TRPV1 expression is downregulated in neuropathic pain secondary to injury (Lauria et al., 2006). It has been hypothesized that the downregulation of TRPV1 expression in diabetic skin is related to the diminished NGF levels (Facer et al., 2007). As reviewed elsewhere (Knotkova et al., 2008), a traditional indication for capsaicin-containing topical preparations is diabetic neuropathy. However, the clinical experience with capsaicin is conflicting, with some studies reporting significant pain relief, whereas others have been unable to replicate these results. In the skin of patients with diabetic neuropathy, TRPV1-expressing epidermal nerve fibers are markedly reduced, accompanied by decreased TRPV3 expression in keratinocytes (Facer et al., 2007). Although strictly speaking not a disease, it should be mentioned that chronic morphine administration upregulates TRPV1 expression in the spinal cord in a MAP kinase-dependent manner (Chen et al., 2008). This is intriguing because morphine tolerance is often associated with the development of thermal hyperalgesia. In fact, intrathecal pretreatment with the TRPV1 antagonist SB366791 (N-[3-methoxyphenyl]-4-chlorocinnamide) has been shown to attenuate morphine tolerance and to prevent thermal hyperalgesia (Chen et al., 2008). It is hoped that TRPV1 antagonists will reduce the need for opioids and, as an added benefit, will also prevent tolerance to opioids. Interestingly, acute morphine administration has the opposite effect since it negatively modulates TRPV1 via inhibition of adenylate cyclase (Vetter et al., 2006).
2.8 TRPS ON NOCICEPTIVE NEURONS AS TARGETS FOR NOVEL ANALGESIC DRUGS: ATTRACTIVE BUT NOT SO INNOCENT 2.8.1 The Capsaicin Receptor TRPV1 As discussed above, the role of TRPV1 in inflammatory pain was confirmed by genetic deletion (Caterina et al., 2000; Davis et al., 2000) and pharmacological blockade experiments (Gunthorpe and Szallasi, 2008). The initial enthusi-
82
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
asm for TRPV1 antagonists was generated by two basic tenets. First, the expression of TRPV1 was believed to be fairly selective for primary sensory neurons (Holzer, 1991). And second, TRPV1 was thought to be “silent” under physiological conditions (Holzer, 1991). Sadly, neither postulate turned out to be true. Now it is clear that the tissue expression of TRPV1 is extremely wide, ranging from CNS neurons through epithelial cells (e.g., keratinocytes and urothelial cells), vascular endothelium, and immune cells (mast cells and lymphocytes) to hepatocytes and fibroblasts (Nilius, 2007; Cortright and Szallasi, 2009a; Gunthorpe and Szallasi, 2008). Compared to DRG neurons, the expression of TRPV1 is fairly low in these other cell types. Nevertheless, TRPV1 appears to be functional in a variety of tissues. Hypotheses are abundant regarding the role of TRPV1 in these other cell types, but experimental evidence is scarce. Notable suggestions include a role for brain TRPV1 in memory formation and in mood disorders (Gibson et al., 2008) and a contribution of TRPV1 on keratinocytes to hair growth and dermatologic disorders (Bodó et al., 2005). It was speculated that TRPV1-expressing brain neurons may play a role in various neurological and psychiatric disorders including schizophrenia (Chahl, 2007), Parkinson’s disease (Szallasi et al., 2007), Huntington chorea, and Alzheimer’s disease (Yamamoto et al., 2007). Of note, other than some spotty incontinence (Birder et al., 2002), the phenotype of TRPV1 knockout mice is fairly unremarkable. Knockout animals, however, often compensate for the missing protein. Therefore, conditional TRPV1 knockdowns would be better models to evaluate the potential role of non-DRG TRPV1 receptors. TRPV1 involvement in body temperature regulation seems to have an endogenous tone, as implied by the hyperthermic action of TRPV1 antagonists (Gavva, 2008; see also the chapter by Garami et al. in this volume). It has been known for over a century that capsaicin evokes the opposite effect, that is, hypothermia (Holzer, 1991; Szallasi and Blumberg, 1999). Currently, this concept is still controversial. Several classes of structurally unrelated TRPV1 antagonists evoke hyperthermia (Gavva, 2008; Gunthorpe and Szallasi, 2008). In fact, this adverse effect can be so severe that Amgen decided to discontinue the clinical trials with its lead compound after body temperature had reached 40 °C in one patient (Gavva, 2008; Gunthorpe and Szallasi, 2008). Other potent TRPV1 antagonists (e.g., GRC6211 by Glenmark/Lilly) have no effect on body temperature (S. Narayanan, pers. comm.) or, conversely, cause hypothermia following a very mild and transient initial hyperthermic response (e.g., A-425619). Clearly, more research is needed to resolve these conflicting findings. 2.8.2 TRPV3, a Close Relative of TRPV1 TRPV3 is a warm-sensitive (>33 °C) channel that, in contrast to TRPV1, is insensitive to acid or capsaicin (Peier et al., 2002b; Smith et al., 2002; Xu et al., 2002; Chung et al., 2004). The preclinical proof of concept for the role of TRPV3 in thermal nociception and hyperalgesia was furnished by knockout
TRPS ON NOCICEPTIVE NEURONS AS TARGETS
83
experiments (Moqrich et al., 2005). Indeed, GRC15133, which is a selective TRPV3 antagonist developed at Glenmark, was shown to relieve both inflammatory and neuropathic pain in animal models (Gullapalli et al., 2008). Similar to TRPV1, TRPV3 is expressed in keratinocytes (Peier et al., 2002b; Chung et al., 2004) where it has been suggested to mediate the release of IL-1, a proinflammatory agent that, in turn, may sensitize nociceptive neurons (Xu et al., 2006). In the human skin, TRPV3 shows interesting disease-related changes in expression. For example, TRPV3 is downregulated in the skin of patients with diabetes (Facer et al., 2007), whereas TRPV3-like immunoreactivity is increased in skin biopsies obtained from the breasts of women with mastalgia secondary to macromastia or other conditions that cause breast tenderness (Gopinath et al., 2005). While the existence of warm-activated TRPV3 in keratinocytes is well established (Peier et al., 2002b; Chung et al., 2004), the presence of TRPV3 in nerve fibers innervating the skin is controversial. In human skin samples, no TRPV3-like immunoreactivity was detected in the epidermal nerve endings (Gopinath et al., 2005). However, strong TRPV3-like immunoreactivity was found in the brachial nerve plexus following nerve injury (Facer et al., 2007). In rodents, TRPV3 is not only highly colocalized with TRPV1 but may also compensate for TRPV1. Indeed, increased TRPV3 expression was observed in mice when TRPV1 was genetically inactivated by “knockdown” via RNA interference (transgenic short hairpin RNA, shRNAtg, animals), although TRPV3 expression was not increased in TRPV1 “knockout” mice (Christoph et al., 2008). TRPV3 knockout mice have a fairly unremarkable phenotype with only mild alterations in hair texture (G. Story, pers. comm.). This is in sharp contrast to animals with constitutively active, gain-of-function TRPV3 mutations that suffer from severe alopecia (Asakawa et al., 2006) and a skin condition that mimics human atopic dermatitis (Imura et al., 2007; Xiao et al., 2008). Most recently, incensole acetate, an incense ingredient, was shown to exert potent anxiolytic-like and antidepressant-like behavioral activity in wild-type, but not in TRPV3 knockout, mice (Moussaieff et al., 2008). These findings were interpreted to imply a role for brain TRPV3 in emotional life (at least in the mouse). It remains to be seen if this observation has relevance for humans. However, some caution is no doubt appropriate, especially since brain TRPV1 has been implicated in rimonabant-induced mood disorders (Gibson et al., 2008). An attractive clinical indication for TRPV3 antagonists that block brain TRPV3 is neuroprotection via hypothermic effects (Guatteo et al., 2005; Lipski et al., 2006). 2.8.3 TRPV4, a Mechanosensor TRP with Multiple Functions TRPV4 was originally defined as an osmosensor, hence the alternative name VR-OAC (osmotically activated channel) (Table 2.1). Indeed, TRPV4 is essential for the normal response to changes in osmotic pressure (Liedtke and Friedman, 2003) and in mechanical pressure (Suzuki et al., 2003).
84
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
Subsequently, TRPV4 has been shown to be warm-sensitive (25–34 °C) and is therefore a thermoTRP channel (Gu" ler et al., 2002). Experiments with TRPV4 (–/–) mice suggest that TRPV4 plays a role in normal warm sensation (Lee et al., 2005) and also participates in thermal hyperalgesia following inflammation (Todaka et al., 2004). Warm temperatures have been shown to activate TRPV4 in keratinocytes (Chung et al., 2003, 2004). Consistent with the role of TRPV4 as a mechanosensor (Suzuki et al., 2003), TRPV4 knockout mice show reduced mechanical hyperalgesia (Chen et al., 2007). Arterial response to shear is mediated by TRPV4 expressed on vascular endothelial cells (Hartmannsgruber et al., 2007). In the kidney, TRPV4 serves a double role, both as a flow sensor (mechanosensation) and as an osmosensor (Wu et al., 2007). TRPV4 has been proposed to play a pivotal role in visceral hypersensitivity (Cenac et al., 2008). Of relevance, TRPV4 is sensitized by PAR-2 to cause mechanical hyperalgesia in mice (Grant et al., 2007; Sipe et al., 2008). This is significant since gut bacteria produce large quantities of PAR-2. Consequently, it has been postulated that TRPV4 is an important mediator of colic pain in patients with inflammatory bowel conditions (Brierley et al., 2008). Many pain experts believe that mechanical hyperalgesia is a more important player than thermal hyperalgesia in chronic human pain. Unfortunately, TRPV4 knockout mice have a severe phenotype (incontinent [Gevaert et al., 2007] and deaf [Tabuchi et al., 2005]) that casts a big dark cloud over the clinical utility of TRPV4 antagonists. Even worse, TRPV4 (–/–) animals have impaired osmoregulation due to abnormal antidiuretic hormone (ADH) secretion, and pharmacological TRPV4 blockade has been suggested to cause a sicca syndrome-like condition (Liedtke, 2008). Given the essential role of TRPV4 in osmotransduction and in mechanosensation (Liedtke, 2007), the deleterious adverse effects of TRPV4 blockade are hardly unexpected. Consequently, drug discovery activity directed toward TRPV4 has been marginalized. New findings, however, have rekindled interest in drugs targeting TRPV4 that do not get absorbed into the systemic circulation. It has been suggested that inhaled TRPV4 agonists may be beneficial in cystic fibrosis patients and that TRPV4-containing eye drops may protect the cornea of patients with sicca syndrome (Sjogren’s) (Liedtke, 2008). In theory, enemas containing TRPV4 antagonists may relieve colic pain, and TRPV4 antagonists injected directly into the TG via the foramen ovale are expected to ameliorate migraine pain (Liedtke, 2008). Parenthetically, TRPV4 is essential for the structural integrity of the broncho-alveolar unit (Alvarez et al., 2006; Reiter et al., 2006). TRPV4 is negatively regulated by cGMP. Since activation of TRPV4 was shown to cause endothelial failure and circulatory collapse (Willette et al., 2008), TRPV4 blockade is predicted to exert a protective action in pulmonary circulation. Last, TRPV4 deficiency suppresses bone loss in animal experiments (Mizoguchi et al., 2008). This finding implies that TRPV4 inhibitors may be of clinical value to prevent osteoporosis in postmenopausal women.
TRPS ON NOCICEPTIVE NEURONS AS TARGETS
85
2.8.4 TRPA1, a Sensor of Reactive Oxidants and a Potential Target to Block Pathological Cold Pain Of thermoTRPs, TRPA1 is unique in that it is activated by reversible covalent modification of the sulfhydryl (SH) groups of cysteine residues, rather than by conventional ligand–receptor interaction (Macpherson et al., 2007a). In fact, TRPA1 has emerged as a major chemosensor for reactive oxidants (e.g., unsaturated dialdehydes) in airways (Andersson et al., 2008; Bessac et al., 2008) where, among other noxious stimuli, it is activated by cigarette smoke (André et al., 2008), exhaust fumes, and tear gases (McMahon and Wood, 2006). Similar to TRPV4, TRPA1 is a candidate mechanosensor with postulated roles in mechanonociception (Andrade et al., 2008), colitis (Penuelas et al., 2007; Yang et al., 2008), and overactive bladder (Du et al., 2007, 2008). Indeed, TRPA1 knockout mice have impaired bradykinin-induced mechanical hyperalgesia (but no hearing deficits). TRPA1 is also a cold thermosensor that is active when temperature drops below 17 °C (Story et al., 2003; Bandell et al., 2004). Antisense knockdown of TRPA1 results in reduced cold hyperalgesia but has no influence on normal cold sensing (Katsura et al., 2006). TRPA1 is upregulated during inflammation, an effect most likely mediated by NGF (Diogenes et al., 2007), and after nerve injury (Frederick et al., 2007; Ji et al., 2008). It has been postulated that TRPA1 antagonists (Petrus et al., 2007) may reduce inflammatory pain caused by prostaglandins and by other fatty acid metabolites (Trevisani et al., 2007; Taylor-Clark et al., 2008). Interestingly, TRPA1 is a target for irritation by the commonly used antifungal agent clomitrazol (Meseguer et al., 2008) and may be also responsible for the paradoxical postoperative pain caused by anesthetics (Matta et al., 2008). TRPA1 antagonists, however, may prove a double-edged sword. They may be beneficial by relieving pain and neurogenic inflammation, but, at the same time, they may be potentially dangerous by blocking a major sensor for noxious environmental chemicals (Macpherson et al., 2007b; Tai et al., 2008). In fact, mice whose TRPA1 channel has been deleted by genetic manipulation show deficiencies in respiratory behavior to oxidants (Bessac et al., 2008).
2.8.5 TRPM8, a Cool Receptor Although TRPM8 is best known as the menthol receptor (Bautista et al., 2007; Patel et al., 2007), the “M” stands not for the menthol but for melastatin, a protein identified by comparing benign nevi to malignant melanoma (Nilius et al., 2007). In fact, TRPM8 activation suppresses the viability of human melanoma (Yamamura et al., 2008). Parenthetically, TRPM8 also plays a role in the differentiation of prostatic epithelium (Bidaux et al., 2007), and it has been suggested that TRPM8 ligands may be of clinical value in controlling the growth of prostatic carcinoma (Prevarskaya et al., 2007). TRPM8 was the first cold receptor to be cloned (McKemy et al., 2002; Dhaka et al., 2007). TRPM8 is upregulated following mechanical nerve injury
86
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
(Frederick et al., 2007), and it has been postulated to play a role in cold allodynia (Xing et al., 2007). TRPM8 agonists have been suggested to induce analgesia to mechanical and thermal allodynia (Proudfoot et al., 2006) and to relieve pruritus (Biró et al., 2007); in fact, menthol is a traditional treatment for itch. Mouse genetics has shown that TRPM8 is required for cold hypersensitivity after nerve injury and inflammation (Colburn et al., 2007). New functions of TRPM8 seem to include cold sensation in airways in response to inhaled air (Sabnis et al., 2008; Xing et al., 2008) and control of bladder activity (Du et al., 2008; Lashinger et al., 2008).
2.9
CONCLUDING REMARKS
Heat- and cold-sensitive TRP channels, so-called thermoTRPs, are in the focus of attention as potential targets for novel analgesic drugs (FleetwoodWalker et al., 2007; Levine and Alessandri-Haber, 2007; Cortright and Szallasi, 2009b; Patapoutian et al., 2009;). These channels are expressed on nociceptive neurons where they play a pivotal role in sensing and integrating noxious stimuli (Fig. 2.1). Some of these channels, as exemplified by TRPV1, are not only polymodal (i.e., they react to an array of seemingly unrelated stimuli) (Table 2.1), but they also have a dynamic threshold of activation. For example, agents in “inflammatory soup” act in concert to sensitize TRPV1 in order to reduce its activation threshold to heat (Fig. 2.1) (Szallasi et al., 2007). TRPV1 is also a downstream target for bradykinin, NGF, and other endogenous proalgesic substances. Therefore, TRPV1 functions as a “molecular gateway to the pain pathway” (Caterina and Julius, 2001). Targeting TRP channels on nociceptors is an attractive new and logical strategy in drug development. TRP channel antagonists aim to prevent pain by blocking a receptor where pain is generated (Fig. 2.1). TRPV1, arguably the most important signal integrator in nociceptive neurons, has many “firsts” in this field. TRPV1 was the first thermoTRP to be discovered on sensory neurons (Caterina et al., 1997). Genetic deletion (Caterina et al., 2000; Davis et al., 2000) and pharmacological blockade of TRPV1 (Gunthorpe and Szallasi, 2008) furnished the first proof of concept that TRP inhibitors may relieve hyperalgesia and pain. Most important, potent and selective small-molecule TRPV1 antagonists were the first to move into clinical trials as potential analgesic drugs (Szallasi et al., 2007). TRPV1 also turned out to be a receptor with many unsuspected assets. There is emerging evidence that TRPV1 may play an important role in various disease states, ranging from type-1 diabetes (Suri and Szallasi, 2008) through neurological and psychiatric disorders (Chahl, 2007) to obesity and cancer (Prevarskaya et al., 2007). These observations have opened up new avenues for drug development but also serve as warning signals for unforeseen adverse effects. TRPA1 and TRPV3 are now emerging as intriguing new targets for drug development. TRPA1 is believed to function as a sensor of tissue damage by
REFERENCES
87
noxious chemicals, including reactive oxidants in inhaled air (Bessac et al., 2008; Simon and Liedtke, 2008). TRPA1 is a target for both algesic and analgesic prostaglandin metabolites (Trevisani et al., 2007), and it has been linked to both mechanical and cold hyperalgesia. TRPV3 is upregulated following neuronal injury (Frederick et al., 2007). Indeed, small-molecule TRPV3 antagonists relieve neuropathic pain in preclinical models (Gullapalli et al., 2008). In summary, TRP channel antagonists are predicted to inhibit various pain modalities from post-inflammatory heat or cold hyperalgesia to spontaneous (ongoing) pain. Since these channels are preferentially (though not exclusively) expressed on nociceptors, TRP channel inhibitors are hoped to block pain without the mechanistic limitations that plague the use of existing analgesic compounds. Preclinical experiments and clinical trials are ongoing, and it remains to be seen if TRP channel antagonists will live up to these expectations. REFERENCES Akbar A, Yiangou Y, Facer P, Walters JR, Anand P, and Ghosh S (2008) Increased capsaicin receptor TRPV1-expressing sensory fibers in irritable bowel syndrome and their correlation with abdominal pain. Gut 57:923–929. Akopian AN, Ruparel NB, Patwardhan A, and Hargreaves KM (2008) Cannabinoids desensitize capsaicin and mustard oil responses in sensory neurons via TRPA1 activation. J Neurosci 28:1064–1075. Alessandri-Haber N, Dina OE, Joseph EK, Reichling DB, and Levine JD (2008) Interaction of transient receptor vanilloid 4, integrin, and SRC tyrosine kinase in mechanical hyperalgesia. J Neurosci 28:1046–1057. Alessandri-Haber N, Dina OE, Yeh JJ, Parada CA, Reichling DB, and Levine JD (2004) Transient receptor potential 4 is essential in chemotherapy-induced neuropathic pain in the rat. J Neurosci 24:4444–4452. Alvarado LT, Perry GM, Hargreaves KM, and Henry MA (2007) TRPM8 axonal expression is decreased in painful human teeth with irreversible pulpitis and cold hyperalgesia. J Endod 33:1167–1171. Alvarez DF, King JA, Weber D, Addison E, Liedtke W, and Townsley MI (2006) Transient receptor potential vanilloid 4-mediated disruption of the alveolar septal barrier: a novel mechanism of acute lung injury. Circ Res 99:988–995. Amadesi S, Nie J, Vergnolle N, Cottrell GS, Grady EF, Trvisani M, Manni C, Geppetti P, McRoberts JA, Ennes H, Davis JB, Mayer EA, and Bunnett NW (2004) Proteaseactivated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid 1 to induce hyperalgesia. J Neurosci 24:4300–4312. Anand U, Otto WR, Facer P, Zebda N, Selmer I, Gunthorpe MJ, Chessell IP, Sinisi M, Birch R, and Anand P (2008) TRPA1 receptor localization in the human peripheral nervous system and functional studies in cultured human and rat sensory neurons. Neurosci Lett 438:221–227. Andersson DA, Gentry C, Moss S, and Bevan S (2008) Transient receptor potential A1 is a sensory receptor for multiple products of oxidative stress. J Neurosci 28: 2485–2494.
88
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
Andrade EL, Luiz AP, Ferreira J, and Calixto JB (2008) Pronociceptive response elicited by TRPA1 receptor activation in mice. Neuroscience 152:511–520. André E, Campi B, Materazzi S, Trevisani M, Amadesi S, Massi D, Creminon C, Vaksman N, Nassini R, Civelli M, Baraldi PG, Poole DP, Bunnett NW, Geppetti P, and Patacchini R (2008) Cigarette smoke-induced neurogenic inflammation is mediated by α,β-unsaturated aldehydes and the TRPA1 receptor in rodents. J Clin Invest 118:2574–2582. Andrews PL and Bhandari P (1993) Resiniferatoxin, an ultrapotent capsaicin analogue, has antiemetic properties in the ferret. Neuropharmacology 32:799–806. Appendino G, Minassi A, Pagani A, and Ech-Chahad A (2008) The role of natural products in the ligand deorphanization of TRP channels. Curr Pharm Des 14:2–17. Asakawa M, Yoshioka T, Matsutani T, Hikata I, Suzuki M, Oshima I, Tsukahara K, Arimura A, Horikawa T, Hirasawa T and Sakata T (2006) Association of a mutation in TRPV3 with defective hair growth in rodents. J Invest Dermatol 126: 2664–2672. Bandell M, Macpherson LJ, and Patapoutian A (2007) From chills to chilies: mechanisms for thermosensation and chemesthesis via thermoTRPs. Curr Opin Neurobiol 17:490–497. Bandell M, Story GM, Hwang SW, Viswanath V, Eid SR, Petrus MJ, Earley TJ, and Patapoutian A (2004) Noxious cold ion channel TRPA1 is activated by pungent compounds and bradykinin. Neuron 41:849–857. Bautista DM, Siemens J, Glazer JM, Tsuruda PR, Basbaum AI, Stucky CL, Jordt SE, and Julius JD (2007) The menthol receptor TRPM8 is the principal detector of environmental cold. Nature 448:204–208. Belmonte C and Cervero F, eds. (1996) Neurobiology of Nociceptors. Oxford University Press, Oxford, UK. Bessac BF, Sivula M, von Hehn CA, Escalera J, Cohn L, and Jordt SE (2008) TRPA1 is a major oxidant sensor in murine airway sensory neurons. J Clin Invest 118:1899– 1910. Bhat YM and Bielefeldt K (2006) Capsaicin receptor (TRPV1) and non-erosive reflux disease. Eur J Gastroenterol Hepatol 18:263–270. Bidaux G, Flourakis M, Thebault S, Zholos A, Beck B, Gkika D, Roudbaraki M, Bonnal JL, Mauroy B, Shuba Y, Skryma R, and Prevarskaya N (2007) Prostate cell differentiation status determines transient receptor potential melastatin member 8 channel subcellular localization and function. J Clin Invest 117:1647–1657. Binshtok AM, Bean BP, and Woolf CJ (2007) Inhibition of nociceptors by TRPV1mediated entry of impermeant sodium channel blockers. Nature 449:607–610. Birder LA (2005) More than just a barrier: urothelium as a drug target for urinary bladder pain. Am J Physiol Renal Physiol 289:F489–F495. Birder LA (2006) Urinary bladder urothelium: molecular sensors of chemical/thermal/ mechanical stimuli. Vascul Pharmacol 45:221–226. Birder LA (2007) TRPs in bladder disease. Biochim Biophys Acta 1772:879–884. Birder LA, Nakamura Y, Kiss S, Nealen ML, Barrick S, Kanai AJ, Wang E, Ruiz G, De Groat WC, Apodaca G, Watkins S, and Caterina MJ (2002) Altered urinary bladder function in mice lacking the vanilloid receptor TRPV1. Nat Neurosci 5: 856–860.
REFERENCES
89
Bíró T, Tóth BI, Marincsák R, Dobrosi N, Géczy T, and Paus R (2007) TRP channels as novel players in the pathogenesis and therapy of itch. Biochim Biophys Acta 1772:1004–1021. Bodó E, Bíró T, Telek A, Czifra G, Griger Z, Tóth BI, Mescalchin A, Ito T, Bettermann A, Kovács L, and Paus R (2005) A hot new twist to hair biology: involvement of vanilloid receptor-1 (VR1/TRPV1) signaling in human hair growth control. Am J Pathol 166:985–998. Brauchi S, Orta G, Mascayano C, Salazar M, Raddatz N, Urbina H, Risenmann E, Gonzalez-Nilo F, and Latorre R (2007) Dissection of the components for PIP2 activation and thermosensation in TRP channels. Proc Natl Acad Sci U S A 104: 10246–10251. Brierley SM, Page AJ, Hughes PA, Adam B, Liebregts T, Cooper NJ, Holtmann G, Liedtke W, and Blackshaw LA (2008) Selective role for TRPV4 ion channels in visceral sensory pathways. Gastroenterology 134:2059–2069. Brooks SM (2008) Irritant-induced chronic cough: irritant-induced TRPpathy. Lung 186(Suppl 1):S88–S93. Brophy JM (2007) Cardiovascular effects of cyclooxygenase-2 inhibitors. Curr Opin Gatroenterol 23:617–624. Brown DC, Iadarola MJ, Perkpwski SZ, Erin H, Shofer F, Laszlo KJ, Olah Z, and Mannes AJ (2005) Physiologic and antinociceptive effects of intrathecal resiniferatoxin in a canine bone cancer model. Anesthesiology 103:1052–1059. Campbell JN, Basbaum AI, Dray A, Dubner R, Dworkin RH, and Sang CN, eds. (2006) Emerging Strategies for the Treatment of Neuropathic Pain. IASP Press, Seattle, WA. Caterina MJ and Julius D (2001) The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 24:487–517. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, and Julius D (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288:306–313. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, and Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389:816–824. Cenac N, Altier C, Chapman K, Liedtke W, Zamponi G, and Vergnolle N (2008) Transient receptor potential-4 has a major role in visceral hypersensitivity symptoms. Gastroenterology 135:937–946. Chahl L (2007) TRPs: links to schizophrenia? Biochim Biophys Acta 1772:968– 977. Chan CL, Facer P, Davis JB, Smith GD, Egerton J, Bountra C, Williams NS, and Anand P (2003) Sensory fibers expressing capsaicin receptor TRPV1 in patients with rectal hypersensitivity and faecal urgency. Lancet 361:385–391. Chen X, Alessandri-Haber N, and Levine JD (2007) Marked attenuation of inflammatory mediator-induced C-fiber sensitization for mechanical and hypotonic stimuli in TRPV4-/- mice. Mol Pain 3:31–44. Chen Y, Geis C, and Sommer C (2008) Activation of TRPV1 contributes to morphine tolerance: involvement of the mitogen-activated protein kinase signaling pathway. J Neurosci 28:5836–5845.
90
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
Cheng JK and Ji RR (2008) Intracellular signaling in pain: sensory neurons and persistent pain. Neurochem Res 33:1970–1978. Christoph T, Bahrenberg G, De Vry J, Englberger W, Erdmann VA, Frech M, Kögel B, Röhl T, Schiene K, Schröder W, Seibler J, and Kurreck J (2008) Investigation of TRPV1 loss-of-function phenotypes in transgenic shRNA expressing and knockout mice. Mol Cell Neurosci 37:579–589. Christoph T, Gru" nweller A, Mika J, Schäfer MK, Wade EJ, Weihe E, Erdmann VA, Frank R, Gillen C, and Kurreck J (2006) Silencing of vanilloid receptor TRPV1 by RNAi reduces neuropathic and visceral pain in vivo. Biochem Biophys Res Commun 350:238–243. Chung MK, Lee H, and Caterina MJ (2003) Warm temperatures activate TRPV4 in mouse 308 keratinocytes. J Biol Chem 278:32037–32046. Chung MK, Lee H, Mizuno A, Suzuki M, and Caterina MJ (2004) TRPV3 and TRPV4 mediate warmth-evoked currents in primary mouse keratinocytes. J Biol Chem 279:21569–21575. Colburn RW, Lubin MI, Stone DJ, Wang Y, Lawrence D, D’Andrea MR, Brandt MR, Liu Y, Flores CM, and Qin N (2007) Attenuated cold sensitivity in TRPM8 null mice. Neuron 54:379–386. Cortright DN, Krause JE, and Broom DC (2007) TRP channels and pain. Biochim Biophys Acta 1772:978–988. Cortright DN and Szallasi A (2009a) The role of TRPV1 and related receptors in nociceptor function and neuroimmune regulation. In NeuroImmune Biology, Vol. 8: Neurogenic Inflammation in Health and Disease (Bérczy I, ed.). Elsevier, London, pp. 101–117. Cortright DN and Szallasi A (2009b) TRP channels and pain. Curr Pharm Des 15:1736– 1749. Cuypers E, Yanagihara A, Karlsson E, and Tytgat J (2006) Jellyfish and other cnidarian envenomations cause pain by affecting TRPV1 channels. FEBS Lett 580:5728– 5732. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries HM, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, and Sheardown SA (2000) Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405:183–187. Denda M, Fuziwara S, Inoue K, Denda S, Akamatsu H, Tomitaka A, and Matsunaga K (2001) Immunoreactivity of VR1 on epidermal keratinocytes of human skin. Biochem Biophys Res Commun 285:1250–1252. Dhaka A, Murray AN, Mathur J, Earley TJ, Petrus MJ, and Patapoutian A (2007) TRPM8 is required for cold sensation in mice. Neuron 54:371–378. Dhaka A, Viswanath V, and Patapoutian A (2006) TRP ion channels and temperature sensation. Annu Rev Neurosci 29:135–161. Di Marzo V, Blumberg PM, and Szallasi A (2002) Endovanilloid signaling in pain. Curr Opin Neurobiol 12:372–380. Diogenes A, Akopian AN, and Hargreaves KM (2007) NGF up-regulates TRPA1: implications for orofacial pain. J Dent Res 86:550–556. Dray A (2008) Neuropathic pain: emerging targets. Br J Anaesth 101:48–58.
REFERENCES
91
Du S, Araki I, Kobayashi H, Zakoji H, Sawada N, and Takeda M (2008) Differential expression profile of cold (TRPA1) and cool (TRPM8) receptors in human urogenital organs. Urology 72:450–455. Du S, Araki I, Yoshiyama M, and Takeda M (2007) Transient receptor potential A1 involved in sensory transduction of rat urinary bladder through C-fiber pathway. Urology 70:826–831. Eid SR and Cortright DN (2009) TRP channels on sensory nerves. Handb Exp Pharmacol 194:261–281. Eijkelkamp N, Kavelaars A, Elsenbruch S, Schedlowski M, Holtmann G, and Heijnen CJ (2007) Increased visceral sensitivity to capsaicin after DSS-induced colitis in mice: spinal cord c-Fos expression and behavior. Am J Physiol Gastrointest Liver Physiol 293:G749–G757. Eysselein VE, Reishagen M, Cominelli F, Sternini C, Davis D, Patel A, Nast CC, Bernstein D, Anderson K, Kahn H, and Snape W (1991) Calcitonin gene-related peptide and substance P decrease in the rabbit colon during colitis. Gastroenterology 101:1211–1219. Facer P, Casula MA, Smith GD, Benham CD, Chessell IP, Bountra C, Sinisi M, Birch R, and Anand P (2007) Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy. BMC Neurol 7:11–23. Fleetwood-Walker SM, Proudfoot CW, Garry EM, Allchorne A, Vinuela Fernandez I, and Mitchell R (2007) Cold comfort pharmacology. Trends Pharmacol Sci 28: 621–628. Frederick J, Buck ME, Matson DJ, and Cortright DN (2007) Increased TRPA1, TRPM8 and TRPV2 expression in dorsal root ganglia by nerve injury. Biochim Biophys Res Commun 358:1058–1064. Gallagher RM and Rosenthal LJ (2008) Chronic pain and opiates: balancing pain control and risks in long-term opioid treatment. Arch Phys Med Rehabil 89:S77–S82. Garcia-Sanz N, Valente P, Gomis A, Fernandez-Carvajal A, Fernandez-Ballester G, Viana F, Belmonte C, and Ferrer-Montiel A (2007) A role of the transient receptor potential domain of vanilloid receptor 1 in channel gating. J Neurosci 27:11641– 11650. Gavva N (2008) Predominant function of the vanilloid receptor TRPV1 is body temperature maintenance. Trends Pharmacol Sci 29:550–557. Geppetti P, Capone JG, Trevisani M, Nicoletti P, Zagli G, and Tola MR (2005) CGRP and migraine: neurogenic inflammation revisited. J Headache Pain 6:61–70. Geppetti P and Holzer P, eds. (1996) Neurogenic Inflammation. CRC Press, Boca Raton, FL. Gevaert T, Vriens J, Segal A, Everaerts W, Roskams T, Talavera K, Owsianik G, Liedtke W, Daelemans D, Dewachter I, Van Leuven F, Voets T, De Ridder D, and Nilius B (2007) Deletion of the transient receptor potential cation channel TRPV4 impairs murine bladder voiding. J Clin Invest 117:3453–3462. Ghilardi JR, Röhrich H, Lindsay TH, Sevcik MA, Schwei MJ, Kubota K, Halvorson KG, Poblete J, Chaplan SR, Dubin AE, Carruthers NI, Swanson D, Kuskowski M, Flores CM, Julius D, and Mantyh PW (2005) Selective blockade of the capsaicin receptor TRPV1 attenuates bone cancer pain. J Neurosci 25:3126–3131.
92
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
Gibson HE, Edwards JG, Page RS, Van Hook MJ, and Kauer JA (2008) TRPV1 channels mediate long-term depression at synapses on hippocampal interneurons. Neuron 57:746–759. Gidal B and Billington R (2006) New and emerging treatment options for neuropathic pain. Am J Manag Care 12:S269–S278. Goadsby PJ (2005) Calcitonin gene-related peptide antagonists as treatments of migraine and other primary headaches. Drugs 65:2557–2567. Goadsby PJ (2008) Calcitonin gene-related peptide (CGRP) antagonists and migraine: is this a new era? Neurology 70:1300–1301. Gopinath P, Wan E, Holdcroft A, Facer P, Davis JB, Smith GD, Bountra C, and Anand P (2005) Increased capsaicin receptor TRPV1 in skin fibers and related vanilloid receptors TRPV3 and TRPV4 in keratinocytes in human breast pain. BMC Womens Health 5:2–8. Goso C, Evangelista S, Tramontana M, Manzini S, Blumberg PM, and Szallasi A (1993) Topical capsaicin administration protects against trinitrobenzene sulfonic acidinduced colitis in the rat. Eur J Pharmacol 249:185–190. Gram DX (2003) Capsaicin-sensitive nerves in experimental diabetes mellitus. PhD thesis. The Royal Veterinary and Agricultural University, Denmark. Gram DX and Hansen AJ (2007) The role of TRPV1 in impaired glucose tolerance in mice. Abstract L116. In Neuropeptides 2007: Functions, Dysfunctions & Therapeutic Options, p. 36. Santorini, Greece. Grant AD, Cottrell GS, Amadesi S, Trevisani M, Nicoletti P, Materazzi S, Altier C, Cenac N, Zamponi GW, Bautista-Cruz F, Lopez CB, Joseph EK, Levine JD, Liedtke W, Vanner S, Vergnolle B, Geppetti P, and Bunnett NW (2007) Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice. J Physiol 578:715–733. Guatteo E, Chung KK, Bowata TK, Bernardi G, Mercuri NB, and Lipski J (2005) Temperature sensitivity of dopaminergic neurons of the substantia nigra pars compacta: involvement of transient receptor potential channels. J Neurophysiol 94: 3069–3080. " ler AD, Lee H, Iida T, Shimizu I, Tominaga M, and Caterina MJ (2002) Heat-evoked Gu activation of the ion channel, TRPV4. J Neurosci 22:6408–6414. Gullapalli S, Thomas A, Rao P, Kattige V, Gudi GS, and Khairatkar-Joshi N (2008) GRC-15133: a novel, selective TRPV3 antagonist with antihyperalgesic effects in inflammatory and neuropathic pain. World Pharmaceutical Congress, Philadelphia, PA, June 9–11, 2009. Gunthorpe MJ and Szallasi A (2008) Peripheral TRPV1 receptors as targets for drug development: new molecules and mechanisms. Curr Pharm Des 14:32–41. Hartmannsgruber V, Heyken WT, Kacik M, Kaistha A, Grgic I, Harteneck C, Liedtke W, Hoyer J, and Kohler R (2007) Arterial response to shear stress critically depends on endothelial TRPV4 expression. PLoS ONE 2:e827. Hicks GA (2006) TRP channels as therapeutic targets: hot property, or time to cool down? Neurogastroenterol Motil 18:590–594. Hjerling-Leffner J, Alqatari M, Ernfors P, and Koltzenburg M (2007) Emergence of functional sensory receptor subtypes as defined by transient receptor potential channel expression. J Neurosci 27:2435–2443.
REFERENCES
93
Holzer P (1991) Capsaicin: cellular targets, mechanisms of action, and selectivity for thin sensory neurons. Pharmacol Rev 43:143–201. Holzer P (2003) Acid-sensitive ion channels in gastrointestinal function. Curr Opin Pharmacol 3:618–625. Holzer P (2004) Vanilloid receptor TRPV1: hot in the tongue and inflaming in the colon. Neurogastroenterol Motil 16:697–699. Imura K, Yoshioka T, Hikita I, Tsukahara K, Hirasawa T, Higashino K, Gahara Y, Arimura A, and Sakata T (2007) Influence of TRPV3 mutation on hair growth cycle in mice. Biochem Biophys Res Commun 363:479–483. Jancsó G, Obál F, Tóth-Kása I, Katona M, and Husz S (1985) The modulation of cutaneous inflammatory reactions by peptide-containing sensory nerves. Int J Tissue React 7:449–457. Ji G, Zhou A, and Carlton SM (2008) Intact Aδ-fibers up-regulate transient receptor potential A1 and contribute to cold hypersensitivity in neuropathic rats. Neuroscience 154:1054–1066. Ji G, Zhou S, Kochukov MY, Westlund KN, and Carlton SM (2007) Plasticity in intact Aδ- and C-fibers contributes to cold hypersensitivity in neuropathic rats. Neuroscience 150:182–193. Johanek LM, Heitmiller DR, Turner M, Nader N, Hodges J, and Simone DA (2001) Cannabinoids attenuate capsaicin-evoked hyperalgesia through spinal and peripheral mechanisms. Pain 93:303–315. Jones RC III, Xu L, and Gebhart GF (2005) The mechanosensitivity of mouse colon afferent fibers and their sensitization by inflammatory mediators require transient receptor potential vanilloid 1 and acid-sensing ion channel 3. J Neurosci 25: 10981–10999. Jordt SE, Bautista DM, Chuang HH, McKemy DD, Zygmunt PM, Högestätt EN, Meng ID, and Julius D (2004) Mustard oil and cannabinoids excite sensory nerve fibres through the TRP channel ANKTM1. Nature 427:260–265. Jordt SE and Ehrlich BE (2007) TRP channels in disease. Subcell Biochem 45:253–271. Katsura H, Obata K, Mizushima T, Yamanaka H, Kobayashi K, Dai Y, Fukuoka T, Tokunaga A, Sakagami M, and Noguchi K (2006) Antisense knock-down of TRPA1, but not TRPM8, alleviates cold hyperalgesia after spinal nerve ligation in rats. Exp Neurol 200:112–123. Katz NA and Berkin RL (2008) Dilemmas in chronic/persistent pain management. Am J Ther 15:256–264. Kim D and Baraniuk JN (2007) Sensing the air around us: the voltage-gated-like ion channel family. Curr Allergy Asthma Rep 7:85–92. Kim AY, Tang Z, Liu Q, Patel KN, Maag D, Geng Y, and Dong X (2008) Pirt, a phosphoinositide-binding protein, functions as a regulatory subunit of TRPV1. Cell 133:475–485. Knotkova H, Pappagallo M, and Szallasi A (2008) Capsaicin (TRPV1 agonist) therapy for pain relief: farewell or revival? Clin J Pain 24:142–154. Kobayashi K, E Fukuoka T, Obata K, Yamanaka H, Dai Y, Tokunaga A, and Noguchi K (2005) Distinct expression of TRPM8, TRPA1 and TRPV1 mRNAs in rat primary afferent neurons with Aδ- and C-fibers and colocalization with trk receptors. J Comp Neurol 493:596–606.
94
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
Lashinger ES, Steiginga MS, Hieble JP, Leon LA, Gardner SD, Nagilla R, Davenport ES, Hoffman BE, Laping Nj, and Su X (2008) AMTB, a TRMP8 channel blocker: evidence in rats for activity in overactive bladder and painful bladder syndrome. Am J Physiol Renal Physiol 295: F803–F810. Lauria G, Morbin M, Lombardi R, Capobianco R, Camozzi F, Pareyson D, Manconi M, and Geppetti P (2006) Expression of capsaicin receptor immunoreactivity in human peripheral nervous system and painful neuropathies. J Peripher Nerv Syst 11:262–271. Lawson JJ, McIlwrath SL, Woodbury CJ, Davis BM, and Koerber HR (2008) TRPV1, unlike TRPV2, is restricted to a subset of mechanically insensitive cutaneous nociceptors responding to heat. J Pain 9:298–308. Lee H, Iida T, Mizuno A, Suzuki M, and Caterina MJ (2005) Altered thermal selection behavior in mice lacking transient receptor potential vanilloid 4. J Neurosci 25:1304–1310. Levine JD and Alessandri-Haber N (2007) TRP channels: targets for the relief of pain. Biochim Biophys Acta 1772:989–1003. Liapi A and Wood JN (2005) Extensive co-localization and heteromultimer formation of the vanilloid receptor-like protein TROV2 and the capsaicin receptor TRPV1 in the adult rat cerebral cortex. Eur J Neurosci 22:825–834. Liedtke W (2007) TRPV channels’ role in osmotransduction and mechanotransduction. Handb Exp Pharmacol 179:473–487. Liedtke W (2008) Molecular mechanisms of TRPV4-mediated neural signaling. Ann N Y Acad Sci 1144: 42–52. Liedtke W and Friedman JM (2003) Abnormal osmotic regulation in trpv4-/- mice. Proc Natl Acad Sci U S A 100:13698–13703. Liedtke W and Heller S, eds. (2007) TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades. Taylor and Francis, Boca Raton, FL. Lipski J, Park TT, Li D, Trevarton AJ, Chung KK, Freestone PS, and Bai JZ (2006) Involvement of TRP-like channels in the acute ischemic response of hippocampal CA1 neurons in brain slices. Brain Res 1077:187–199. Lishko PV, Procko E, Jin X, Phelps CB, and Gaudet R (2007) The ankyrin repeats in TRPV1 bind multiple ligands and modulate channel sensitivity. Neuron 54: 905–918. Liu B and Qin F (2005) Functional control of cold- and methol-sensitive TRPM8 ion channels by phosphatidylinositol 4,5-bisphosphate. J Neurosci 25:1674–1681. Lukacs V, Thyagarajan B, Varnai P, Balla A, Balla T, and Rohacs T (2007) Dual regulation of TRPV1 by phosphoinositides. J Neurosci 27:7070–7080. Lundberg JM, Martling CR, Saria A, Folkers K, and Rosell S (1983) Cigarette smokeinduced airway edema is due to activation of capsaicin-sensitive vagal afferents and substance P. Neuroscience 10:1361–1368. Lundberg JM and Saria A (1983) Capsaicin-induced desensitization of airway mucosa to cigarette smoke, mechanical and chemical irritants. Nature 302:251–258. Ma QP (2002) Expression of capsaicin receptor (VR1) by myelinated primary afferent neurons in rats. Neurosci Lett 319:87–90. Macpherson LJ, Dubin AE, Evans MK, Marr F, Schultz PG, Cravatt BF, and Patapoutian A (2007a) Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature 445:541–545.
REFERENCES
95
Macpherson LJ, Xiao B, Kwan KY, Petrus MJ, Dubin AE, Cravatt B, and Patapoutian A (2007b) An ion channel essential for sensing chemical damage. J Neurosci 27:11412–11415. Macpherson LJ, Geigerstanger BH, Viswanath V, Bandell E, Eid SR, Hwang S, and Patapoutian A (2005) The pungency of garlic: activation of TRPA1 and TRPV1 in response to allicin. Curr Biol 15:929–934. Macpherson LJ, Hwang SW, Miyamoto T, Dubin AE, Patapoutian A, and Story GM (2006) More than cool: promiscuous relationships of menthol and other sensory compounds. Mol Cell Neurosci 32:335–343. Malmberg AB and Bley K, eds. (2005) Turning Up the Heat on Pain: TRPV1 Receptors in Pain and Inflammation. Birkhäuser, Basel. Matta JA, Cornett PM, Miyares RL, Abe K, Sahibzada N, and Ahern GP (2008) General anesthetics activate a nociceptive ion channel to enhance pain and inflammation. Proc Natl Acad Sci U S A 105:8784–8789. Matthews PJ, Aziz Q, facer P, Davis JB, Thompson DG, and Anand P (2004) Increased capsaicin receptor TRPV1 nerve fibers in the inflamed human oesophagus. Eur J Gastroenterol Hepatol 16:897–902. McKemy DD, Neuhausser WM, and Julius D (2002) Identification of a cold receptor reveals a general role for TRP channels in thermosensation. Nature 416:52–58. McLeod RL, Correll CC, Jia Y, and Anthes JC (2008) TRPV1 antagonists as potential antitussive agents. Lung 186(Suppl 1):S59–S65. McMahon SB and Wood JN (2006) Increasingly irritable and close to tears: TRPA1 in inflammatory pain. Cell 124:1123–1125. Menendez L, Juarez L, Garcia E, Garcia-Suarez O, Hidalgo A, and Baamonde A (2006) Analgesic effects of capsazepine and resiniferatoxin on bone cancer pain in mice. Neurosci Lett 393:70–73. Meseguer V, Karashima Y, Talavera K, D’Hoedt D, Donovan-Rodriguez T, Viana F, Nilius B, and Voets T (2008) Transient receptor potential channels in sensory neurons are targets of the antimycotic agent clomitrazole. J Neurosci 28:576–586. Miranda A, Nordstrom E, Mannem A, Smith C, Banarjee B, and Sengupta JN (2007) The role of transient receptor potential vanilloid 1 in mechanical and chemical hyperalgesia following experimental colitis. Neuroscience 148:1021–1032. Mitrovic M and Holzer P (2008) Enhancement of TRPA1- and TRPV1-mediated noxious input to the spinal cord in mild colitis. IASP Congress, Glasgow, Scotland. Mizoguchi F, Mizuno A, Hayata T, Heller S, Ushida T, Sokabe M, Miyasaka N, Suzuki M, Ezura Y, and Noda M (2008) Transient receptor potential vanilloid 4 deficiency suppresses unloading-induced bone loss. J Cell Physiol 216:47–53. Moller AR, ed. (2002) Sensory Systems: Anatomy and Physiology. Academic Press, San Diego, CA. Moqrich A, Hwang SW, Earley TJ, Petrus MJ, Murray AN, Spencer KS, Andahazy M, Story GM, and Patapoutian A (2005) Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin. Science 307:1468–1472. Motter AL and Ahern GP (2008) TRPV1-null mice are protected from diet-induced obesity. FEBS Lett 582:2257–2262. Moussaieff A, Rimmerman N, Bregman T, Straiker A, Folder CC, Shoham S, Kashman Y, Huang SM, Lee H, Shohami E, Mackie K, Caterina MJ, Walker JN, Fride E,
96
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
and Mechoulam R (2008) Incensole acetate, an incense component, elicits physicoactivity by activating TRPV3 channels in the brain. FASEB J 22:3024–3034. Mózsik G, Szolcsányi J, and Dömötör A (2007) Capsaicin research as a new tool to approach of the human gastrointestinal physiology, pathology and pharmacology. Inflammopharmacology 15:232–245. Namer B, Kleggetveit IP, Handwerker H, Schmelz M, and Jorum E (2008) Role of TRPM8 and TRPA1 for cold allodynia in patients with cold injury. Pain 139:63–72. Namer B, Seifert F, Handwerker HO, and Maihöfner C (2005) TRPA1 and TRPM8 activation in humans: effects of cinnamaldehyde and menthol. Neuroreport 16:955–959. Nassenstein C, Kwong K, Taylor-Clark T, Kollarik M, Macglashan DM, Braun A, and Undem BJ (2008) Expression and function of the ion channel TRPA1 in vagal afferent nerves innervating mouse lungs. J Physiol 586:1595–1604. Neubert JK, Mannes AJ, Karai LJ, Jenkins AC, Zawatski L, Abu-Asab M, and Iadarola M (2008) Perineural resiniferatoxin selectively inhibits inflammatory hyperalgesia. Mol Pain 4:3–11. Niiyama Y, Kawamata T, Yamamoto J, Omote K, and Namiki A (2007) Bone cancer increases transient receptor potential vanilloid subfamily 1 expression within distinct subpopulations of dorsal root ganglion neurons. Neuroscience 148:560–572. Nilius B (2007) TRP channels in disease. Biochim Biophys Acta 1772:805–812. Nilius B, Owsianik G, Voets T, and Peters JA (2007) Transient receptor potential cation channels in disease. Physiol Rev 87:165–217. Oertel B and Lötsch J (2008) Genetic mutations that prevent pain: implications for future pain medication. Pharmacogenomics 9:179–194. Owen RT (2007) Pregabalin: its efficacy, safety and tolerability profile in generalized anxiety. Drugs Today 43:601–610. Patacchini R, Maggi CA, and Meli A (1990) Capsaicin-like activity of some natural pungent substances on peripheral endings of visceral primary afferents. NaunynSchmiedebergs Arch Pharmacol 342:72–77. Patapoutian A, Tate S, and Woolf C (2009) TRP channels: targeting pain at the source. Nat Rev Drug Discov 8:55–68. Patel T, Ishiuju Y, and Yosipovitch G (2007) Menthol: a refreshing look at this ancient compound. J Am Acad Dermatol 57:873–878. Paus R, Schmelz M, Bíró T, and Steinhoff M (2006) Frontiers in pruritus research: scratching the brain for more effective itch therapy. J Clin Invest 116:1174–1185. Peier AM, Moqrich A, Hergarden AC, Reeve AJ, Andersson DA, Story GM, Earley TJ, Dragoni I, McIntyre P, Bevan S, and Patapoutian A (2002a) A TRP channel that senses cold stimuli and menthol. Cell 108:705–715. Peier AM, Reeve AJ, Andersson DA, Moqrich E, Earley TJ, Hergarden AC, Story GM, Colley S, Hogenesch JB, McIntyre P, Bevan S, and Patapoutian A (2002b) A heat-sensitive TRP channel expressed in keratinocytes. Science 296:2046–2049. Penuelas A, Tashima K, Tsuchiya S, Matsumoto K, Nakamura T, Horie S, and Yano S (2007) Contractile effects of TRPA1 receptor agonists in the isolated mouse intestine. Eur J Pharmacol 576:143–150.
REFERENCES
97
Petrus M, Peier AM, Bandell M, Hwang SW, Huynh T, Olney N, Jegla T, and Patapoutian A (2007) A role of TRPA1 in mechanical hyperalgesia is revealed by pharmacological inhibition. Mol Pain 3:40–48. Pingle SC, Matta JA, and Ahern GP (2007) Capsaicin receptor TRPV1: a promiscuous TRP channel. Handb Exp Pharmacol 179:155–171. Plant TD, Zöllner C, Kepura F, Mousa SS, Eichhorst J, Schaefer M, Furkert J, Stein C, and Oksche A (2007) Endothelin potentiates TRPV1 via ETA receptormediated activation of protein kinase C. Mol Pain 3:35–46. Prescott ED and Julius D (2003) A modular PIP2 binding site as a determinant of capsaicin receptor sensitivity. Science 300:1284–1288. Prevarskaya N, Zhang L, and Barritt G (2007) TRP channels and cancer. Biochim Biophys Acta 1772:937–946. Proudfoot CJ, Garry EM, Cottrell DF, Rosie R, Anderson H, Robertson DC, Fleetwood-Walker SM, and Mitchell R (2006) Analgesia mediated by the TRPM8 receptor in chronic neuropathic pain. Curr Biol 16:1591–1605. Qin F (2007) Regulation of TRP ion channels by phosphatidylinositol 4,5-bisphosphate. Handb Exp Pharmacol 179:509–522. Rashid HM, Inoue M, Bakoshi S, and Ueda H (2003) Increased expression of vanilloid receptor-1 on myelinated primary afferent neurons contributes to the antihyperalgesic effects of capsaicin cream in diabetic neuropathic pain in mice. J Pharmacol Exp Ther 306:709–717. Reiter B, Kraft R, Gunzel D, Zeissig S, Schultzke JD, Fromm M, and Harteneck C (2006) TRPV4-mediated regulation of epithelial permeability. FASEB J 20:1802– 1812. Roberts LA and Connor M (2006) TRPV1 antagonists as a potential treatment for hyperalgesia. Recent Pat CNS Drug Discov 1:65–76. Sabnis AS, Shahid M, Yost GS, and Reilly CA (2008) Human lung epithelial cells express a functional cold-sensing TRPM8 variant. Am J Respir Cell Mol Biol 39: 466–474. Scanzello CR, Moskowitz NK, and Gibofsky A (2008) The post-NSAID era: what to use now for the pharmacologic treatment of pain and inflammation in osteoarthritis. Curr Rheumatol Rep 10:49–56. Sharkey KA, Cristino L, Oland LD, Van Sickle MD, Starowicz K, Pittman QJ, Guglielmotti V, Davison JS, and Di Marzo V (2007) Arvanil, anandamide and N-arachidonoyl-dopamine (NADA) inhibits emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur J Neurosci 25:2772–2782. Sicuteri F, Fusco BM, Marabini S, Campagnolo V, Maggi CA, Geppetti P, and Fanciullacci M (1989) Beneficial effect of capsaicin application to the nasal mucosa in cluster headache. Clin J Pain 5:49–53. Siemens J, Zhou S, Piskorowski R, Nikai T, Lumpkin EA, Basbaum AI, King D, and Julius D (2006) Spider toxins activate the capsaicin receptor to produce inflammatory pain. Nature 444:208–212. Simon SA and Liedtke W (2008) How irritating: the role of TRPA1 in sensing cigarette smoke and aerogenic oxidants in the airways. J Clin Invest 118:2383– 2386.
98
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
Sipe WE, Brierley SM, Martin CM, Phillis BD, Cruz FB, Grady EF, Liedtke W, Cohen DM, Vanner S, Blackshaw LA, and Bunnett NW (2008) Transient receptor potential vanilloid 4 mediates protease activated receptor 2-induced sensitization of colonic afferent nerves and visceral hyperalgesia. Am J Physiol Gastrointest Liver Physiol 294:G1288–1298. Smith GD, Gunthorpe MJ, Kelsell RE, Hayes PD, Reilley P, Facer P, Wright JE, Jerman JC, Walhin JP, Ooi L, Egerton J, Charles KJ, Smart D, Randall AD, Anand P, and Davis JB (2002) TRPV3 is a temperature-sensitive vanilloid receptorlike protein. Nature 418:186–190. Smith PL, Maloney KN, Pothen RG, Clardy J, and Clapham DE (2006) Bisandrographolide from Andrographis paniculata activates TRPV4 channels. J Biol Chem 281:29897–29904. Southall MD, Li T, Gharibova LS, Pei Y, Nicol GD, and Travers JB (2003) Activation of epidermal vanilloid receptor-1 induces release of proinflammatory mediators in human keratinocytes. J Pharmacol Exp Ther 304:217–222. Spencer NJ, Kerrin A, Singer CA, Hennig GW, Gerthoffer WT, and McDonnell O (2008) Identification of capsaicin-sensitive rectal mechanoreceptors activated by rectal distension in mice. Neuroscience 153:518–534. Story GM, Peier AM, Reeve AJ, Eid SR, Mosbacker J, Hricik TR, Earley TJ, Hergarden AC, Andersson DA, Hwang SW, McIntye P, Jegla T, Bevan S, and Patapoutian A (2003) ANKTM1, a TRP-like channel expressed in nociceptive neurons, is activated by cold temperatures. Cell 112:819–829. Stotz SC, Vriens J, Martyn D, Clardy J, and Clapham DE (2008) Citral sensing by TRANSient receptor potential channels in dorsal root ganglion neurons. PLoS ONE 3:e2082. Stucky CL, Gold MS, and Zhang X (2001) Mechanisms of pain. Proc Natl Acad Aci U S A 98:11845–11846. Sugiura T, Bielefeld K, and Gebhart GF (2007) Mouse colon sensory neurons detect extracellular acidosis via TRPV1. Am J Physiol Cell Physiol 292:C1768–1774. Suri A and Szallasi A (2008) The emerging role of TRPV1 in diabetes and obesity. Trends Pharmacol Sci 29:29–36. Surprenant A (2007) Pain TRP-ed up by PARs. J Physiol 578:631. Suzuki M, Mizuno A, Kodaira K, and Imai M (2003) Impaired pressure sensation in mice lacking TRPV4. J Biol Chem 278:22664–22668. Szallasi A and Blumberg PM (1999) Vanilloid (capsaicin) receptors and mechanisms. Pharmacol Rev 51:159–212. Szallasi A, Cortright DN, Blum CA, and Eid SR (2007) The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 6:357–372. Szallasi A, Cruz F, and Geppetti P (2006) TRPV1: a therapeutic target for novel analgesic drugs? Trends Mol Med 12:545–554. Tabuchi K, Suzuki M, Mizuno A, and Hara A (2005) Hearing impairment in TRPV4 knockout mice. Neurosci Lett 382:304–308. Tai C, Zhu S, and Zhou N (2008) TRPA1: the central molecule for chemical sensing in pain pathway? J Neurosci 28:1019–1021. Talavera K, Nilius B, and Voets T (2008) Neuronal TRP channels: thermometers, pathfinders and life-savers. Trends Neurosci 31:287–295.
REFERENCES
99
Taylor-Clark TE, Undem BJ, Macglashan DW, Ghatta S, Carr MJ, and McAlexander MA (2008) Prostaglandin-induced activation of nociceptive neurons via direct interaction with transient receptor potential A1 (TRPA1). Mol Pharmacol 73:274–281. Todaka H, Taniguchi J, Satoh J, Mizuno A, and Suzuki M (2004) Warm temperaturesensitive transient receptor potential vanilloid 4 (TRPV4) plays an essential role in thermal hyperalgesia. J Biol Chem 279:35133–35138. Trevisani M, Siemens J, Materazzi S, Bautista DM, Nassini R, Campi B, Imamachi N, Andre E, Patacchini R, Cottrell GS, Gatti R, Basbaum AI, Bunnett NW, Julius JD, and Geppetti P (2007) 4-Hydroxynonenal, an endogenous aldehyde, causes pain and neurogenci inflammation through activation of the irritant receptor TRPA1. Proc Natl Acad Sci U S A 104:13519–13524. Venkatachalam K and Montell C (2007) TRP channels. Annu Rev Biochem 76:387– 417. Vetter I, Wyse BD, Monteith GR, Roberts-Thomson SJ, and Cabot PJ (2006) The mu opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase A pathway. Mol Pain 2: 22–27. Vetter I, Wyse BD, Monteith GR, Roberts-Thomson SJ, Monteith GR, and Cabot PJ (2008) Mechanisms involved in potentiation of transient receptor potential vanilloid 1 responses by ethanol. Eur J Pain 12:441–454. Wallace MS (2006) Ziconotide: a new nonopioid intrathecal analgesic for the treatment of chronic pain. Expert Rev Neurother 6:1428–1438. Wang ZY, Wang P, Merriam FV, and Bjorling DE (2008) Lack of TRPV1 inhibits cystitis-induced increased mechanical sensitivity in mice. Pain 139:158–167. Weil A, Moore SE, Waite NJ, Randal A, and Gunthorpe MJ (2005) Conservation of functional and pharmacological properties in the distantly related temperature sensors TRPV1 and TRPM8. Mol Pharmacol 68:518–527. Wilder-Smith EP, Ong WY, Guo Y, and Chow AW (2007) Epidermal transient receptor potential vanilloid 1 in idiopathic small nerve fibre disease, diabetic neuropathy and healthy human subjects. Histopathology 51:674–680. Willette R, Bao W, Nerurkar S, Yue TL, Doe CP, Stankus G, Turner GH, Ju H, Thomas H, Fishman C, Sulpizio A, Belum D, Hoffman S, Lin Z, Lozinskaya I, Casillas L, Lin M, Trout RE, Thorlenoe K, Lashinger ES, Figueroa DJ, Votta B, Marquis R, and Xu X (2008) Systemic activation of transient receptor potential V4 channel causes endothelial failure and circulatory collapse. J Pharmacol Exp Ther 326:443–452. Winston J, Shenoy M, Medley D, Naniwadekar A, and Pasricha PJ (2007) The vanilloid receptor initiates and maintains colonic hypersensitivity induced by neonatal colon irritation in rats. Gastroenterology 132:615–627. Wu L, Gao X, Brown RC, Heller S, and O’Neil RG (2007) Dual role of the TRPV4 channel as a sensor of flow and osmolality in renal epithelial cells. Am J Physiol Renal Physiol 293:F1699–1713. Xiao R, Tian J, Tang J, and Zhu MX (2008) The TRPV3 mutation associated with the hairless phenotype in rodents is constitutively active. Cell Calcium 43:334–343. Xing H, Chen M, Ling J, Tan W, and Gu JG (2007) TRPM8 mechanisms of cold allodynia after chronic nerve injury. J Neurosci 27:13680–13690.
100
ROLE OF TRP CHANNELS IN PAIN: AN OVERVIEW
Xing H, Ling JX, Chen M, Johnson RD, Tominaga M, Wang CY, and Gu J (2008) TRPM8 mechanism of autonomic nerve response to cold in respiratory airway. Mol Pain 4:22–31. Xu H, Blair NT, and Clapham DE (2005) Camphor activates and strongly desensitizes the transient receptor potential vanilloid subtype 1 channel in a vanilloidindependent mechanism. J Neurosci 25:8924–8937. Xu H, Delling M, Jun JC, and Clapham DE (2006) Oregano, thyme and clove-derived flavors and skin sensitizers activate specific TRP channels. Nat Neurosci 9:628– 635. Xu XJ, Farkas-Szallasi T, Lundberg JM, Hökfelt T, Wiesenfeld-Hallin Z, and Szallasi A (1997) Effects of the capsaicin analog resiniferatoxin on spinal nociceptive reflexes in the rat: behavioral, electrophysiologic and in-situ hybridization studies. Brain Res 752:52–60. Xu H, Ramsey IS, Kotecha SA, Moran MM, Chong JA, Lawson D, Ge P, Lilly J, Silos-Santiago I, Xie I, DiStefano PS, and Clapham DE (2002) TRPV3 is a calciumpermeable temperature-sensitive cation channel. Nature 418:181–186. Yamamoto S, Wajima T, Hara Y, Nishida M, and Mori Y (2007) Transient receptor potential channels in Alzheimer’s disease. Biochim Biophys Acta 1772:958–967. Yamamura H, Ugawa S, Ueda T, Morita A, and Shoichi S (2008) TRPM8 activation suppresses cellular viability in human melanoma. Am J Physiol Cell Physiol 295: C296–C301. Yang J, Li Y, Zuo Y, Yu Y, and Gao L (2008) Transient receptor potential ankyrin-1 participates in visceral hyperalgesia following experimental colitis. Neurosci Lett 440:237–241. Yiangou Y, Facer P, Dyer NH, Chan CC, Knowles C, Williams C, and Anand P (2001) Vanilloid receptor 1 immunoreactivity in inflamed human bowel. Lancet 357: 1338–1339. Yin J, Hoffmann J, Kaestle SM, Neye N, Wang L, Bauerle J, Liedtke W, Wu S, Kuppe H, Pries AR, and Kuebler WM (2008) Negative feed-back loop attenuates hydrostatic lung edema via a cGMP-dependent regulation of transient receptor potential vanilloid 4. Circ Res 102:966–974. Zhang Y, Wang GW, Ge HY, Arendt-Nielsen L, Wang R, and Yue SW (2008) A transient receptor potential vanilloid 4 contributes to mechanical allodynia following chronic compression of dorsal root ganglion in rats. Neurosci Lett 432:222– 227. Zhuo M, ed. (2008) Molecular Pain. Springer-Verlag, Secaucus, NJ.
3 BIOCHEMICAL PHARMACOLOGY OF TRPV1: MOLECULAR INTEGRATOR OF PAIN SIGNALS Carol S. Surowy, Philip R. Kym, and Regina M. Reilly
3.1
INTRODUCTION
The transient receptor potential vanilloid 1 (TRPV1) receptor is a nonselective cation channel, which is highly permeable to calcium. TRPV1 is expressed on peripheral and central terminals of small- and medium-sized primary sensory neurons, as well as in discrete areas of the brain, and plays a key role in the detection and modulation of nociceptive stimuli (Caterina and Julius, 2001). Over the past few years, the field has yielded a plethora of information on the biochemical pharmacology of this channel. This review will elaborate upon this knowledge and will summarize the current understanding of how TRPV1 functions as a molecular integrator of pain signals.
3.2 TRPV1 STRUCTURE TRPV1 is the first discovered mammalian member of the TRP superfamily. Members of this superfamily are predicted to contain six transmembrane helices (TM1–TM6) with a pore domain between helices 5 and 6 and both the N- and C-termini on the cytosolic side of the cell membrane (Fig. 3.1). TRPV1 channels are opened or closed by conformational changes induced by ligand binding or by other modifications of the protein. Vanilloid Receptor TRPV1 in Drug Discovery, Edited by Arthur Gomtsyan & Connie R. Faltynek Copyright © 2010 John Wiley & Sons, Inc.
101
102
BIOCHEMICAL PHARMACOLOGY OF TRPV1
Figure 3.1 Representation of TRPV1 highlighting the six transmembrane domain ion channel topology and key residues involved in ligand-mediated activation (blue), proton-mediated activation (V538/Val538, T633/Thr633, E648/Glu648) or potentiation (E600/Glu600) (green), and heat activation (red oval). A indicates the ankyrin repeat domains in the N-terminus. Phosphatidylinositol (4,5)-bisphosphate (PIP) is reported to tonically inhibit TRPV1 via the indicated region (dashed square) in the C-terminus. The blue circle represents the TRP domain and the overlapping PIP activation domain. CaM indicates calmodulin-binding sites in both the N- and C-terminal domains of the channel. The receptor is activated by capsaicin, endogenous vanilloid lipids such as N-arachidonyl dopamine (NADA), heat >42 °C, or protons (pH < 5.5). (See color insert.)
It is generally accepted that the topology of TRPV1 is similar to that reported for other ion channels for which high-resolution X-ray crystal structures (Kcsa [Doyle et al., 1998], Kv1.2 [Long et al., 2005], MthK [Jiang et al., 2002]) have been obtained. The first low-resolution (19 Å) three-dimensional structure of TRPV1, determined by single-particle electron microscopy, has revealed a protein that is arranged in two distinct domains: a relatively compact domain that is consistent with a six-helix transmembrane protein structure and a large, open, basketlike domain that resides in the intracellular compartment (Moiseenkova-Bell et al., 2008). Another feature of TRPV1 architecture confirmed by this structure is the symmetrical assembly of four TRPV1 subunits to form the channel pore. TRPV1 contains three ankyrin repeat domains (ARDs) in its long N-terminal region. Calmodulin (CaM) has been shown to interact with TRPV1 by binding to the first ARD. The crystal structures of ARD domains for TRPV1 (Lishko et al., 2007), TPRV2 (Jin et al., 2006), and TPRV6 (Phelps et al., 2008) have been solved. The 1.7-Å crystal structure of the TRPV6 ARD (Phelps et al., 2008) reveals structural features that are
ACTIVATION OF TRPV1—A POLYMODAL RECEPTOR
103
unique to TRPV proteins. Conserved TRPV residues induce a pronounced twist in the ARD and define a specific orientation of finger loop 3 that may create access to a putative regulatory phosphorylation site. These features make TRPV ARDs distinct from other ARDs. The functional role of the unique TRPV ARD in determining binding sites for specific interacting partner proteins has not yet been reported. The large intracellular C-terminal region of TRPV1 acts as a modulatory domain for the receptor and includes the transient receptor potential (TRP) domain, phosphatidylinositol 4,5-bisphosphate (PIP2) binding sites, a CaMbinding site, and a number of key sites of phosphorylation. The highly conserved TRP domain, comprising the region spanning Glu 696 to Arg 722 (rat TRPV1 sequence numbering, Swiss-Prot O35433), has a high probability of adopting an α-helical, coiled-coil, secondary structure. The domain acts as an association domain of the protein by contributing to the tetramerization of TRPV1 to form functional channels (Garcia-Sanz et al., 2004). It also plays a role in channel gating, through intersubunit interactions near the channel gate that contribute to the coupling of stimulus sensing to channel opening (GarciaSanz et al., 2007). In addition, the TRP domain functions in the requirement of PIP2 for TRPV1 activation (Brauchi et al., 2007). These findings support a significant role for the TRP domain in several aspects of TRPV1 function. The distal C-terminal domain (amino acids 777–820) is also important in modulating TRPV1 activity by several mechanisms. This domain not only contains the proposed site involved in tonic inhibition by PIP2 but also contains Ser 800, which is a critical site for protein kinase C (PKC)-dependent phosphorylation, and overlaps the 35 amino acid segment necessary for C-terminal CaM binding.
3.3 ACTIVATION OF TRPV1—A POLYMODAL RECEPTOR TRPV1 as a polymodal receptor can be activated by numerous exogenous and endogenous agonists, by noxious heat (>42 °C), by extracellular protons (pH < 6.0), and by voltage. The physiological relevance of TRPV1 activation by several endogenous agonists, including the endocannabinoid anandamide, N-arachidonyl dopamine (NADA), N-oleoyldopamine (OLDA), metabolites from the lipoxygenase pathway, such as 12-hydroperoxyeicosatetraenoic acid, and lipids, such as diacylglycerol (DAG), is still being investigated (Caterina et al., 1997; Tominaga et al., 1998; Hwang et al., 2000; Smart et al., 2000; Huang et al., 2002). The ability of TRPV1 to act as a molecular integrator of multiple stimuli, as well as evidence that differing regions of the receptor are involved in activation by the various stimuli, underscores the complexity and dynamic nature of TRPV1 activation. 3.3.1
Best Characterized Activators of TRPV1
3.3.1.1 Activation by Capsaicin TRPV1 is widely known for its ability to be activated by capsaicin, the pungent ingredient in hot chili peppers
104
BIOCHEMICAL PHARMACOLOGY OF TRPV1
(Caterina et al., 1997; Tominaga et al., 1998; Szallasi et al., 2007). Capsaicin (EC50 ∼100 nM−1 μM, dependent on assay conditions) potently activates TRPV1. Activation of TRPV1 by capsaicin induces robust inward currents (when held at −60 mV) with a short latency that, upon washout, are quickly recovered as the channel deactivates. Current–voltage relations show that capsaicin responses exhibit outward rectification with a reversal potential close to 0 mV. Based on Hill coefficients of ∼2, it appears that full activation of TRPV1 involves the binding of more than one agonist molecule (Caterina et al., 1997). TRPV1 is a nonselective cation channel that demonstrates very high permeability to calcium ions, (PCa/PNa) ∼10. This permeability for calcium ions has implications with respect to function of TRPV1, as well as its desensitization. Activation of TRPV1 by capsaicin appears to require prior phosphorylation by Ca2+/CaM-dependent kinase (CaMKII) (Jung et al., 2004). TRPV1 activation is also subject to dual regulation by the membrane phospholipid PIP2. In the absence of an agonist or at low concentrations of capsaicin (and other moderate stimuli such as heat), PIP2 exerts a tonic and partial inhibition of TRPV1 (Chuang et al., 2001; Lukacs et al., 2007), and hydrolysis of PIP2 by phospholipase C (PLC) can activate TRPV1 (Chuang et al., 2001). At higher concentrations of agonists, PIP2 contributes to activation of TRPV1 and is required to maintain channel activity (Stein et al., 2006; Lukacs et al., 2007). The balance between the inhibitory and stimulatory effects of PIP2 appears to depend on the strength of receptor stimulation. 3.3.1.2 Activation by Toxins Resiniferatoxin (RTX), a toxin derived from the plant Euphorbia resinifera, is the most potent of the known TRPV1 agonists, with approximately 10- to 20-fold greater potency than capsaicin. Like capsaicin, RTX induces robust currents, but kinetic studies demonstrate slower activation by RTX and lack of rapid deactivation upon washout (Caterina et al., 1997; Raisinghani et al., 2005). RTX-induced currents show less outward rectification than currents induced by capsaicin. Thus, RTX induces sustained currents, and the open channel probability at all membrane potentials is significantly more than that obtained with capsaicin. A number of animal toxins known to cause pain have recently been identified as potent TRPV1 agonists. These include three Cys knot peptides from a tarantula toxin (Siemens et al., 2006) and several jellyfish venoms (Cuypers et al., 2006). 3.3.1.3 Lipid Agonists Just as capsaicin and other exogenous agonists described above are highly lipophilic, there are numerous endogenous lipidlike molecules that can directly activate TRPV1. Endogenous fatty acid-like molecules, including the endocannabinoid anandamide, and arachidonic acid metabolites, such as NADA and OLDA, are the most well-characterized putative endogenous agonists of TRPV1 (Zygmunt et al., 1999; Huang et al., 2002; Chu et al., 2003). Compared with capsaicin, anandamide has lower potency (in the range of 0.3–5.0 μM) as an
ACTIVATION OF TRPV1—A POLYMODAL RECEPTOR
105
agonist at TRPV1 (Ross, 2003). Moreover, anandamide acts as a partial agonist at TRPV1 in many systems, particularly when receptor reserves are limiting, as in native systems. When receptor reserves are not as limited, such as in recombinant expression systems, anandamide can demonstrate full efficacy (Ross, 2003). The low intrinsic agonist efficacy of anandamide can have important physiological implications, including the ability to attenuate the effects of a full agonist (Ross, 2003). Coapplication of anandamide with capsaicin to trigeminal neurons significantly reduces the currents induced by capsaicin (Roberts et al., 2002). However, anandamide has complex pharmacology, including its roles as an endogenous cannabinoid agonist and as a substrate for fatty acid amide hydrolase, in addition to its effects on TRPV1. Depending on the local environment, anandamide binding to TRPV1 may have the potential to enhance or to counteract pain. In this context, anandamide has been shown to mediate calcitonin gene-related peptide (CGRP) release from capsaicin-sensitive sensory neurons in part through its action on TRPV1 (Ahluwalia et al., 2003). The increased expression of TRPV1 in dorsal root ganglion (DRG) neurons of undamaged Aδ- and C-fibers in a neuropathic pain model may provide an environment where the effect of anandamide at TRPV1 receptors is increased, thus contributing to enhanced pain. Another fatty acid-like molecule, NADA, is more potent than anandamide, with a potency similar to capsaicin in some systems. Like capsaicin, NADA appears to be a full agonist (Huang et al., 2002). NADA potently activates native TRPV1 on DRG neurons and induces the release of substance P and CGRP from spinal cord slices. Significantly, intradermal administration of NADA causes TRPV1-mediated hyperalgesia. Intraplantar NADA enhances spontaneous and heat-evoked activity in spinal nociceptive neurons via its action on TRPV1 (Huang and Walker, 2006), consistent with a role for this endogenous agonist in pain. The related molecule OLDA also produces thermal hyperalgesia (Chu et al., 2003). In contrast, another fatty acid amide, oleoylethanolamide, appears to be an antagonist at TRPV1 and produces antinociceptive effects on visceral and inflammatory pain (Suardiaz et al., 2007). Moreover, a minor modification to OLDA, to produce 3-methyl OLDA, maintains agonist activity at TRPV1, whereas the related 4-methyl OLDA is an antagonist (Almasi et al., 2008). Thus, minor differences in endogenous fatty acid amides may have quite diverse or opposite effects on TRPV1 activity in vivo. The related fatty acid-like molecules, N-acyl taurines, have also been reported to activate TRPV1 with EC50 values similar to that of anandamide (Saghatelian et al., 2006), although a connection to pain has not yet been reported. Various lipoxygenase products of arachidonic acid are activators of TRPV1, with 12-(S)- and 15-(S)-hydroxyperoxyeicosatetraenoic acid and leukotriene B4 as the most potent (Hwang et al., 2000). Interestingly, 12-(S)hydroxyperoxyeicosatetraenoic acid can be induced by bradykinin (Shin et al., 2002), thus implicating it in inflammatory pain.
106
BIOCHEMICAL PHARMACOLOGY OF TRPV1
DAG directly activates TRPV1, with an EC50 of ∼40 μM (Woo et al., 2008). DAG, which is involved in several signaling pathways via activation/translocation mechanisms, is produced from the action of PLC. A membrane-permeable analogue of DAG, 1-oleoyl-2-acetyl-sn-glycerol, is a partial agonist of TRPV1, inducing Ca2+ influx in rat DRG neurons. Activation of rat TRPV1 by DAG requires the Tyr 511 residue also required by capsaicin. It has been proposed that DAG may represent a direct physiological activator of TRPV1, although its primary effect is often considered to be indirect via activation of PKC. The omega-3 polyunsaturated fatty acids (n-3 PUFAs) can also directly activate TRPV1 (in a PKC-dependent manner). In some cases, n-3 PUFAs, such as linolenic acid (LNA) and eicosapentanoic acid (EPA), competitively antagonize TRPV1 activation by vanilloids (Matta et al., 2007). Interestingly, n-3 PUFAs have been shown to produce analgesic effects in humans, possibly by antagonizing the effects of endovanilloids on TRPV1. The antagonistic effects of LNA and EPA occur in the concentration range of 1–10 μM, suggesting potential utility in pain management. In fact, EPA shows profound effects on capsaicin-induced pain behaviors in mice (Matta et al., 2007). Although the potency of these endogenous lipid-like molecules is generally not as high as capsaicin or RTX, it may be significantly increased under pathological conditions. For example, the potency of NADA in inducing TRPV1 current and in depolarizing DRG neurons via TRPV1 activation is dramatically increased when the receptors are sensitized by PKC (Premkumar et al., 2004). 3.3.1.4 Activation by Heat TRPV1 is also a heat-gated channel, being activated by temperatures >42 °C at a resting membrane potential of −60 mV (Caterina et al., 1997). TRPV1 currents induced by heat are quite large (about 25% the magnitude of currents evoked by capsaicin), are outwardly rectifying, and can desensitize during stimulus application. Single-channel recordings using excised membrane patches from cells expressing TRPV1 show significant currents induced by heat, strongly suggesting that heat gates TRPV1 directly (Tominaga et al., 1998). Cation permeability evoked by heat is similar to that evoked by capsaicin, although the PCa/PNa ratio of 3.8 is smaller than with capsaicin-induced activation (Tominaga et al., 1998). Despite its wellestablished role as an activator of TRPV1, the molecular mechanisms involved in heat gating are presently unclear, and the amino acid residues involved in heat activation are not well defined. However, TRPV1 activation by both heat and capsaicin is blocked by capsazepine and ruthenium red (Tominaga et al., 1998), as well as by several novel antagonists recently described in the literature (El Kouhen et al., 2005; Gavva et al., 2005; Doherty et al., 2007; Surowy et al., 2008). As might be anticipated for a thermosensor, TRPV1 exhibits steep temperature dependence, with a Q10 value of 20 (Liu et al., 2003). TRPV1 knockout mice show decreased thermal hyperalgesia under inflammatory conditions (Caterina et al., 2000; Davis et al., 2000). The extent to which TRPV1, versus other heat-sensitive channels, contributes to detection of noxious thermal stimuli remains to be determined, but the studies with TRPV1
ACTIVATION OF TRPV1—A POLYMODAL RECEPTOR
107
knockout mice suggest that TRPV1 plays a major role. Importantly, the conductance and rectification properties of recombinant TRPV1 resemble those characterized for native heat-activated currents in sensory neurons (Cesare and McNaughton, 1996). 3.3.1.5 Activation of TRPV1 by Protons One of the most wellcharacterized endogenous agonist responses of TRPV1 is that induced by protons. The first indication that protons directly gate the TRPV1 receptor came from the studies of Bevan and Yeats (1991), who identified a proton-activated, sustained, and slowly inactivating inward current in DRG neurons clamped at negative holding potential. This current appeared to be restricted to those cells that responded to capsaicin, about 45% of the DRG population. This observation, together with the similar ion selectivity of the proton-activated conductance and the capsaicin-activated currents, raised the possibility that these distinct agents activated the same ion channels. This was confirmed by the studies of Tominaga et al. (1998), who demonstrated that protons directly gate recombinant TRPV1. Local acidosis (pH ≤ 6) that occurs during inflammation, ischemia, and infection contributes to the pain and hyperalgesia under these conditions (Steen et al., 1992; Steen and Reeh, 1993). There is compelling evidence that the slow, sustained response of primary afferents to acidic pH observed with inflammation or injury is, in fact, mediated by TRPV1 (Caterina et al., 2000). TRPV1 activation by protons shows a concentration-dependent increase in inward current, with an EC50 value of ∼pH 5.4 (Bevan and Yeats, 1991; Tominaga et al., 1998; Neelands et al., 2005). TRPV1 currents induced by protons are relatively rapidly induced and show rapid deactivation after washout (Tominaga et al., 1998; Neelands et al., 2005). Activation rates of TRPV1 by protons are similar to those induced by capsaicin, although the deactivation rates after proton activation are significantly faster (Neelands et al., 2005). However, the maximal current induced by protons is not as large as that induced by capsaicin and, as a result, protons have been proposed to act as partial agonists of TRPV1 (Tominaga et al., 1998). Despite different binding sites, both proton- and capsaicin-induced TRPV1 currents are blocked by the capsaicin-site competitive antagonist capsazepine (Tominaga et al., 1998), as well as by several other chemically distinct TRPV1 antagonists (El Kouhen et al., 2005; Gavva et al., 2005; Doherty et al., 2007; Surowy et al., 2008). However, TRPV1 antagonists that do not block proton activation of TRPV1 have also been reported (Lehto et al., 2008). These findings suggest some commonality in gating mechanism by these different agonists and reveal aspects of the polymodal nature of this receptor. 3.3.2 Amino Acids Involved in TRPV1 Activation Although mutagenesis data have identified a number of key residues (Tyr 511, Ser 512, Thr 550, and Tyr 666) (rat sequence numbering) important for TRPV1 agonist binding (Fig. 3.1), diverging hypotheses have emerged on the precise
108
BIOCHEMICAL PHARMACOLOGY OF TRPV1
orientation of agonist binding. Tyr 511 has been shown to be essential for capsaicin and anandamide activation of TRPV1, but is not critical for activation by acidic pH or heat (Jordt and Julius, 2002). In the capsaicin-binding model proposed by Julius and Jordt, the vanillyl functionality of capsaicin is proposed to interact with Tyr 511 located in the cytosolic region linking TM2 and TM3. An alternative model has been proposed by Gavva and coworkers, in which capsaicin binds in a manner such that the vanillyl functionality has a favorable electrostatic interaction with Thr 550 (Gavva et al., 2004). Alanine scanning mutagenesis of the inner pore region of the TRPV1 channel has shown that replacement of Tyr 666 results in loss of activation by both capsaicin and heat (Susankova et al., 2007). Ser 512 has been shown to be important for TRPV1 activation by both capsaicin and protons. Intracellular agonist recognition sites in both the N- (Arg 114) and C- (Glu 761) terminal regions (rat sequence numbering) have also been identified (Jung et al., 2002). Point mutation of these amino acids results in the loss of sensitivity to capsaicin but does not affect channel activation by heat. Thus, while multiple groups have provided data on key amino acids involved in TRPV1 activation by capsaicin, consensus does not exist on whether the agonist binds in transmembrane or in cytoplasmic binding sites. Moreover, differing binding orientations of agonists (typically, capsaicin) in putative transmembrane sites have been proposed (Conway, 2008). Based on their structural similarity, it is generally believed that endogenous lipid-like agonists such as anandamide and NADA bind the same, or an overlapping, region of TRPV1 as capsaicin and RTX. In some cases, this has been confirmed by binding studies (Ross et al., 2001; Shin et al., 2002; Toth et al., 2003). The binding sites for other molecules required for capsaicin, RTX, and lipid-based agonist activation have also been defined to some extent. The contribution of PIP2 to activation of TRPV1 by capsaicin requires the TRP domain, including two positively charged amino acids (Arg 701 and Lys 710) within the C-terminus of the rat receptor (Brauchi et al., 2007). Amino acids 777–810 (rat sequence numbering) have been proposed as a PIP2 tonic inhibitory site (Prescott and Julius, 2003). The requirement for CaMKII-mediated phosphorylation prior to TRPV1 agonist-induced activation depends on the phosphorylation of Ser 502 and Thr 704 (Jung et al., 2004). Site-directed mutagenesis has shown that Glu 648, located on the putative extracellular domain adjacent to the pore-forming loop between TM5 and TM6, plays an important role in TRPV1 activation by protons (Tominaga and Tominaga, 2005). Single-residue mutations in both the pore helix (Thr633Ala) and the TM3–TM4 linker domain (Val538Leu) have been shown to abrogate activation of TRPV1 by protons but have no effect on activation by capsaicin or heat (Ryu et al., 2007) (Fig. 3.1). For heat activation, the conformational changes that lead to channel opening at temperatures >42 °C are not known. Moreover, there have been no reported mutations of TRPV1 that selectively block activation by heat, relative to activation by other stimuli. However, substituting the entire
ACTIVATION OF TRPV1—A POLYMODAL RECEPTOR
109
C-terminal domain of TRPV1 with the C-terminal domain of the cold receptor TRPM8 confers cold sensitivity to the chimeric protein, suggesting that the intracellular C-terminal domain plays a key role in the activation of the TRPV1 channel by heat (Brauchi et al., 2006). A proposed α-helical segment of the proximal part of the C-terminus of rat TRPV1 located just downstream of the TRP domain and extending from Glu 727 to Trp 752 has been defined as the minimal portion of TRPV1 that confers heat sensitivity (Brauchi et al., 2007) (Fig. 3.1). 3.3.3
Other Agents Reported to Activate TRPV1
3.3.3.1 Activation by Other Naturally Occurring Molecules Several other naturally occurring molecules are also TRPV1 agonists. These include piperine, the pungent ingredient in black pepper, which activates TRPV1 with threefold greater efficacy and faster desensitization than capsaicin. Piperine is structurally similar to capsaicin but lacks the vanilloid moiety and instead contains a methylene dioxy moiety (McNamara et al., 2005). Camphor, isolated from the camphor laurel tree, activates TRPV1 less effectively and also desensitizes TRPV1 more rapidly and completely than capsaicin. Camphor activation of TRPV1 appears to be mediated via a different region of the receptor than capsaicin since activation is not blocked by capsazepine (Xu et al., 2005). Camphor-induced desensitization of TRPV1 likely contributes to its analgesic action. However, camphor is not selective for TRPV1 since it also activates TRPV3 (Moqrich et al., 2005) and blocks TRPA1 (Xu et al., 2005). Another naturally occurring compound methylsalicylate (oil of wintergreen) activates TRPV1 (Ohta et al., 2009) and, like camphor, markedly desensitizes the receptor with continuous application. The activity of methylsalicylate is maintained when capsaicin- or allicin-sensitive mutants of TRPV1 are used, suggesting that methylsalicylate-induced TRPV1 activation is mediated via a distinct region of the receptor. Other naturally occurring nonselective TRPV1 agonists recently discovered include citral (Stotz et al., 2008) and diallyl sulfides from garlic such as allicin, which are significantly less potent than capsaicin (Koizumi et al., 2009). A single Cys in the N-terminal domain of TRPV1 appears necessary for activation by allicin and related compounds (Salazar et al., 2008). This mode of activation, through interaction with a specific Cys residue, parallels activation of the TRPA1 receptor via several noxious chemicals (Macpherson et al., 2007). As such, it provides new insights into the diversity of mechanisms that may be involved in the detection of noxious stimuli by TRPV1. 3.3.3.2 Activation by Phorbol Esters Phorbol esters such as phorbol 12-myristate 13-acetate (PMA) can directly activate TRPV1, albeit relatively weakly. Direct activation of TRPV1 by PMA, in addition to the indirect activation via PKC-mediated phosphorylation of the receptor, was confirmed by activation with 4α-PMA, an analogue that does not activate PKC (Premkumar
110
BIOCHEMICAL PHARMACOLOGY OF TRPV1
and Ahern, 2000; Bhave et al., 2003). In addition to direct activation of TRPV1 by phorbol esters, PKC-mediated TRPV1 phosphorylation modulates activation by other agents. 3.3.3.3 Activation by Synthetic Pharmacological Agents Several synthetic small-molecule pharmacological agents have recently been shown to exert at least some of their effects through activation of TRPV1. Some of these agents have been used as anesthetic or as analgesic drugs for some time. For example, the local anesthetic lidocaine directly activates TRPV1, likely accounting for the burning pain sensation that occurs upon application (Leffler et al., 2008). Activation of TRPV1 by lidocaine requires amino acid residues in the vanilloid binding domain and Arg 701 (rat sequence) in the proximal C-terminal TRP domain, as well as the presence of PIP2. Like capsaicin, lidocaine-induced TRPV1 activation causes CGRP release and may thus promote neurogenic inflammation. The analgesic tramadol, which reduces pain through multiple mechanisms, including activation of mu opioid receptors, inhibition of neurotransmitter reuptake, and inhibition of various ligandand voltage-gated ion channels, also activates TRPV1. Activation of the TRPV1 by tramadol may account for the initial local side effects of burning pain and erythema induced by this drug (Marincsak et al., 2008). 3.3.3.4 Activation by Basic pH Recently, TRPV1 has been shown to be directly activated by intracellular basic pH (pH 7.8–9.5) (Dhaka et al., 2009). This activation of TRPV1 occurs via a distinct mechanism, different from activation by vanilloids, lipids, heat, or protons, and depends on an intracellular histidine in the N-terminal domain of the receptor. TRPV1 appears to be the first ion channel reported with the ability to be activated by both acidic and basic pH. Of potential relevance, neuronal activity causes changes in pH, both alkaline and acidic, which can affect ion channel or receptor function and neural transmission if of sufficient magnitude (Chesler, 2003). 3.3.3.5 Activation by Cations Various cations besides protons have also been reported to activate TRPV1. The divalent cations Mg2+ and Ca2+ (Ahern et al., 2005) and the polyvalent cations gadolinium (Gd3+) (Tousova et al., 2005) and various polyamines (Ahern et al., 2006) gate TRPV1. Like protons, polyamines and other cations appear to require the extracellular Glu 648 for TRPV1 activation. 3.3.3.6 Voltage-Dependent Activation Several recent studies have indicated that TRPV1 activity is regulated to some extent in a voltagesensitive manner, contradicting the long-standing dogma that, despite its structural similarity to voltage-gated potassium channels, TRPV1 gating is voltage-independent. It was initially demonstrated that depolarization alone can activate TRPV1 at room temperature but with a high threshold (Voets et al., 2004), suggesting
ACTIVATION OF TRPV1—A POLYMODAL RECEPTOR
111
that these channels are weakly voltage-dependent. However, binding of various ligands or physical stimuli, such as heat, shift this voltage dependence toward physiologically relevant membrane potentials (Nilius et al., 2005). A hypothesis was proposed, based on thermodynamic principles, that small changes in the free energy of activation of the TRPV1 channel result in a large shift in the voltage-dependent activation curve, and thus gating, of the channel by different agents. More recent characterization has offered a somewhat different view and has defined TRPV1 as partially activated by voltage (Matta and Ahern, 2007). This is based on findings that maximum open channel probability is not attained with voltage activation alone and that higher concentrations of agonists such as capsaicin or RTX, as well as heat, protons, and PKC-mediated phosphorylation of TRPV1, enhance both the efficacy and sensitivity of voltage-dependent activation. Consequently, an allosteric model of channel gating has been proposed in which voltage acts distinctly, but in concert with other mechanisms, to regulate channel activation (Matta and Ahern, 2007). Despite these recent developments, the precise location of the voltage sensor within TRPV1 has not yet been clearly defined. Although charged amino acids within the TM4 (S4) domain may play a role, as they do in other voltage-gated channels, these are reduced in number in TRPV1. In combination, these data provide new support for voltage sensitivity of TRPV1. This may have direct implications for pain, since neurons involved in sensing or transmitting pain become depolarized by multiple mechanisms, including via TRPV1 activation itself. Recently, a competitive TRPV1 antagonist (SB-705498) has been shown to inhibit recombinant human TRPV1 activity with a degree of voltage dependence, being more potent at −70 mV than at +70 mV (Gunthorpe et al., 2007). To date, this property has not been reported for other TRPV1 channel antagonists and awaits further elucidation of mechanism of action and any connection to the voltage-sensitive gating described above. 3.3.4
Dynamic Ion Selectivity
In addition to Na+ and Ca2+ permeability, TRPV1 has been reported to be permeable to larger cations, although the underlying mechanism has not been defined. Recently, the dogma of static ion selectivity during TRPV1 activation has been challenged by the intriguing finding of dynamic ionic selectivity during sustained agonist stimulation (Chung et al., 2008). These effects can span several seconds to several minutes. Activation of either native or recombinant TRPV1 by capsaicin or by protons leads to time- and agonist concentration-dependent changes in permeability to large cations and changes in Ca2+ permeability. The effective size of the pore is apparently increased following initial channel gating. These changes appear to be a result of alterations in the TRPV1 selectivity filter in the inner pore of the channel and define a new role for this region in not only quantitative but also qualitative aspects of channel gating. Moreover, the various TRPV1 agonists change ion selectivity
112
BIOCHEMICAL PHARMACOLOGY OF TRPV1
differentially. Both capsaicin and NADA produce biphasic responses, albeit with different kinetics, whereas heat evokes a transient current without a robust second phase (Chung et al., 2008). Activation-dependent changes in TRPV1 Ca2+ selectivity causes an up to fivefold increase in PCa/PNa, depending on concentrations of both capsaicin and Ca2+. Phosphorylation of TRPV1 by PKC at Ser 800 enhances ionic selectivity. The mode of activation of TRPV1 also affects the calcium current. The fraction of current carried by Ca2+ is smaller for proton- and heat-induced activation (Tominaga et al., 1998; Samways et al., 2008) than it is for capsaicin-induced activation. The differences in proton-induced ion selectivity during activation are the result of protonation of three acidic amino acids, including Glu 648, that line the mouth of the pore (Samways et al., 2008). Interestingly, conformational changes in the outer pore region appear to be critical for determining the balance between open and closed states, providing evidence for a general role for this domain in TRP channel activation (Myers et al., 2008). The potential consequences of increased pore size and permeability to Ca2+ and large cations are severalfold. Ca2+ influx has numerous downstream effects, including Ca2+-dependent desensitization of TRPV1 or other channels, activation of signaling molecules, and release of inflammatory mediators and neurotransmitters (Chung et al., 2008). The enhanced Ca2+ permeability induced by PKC-mediated phosphorylation of TRPV1 suggests that this may be one mechanism by which inflammatory mediators that sensitize TRPV1 contribute to pain hypersensitivity. Moreover, since prolonged exposure to capsaicin can selectively destroy TRPV1-expressing neurons, the enhanced permeability to Ca2+ or other large cations may initiate apoptotic pathways, including during the use of capsaicin as an analgesic where neuronal death is a mechanism of action of the analgesia that occurs with topical treatment. As such, dynamic ion selectivity adds a new and important dimension to the impact of TRPV1 activation and its role as an integrator of pain signals. 3.3.5
Desensitization of TRPV1
Desensitization of TRPV1 after activation can occur by one of two mechanisms: acute desensitization and tachyphylaxis. Tachyphylaxis is loss of sensitivity to repeated stimulation and appears to occur due to failure to recover from acute desensitization (Liu and Simon, 1996). Physiological consequences of TRPV1 desensitization include adaptation of neurons, which decreases pain perception. The process of acute desensitization is initiated by the entry of Ca2+ into cells upon TRPV1 receptor activation (Koplas et al., 1997). A prominent mechanism responsible for this desensitization is the Ca2+/CaM-dependent phosphatase calcineurin (Docherty et al., 1996; Mohapatra and Nau, 2005). However, no single mechanism appears to be solely responsible for desensitization. Both dephosphorylation, by calcineurin, of two CaMKII phosphorylated residues, Ser 502 and Thr 704 (rat sequence numbering) (Jung et al.,
ACTIVATION OF TRPV1—A POLYMODAL RECEPTOR
113
2004), as well as depletion of PIP2 (implicating Ca2+-dependent PLC) contribute to TRPV1 desensitization (Liu et al., 2005; Yao and Qin, 2009). Tyr 671 within the internal pore of the channel plays a role in the structural rearrangements that occur during desensitization (Mohapatra et al., 2003), and the whole process is accompanied by a change in voltage dependence (Piper et al., 1999; Gunthorpe et al., 2000). Arg 701 (rat sequence numbering), which is part of a stringent CaMKII-binding site within the TRP box and is critical for PIP2 activation of TRPV1, is also strongly implicated in the slowed gating kinetics of the desensitized channel, suggesting that acute desensitization may alter coupling between the capsaicin-binding site and the PIP2-sensitive gating mechanisms of TRPV1 (Novakova-Tousova et al., 2007). Addition of CaMKII reverses the Ca2+-dependent TRPV1 desensitization induced by capsaicin (Jung et al., 2004), as anticipated from the role of CaMKII-mediated phosphorylation in capsaicin-induced TRPV1 activation. Thus, desensitization of TRPV1 may occur when the receptor loses its ability to bind ligands after dephosphorylation. Acute Ca2+-mediated desensitization can also be decreased by protein kinase A (PKA)- or PKC-mediated phosphorylation at discrete sites on TRPV1 (Bhave et al., 2002; Mohapatra and Nau, 2003; Mohapatra et al., 2003; Mandadi et al., 2004, 2006). Thus, sensitization of the channel can counteract acute desensitization and can enhance TRPV1 activation in response to tissue injury or inflammation. The predominant sites involved in PKA-mediated decreased desensitization appear to be the amino acid Ser 116 and, to a lesser extent, Thr 370 (rat TRPV1 sequence numbering) (Mohapatra and Nau, 2003). PKCε-mediated decrease in desensitization occurs via phosphorylation of Ser 800 (rat TRPV1 sequence numbering) (Mandadi et al., 2006). In addition to Ca2+-dependent desensitization, there is evidence of Ca2+independent desensitization by some agonists such as camphor (Xu et al., 2005) and, to some extent, piperine (McNamara et al., 2005). Finally, TRPV1 agonists can cross desensitize (Tominaga et al., 1998; Vlachova et al., 2001). For example, capsaicin-induced Ca2+-dependent desensitization is accompanied by a decreased response to both heat and voltage. Tachyphylaxis of TRPV1 requires the activity of the calcium-binding protein CaM, whereas either ATP or PIP2 can prevent this process (Lishko et al., 2007). CaM interacts with the C-terminal domain in a Ca2+-independent manner but with the N-terminal domain in a Ca2+-dependent manner (Numazaki et al., 2003; Rosenbaum et al., 2004). Mutations in the ARD prevent tachyphylaxis, and it appears that ATP and CaM may compete for binding to an ARD-binding site on TRPV1 to prevent or to induce tachyphylaxis, respectively. PIP2 also causes a partial reduction in tachyphylaxis in the absence of ATP, although neither the mechanism nor binding site for this effect has been fully defined (Lishko et al., 2007). Although adaptation is an important feature of many sensory receptors, allowing them to continuously respond to varying intensity of stimuli, adaptation has not yet been clearly demonstrated in nociceptive systems. During
114
BIOCHEMICAL PHARMACOLOGY OF TRPV1
desensitization, Ca2+ influx through TRPV1 causes depletion of PIP2. The depletion of PIP2 has a time course that is synchronous with TRPV1 desensitization and reaches a level where there is a significant shift in agonist sensitivity while still maintaining a maximal response. Thus, the level of interaction of TRPV1 with PIP2 through the Ca2+-mediated desensitization process may confer adaptation onto the TRPV1 receptor (Yao and Qin, 2009).
3.4 TRPV1 AS A MOLECULAR INTEGRATOR TRPV1 activation by specific stimuli/agonists when applied alone often produces only submaximal activation. A maximal response is achieved through the synergistic interaction of two or more stimuli, which work in tandem to open the channel at lower activation thresholds (Tominaga et al., 1998). This polymodal activation of TRPV1 plays a major role in its function as a molecular integrator of pain signals. At 37 °C, an abrupt but relatively small decrease in extracellular pH (pH 6.4) evokes significant TRPV1 currents, demonstrating that protons can activate the channel at normal body temperature. With a more significant but still moderate decrease in pH (pH ≤ 5.9), protons can activate TRPV1 at room temperature (Tominaga et al., 1998). Protons thus substantially decrease the temperature threshold for TRPV1 activation and, because different regions of TRPV1 are involved in responses to the various activators, are likely do so in a synergistic manner. A molecular determinant of proton-induced potentiation of TRPV1 activation is the extracellular amino acid Glu 600, localized in the region linking TM5 and the pore-forming region of the channel (Jordt et al., 2000). Based on electrophysiological data using mildly acidic solutions at pH 6.6, it has been proposed that protons may act by increasing the probability of channel opening caused by other ligands rather than by altering unitary conductance (Baumann and Martenson, 2000). Protons potentiate capsaicin action by increasing potency without altering efficacy (Caterina et al., 1997; Tominaga et al., 1998). When the pH is lowered from pH 7.4 to pH 5.5, capsaicin shows a >10-fold decrease in EC50 (Neelands et al., 2005). In kinetic studies, acidic pH causes both an increase in activation rate and a decrease in deactivation rate of capsaicin-activated currents. The acid-induced increase in activation rate is dependent on the concentration of protons, with a modest increase at pH 6.8 and a greater increase at pH 5.0. In the reverse protocol, capsaicin increases the activation rate for protons almost 10-fold, suggesting that capsaicin binding can increase the affinity of protons for TRPV1 (Neelands et al., 2005). The decrease in the deactivation rate of capsaicin-evoked currents caused by acidic pH, as assessed using paired-pulse and single-pulse protocols, is quite significant. It is possible that the presence of protons results in an allosteric change that prevents the release of capsaicin from its binding site (Neelands et al., 2005). Synergistic interaction also occurs when TRPV1 is activated by an agonist at elevated temperatures (Vlachova et al., 2001; Neelands et al., 2008).
TRPV1 AS A MOLECULAR INTEGRATOR
115
Investigation of such interactions using freshly isolated DRG neurons has demonstrated profound effects on membrane excitability (Neelands et al., 2008). Increasing the temperature causes larger membrane depolarization and an altered pattern and onset of the action potential train evoked by capsaicin. Moreover, anandamide, which does not normally cause action potentials but rather causes a slow depolarization, at elevated temperature causes rapid and significant depolarization accompanied by a short burst of action potentials. The changes in firing properties of DRG neurons produced by heat effects in the presence of another agonist may be important in the temporal coding of pain (Neelands et al., 2008). 3.4.1
Sensitization of TRPV1
Sensitization of TRPV1 is central to its role as an effective transducer of pain signals and contributes substantially to the development of persistent pain. At the cellular level, sensitization reduces the thresholds for activation and heightens responsiveness to multiple stimuli, leading to increased neuronal firing. In inflammatory pain, hypersensitivity arises from release of proalgesic agents, including neurogenic peptides, cytokines, chemokines, prostaglandins, and growth factors, which are released at the injured site from sensory nerve terminals or from infiltrating immune cells. Together these mediators reduce the nociceptive threshold by binding to their cognate receptors, ultimately activating multiple protein kinase cascades that phosphorylate TRPV1 and elicit dynamic changes in the activity and localization of TRPV1. The sensitized form of the channel exhibits enhanced activity and prevents desensitization to subsequent, persistent stimulation by agonists. At the molecular level, TRPV1 is sensitized by phosphorylation of Ser 502 by PKA or PKC in response to inflammatory mediators, such as prostaglandins (Moriyama et al., 2005), bradykinin (Tominaga et al., 2004; Moriyama et al., 2005), and other molecules. PKC-dependent phosphorylation of Ser 502 and Ser 800 potentiates capsaicin or proton-evoked TRPV1 activation and reduces the temperature threshold for activation (Vellani et al., 2001; Numazaki et al., 2002; Bhave et al., 2003). 3.4.2 TRPV1 and Inflammatory Mediators Bradykinin, a neurogenic peptide processed from a precursor at the site of injury or inflammation, is a potent sensitizer of TRPV1. Stein et al. (2006) propose that TRPV1 sensitization by bradykinin is due to the generation of DAG, which, in turn, has the potential to activate both PKC (Cesare et al., 1999; Ferreira et al., 2005) and TRPV1 directly (Woo et al., 2008). Activation of the PKC and PLC pathways by bradykinin can result in generation of lipoxygenase products (e.g., anandamide and NADA), which directly activate or sensitize TRPV1 on sensory neurons (Premkumar and Ahern, 2000; Shin et al., 2002; Ferreira et al., 2004; Tang et al., 2004). Thus, upon injury or
116
BIOCHEMICAL PHARMACOLOGY OF TRPV1
inflammation, mediators like bradykinin and arachidonic acid metabolites reduce the threshold for activation of TRPV1 by noxious stimuli. Substance P is a tachykinin released from postsynaptic dorsal horn and sensory neurons, which contributes to neurogenic inflammation by binding to the neurokinin-1 (NK-1) receptor on endothelial and immune cells to modulate pain transmission and sensitization. The recent demonstration that NK-1 and TRPV1 are colocalized on DRG neurons suggests the potential for cross talk (Zhang et al., 2007). Binding of substance P to NK-1 enhances TRPV1 currents (Sculptoreanu et al., 2008) and induces translocation of PKCε to the plasma membrane of sensory neurons where it is responsible for phosphorylation of TRPV1. Conversely, inhibition of PKCε prevents substance P-mediated activation and translocation of TRPV1 (Zhang et al., 2007). Involvement of the proinflammatory cytokine tumor necrosis factor (TNF)α in pain is well established, but the role of TNFα is complex and is incompletely understood. Recent studies suggest that the hyperalgesic effect of TNFα occurs through mechanisms involving TRPV1. Compelling evidence is provided by studies that demonstrate a thermal hyperalgesic response to intraplantar injection of TNFα in wild-type, but not in TRPV1 null, mice (Jin and Gereau, 2006; Russell et al., 2009). Greater than 90% of rat TRPV1-positive trigeminal neurons also express TNFα receptors (Khan et al., 2008). TNFα enhances the activation of sensory neurons by capsaicin through both transcriptional and posttranscriptional mechanisms. The sensitization and upregulation of TRPV1 expression by TNFα appears to contribute to the proalgesic effect of the cytokine. Prostaglandin E2 (PGE2) is an inflammatory mediator, critical to pain sensation. PGE2 sensitizes TRPV1 responses, appreciably reducing the temperature threshold in a PKC-dependent manner, as demonstrated in both TRPV1 recombinant cells and cultured mouse DRG neurons (Moriyama et al., 2005). This sensitization appears to be a result of EP1 receptor activation. A PKA pathway for sensitization of TRPV1 via EP4 receptors also appears to exist in mouse DRG neurons (Moriyama et al., 2005). Intraplantar injection of PGE2 induces edema in rodent paws through activation of TRPV1; the response is abated by administration of a selective TRPV1 antagonist. The use of selective pharmacological agents has indicated that in this case, PGE2 sensitizes TRPV1 through a PKC-dependent mechanism involving the EP3 receptor, the NK-1 receptor, and the mitogen-activated kinases (MAPKs) (Claudino et al., 2006). 3.4.3
Kinases and Sensitization
TRPV1 lies at the nexus of a network that directs the function, subcellular localization, and sensitization state of the channel (Cesare and McNaughton, 1996; Shin et al., 2002; Sugiura et al., 2002; Bonnington and McNaughton, 2003; Moriyama et al., 2003; Amadesi et al., 2004; Carlton et al., 2004; Dai et al., 2004; Ferreira et al., 2004; Zhang et al., 2005a,b). The dynamic phosphorylation status of TRPV1 imparts the ability of this channel to respond
TRPV1 AS A MOLECULAR INTEGRATOR
117
instantaneously to environmental changes or to maintain conditions conducive to peripheral sensitization and persistent pain. The human TRPV1 sequence (Swiss-Prot Q8NER1) encodes at least 11 putative phosphorylation sites (Table 3.1), similarly reflected across orthologs, inviting engagement and possible convergence of multiple kinase cascades. Activation of PKA by cAMP is critical to the induction and persistence of hyperalgesia and maintenance of TRPV1 in its sensitized state, as demonstrated by the peripheral sensitization and hyperalgesia elicited by intradermal injection of cAMP analogues, adenylate cyclase activators, or PKA inhibitors and by the use of genetic mutants of PKA (Kress et al., 1996; Malmberg et al., 1997; Aley and Levine, 1999; Hu et al., 2001). The effects of specific PKA activators and inhibitors have demonstrated that the PKA pathway
TABLE 3.1
Consensus Phosphorylation Sites of TRPV1 Consensus Sites for Phosphorylation of TRPV1
Modification Site in Human TRPV1
Modification Site in Rat TRPV1
Kinase
References
Ser 6 Ser 117 Thr 145
Ser 6 Ser 116 Thr 144
Bhave et al. (2002) Bhave et al. (2002) Bhave et al. (2002, 2003)
Tyr 200 Thr 371 Thr 407 Ser 502
Tyr 199 Thr 370 Thr 406 Ser 502
PKA PKA PKA PKC Src PKA Cdk5 PKA PKCε CaMKII
Thr 705
Thr 704
Ser 775
Ser 774
Ser 801
Ser 800
PKC CaMKII PKA PKC PKCε
Ser 821
Ser 820
PKA
Lishko et al. (2007) Bhave et al. (2002) Pareek et al. (2007) Zhang et al. (2007), Novakova-Tousova et al. (2007), Jung et al. (2004), Bhave et al. (2003, 2002), Numazaki et al. (2002), and Mandadi et al. (2006) Bhave et al. (2003) and Jung et al. (2004) Bhave et al. (2002, 2003) Zhang et al. (2007), Bhave et al. (2003), Ahern (2003), and Numazaki et al. (2002) Bhave et al. (2002)
Residues assigned on the basis of rat TRPV1 sequence recorded as O35433 and extrapolated to human TRPV1 sequence represented by Q8NER1 in the Swiss-Prot database.
118
BIOCHEMICAL PHARMACOLOGY OF TRPV1
modulates hyperexcitability of injured primary sensory neurons (Hu et al., 2001) and functions in TNFα-induced firing of rat L4 and L5 DRG neurons (Zhang et al., 2002). While the literature is replete with reports on phosphorylation of TRPV1 by multiple kinases (summarized in Table 3.1), until recently, relatively little has been known about the molecular organization of the associated scaffolding proteins involved in ensuring appropriate targeting (Jeske et al., 2008; Schnizler et al., 2008). PKA phosphorylation of TRPV1 is facilitated by A-kinase anchoring proteins (AKAPs) that bind the regulatory subunit of PKA and mediate interactions between PKA and its substrates (Wong and Scott, 2004; Dell’Acqua et al., 2006; Beene and Scott, 2007). Experiments that demonstrate effects of an AKAP inhibitory peptide (Rathee et al., 2002; Sugiuar et al., 2004) and colocalization of scaffolding proteins with TRPV1 in mouse DRG and rat trigeminal neurons identify AKAP150 as the operative scaffolding protein in rodents (Jeske et al., 2008; Schnizler et al., 2008). Recently, prevention of AKAP150/79 binding to a C-terminal region of TRPV1 has been shown to abrogate sensitization by either bradykinin or PGE2, suggesting that this protein is a common element in inflammatory mediator action on TRPV1 (Zhang et al., 2008). Activation of PKC specifically sensitizes thermal responses by amplifying heat-activated currents and by reducing thresholds for detecting heat stimuli as noxious (Cesare and McNaughton, 1996; Vellani et al., 2001). PKCε is translocated to the plasma membrane in cultured rat DRG following stimulation with bradykinin (Cesare et al., 1999) and is responsible for phosphorylation of TRPV1 at Ser 502 and Ser 801 (human sequence numbering) (Numazaki et al., 2002). The rapid response, within 5 s of exposure to bradykinin, is consistent with the time course of sensitization and suggests that PKCε is responsible for bradykinin-induced sensitization of TRPV1 to heat. A subsequent study confirms that TRPV1 and PKCε are coexpressed in rat DRG neurons and further demonstrates that inflammation induces upregulation of PKCε expression, suggesting a critical role of PKCε in TRPV1 function (Zhou et al., 2003). This is consistent with the phenotype of PKCε null mice, which exhibit reduced hyperalgesic responses (Khasar et al., 1999). Development of a novel viral delivery system for a dominant negative form of PKCε confirms the direct functional relationship between PKCε and TRPV1 sensitization (Srinivasan et al., 2008). The observation that these recombinant constructs are analgesic in capsaicin-inflamed rat hind paws further emphasizes the significance of PKCε in the activation of TRPV1. In rat DRG neurons, PKCε appears to be essential for maintenance of basal phosphorylation and agonist-induced responses of TRPV1. Nerve growth factor (NGF) rapidly sensitizes nociceptive sensory neurons that express the NGF receptor TrkA to noxious thermal stimuli and activates second messenger signaling cascades leading to sensitization of TRPV1 (Lewin et al., 1993; Shu and Mendell, 2001). Although some aspects of the specific mechanisms underlying these processes remain unresolved, a consensus is
TRPV1 AS A MOLECULAR INTEGRATOR
119
emerging that explains the observed sensitization of TRPV1 by NGF in the context of the phosphatidylinositol-3-kinase (PI3K), PKC, and CaMKII pathways. Wortmannin, a selective PI3K inhibitor, completely prevents the sensitizing effects of NGF on TRPV1, as monitored by ratiometric Ca2+ imaging of neonatal mouse DRG neurons. Similarly, inhibition of PKC and CamKII also blocks TRPV1 sensitization by NGF. These elegant studies by Bonnington and McNaughton (2003) conclude that PI3K is essential in the early stages of NGF-facilitated sensitization of TRPV1, while PKC and CaMKII are involved later. Recent studies confirm that PI3K, but not PLC, is integrally involved in NGF sensitization of TRPV1 (Zhu and Oxford, 2007). Along with PI3K, Ras and PLC have been implicated in downstream effects following NGF binding to TrkA. Ras does not seem to affect TRPV1 directly but rather binds to the catalytic domain of PI3K, enhancing its activity. In contrast to the findings with recombinant HEK293 cells (Chuang et al., 2001), PLC appears not to be involved in NGF-mediated sensitization of TRPV1 on mouse DRG neurons, perhaps owing to differences in the expression levels and distribution in the host cells or to posttranslational modification or the oligomerization status of the channel (Bonnington and McNaughton, 2003). MAPKs are activated by inflammatory mediators in a cascade of sequential phosphorylations in sensory and dorsal horn neurons as well as in spinal glial cells. MAPKs contribute significantly to the development of hyperalgesia and sensitization through transcription, translation, and posttranslational modification. Inhibition of any of the three principal MAPK pathways (extracellular signal-regulated protein kinase [ERK], p38 MAPK, and c-Jun N-terminal kinase [JNK]) can abate inflammatory or neuropathic pain without affecting the protective ability to detect noxious stimuli in the absence of injury. Conversely, intrathecal administration of inhibitors of ERK, p38, and JNK reverses the associated mechanical allodynia in the rat spinal nerve ligation (SNL) model of neuropathic pain (Obata et al., 2004). SNL induces activation of all three kinases in distinct DRG neurons, but their activation is differentially regulated. Levels of phospho-p38 are increased in SNL rats in the ipsilateral lumbar region of the spinal cord and in small- to medium-diameter capsaicinresponsive DRG neurons. Phospho-p38 levels peak at 1 day post-ligation in DRG neurons and at 3 days in the spinal cord (Jin et al., 2003; Schafers et al., 2003a,b,c). During this period, phospho-p38 propagates pain signaling and sensitization by phosphorylating transcription factors, some of which regulate production of inflammatory mediators, including TNFα. By monitoring the time course for p38 activation, Ji et al. (2002) established a causal link and chronology between the effectors, p38 and TNFα, and the induction of neuropathic pain; TNFα is engaged early in the process. Whereas the basal level of phospho-p38 is low in lumbar DRG neurons of naive rats (Ji et al., 2002; Kim et al., 2002; Schafers et al., 2003a,b,c), the TRPV1 agonist, capsaicin, causes a rapid (2 min), transient (10 min) elevation, especially in small- to medium-diameter neurons (Mizushima et al., 2005).
120
BIOCHEMICAL PHARMACOLOGY OF TRPV1
Likewise, heating of the rat hind paw by immersion in hot (54 °C) water induces phosphorylation of p38; the majority of the neurons showing activated p38 coexpress TRPV1. Intrathecal injection of a small-molecule p38 inhibitor reduces phospho-p38 levels in DRG neurons and thermal hypersensitivity, but does not affect mechanical allodynia. These observations suggest that activation of TRPV1 by capsaicin or heat induces activation of p38. Inhibition of p38 prevents thermal hypersensitivity and upregulation of TRPV1 following inflammation and mechanical allodynia associated with nerve injury (Milligan et al., 2003). The ERK pathway transduces sensory input into cellular responses through sequential phosphorylation events. NGF activates ERK in DRG neurons and contributes to pain hypersensitivity and TRPV1 sensitization by both transcriptional and posttranslational mechanisms. The L5 SNL model induces phosphorylation of ERK predominantly in large-diameter DRG neurons and satellite glial cells (Obata et al., 2004). Stimulation of C-fiber nociceptors by capsaicin induces phosphorylation of ERK and its downstream substrate, the kinase AKT, within 2 min in dissociated cultures of rat DRG neurons. Elevated levels of both phosphorylated ERK and AKT peak at 10 min and are sustained for >90 min (Zhuang et al., 2004). Use of selective pharmacological reagents, including wortmannin, confirms that these phosphorylation events require Ca2+ influx and are positioned downstream of PI3K. Inhibition of the ERK pathway reduces hyperalgesia induced by capsaicin (Dai et al., 2002) and NGF (Zhuang et al., 2004). Immunofluorescent monitoring of rat hind paw sections has demonstrated that intraplantar injection of capsaicin elicits increased phosphorylation of AKT in small C-fiber neurons (Zhuang et al., 2004). JNK1 is involved in nociceptive signaling in both neuropathic and inflammatory pain and appears to play a role in TRPV1-induced signaling. However, the role for JNK activation in TRPV1-mediated nociception is not yet clearly understood. Levels of phosphorylated JNK1 and its associated transcription factor, c-Jun, increase rapidly in damaged rat small-diameter DRG neurons and in astrocytes in the dorsal horn, and remain transiently elevated after the nerve ligation. In addition, inhibitors that block activation prevent mechanical allodynia (Ma and Quirion, 2002; Obata et al., 2004; Daulhac et al., 2006; Zhuang et al., 2006). Similarly, inhibition of JNK also reduces mechanical hypersensitivity and thermal hyperalgesia associated with peripheral nerve and tissue injury induced upon intraplantar injection of irritants, such as capsaicin, bee venom, complete Freund’s adjuvant, endothelin, or NGF, into rat paws (Guo et al., 1999; Jin et al., 2003; Doya et al., 2005; Motta et al., 2006; Zhuang et al., 2006; Cao et al., 2007; Plant et al., 2007).
3.5 TRAFFICKING In addition to expression on the plasma membrane, TRPV1 is also expressed in intracellular compartments including the endoplasmic reticulum and the cytoplasmic vesicles (Guo et al., 1999; Morenilla-Palao et al., 2004). Cytoplasmic
SUMMARY
121
reserves of TRPV1 can be quickly translocated to the cell surface following cellular activation by several mechanisms, generally involving specific phosphorylation (Morenilla-Palao et al., 2004). The transport of TRPV1 from intracellular vesicles to the plasma membrane is facilitated through synaptosomal-associated protein 25 receptor (SNARE)-dependent exocytosis (Nakata et al., 1998; Ahmari et al., 2000), a process that is sensitized by PKA (Chheda et al., 2001) and PKC (Zhu et al., 2002). PKC and MAPK signaling thereby increases the surface density and sensitization state of TRPV1 expressed on nociceptive terminals (Ji et al., 2002; Morenilla-Palao et al., 2004). This mobilization of TRPV1 serves as an effective means of developing and propagating inflammatory hyperalgesia. In the course of an inflammatory response, when cAMP levels are elevated, PKA activation causes rapid mobilization of inactive TRPV1 monomers from intracellular stores and insertion of multimers into the plasma membrane (Vetter et al., 2008). Src-mediated tyrosine phosphorylation also induces a dramatic translocation of TRPV1 to the surface of HEK293 recombinant cells (Zhang et al., 2005b). Fibronectin can activate src kinase in select cellular models (Meerschaert et al., 1999; Ren et al., 2005; Tvorogov et al., 2005), and a role for fibronectin as a dynamic modulator of TRPV1 translocation to the plasma membrane of trigeminal neurons has recently been defined (Jeske et al., 2009). Fibronectin-induced enhancement in TRPV1 sensitivity to activation results from increases in both levels of TRPV1 expression in the plasma membrane and tyrosine phosphorylation of the channel. 3.5.1 Antagonism of TRPV1 Extensive site-directed mutagenesis of the human ether-a-go-go (hERG) potassium channel (Sanguinetti and Mitcheson, 2005) has been used to infer the binding site of antagonists in structurally related channels. Many groups have mutated residues in the pore region and examined the changes in ion currents in cells containing the overexpressed channels. The general conclusion from these studies is that most channel antagonists bind in the pore region, interacting with residues from all four monomers of the tetrameric channel. A pharmacophore model for TRPV1 antagonist binding has recently been proposed in which antagonists bind in an orientation that achieves hydrogen bond interactions with Tyr 667, as well as interactions with a lipophilic binding site in the pore region of the channel (Kym et al., 2009). In this model, multiple TRPV1 antagonists can be superimposed such that they optimally fit in the TRPV1 pore.
3.6
SUMMARY
TRPV1 was first cloned from rat DRG neurons over a decade ago (Caterina et al., 1997). Since that time, a significant amount of research in the field has defined a key role for this receptor in the detection, transmission, and
122
BIOCHEMICAL PHARMACOLOGY OF TRPV1
integration of diverse pain signals. Some of the recent highlights include the first three-dimensional structure of TRPV1, identification of a domain involved in activation by heat, positive modulation of channel activation by PIP2, the existence of dynamic ion selectivity with prolonged or repeated exposure to agonists with potential consequences on pain signaling, insights into mechanisms and regulation of tachyphylaxis, demonstration of profound effects on membrane excitability caused by the synergistic action of two agonists, sensitizing effects of key inflammatory mediators TNFα and NGF on TRPV1, and increase in plasma membrane trafficking of TRPV1 as a result of inflammatory mediator action. These discoveries underscore the complexity of TRPV1 activation and regulation and the dynamic nature of TRPV1 as a molecular integrator of pain signals. REFERENCES Ahern GP (2003) Activation of TRPV1 by the satiety factor oleoylethanolamide. J Biol Chem 278:30429–30434. Ahern GP, Brooks IM, Miyares RL, and Wang XB (2005) Extracellular cations sensitize and gate capsaicin receptor TRPV1 modulating pain signaling. J Neurosci 25:5109–5116. Ahern GP, Wang X, and Miyares RL (2006) Polyamines are potent ligands for the capsaicin receptor TRPV1. J Biol Chem 281:8991–8995. Ahluwalia J, Urban L, Bevan S, and Nagy I (2003) Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurons by activating both the cannabinoid 1 receptor and the vanilloid receptor 1 in vitro. Eur J Neurosci 17: 2611–2618. Ahmari SE, Buchanan J, and Smith SJ (2000) Assembly of presynaptic active zones from cytoplasmic transport packets. Nat Neurosci 3:445–451. Aley KO and Levine JD (1999) Role of protein kinase A in the maintenance of inflammatory pain. J Neurosci 19:2181–2186. Almasi R, Szoke E, Bolcskei K, Varga A, Riedl Z, Sandor Z, Szolcsanyi J, and Petho G (2008) Actions of 3-methyl-N-oleoyldopamine, 4-methyl-N-oleoyldopamine and N-oleoylethanolamide on the rat TRPV1 receptor in vitro and in vivo. Life Sci 82: 644–651. Amadesi S, Nie J, Vergnolle N, Cottrell GS, Grady EF, Trevisani M, Manni C, Geppetti P, McRoberts JA, Ennes H, Davis JB, Mayer EA, and Bunnett NW (2004) Proteaseactivated receptor 2 sensitizes the capsaicin receptor transient receptor potential vanilloid receptor 1 to induce hyperalgesia. J Neurosci 24:4300–4312. Baumann TK and Martenson ME (2000) Extracellular protons both increase the activity and reduce the conductance of capsaicin- gated channels. J Neurosci 20: RC80. Beene DL and Scott JD (2007) A-kinase anchoring proteins take shape. Curr Opin Cell Biol 19:192–198. Bevan S and Yeats J (1991) Protons activate a cation conductance in a sub-population of rat dorsal root ganglion neurons. J Physiol 433:145–161. Bhave G, Hu HJ, Glauner KS, Zhu W, Wang H, Brasier DJ, Oxford GS, and Gereau RWt (2003) Protein kinase C phosphorylation sensitizes but does not activate the
REFERENCES
123
capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). Proc Natl Acad Sci U S A 100:12480–12485. Bhave G, Zhu W, Wang H, Brasier DJ, Oxford GS, and Gereau RWt (2002) cAMPdependent protein kinase regulates desensitization of the capsaicin receptor (VR1) by direct phosphorylation. Neuron 35:721–731. Bonnington JK and McNaughton PA (2003) Signalling pathways involved in the sensitisation of mouse nociceptive neurons by nerve growth factor. J Physiol 551: 433–446. Brauchi S, Orta G, Mascayano C, Salazar M, Raddatz N, Urbina H, Rosenmann E, Gonzalez-Nilo F, and Latorre R (2007) Dissection of the components for PIP2 activation and thermosensation in TRP channels. Proc Natl Acad Sci U S A 104: 10246–10251. Brauchi S, Orta G, Salazar M, Rosenmann E, and Latorre R (2006) A hot-sensing cold receptor: C-terminal domain determines thermosensation in transient receptor potential channels. J Neurosci 26:4835–4840. Cao FL, Liu MG, Hao J, Li Z, Lu ZM, and Chen J (2007) Different roles of spinal p38 and c-Jun N-terminal kinase pathways in bee venom-induced multiple pain-related behaviors. Neurosci Lett 427:50–54. Carlton SM, Zhou S, Du J, Hargett GL, Ji G, and Coggeshall RE (2004) Somatostatin modulates the transient receptor potential vanilloid 1 (TRPV1) ion channel. Pain 110:616–627. Caterina MJ and Julius D (2001) The vanilloid receptor: a molecular gateway to the pain pathway. Annu Rev Neurosci 24:487–517. Caterina MJ, Leffler A, Malmberg AB, Martin WJ, Trafton J, Petersen-Zeitz KR, Koltzenburg M, Basbaum AI, and Julius D (2000) Impaired nociception and pain sensation in mice lacking the capsaicin receptor. Science 288:306–313. Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, and Julius D (1997) The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 389:816–824. Cesare P, Dekker LV, Sardini A, Parker PJ, and McNaughton PA (1999) Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat. Neuron 23:617–624. Cesare P and McNaughton P (1996) A novel heat-activated current in nociceptive neurons and its sensitization by bradykinin. Proc Natl Acad Sci U S A 93:15435–15439. Chesler M (2003) Regulation and modulation of pH in the brain. Physiol Rev 83:1183– 1221. Chheda MG, Ashery U, Thakur P, Rettig J, and Sheng ZH (2001) Phosphorylation of Snapin by PKA modulates its interaction with the SNARE complex. Nat Cell Biol 3:331–338. Chu CJ, Huang SM, De Petrocellis L, Bisogno T, Ewing SA, Miller JD, Zipkin RE, Daddario N, Appendino G, Di Marzo V, and Walker JM (2003) N-oleoyldopamine, a novel endogenous capsaicin-like lipid that produces hyperalgesia. J Biol Chem 278:13633–13639. Chuang HH, Prescott ED, Kong H, Shields S, Jordt SE, Basbaum AI, Chao MV, and Julius D (2001) Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 411:957–962.
124
BIOCHEMICAL PHARMACOLOGY OF TRPV1
Chung MK, Guler AD, and Caterina MJ (2008) TRPV1 shows dynamic ionic selectivity during agonist stimulation. Nat Neurosci 11:555–564. Claudino RF, Kassuya CA, Ferreira J, and Calixto JB (2006) Pharmacological and molecular characterization of the mechanisms involved in prostaglandin E2-induced mouse paw edema. J Pharmacol Exp Ther 318:611–618. Conway SJ (2008) TRPing the switch on pain: an introduction to the chemistry and biology of capsaicin and TRPV1. Chem Soc Rev 37:1530–1545. Cuypers E, Yanagihara A, Karlsson E, and Tytgat J (2006) Jellyfish and other cnidarian envenomations cause pain by affecting TRPV1 channels. FEBS Lett 580:5728–5732. Dai Y, Iwata K, Fukuoka T, Kondo E, Tokunaga A, Yamanaka H, Tachibana T, Liu Y, and Noguchi K (2002) Phosphorylation of extracellular signal-regulated kinase in primary afferent neurons by noxious stimuli and its involvement in peripheral sensitization. J Neurosci 22:7737–7745. Dai Y, Moriyama T, Higashi T, Togashi K, Kobayashi K, Yamanaka H, Tominaga M, and Noguchi K (2004) Proteinase-activated receptor 2-mediated potentiation of transient receptor potential vanilloid subfamily 1 activity reveals a mechanism for proteinase-induced inflammatory pain. J Neurosci 24:4293–4299. Daulhac L, Mallet C, Courteix C, Etienne M, Duroux E, Privat AM, Eschalier A, and Fialip J (2006) Diabetes-induced mechanical hyperalgesia involves spinal mitogenactivated protein kinase activation in neurons and microglia via N-methyl-Daspartate-dependent mechanisms. Mol Pharmacol 70:1246–1254. Davis JB, Gray J, Gunthorpe MJ, Hatcher JP, Davey PT, Overend P, Harries MH, Latcham J, Clapham C, Atkinson K, Hughes SA, Rance K, Grau E, Harper AJ, Pugh PL, Rogers DC, Bingham S, Randall A, and Sheardown SA (2000) Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia. Nature 405:183–187. Dell’Acqua ML, Smith KE, Gorski JA, Horne EA, Gibson ES, and Gomez LL (2006) Regulation of neuronal PKA signaling through AKAP targeting dynamics. Eur J Cell Biol 85:627–633. Dhaka A, Uzzell V, Dubin AE, Mathur J, Petrus M, Bandell M, and Patapoutian A (2009) TRPV1 is activated by both acidic and basic pH. J Neurosci 29:153–158. Docherty RJ, Yeats JC, Bevan S, and Boddeke HW (1996) Inhibition of calcineurin inhibits the desensitization of capsaicin-evoked currents in cultured dorsal root ganglion neurons from adult rats. Pflugers Arch 431:828–837. Doherty EM, Fotsch C, Bannon AW, Bo Y, Chen N, Dominguez C, Falsey J, Gavva NR, Katon J, Nixey T, Ognyanov VI, Pettus L, Rzasa RM, Stec M, Surapaneni S, Tamir R, Zhu J, Treanor JJ, and Norman MH (2007) Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. J Med Chem 50:3515–3527. Doya H, Ohtori S, Fujitani M, Saito T, Hata K, Ino H, Takahashi K, Moriya H, and Yamashita T (2005) c-Jun N-terminal kinase activation in dorsal root ganglion contributes to pain hypersensitivity. Biochem Biophys Res Commun 335:132–138. Doyle DA, Morais Cabral J, Pfuetzner RA, Kuo A, Gulbis JM, Cohen SL, Chait BT, and MacKinnon R (1998) The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science 280:69–77. El Kouhen R, Surowy CS, Bianchi BR, Neelands TR, McDonald HA, Niforatos W, Gomtsyan A, Lee CH, Honore P, Sullivan JP, Jarvis MF, and Faltynek CR (2005) A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel and selec-
REFERENCES
125
tive transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. J Pharmacol Exp Ther 314:400–409. Ferreira J, da Silva GL, and Calixto JB (2004) Contribution of vanilloid receptors to the overt nociception induced by B2 kinin receptor activation in mice. Br J Pharmacol 141:787–794. Ferreira J, Triches KM, Medeiros R, and Calixto JB (2005) Mechanisms involved in the nociception produced by peripheral protein kinase c activation in mice. Pain 117:171–181. Garcia-Sanz N, Fernandez-Carvajal A, Morenilla-Palao C, Planells-Cases R, FajardoSanchez E, Fernandez-Ballester G, and Ferrer-Montiel A (2004) Identification of a tetramerization domain in the C terminus of the vanilloid receptor. J Neurosci 24:5307–5314. Garcia-Sanz N, Valente P, Gomis A, Fernandez-Carvajal A, Fernandez-Ballester G, Viana F, Belmonte C, and Ferrer-Montiel A (2007) A role of the transient receptor potential domain of vanilloid receptor I in channel gating. J Neurosci 27:11641– 11650. Gavva NR, Klionsky L, Qu Y, Shi L, Tamir R, Edenson S, Zhang TJ, Viswanadhan VN, Toth A, Pearce LV, Vanderah TW, Porreca F, Blumberg PM, Lile J, Sun Y, Wild K, Louis JC, and Treanor JJ (2004) Molecular determinants of vanilloid sensitivity in TRPV1. J Biol Chem 279:20283–20295. Gavva NR, Tamir R, Qu Y, Klionsky L, Zhang TJ, Immke D, Wang J, Zhu D, Vanderah TW, Porreca F, Doherty EM, Norman MH, Wild KD, Bannon AW, Louis JC, and Treanor JJ (2005) AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 313:474–484. Gunthorpe MJ, Hannan SL, Smart D, Jerman JC, Arpino S, Smith GD, Brough S, Wright J, Egerton J, Lappin SC, Holland VA, Winborn K, Thompson M, Rami HK, Randall A, and Davis JB (2007) Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor. J Pharmacol Exp Ther 321: 1183–1192. Gunthorpe MJ, Harries MH, Prinjha RK, Davis JB, and Randall A (2000) Voltage- and time-dependent properties of the recombinant rat vanilloid receptor (rVR1). J Physiol 525(Pt 3):747–759. Guo A, Vulchanova L, Wang J, Li X, and Elde R (1999) Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X3 purinoceptor and IB4 binding sites. Eur J Neurosci 11:946–958. Hu SJ, Song XJ, Greenquist KW, Zhang JM, and LaMotte RH (2001) Protein kinase A modulates spontaneous activity in chronically compressed dorsal root ganglion neurons in the rat. Pain 94:39–46. Huang SM, Bisogno T, Trevisani M, Al-Hayani A, De Petrocellis L, Fezza F, Tognetto M, Petros TJ, Krey JF, Chu CJ, Miller JD, Davies SN, Geppetti P, Walker JM, and Di Marzo V (2002) An endogenous capsaicin-like substance with high potency at recombinant and native vanilloid VR1 receptors. Proc Natl Acad Sci U S A 99: 8400–8405. Huang SM and Walker JM (2006) Enhancement of spontaneous and heat-evoked activity in spinal nociceptive neurons by the endovanilloid/endocannabinoid N-arachidonoyldopamine (NADA). J Neurophysiol 95:1207–1212.
126
BIOCHEMICAL PHARMACOLOGY OF TRPV1
Hwang SW, Cho H, Kwak J, Lee SY, Kang CJ, Jung J, Cho S, Min KH, Suh YG, Kim D, and Oh U (2000) Direct activation of capsaicin receptors by products of lipoxygenases: endogenous capsaicin-like substances. Proc Natl Acad Sci U S A 97:6155–6160. Jeske NA, Diogenes A, Ruparel NB, Fehrenbacher JC, Henry M, Akopian AN, and Hargreaves KM (2008) A-kinase anchoring protein mediates TRPV1 thermal hyperalgesia through PKA phosphorylation of TRPV1. Pain 138:604–616. Jeske NA, Patwardhan AM, Henry MA, and Milam SB (2009) Fibronectin stimulates TRPV1 translocation in primary sensory neurons. J Neurochem 108:591–600. Ji RR, Samad TA, Jin SX, Schmoll R, and Woolf CJ (2002) p38 MAPK activation by NGF in primary sensory neurons after inflammation increases TRPV1 levels and maintains heat hyperalgesia. Neuron 36:57–68. Jiang Y, Lee A, Chen J, Cadene M, Chait BT, and MacKinnon R (2002) Crystal structure and mechanism of a calcium-gated potassium channel. Nature 417:515–522. Jin SX, Zhuang ZY, Woolf CJ, and Ji RR (2003) p38 mitogen-activated protein kinase is activated after a spinal nerve ligation in spinal cord microglia and dorsal root ganglion neurons and contributes to the generation of neuropathic pain. J Neurosci 23:4017–4022. Jin X and Gereau RWt (2006) Acute p38-mediated modulation of tetrodotoxinresistant sodium channels in mouse sensory neurons by tumor necrosis factor-alpha. J Neurosci 26:246–255. Jin X, Touhey J, and Gaudet R (2006) Structure of the N-terminal ankyrin repeat domain of the TRPV2 ion channel. J Biol Chem 281:25006–25010. Jordt SE and Julius D (2002) Molecular basis for species-specific sensitivity to “hot” chili peppers. Cell 108:421–430. Jordt SE, Tominaga M, and Julius D (2000) Acid potentiation of the capsaicin receptor determined by a key extracellular site. Proc Natl Acad Sci U S A 97:8134–8139. Jung J, Lee SY, Hwang SW, Cho H, Shin J, Kang YS, Kim S, and Oh U (2002) Agonist recognition sites in the cytosolic tails of vanilloid receptor 1. J Biol Chem 277:44448– 44454. Jung J, Shin JS, Lee SY, Hwang SW, Koo J, Cho H, and Oh U (2004) Phosphorylation of vanilloid receptor 1 by Ca2+/calmodulin-dependent kinase II regulates its vanilloid binding. J Biol Chem 279:7048–7054. Khan AA, Diogenes A, Jeske NA, Henry MA, Akopian A, and Hargreaves KM (2008) Tumor necrosis factor alpha enhances the sensitivity of rat trigeminal neurons to capsaicin. Neuroscience 155:503–509. Khasar SG, Lin YH, Martin A, Dadgar J, McMahon T, Wang D, Hundle B, Aley KO, Isenberg W, McCarter G, Green PG, Hodge CW, Levine JD, and Messing RO (1999) A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice. Neuron 24:253–260. Kim SY, Bae JC, Kim JY, Lee HL, Lee KM, Kim DS, and Cho HJ (2002) Activation of p38 MAP kinase in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury. Neuroreport 13:2483–2486. Koizumi K, Iwasaki Y, Narukawa M, Iitsuka Y, Fukao T, Seki T, Ariga T, and Watanabe T (2009) Diallyl sulfides in garlic activate both TRPA1 and TRPV1. Biochem Biophys Res Commun 382:545–548.
REFERENCES
127
Koplas PA, Rosenberg RL, and Oxford GS (1997) The role of calcium in the desensitization of capsaicin responses in rat dorsal root ganglion neurons. J Neurosci 17: 3525–3537. Kress M, Rodl J, and Reeh PW (1996) Stable analogues of cyclic AMP but not cyclic GMP sensitize unmyelinated primary afferents in rat skin to heat stimulation but not to inflammatory mediators, in vitro. Neuroscience 74:609–617. Kym PR, Kort ME, and Hutchins CW (2009) Analgesic potential of TRPV1 antagonists. Biochem Pharmacol 78:211–216. Leffler A, Fischer MJ, Rehner D, Kienel S, Kistner K, Sauer SK, Gavva NR, Reeh PW, and Nau C (2008) The vanilloid receptor TRPV1 is activated and sensitized by local anesthetics in rodent sensory neurons. J Clin Invest 118:763–776. Lehto SG, Tamir R, Deng H, Klionsky L, Kuang R, Le A, Lee D, Louis JC, Magal E, Manning BH, Rubino J, Surapaneni S, Tamayo N, Wang T, Wang J, Wang W, Youngblood B, Zhang M, Zhu D, Norman MH, and Gavva NR (2008) Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2(piperidin-1-yl)-4-(tri fluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther 326:218–229. Lewin GR, Ritter AM, and Mendell LM (1993) Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. J Neurosci 13:2136–2148. Lishko PV, Procko E, Jin X, Phelps CB, and Gaudet R (2007) The ankyrin repeats of TRPV1 bind multiple ligands and modulate channel sensitivity. Neuron 54: 905–918. Liu B, Hui K, and Qin F (2003) Thermodynamics of heat activation of single capsaicin ion channels VR1. Biophys J 85:2988–3006. Liu B, Zhang C, and Qin F (2005) Functional recovery from desensitization of vanilloid receptor TRPV1 requires resynthesis of phosphatidylinositol 4,5-bisphosphate. J Neurosci 25:4835–4843. Liu L and Simon SA (1996) Capsaicin-induced currents with distinct desensitization and Ca2+ dependence in rat trigeminal ganglion cells. J Neurophysiol 75:1503– 1514. Long SB, Campbell EB, and Mackinnon R (2005) Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science 309:897–903. Lukacs V, Thyagarajan B, Varnai P, Balla A, Balla T, and Rohacs T (2007) Dual regulation of TRPV1 by phosphoinositides. J Neurosci 27:7070–7080. Ma W and Quirion R (2002) Partial sciatic nerve ligation induces increase in the phosphorylation of extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) in astrocytes in the lumbar spinal dorsal horn and the gracile nucleus. Pain 99:175–184. Macpherson LJ, Dubin AE, Evans MJ, Marr F, Schultz PG, Cravatt BF, and Patapoutian A (2007) Noxious compounds activate TRPA1 ion channels through covalent modification of cysteines. Nature 445:541–545. Malmberg AB, Brandon EP, Idzerda RL, Liu H, McKnight GS, and Basbaum AI (1997) Diminished inflammation and nociceptive pain with preservation of neuropathic pain in mice with a targeted mutation of the type I regulatory subunit of cAMP-dependent protein kinase. J Neurosci 17:7462–7470.
128
BIOCHEMICAL PHARMACOLOGY OF TRPV1
Mandadi S, Numazaki M, Tominaga M, Bhat MB, Armati PJ, and Roufogalis BD (2004) Activation of protein kinase C reverses capsaicin-induced calcium-dependent desensitization of TRPV1 ion channels. Cell Calcium 35:471–478. Mandadi S, Tominaga T, Numazaki M, Murayama N, Saito N, Armati PJ, Roufogalis BD, and Tominaga M (2006) Increased sensitivity of desensitized TRPV1 by PMA occurs through PKCepsilon-mediated phosphorylation at S800. Pain 123: 106–116. Marincsak R, Toth BI, Czifra G, Szabo T, Kovacs L, and Biro T (2008) The analgesic drug, tramadol, acts as an agonist of the transient receptor potential vanilloid-1. Anesth Analg 106:1890–1896. Matta JA and Ahern GP (2007) Voltage is a partial activator of rat thermosensitive TRP channels. J Physiol 585:469–482. Matta JA, Miyares RL, and Ahern GP (2007) TRPV1 is a novel target for omega-3 polyunsaturated fatty acids. J Physiol 578:397–411. McNamara FN, Randall A, and Gunthorpe MJ (2005) Effects of piperine, the pungent component of black pepper, at the human vanilloid receptor (TRPV1). Br J Pharmacol 144:781–790. Meerschaert J, Kelly EA, Mosher DF, Busse WW, and Jarjour NN (1999) Segmental antigen challenge increases fibronectin in bronchoalveolar lavage fluid. Am J Respir Crit Care Med 159:619–625. Milligan ED, Twining C, Chacur M, Biedenkapp J, O’Connor K, Poole S, Tracey K, Martin D, Maier SF, and Watkins LR (2003) Spinal glia and proinflammatory cytokines mediate mirror-image neuropathic pain in rats. J Neurosci 23:1026– 1040. Mizushima T, Obata K, Yamanaka H, Dai Y, Fukuoka T, Tokunaga A, Mashimo T, and Noguchi K (2005) Activation of p38 MAPK in primary afferent neurons by noxious stimulation and its involvement in the development of thermal hyperalgesia. Pain 113:51–60. Mohapatra DP and Nau C (2003) Desensitization of capsaicin-activated currents in the vanilloid receptor TRPV1 is decreased by the cyclic AMP-dependent protein kinase pathway. J Biol Chem 278:50080–50090. Mohapatra DP and Nau C (2005) Regulation of Ca2+-dependent desensitization in the vanilloid receptor TRPV1 by calcineurin and cAMP-dependent protein kinase. J Biol Chem 280:13424–13432. Mohapatra DP, Wang SY, Wang GK, and Nau C (2003) A tyrosine residue in TM6 of the vanilloid receptor TRPV1 involved in desensitization and calcium permeability of capsaicin-activated currents. Mol Cell Neurosci 23:314–324. Moiseenkova-Bell VY, Stanciu LA, Serysheva, II, Tobe BJ, and Wensel TG (2008) Structure of TRPV1 channel revealed by electron cryomicroscopy. Proc Natl Acad Sci U S A 105:7451–7455. Moqrich A, Hwang SW, Earley TJ, Petrus MJ, Murray AN, Spencer KS, Andahazy M, Story GM, and Patapoutian A (2005) Impaired thermosensation in mice lacking TRPV3, a heat and camphor sensor in the skin. Science 307:1468–1472. Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, and Ferrer-Montiel A (2004) Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 279:25665–25672.
REFERENCES
129
Moriyama T, Higashi T, Togashi K, Iida T, Segi E, Sugimoto Y, Tominaga T, Narumiya S, and Tominaga M (2005) Sensitization of TRPV1 by EP1 and IP reveals peripheral nociceptive mechanism of prostaglandins. Mol Pain 1:3. Moriyama T, Iida T, Kobayashi K, Higashi T, Fukuoka T, Tsumura H, Leon C, Suzuki N, Inoue K, Gachet C, Noguchi K, and Tominaga M (2003) Possible involvement of P2Y2 metabotropic receptors in ATP-induced transient receptor potential vanilloid receptor 1-mediated thermal hypersensitivity. J Neurosci 23:6058–6062. Motta EM, Calixto JB, and Rae GA (2006) Mechanical hyperalgesia induced by endothelin-1 in rats is mediated via phospholipase C, protein kinase C, and MAP kinases. Exp Biol Med (Maywood) 231:1141–1145. Myers BR, Bohlen CJ, and Julius D (2008) A yeast genetic screen reveals a critical role for the pore helix domain in TRP channel gating. Neuron 58:362–373. Nakata T, Terada S, and Hirokawa N (1998) Visualization of the dynamics of synaptic vesicle and plasma membrane proteins in living axons. J Cell Biol 140:659–674. Neelands TR, Jarvis MF, Faltynek CR, and Surowy CS (2008) Elevated temperatures alter TRPV1 agonist-evoked excitability of dorsal root ganglion neurons. Inflamm Res 57:404–409. Neelands TR, Jarvis MF, Han P, Faltynek CR, and Surowy CS (2005) Acidification of rat TRPV1 alters the kinetics of capsaicin responses. Mol Pain 1:28. Nilius B, Talavera K, Owsianik G, Prenen J, Droogmans G, and Voets T (2005) Gating of TRP channels: a voltage connection? J Physiol 567:35–44. Novakova-Tousova K, Vyklicky L, Susankova K, Benedikt J, Samad A, Teisinger J, and Vlachova V (2007) Functional changes in the vanilloid receptor subtype 1 channel during and after acute desensitization. Neuroscience 149:144–154. Numazaki M, Tominaga T, Takeuchi K, Murayama N, Toyooka H, and Tominaga M (2003) Structural determinant of TRPV1 desensitization interacts with calmodulin. Proc Natl Acad Sci U S A 100:8002–8006. Numazaki M, Tominaga T, Toyooka H, and Tominaga M (2002) Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cepsilon and identification of two target serine residues. J Biol Chem 277:13375–13378. Obata K, Yamanaka H, Kobayashi K, Dai Y, Mizushima T, Katsura H, Fukuoka T, Tokunaga A, and Noguchi K (2004) Role of mitogen-activated protein kinase activation in injured and intact primary afferent neurons for mechanical and heat hypersensitivity after spinal nerve ligation. J Neurosci 24:10211–10222. Ohta T, Imagawa T, and Ito S (2009) Involvement of transient receptor potential vanilloid subtype 1 in analgesic action of methylsalicylate. Mol Pharmacol 75:307– 317. Pareek TK, Keller J, Kesavapany S, Agarwal N, Kuner R, Pant HC, Iadarola MJ, Brady RO, Kulkarni AB (2007) Cyclin-dependent kinase 5 modulates nociceptive signaling through direct phosphorylation of transient receptor potential vanilloid 1. Proc Natl Acad Sci USA 104:660–665. Phelps CB, Huang RJ, Lishko PV, Wang RR, and Gaudet R (2008) Structural analyses of the ankyrin repeat domain of TRPV6 and related TRPV ion channels. Biochemistry 47:2476–2484. Piper AS, Yeats JC, Bevan S, and Docherty RJ (1999) A study of the voltage dependence of capsaicin-activated membrane currents in rat sensory neurons before and after acute desensitization. J Physiol 518(Pt 3):721–733.
130
BIOCHEMICAL PHARMACOLOGY OF TRPV1
Plant TD, Zollner C, Kepura F, Mousa SS, Eichhorst J, Schaefer M, Furkert J, Stein C, and Oksche A (2007) Endothelin potentiates TRPV1 via ETA receptormediated activation of protein kinase C. Mol Pain 3:35. Premkumar LS and Ahern GP (2000) Induction of vanilloid receptor channel activity by protein kinase C. Nature 408:985–990. Premkumar LS, Qi ZH, Van Buren J, and Raisinghani M (2004) Enhancement of potency and efficacy of NADA by PKC-mediated phosphorylation of vanilloid receptor. J Neurophysiol 91:1442–1449. Prescott ED and Julius D (2003) A modular PIP2 binding site as a determinant of capsaicin receptor sensitivity. Science 300:1284–1288. Raisinghani M, Pabbidi RM, and Premkumar LS (2005) Activation of transient receptor potential vanilloid 1 (TRPV1) by resiniferatoxin. J Physiol 567:771–786. Rathee PK, Distler C, Obreja O, Neuhuber W, Wang GK, Wang SY, Nau C, and Kress M (2002) PKA/AKAP/VR-1 module: a common link of Gs-mediated signaling to thermal hyperalgesia. J Neurosci 22:4740–4745. Ren L, Blanchette JB, White LR, Clark SA, Heffner DJ, Tibbles LA, and Muruve DA (2005) Soluble fibronectin induces chemokine gene expression in renal tubular epithelial cells. Kidney Int 68:2111–2120. Roberts LA, Christie MJ, and Connor M (2002) Anandamide is a partial agonist at native vanilloid receptors in acutely isolated mouse trigeminal sensory neurons. Br J Pharmacol 137:421–428. Rosenbaum T, Gordon-Shaag A, Munari M, and Gordon SE (2004) Ca2+/calmodulin modulates TRPV1 activation by capsaicin. J Gen Physiol 123:53–62. Ross RA (2003) Anandamide and vanilloid TRPV1 receptors. Br J Pharmacol 140: 790–801. Ross RA, Gibson TM, Brockie HC, Leslie M, Pashmi G, Craib SJ, Di Marzo V, and Pertwee RG (2001) Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br J Pharmacol 132:631–640. Russell FA, Fernandes ES, Courade JP, Keeble JE, and Brain SD (2009) Tumour necrosis factor alpha mediates transient receptor potential vanilloid 1-dependent bilateral thermal hyperalgesia with distinct peripheral roles of interleukin-1beta, protein kinase C and cyclooxygenase-2 signalling. Pain 142:264–274. Ryu S, Liu B, Yao J, Fu Q, and Qin F (2007) Uncoupling proton activation of vanilloid receptor TRPV1. J Neurosci 27:12797–12807. Saghatelian A, McKinney MK, Bandell M, Patapoutian A, and Cravatt BF (2006) A FAAH-regulated class of N-acyl taurines that activates TRP ion channels. Biochemistry 45:9007–9015. Salazar H, Llorente I, Jara-Oseguera A, Garcia-Villegas R, Munari M, Gordon SE, Islas LD, and Rosenbaum T (2008) A single N-terminal cysteine in TRPV1 determines activation by pungent compounds from onion and garlic. Nat Neurosci 11: 255–261. Samways DS, Khakh BS, and Egan TM (2008) Tunable calcium current through TRPV1 receptor channels. J Biol Chem 283:31274–31278. Sanguinetti MC and Mitcheson JS (2005) Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol Sci 26:119–124.
REFERENCES
131
Schafers M, Lee DH, Brors D, Yaksh TL, and Sorkin LS (2003a) Increased sensitivity of injured and adjacent uninjured rat primary sensory neurons to exogenous tumor necrosis factor-alpha after spinal nerve ligation. J Neurosci 23:3028–3038. Schafers M, Sorkin LS, Geis C, and Shubayev VI (2003b) Spinal nerve ligation induces transient upregulation of tumor necrosis factor receptors 1 and 2 in injured and adjacent uninjured dorsal root ganglia in the rat. Neurosci Lett 347:179–182. Schafers M, Svensson CI, Sommer C, and Sorkin LS (2003c) Tumor necrosis factoralpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci 23:2517–2521. Schnizler K, Shutov LP, Van Kanegan MJ, Merrill MA, Nichols B, McKnight GS, Strack S, Hell JW, and Usachev YM (2008) Protein kinase A anchoring via AKAP150 is essential for TRPV1 modulation by forskolin and prostaglandin E2 in mouse sensory neurons. J Neurosci 28:4904–4917. Sculptoreanu A, Aura Kullmann F, and de Groat WC (2008) Neurokinin 2 receptormediated activation of protein kinase C modulates capsaicin responses in DRG neurons from adult rats. Eur J Neurosci 27:3171–3181. Shin J, Cho H, Hwang SW, Jung J, Shin CY, Lee SY, Kim SH, Lee MG, Choi YH, Kim J, Haber NA, Reichling DB, Khasar S, Levine JD, and Oh U (2002) Bradykinin12-lipoxygenase-VR1 signaling pathway for inflammatory hyperalgesia. Proc Natl Acad Sci U S A 99:10150–10155. Shu X and Mendell LM (2001) Acute sensitization by NGF of the response of smalldiameter sensory neurons to capsaicin. J Neurophysiol 86:2931–2938. Siemens J, Zhou S, Piskorowski R, Nikai T, Lumpkin EA, Basbaum AI, King D, and Julius D (2006) Spider toxins activate the capsaicin receptor to produce inflammatory pain. Nature 444:208–212. Smart D, Gunthorpe MJ, Jerman JC, Nasir S, Gray J, Muir AI, Chambers JK, Randall AD, and Davis JB (2000) The endogenous lipid anandamide is a full agonist at the human vanilloid receptor (hVR1). Br J Pharmacol 129:227–230. Srinivasan R, Wolfe D, Goss J, Watkins S, de Groat WC, Sculptoreanu A, and Glorioso JC (2008) Protein kinase C epsilon contributes to basal and sensitizing responses of TRPV1 to capsaicin in rat dorsal root ganglion neurons. Eur J Neurosci 28:1241–1254. Steen KH and Reeh PW (1993) Sustained graded pain and hyperalgesia from harmless experimental tissue acidosis in human skin. Neurosci Lett 154:113–116. Steen KH, Reeh PW, Anton F, and Handwerker HO (1992) Protons selectively induce lasting excitation and sensitization to mechanical stimulation of nociceptors in rat skin, in vitro. J Neurosci 12:86–95. Stein AT, Ufret-Vincenty CA, Hua L, Santana LF, and Gordon SE (2006) Phosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membrane. J Gen Physiol 128:509–522. Stotz SC, Vriens J, Martyn D, Clardy J, and Clapham DE (2008) Citral sensing by Transient [corrected] receptor potential channels in dorsal root ganglion neurons. PLoS One 3:e2082. Suardiaz M, Estivill-Torrus G, Goicoechea C, Bilbao A, and Rodriguez de Fonseca F (2007) Analgesic properties of oleoylethanolamide (OEA) in visceral and inflammatory pain. Pain 133:99–110.
132
BIOCHEMICAL PHARMACOLOGY OF TRPV1
Sugiuar T, Bielefeldt K, and Gebhart GF (2004) TRPV1 function in mouse colon sensory neurons is enhanced by metabotropic 5-hydroxytryptamine receptor activation. J Neurosci 24:9521–9530. Sugiura T, Tominaga M, Katsuya H, and Mizumura K (2002) Bradykinin lowers the threshold temperature for heat activation of vanilloid receptor 1. J Neurophysiol 88:544–548. Surowy CS, Neelands TR, Bianchi BR, McGaraughty S, El Kouhen R, Han P, Chu KL, McDonald HA, Vos M, Niforatos W, Bayburt EK, Gomtsyan A, Lee CH, Honore P, Sullivan JP, Jarvis MF, and Faltynek CR (2008) (R)-(5-tert-butyl-2,3dihydro-1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo. J Pharmacol Exp Ther 326:879–888. Susankova K, Ettrich R, Vyklicky L, Teisinger J, and Vlachova V (2007) Contribution of the putative inner-pore region to the gating of the transient receptor potential vanilloid subtype 1 channel (TRPV1). J Neurosci 27:7578–7585. Szallasi A, Cortright DN, Blum CA, and Eid SR (2007) The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 6:357–372. Tang HB, Inoue A, Oshita K, and Nakata Y (2004) Sensitization of vanilloid receptor 1 induced by bradykinin via the activation of second messenger signaling cascades in rat primary afferent neurons. Eur J Pharmacol 498:37–43. Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, and Julius D (1998) The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 21:531–543. Tominaga M, Numazaki M, Iida T, Moriyama T, Sugiura T, Togashi K, Higashi T, Murayama N, Tominaga T, and Mizumura K (2004) Molecular mechanisms of TRPV1-mediated thermal hypersensitivity. Prog Pain Res Management 30:37–47. Tominaga M and Tominaga T (2005) Structure and function of TRPV1. Pflugers Arch 451:143–150. Toth A, Kedei N, Wang Y, and Blumberg PM (2003) Arachidonyl dopamine as a ligand for the vanilloid receptor VR1 of the rat. Life Sci 73:487–498. Tousova K, Vyklicky L, Susankova K, Benedikt J, and Vlachova V (2005) Gadolinium activates and sensitizes the vanilloid receptor TRPV1 through the external protonation sites. Mol Cell Neurosci 30:207–217. Tvorogov D, Wang XJ, Zent R, and Carpenter G (2005) Integrin-dependent PLCgamma1 phosphorylation mediates fibronectin-dependent adhesion. J Cell Sci 118: 601–610. Vellani V, Mapplebeck S, Moriondo A, Davis JB, and McNaughton PA (2001) Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J Physiol 534:813–825. Vetter I, Cheng W, Peiris M, Wyse BD, Roberts-Thomson SJ, Zheng J, Monteith GR, and Cabot PJ (2008) Rapid, opioid-sensitive mechanisms involved in transient receptor potential vanilloid 1 sensitization. J Biol Chem 283:19540–19550. Vlachova V, Lyfenko A, Orkand RK, and Vyklicky L (2001) The effects of capsaicin and acidity on currents generated by noxious heat in cultured neonatal rat dorsal root ganglion neurons. J Physiol 533:717–728.
REFERENCES
133
Voets T, Droogmans G, Wissenbach U, Janssens A, Flockerzi V, and Nilius B (2004) The principle of temperature-dependent gating in cold- and heat-sensitive TRP channels. Nature 430:748–754. Wong W and Scott JD (2004) AKAP signalling complexes: focal points in space and time. Nat Rev Mol Cell Biol 5:959–970. Woo DH, Jung SJ, Zhu MH, Park CK, Kim YH, Oh SB, and Lee CJ (2008) Direct activation of transient receptor potential vanilloid 1(TRPV1) by diacylglycerol (DAG). Mol Pain 4:42. Xu H, Blair NT, and Clapham DE (2005) Camphor activates and strongly desensitizes the transient receptor potential vanilloid subtype 1 channel in a vanilloidindependent mechanism. J Neurosci 25:8924–8937. Yao J and Qin F (2009) Interaction with phosphoinositides confers adaptation onto the TRPV1 pain receptor. PLoS Biol 7:e46. Zhang H, Cang CL, Kawasaki Y, Liang LL, Zhang YQ, Ji RR, and Zhao ZQ (2007) Neurokinin-1 receptor enhances TRPV1 activity in primary sensory neurons via PKCepsilon: a novel pathway for heat hyperalgesia. J Neurosci 27:12067–12077. Zhang JM, Li H, Liu B, and Brull SJ (2002) Acute topical application of tumor necrosis factor alpha evokes protein kinase A-dependent responses in rat sensory neurons. J Neurophysiol 88:1387–1392. Zhang N, Inan S, Cowan A, Sun R, Wang JM, Rogers TJ, Caterina M, and Oppenheim JJ (2005a) A proinflammatory chemokine, CCL3, sensitizes the heat- and capsaicingated ion channel TRPV1. Proc Natl Acad Sci U S A 102:4536–4541. Zhang X, Huang J, and McNaughton PA (2005b) NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J 24:4211–4223. Zhang X, Li L, and McNaughton PA (2008) Proinflammatory mediators modulate the heat-activated ion channel TRPV1 via the scaffolding protein AKAP79/150. Neuron 59:450–461. Zhou Y, Li GD, and Zhao ZQ (2003) State-dependent phosphorylation of epsilonisozyme of protein kinase C in adult rat dorsal root ganglia after inflammation and nerve injury. J Neurochem 85:571–580. Zhu H, Hille B, and Xu T (2002) Sensitization of regulated exocytosis by protein kinase C. Proc Natl Acad Sci U S A 99:17055–17059. Zhu W and Oxford GS (2007) Phosphoinositide-3-kinase and mitogen activated protein kinase signaling pathways mediate acute NGF sensitization of TRPV1. Mol Cell Neurosci 34:689–700. Zhuang ZY, Wen YR, Zhang DR, Borsello T, Bonny C, Strichartz GR, Decosterd I, and Ji RR (2006) A peptide c-Jun N-terminal kinase (JNK) inhibitor blocks mechanical allodynia after spinal nerve ligation: respective roles of JNK activation in primary sensory neurons and spinal astrocytes for neuropathic pain development and maintenance. J Neurosci 26:3551–3560. Zhuang ZY, Xu H, Clapham DE, and Ji RR (2004) Phosphatidylinositol 3-kinase activates ERK in primary sensory neurons and mediates inflammatory heat hyperalgesia through TRPV1 sensitization. J Neurosci 24:8300–8309. Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, and Hogestatt ED (1999) Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature 400:452–457.
4 TRPV1 GENETICS Ruslan Dorfman, Hubert Tsui, Michael W. Salter, and H.-Michael Dosch
4.1
OVERVIEW
In this chapter, we will summarize how TRPV1 genetic variability impacts the pharmacological properties of TRPV1 in different species. We will also review site-directed mutagenesis experiments that identify binding sites for biological and pharmacological substrates and modify conductivity of the channel. These studies have been essential for unraveling the complex structure–function paradigm of TRPV1. With this background information, we will then discuss the genetic heterogeneity of the human trpv1 gene, which likely will be a major element in our current progression toward translating the insights gained to better understanding and, hopefully, to new therapeutic strategies, some already effective in animals. 4.2
trpv1 GENE STRUCTURE IN DIFFERENT SPECIES
The human trpv1 gene1 is found on the small arm of chromosome 17 at p13.2, coordinates 3,415,493-3,447,085 (ENSEMBL assembly release 48, National Center for Biotechnology Information [NCBI] version 36). Human trpv1 is polymorphic, with 76 validated single-nucleotide polymorphisms (SNPs), 9 of which map to coding regions of the gene.2 1
http://www.ensembl.org/Homo_sapiens/geneview?gene=ENSG00000196689. http://www.ncbi.nlm.nih.gov.myaccess.library.utoronto.ca/SNP/snp_ref.cgi?locusId=7442&choo seRs=het. 2
Vanilloid Receptor TRPV1 in Drug Discovery, Edited by Arthur Gomtsyan & Connie R. Faltynek Copyright © 2010 John Wiley & Sons, Inc.
134
ALTERNATIVE SPLICING OF trpv1 RESULTS
135
The mouse gene3 maps to chromosome 11 (band B4) at location 73,047,794– 73,074,744. The mouse gene is also highly polymorphic,4 with a large number of SNPs (111 in total, 6 in coding sequences) that differ across 17 mouse strains genotyped by different consortia. This genetic variability was used to map a large number of quantitative trait loci (QTL) by using collections of recombinant inbred mouse lines derived from different parental strains.5 The rat trpv1 gene on chromosome 10 maps to location 60,109,656– 60,135,405 (Chr10q24). Several rat QTLs (23) were mapped to this region, conferring potential roles of trpv1 polymorphisms in the regulation of blood pressure, risk of arthritis, bone mineral density, stress responses, resistance to toxoplasma infection and thermal sensitivity.6 However, there is also a high degree of conservation at the genomic level, where the exonic sequences are the most conserved and where intron 1 of the trpv1 gene includes a large conserved region. In the intronic sequences of the human trpv1 gene, there are several highly conserved binding sites for AP1, SRF, ARP1, NRSF, CDP, FOXO1, RP58, PPARG, and PPARA transcription factors, which are predicted by the multiple alignments of noncoding genomic DNA sequences from different species.7 These transcription factors likely play significant roles in the regulation of TRPV1 expression. 4.3 ALTERNATIVE SPLICING OF trpv1 RESULTS IN DIFFERENT FUNCTIONAL VARIANTS There are at least six different splice variants of the human trpv1 gene; four variants utilize alternative promoters, with the most distant promoter lying in the 3′UTR of the CARKL gene. However, these four alternative variants with different promoters give rise to an identical protein sequence of 839 amino acids in the canonical TRPV1 protein. There are other alternative splice variants of the trpv1 gene that differ in the length of mature protein, varying from 510 to 849 amino acid residues. The trpv1 genes of mouse and rat use at least three different promoters. Such diversity in promoters most probably plays a role in the regulation of TRPV1 expression and function in different tissues. In addition, at least three dominant-negative splicing variants of different sizes have been described. One variant, TRPV1beta, cloned from murine dorsal root ganglia (DRGs), codes for 829 amino acids and has an alternative intronic recognition signal within exon 7 of the trpv1 gene (Wang et al., 2004). TRPV1beta was not functional by itself, but its coexpression inhibited the function of TRPV1 (Wang et al., 2004). The second dominant-negative splice 3
http://www.ensembl.org/Mus_musculus/geneview?gene=ENSMUSG00000005952. http://phenome.jax.org/pub-cgi/phenome/mpdcgi?rtn=snps/retrieve&gregion=gene&genesym= Trpv1. 5 http://www.webqtl.org/. 6 http://www.ensembl.org/Rattus_norvegicus/geneview?gene=ENSRNOG00000019486. 7 http://genome.ucsc.edu/. 4
136
TRPV1 GENETICS
TABLE 4.1 Splice Variant
Number of Exons
Transcript length (bps)
Protein length (aa)
Function
TRPV1-201 TRPV1-202 TRPV1-203 TRPV1-204 TRPV1-205
16 14 10 14 16
4,044 4,233 2,060 4,483 4,446
839 779 510 837 850
TRPV1-206 TRPV1-207
16 15
4,087 3,964
839 839
Canonical promoter TRPV1b Possibly dominant-negative Alternative promoter Includes alternative 3rd coding exon that is skipped in all other splice variants Alternative promoter Shortest promoter
variant TRPV1(VAR) was identified in rat kidney (Tian et al., 2006). This variant was predicted to encode a form of TRPV1, which was truncated at amino acid residue 253, but utilized the same promoter as canonical TRPV1. Upon heterologous expression, TRPV1(VAR) had a dominant-negative effect, partially blocking TRPV1-dependent resiniferatoxin (RTX) responsiveness in the COS-7 epithelial cell line, but an opposite effect was observed when TRPV1(VAR) was expressed in HEK293 cells (Tian et al., 2006). A third human TRPV1 splice variant, TRPV1b of 779 amino acids, was also cloned from DRG. TRPV1b lacks exon 7, which encodes the third ankyrin domain (Vos et al., 2006). Human TRPV1b also inhibited normal TRPV1 channel function in response to capsaicin, acidic pH, heat, and endogenous vanilloids (Vos et al., 2006). The EMBL protein database contains two additional, alternatively spliced TRPV1 protein sequences of 667 and 510 residues, respectively, both of which lack the full third ankyrin domain and the poreforming sequences, and presumably may also represent dominant-negative variants (Table 4.1). 4.4 FUNCTIONAL TRPV1 DIFFERENCES IN NONCONSERVED AMINO ACID POSITIONS Although highly conserved, overall, substantial differences do exist in TRPV1 protein sequences, which affect the function of TRPV1. The evolutionary changes in different species led to remarkable variability of TRPV1 responses to distinct agonists and antagonists. A number of in vitro studies, based on TRPV1 channels derived from various species through reciprocal site-directed mutagenesis, led to identification of key residues essential for binding of capsaicin and other agonists (Fig. 4.1). Jordt and Julius (2002) focused attention on the avian TRPV1, which was known to be insensitive to capsaicin but had a normal response to low pH and heat. The cloning of TRPV1 from chicken DRG and comparison with the rat sequence identified a number of changes in the TM2 and TM4 domains. Site-directed mutagenesis of the rat TRPV1 channel led to establishment of the
FUNCTIONAL TRPV1 DIFFERENCES
137
(a) Cladogram human chimp cow dog guinea_pig mouse rat chicken rabbit
(b) CLUSTAL 2.0.3 multiple sequence alignment of TRPV1 proteins mouse rat guinea_pig cow dog human chimp rabbit chicken
-------MEKWASLDSDES----EPPAQENSCPDPPDRDPNSKPPPAKPHIFAT-RSRTR -------MEQRASLDSEES----ESPPQENSCLDPPDRDPNCKPPPVKPHIFTT-RSRTR -------MKKRASVDSKES----EDPPQEDYSLDPLDVDANSKTPPAKPHTFSVSKSRNR -------MKKWGSSESRES----QDLPQEDSCPDPLDGDPNYRPAPTKPHSFPTAKSRSR -------MKNWGSSDSGGS----EDPPQEDSCLDPLDGDPNSRPVPAKPHIFPTAKSRSR -------MKKWSSTDLGAA----ADPLQKDTCPDPLDGDPNSRPPPAKP-QLSTAKSRTR -------MKKWSSTDLGAA----ADPLQKDTCPDPLDGDPNSRPPPAKP-QLSTAKSRTR -------MKRWVSLDSGES----EDPLPEDTCPDLLDGDSNAKPPPAKPHIFSTAKSRSR MSSILEKMKKFGSSDIEESEVTDEHTDGEDSALETADNLQGTFSNKVQPSKSNIFARRGR
48 48 49 49 49 48 48 49 60
mouse rat guinea_pig cow dog human chimp rabbit chicken
LFGKGDSEEASPMDCPYEEGGLASCPIITVSSVVTLQRSVDGPTCLRQTSQDSVSTGV-E LFGKGDSEEASPLDCPYEEGGLASCPIITVSSVLTIQRPGDGPASVRPSSQDSVSAG--E LFGKSDLEESSPIDCSFREGEAASCPTITVSSVVTSPRPADGPTSTRQLTQDSIPTSA-E LFGKGDSEDTSLMDCSYEEGQLASCPAITISPVVIIQRSGDGPTCVRQLSQDSAAT---LFGKCDSEEAS-MDCSYEEGQLASCPAITVSPVVMIPKHEDSPTCARQPSQDSVTAG-SE LFGKGDSEEAFPVDCPHEEGELDSCPTITVSPVITIQRPGDGPTGARLLSQDSVAAS-TE LFGKGDLEEAFPVDCPHEEGELDSCPTITVSPVITIQRPGDGPTGARLLSQDSVAAS-TE LFGKGDSEETSPMDCSYEEGELAPCPAITVSSVIIVQRSGDGPTCARQLSQDSVAAAGAE FVMGDCDKDMAPMDSFYQMDHLMAP------SVIKFHANMERGKLHKLLSTDSITGCS-E
107 106 108 105 107 107 107 109 113
mouse rat guinea_pig cow dog human chimp rabbit chicken
TPPRLYDRRSIFDAVAQSNCQELESLLSFLQKSKKRLTDSEFKDPETGKTCLLKAMLNLH KPPRLYDRRSIFDAVAQSNCQELESLLPFLQRSKKRLTDSEFKDPETGKTCLLKAMLNLH KPLKLYDRRSIFDAVAQNNCQDLDSLLPFLQKSKKRLTDTEFKDPETGKTCLLKAMLNLH ENLKLYDRRKIFEAVAQNNCEELESLLLFLQKSKKHLMDSEFKDPETGKTCLLKAMLNLH KSLKLYDRRKIFEAVAQNNCEELQSLLLFLQKSKKHLMDSEFKDPETGKTCLLKAMLNLH KTLRLYDRRSIFEAVAQNNCQDLESLLLFLQKSKKHLTDNEFKDPETGKTCLLKAMLNLH KTLRLYDRRSIFEAVAQNNCQDLESLLLFLQKSKKHLTDNEFKDPETGKTCLLKAMLNLH KPLKLYDRRRIFEAVAQNNCQELESLLCFLQRSKKRLTDSEFKDPETGKTCLLKAMLNLH KAFKFYDRRRIFDAVARGSTKDLDDLLLYLNRTLKHLTDDEFKEPETGKTCLLKAMLNLH
167 166 168 165 167 167 167 169 173
mouse rat guinea_pig cow dog human chimp rabbit chicken
NGQNDTIALLLDIARKTDSLKQFVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGAD NGQNDTIALLLDVARKTDSLKQFVNASYTDSYYKGETALHIAIERRNMTLVTLLVENGAD NGQNDTISLLLDIARQTNSLKEFVNASYTDSYYRGQTALHIAIERRNMVLVTLLVENGAD NGQNDTIPLLLEIARQTDSLKELVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGAN DGQNDTIPLLLEIARQTDSLKELVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGAD DGQNTTIPLLLEIARQTDSLKELVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGAD DGQNNTIPLLLEIARQTDSLKEFVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGAD SGQNDTIPLLLEIARQTDSLKEFVNASYTDSYYKGQTALHIAIERRNMALVTLLVENGAD DGKNDTIPLLLDIAKKTGTLKEFVNAEYTDNYYKGQTALHIAIERRNMYLVKLLVQNGAD
227 226 228 225 227 227 227 229 233
Figure 4.1 Multiple sequence alignment for TRPV1 protein by CLUSTAL 2.0. (a) Cladogram of homology for TRPV1 orthologs. (b) Conserved ankyrin domains are boxed; the transmembrane domains are underlined in bold. The bold Lys at positions 155 and 160 are essential for ATP binding and are marked with diamonds, as well as Gln at 202 and Tyr at 199, which also is a phosphorylation site. The pentagon marks Cys, which can be reduced either by DTT or by GST and affects the TRPV1 activity. The stars at the TM6 indicate the amino acids where mutation generates dominantnegative mutant proteins; other pore-forming amino acids are highlighted in bold. The pore loop is underlined in a dashed line. Polymorphic amino acids in relevant species are bold-faced and boxed.
138
TRPV1 GENETICS
mouse rat guinea_pig cow dog human chimp rabbit chicken
VQAAANGDFFKKTKGRPGFYFGELPLSLAACTNQLAIVKFLLQNSWQPADISARDSVGNT VQAAANGDFFKKTKGRPGFYFGELPLSLAACTNQLAIVKFLLQNSWQPADISARDSVGNT VQAAANGDFFKKTKGRPGFYFGELPLSLAACTNQLAIVKFLLQNSWQPADISARDSVGNT VQAAANGDFFKKTKGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQPADISARDSVGNT VQAAANGDFFKKTKGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQPADISARDSVGNT VQAAAHGDFFKKTKGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQTADISARDSVGNT VQAAAHGDFFKKTKGRPGFYFGELPLSLAACTNQLGIVKFLLQNSWQTADISARDSVGNT VQAAANGDFFKKTKGRPGFYFGELPLSLAACTNQLAIVKFLLQNSWQPADISARDSVGNT VHARACGEFFRKIKGKPGFYFGELPLSLAACTNQLCIVKFLLENPYQAADIAAEDSMGNM
287 286 288 285 287 287 287 289 293
mouse rat guinea_pig cow dog human chimp rabbit chicken
VLHALVEVADNTADNTKFVTNMYNEILILGAKLHPTLKLEELTNKKGLTPLALAASSGKI VLHALVEVADNTVDNTKFVTSMYNEILILGAKLHPTLKLEEITNRKGLTPLALAASSGKI VLHALVEVADNTADNTKFVTSMYNEILILGAKLYPTLKLEELTNKKGFTPLALAASSGKI VLHALVEVADNTADNTKFVTSMYNEILILGAKIHPTLKLEELTNKKGLTPLALAARSGKI VLHALVEVADNTADNTKFVTSMYNEILILGAKLHPTLKLEGLTNKKGLTPLALAARSGKI VLHALVEVADNTADNTKFVTSMYNEILMLGAKLHPTLKLEELTNKKGMTPLALAAGTGKI VLHALVEVADNTADNTKFVTSMYNEILILGAKLHPTLKLEELTNKKGMTPLALAAGTGKI VLHALVEVADNTPDNTKFVTSMYNEILILGAKLHPTLKLEELINKKGLTPLALAAGSGKI VLHTLVEIADNTKDNTKFVTKMYNNILILGAKINPILKLEELTNKKGLTPLTLAAKTGKI
347 346 348 345 347 347 347 349 353
mouse rat guinea_pig cow dog human chimp rabbit chicken
GV----------LAYILQREIHEPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVL GV----------LAYILQREIHEPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVL GV----------LAYILQREIPEPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVL GV----------LAYILQREIQEPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVL GVGGGVLPELGVLAYILQREIQEPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVL GV----------LAYILQREIQEPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVL GV----------LAYILQREIQEPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVL GV----------LAYILQREILEPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCERNSVL GI----------FAYILRREIKDPECRHLSRKFTEWAYGPVHSSLYDLSCIDTCEKNSVL
397 396 398 395 407 397 397 399 403
mouse rat guinea_pig cow dog human chimp rabbit chicken
EVIAYSSSETPNRHDMLLVEPLNRLLQDKWDRFVKRIFYFNFFVYCLYMIIFTTAAYYRP EVIAYSSSETPNRHDMLLVEPLNRLLQDKWDRFVKRIFYFNFFVYCLYMIIFTAAAYYRP EVIAYSSSETPNRHDMLLVEPLNRLLQDKWDRFVKRIFYFNFFIYCLYMIIFTMAAYYRP EVIAYSSSETPNRHDMLLVEPLNRLLQDKWDRFVKRIFYFNFFVYCLYMIIFTTVAYYRP EVIAYSSSETPNRHDMLLVEPLNRLLQDKWDRFVKRIFYFNFFIYCLYMIIFTTAAYYRP EVIAYSSSETPNRHDMLLVEPLNRLLQDKWDRFVKRIFYFNFLVYCLYMIIFTMAAYYRP EVIAYSSSETP------------------------------------------------EVIAYSSSETPNRHDMLLVEPLNRLLQDKWDRVVKRIFYFNFFVYCLYMIIFTTAAYYRP EIIAYSS-ETPNRHEMLLVEPLNRLLQDKWDRFVKHLFYFNFFVYAIHISILTTAAYYRP
457 456 458 455 467 457 408 459 462
mouse rat guinea_pig cow dog human chimp rabbit chicken
VE--GLPPYKLNNTVGDYFRVTGEILSVSGGVYFFFRGIQYFLQRRPSLKSLFVDSYSEI VE--GLPPYKLKNTVGDYFRVTGEILSVSGGVYFFFRGIQYFLQRRPSLKSLFVDSYSEI VD--GLPPYKMKNTVGDYFRVTGEILSVIGGFHFFFRGIQYFLQRRPSVKTLFVDSYSEI AG--GRPPFKPKHTVGDYFRITGEIISVAGGIYFFSRGIQYFLQRRPSLKTLFVDSYSEM VD--GLPPYKLKHTVGDYFRVTGEILSVLGGVYFFFRGIQYFLQRRPSLKTLFVDSYSEM VD--GLPPFKMEKT-GDYFRVTGEILSVLGGVYFFFRGIQYFLQRRPSMKTLFVDSYSEM ------PPFKMEKT-GDYFRVTGEILSVLGGVYFFFRGIQYFLQRRPSMKTLFVDSYSEM VD--GLPPYKLRNLPGDYFRVTGEILSVAGGVYFFFRGIQYFLQRRPSMKALFVDSYSEM VQKGDKPPFAFGHSTGEYFRVTGEILSVLGGLYFFFRGIQYFVQRRPSLKTLIVDSYSEV
515 514 516 513 525 514 461 517 522
mouse rat guinea_pig cow dog human chimp rabbit chicken
LFFVQSLFMLVSVVLYFSHRKEYVASMVFSLAMGWTNMLYYTRGFQQMGIYAVMIEKMIL LFFVQSLFMLVSVVLYFSQRKEYVASMVFSLAMGWTNMLYYTRGFQQMGIYAVMIEKMIL LFFVQSLFLLASVVLYFSHRKEYVACMVFSLALGWTNMLYYTRGFQQMGIYAVMIEKMIL LFFMQSLFMLATVVLYFCHRKEYVASMVFSLAMGWTNMLYYTRGFQQMGIYAVMIEKMIL LFFVQSLFMLGTVVLYFCHHKEYVASMVFSLAMGWTNMLYYTRGFQQMGIYAVMIEKMIL LFFLQSLFMLATVVLYFSHLKEYVASMVFSLALGWTNMLYYTRGFQQMGIYAVMIEKMIL L--------------------------------------------------------MIL LFFVQALFMLATVVLYFSHCKEYVATMVFSLALGWINMLYYTRGFQQMGIYAVMIEKMIL LFFVHSLLLLSSVVLYFCGQELYVASMVFSLALGWANMLYYTRGFQQMGIYSVMIAKMIL
575 574 576 573 585 574 465 577 582
Figure 4.1 Continued
FUNCTIONAL TRPV1 DIFFERENCES
139
mouse rat guinea_pig cow dog human chimp rabbit chicken
RDLCRFMFVYLVFLFGFSTAVVTLIEDGKNNSLPVESPPHKCRGSACRPG-NSYNSLYST RDLCRFMFVYLVFLFGFSTAVVTLIEDGKNNSLPMESTPHKCRGSACKPG-NSYNSLYST RDLCRFMFVYLVFLFGFSTAVVTLIEDGKNESLSAE--PHRWRGPGCRSAKNSYNSLYST RDLCRFMFVYLVFLFGFSTAVVTLIEDEKNDSVSVELSQHRWRGHGCRSADS-YNSLYST RDLCRFMFVYLVFLFGFSTAVVTLIEDGKNNSVPTESTLHRWRGPGCRPPDSSYNSLYST RDLCRFMFVYIVFLFGFSTAVVTLIEDGKNDSLPSESTSHRWRGP-CRPPDSSYNSLYST RDLCRFMFVYVVFLFGFSTAVVTLIEDGKNDSLPSESTSH-------------YNSLYST RDLCRFMFVYLVFLFGFSTAVVTLIEDGKNSSTSAESTSHRWRGFGCRSSDSSYNSLYST RDLCRFMFVYLVFLLGFSTAVVTLIED--DNEGQDTNSSEYARCSHTKRGRTSYNSLYYT
634 633 634 632 645 633 512 637 640
mouse rat guinea_pig cow dog human chimp rabbit chicken
CLELFKFTIGMGDLEFTENYDFKAVFIILLLAYVILTYILLLNMLIALMGETVNKIAQES CLELFKFTIGMGDLEFTENYDFKAVFIILLLAYVILTYILLLNMLIALMGETVNKIAQES CLELFKFTIGMGDLEFTENYDFKAVFIILLLAYVILTYILLLNMLIALMGETVNKIAQES CLELFKFTIGMGDLEFTENYDFKAVFVILLLAYVILTYILLLNMLIALMGETVNKIAQES CLELFKFTIGMGDLEFTENYDFKAVFIILLLAYVILTYILLLNMLIALMGETVNKIAQES CLELFKFTIGMGDLEFTENYDFKAVFIILLLAYVILTYILLLNMLIALMGETVNKIAQES CLELFKFTIGMGDLEFTENYDFKAVFIILLLAYVILTYILLLNMLIALMGETVNKIAQES CLELFKFTIGMGDLEFTENYDFKAVFIILLLAYVILTYILLLNMLIALMGETVNKIAQES CLELFKFTIGMGDLEFTENYRFKSVFVILLVLYVILTYILLLNMLIALMGETVSKIAQES
694 693 694 692 705 693 572 697 700
mouse rat guinea_pig cow dog human chimp rabbit chicken
KNIWKLQRAITILDTEKSFLKCMRKAFRSGKLLQVGFTPDGKDDFRWCFRVDEVNWTTWN KNIWKLQRAITILDTEKSFLKCMRKAFRSGKLLQVGFTPDGKDDYRWCFRVDEVNWTTWN KNIWKLQRAITILDTEKSFLKCMRKAFRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTTWN KNIWKLQRAITILDTEKSFLKCMRKAFRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTTWN KNIWKLQRAITILDTEKSFLKCMRKAFRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTTWN KNIWKLQRAITILDTEKSFLKCMRKAFRSGKLLQVGYTPDGKDDYRWCFRVDEVNWTTWN KNIWKLQRAITILDTEKSFLKCMRKAFRSGKLLQVGYTPDGKDDYRW-FRVDEVNWTTWN KSIWKLQRAITILDTEKGFLKCMRKAFRSGKLLQVGYTPDGKDDCRWCFRVDEVNWTTWN KSIWKLQRAITILDIENSYLNCLRRSFRSGKRVLVGITPDGQDDYRWCFRVDEVNWSTWN
754 753 754 752 765 753 631 757 760
mouse rat guinea_pig cow dog human chimp rabbit chicken
TNVGIINEDPGNCEGVKRTLSFSLRSGRVSGRNWKNFALVPLLRDASTRDRHSTQPEEVQ TNVGIINEDPGNCEGVKRTLSFSLRSGRVSGRNWKNFALVPLLRDASTRDRHATQQEEVQ TNVGIINEDPGNCEGVKRTLSFSLRSGRVSGRNWKNFALVPLLRDASTRDRHSAQPEEVH TNVGIINEDPGNCEGIKRTLSFSLRSSRVAGRNWKNFALVPLLRDASTRERHPAQPEEVH TNVGIINEDPGNCEGIKRTLSFSLRSGRVSGRNWKNFSLVPLLRDASTRERHPAQPEEVH TNVGIINEDPGNCEGVKRTLSFSLRSSRVSGRHWKNFALVPLLREASARDRQSAQPEEVY TNVGIINEDPGNCEGVKRTLSFSLRSSRVSGRHWKNFALVPLLREASARDRQSAQPEEVY TNVGIINEDPGNCEGVKRTLSFSLRSGRVSGRNWKNFALVPLLRDASTRDRHPXPPEDVH TNLGIINEDPGCSGDLKRNPSYCIKPGRVSGKNWK--TLVPLLRDGSRREETPKLPEEIK
814 813 814 812 825 813 691 817 818
mouse rat guinea_pig cow dog human chimp rabbit chicken
LKHYTG-SLKPEDAEVFKDSMAPGEK LKHYTG-SLKPEDAEVFKDSMVPGEK LKHFSG-SLKPEDAEVFKDSAVPGEK LRHFTG-SLKPEDAEIINDSVALGEK LRHFAG-SLKPEDAEIFKDPVGLGEK LRQFSG-SLKPEDAEVFKSPAASGEK LRQFSG-SLKPEDAEVFKSPAASGEK LRPFVG-SLKPGDAELFKDSVAAAEK LKPILEPYYEPEDCETLKESLPKSV-
839 838 839 837 850 838 716 842 843
Figure 4.1 Continued
essential roles of Y511 and adjacent S512, since changes in either position abolished the response to capsaicin, while the response to pH and heat remained intact (Jordt and Julius, 2002). Replacement of R491 with 491E also reduced the response of rat TRPV1 to vanilloids (Jordt and Julius, 2002). Later reports indicated that the S512Y mutation in human TRPV1 also resulted in severely compromised activation by capsaicin (Sutton et al., 2005; Johnson et al., 2006). Similar comparative genetic approaches were later used to analyze which amino acid replacements in the rodent TRPV1 make the channel responsive
140
TRPV1 GENETICS
to inhibition by capsazepine, that effectively blocks the human and guinea pig TRPV1 variants (Correll et al., 2004; Phillips et al., 2004; Ohta et al., 2005). Several key amino acid differences were identified between human and rat in the TM3-TM4 domains. The evolutionary changes of M in position 514 to I in rat (M514I), L at 518 to V (L518V) and L at 547 to M (L547M) were determined to underlie the insensitivity of the rat channel to capsazepine. Exchange of these amino acids in the rat TRPV1 to human sequences (514M, 518L, and 547L) led to a dramatic increase in the capsazepine sensitivity of the mutated rat TRPV1 (Phillips et al., 2004). The sensitivity of human TRPV1 to the phorbol 12-phenylacetate 13acetate 20-homovanillate (PPAHV) agonist also differed from that in rat. Although a single change in position 547 was again found to be critical, the sensitivity differed between the PPAHV and capsaicin agonists. When the rat sequence at this position was changed to L, as in the human/guinea pig protein, the sensitivity of the channel to PPAHV was reduced 20-fold, while the sensitivity to capsaicin remained unchanged. Reciprocal change in the human or guinea pig channel in position 547 to the rat variant M led to specific PPAHV responsiveness in both human and guinea pig channels, again without affecting capsaicin sensitivity (Phillips et al., 2004). Another evolutionary change in the rabbit TRPV1 sequence allowed for identification of an essential role of the neighboring T550 in response to capsaicin. Rabbit and chicken TRPV1 channels are nonresponsive to capsaicin but respond to pH and heat; the single substitution of I to T in position 550 made the rabbit TRPV1-I550T as responsive as other mammalian TRPV1 channels to capsaicin (Jordt and Julius, 2002; Gavva et al., 2004). Local anesthetics act through Na+ channel blockade. However, at high concentrations, they increase intracellular levels of Ca2+, thus causing neurotoxicity (Lambert et al., 1994). Such neurotoxicity was suspected to involve activation of TRP channels. Recently, the genetic differences between rabbit and rat TRPV1 in response to lidocaine have helped elucidate the key role of capsaicin-binding domains for the action of lidocaine, which indeed binds and robustly activates TRPV1 at concentrations above 3 mM (Leffler et al., 2008). Lidocaine activates rat but not rabbit TRPV1; transplanting the key rat domain for capsaicin binding (S505-T550) to the rabbit channel resulted in strong activation of the chimera (Leffler et al., 2008). However, lidocaine was able to activate rat TRPV1-Y511A mutant channels, which are insensitive to capsaicin. The activation of TRPV1-positive neurons by high concentrations of lidocaine resulted in release of calcitonin gene-related peptide (CGRP), a physiological response pathway (Leffler et al., 2008). Species-specific TRPV1 response variants were also discovered using the highly potent agonist RTX. In dogs, a single administration of RTX resulted in prolonged blockade of experimental inflammatory hyperalgesia (Karai et al., 2004). The phosphorylation of TRPV1 by protein kinases PKC and PKA was known to desensitize the channel (Cesare and McNaughton, 1996; Cesare et al., 1999; Bhave et al., 2002). When dog TRPV1 was cloned, it was found to lack a conserved PKA phosphorylation site (S117), which is present in other
STRUCTURE–FUNCTION ANALYSIS
141
orthologs (Phelps et al., 2005). The reversion of the dog K117 to S resulted in increased sensitivity to capsaicin and prolonged activation of dog TRPV1K117S, compared to wild-type dog TRPV1 (Phelps et al., 2005).
4.5
STRUCTURE–FUNCTION ANALYSIS
The N-terminal domain of TRPV1 contains six ankyrin repeat domains (ARDs), which are structurally similar to the six ankyrin repeats of TRPV2 (Lishko et al., 2007). However, the TRPV1 ARD is more positively charged and, more importantly, is capable of binding ATP, whereas the TRPV2 ARD is not. The ATP-binding site of the TRPV1 ARD is different from the typical Walker B structure. Three essential amino acids for ATP binding were identified. Replacement of K155 or K160 by A completely abolished ATP binding; replacement of Y199 or Q202 with A significantly reduced ATP binding (Lishko et al., 2007). A functional consequence of ATP binding to TPRV1 ARD is loss of the attenuation of TRPV1 activity that usually occurs following repeated activation, a process known as tachyphylaxis. Repeated stimulation of wild-type TRPV1 by capsaicin in the presence of ATP prevents tachyphylaxis, with full activation maintained. Unexpectedly, mutation of any of the ATP-binding amino acids completely abolished tachyphylaxis and increased sensitivity to capsaicin, prompting authors to look for another binding partner that normally promotes tachyphylaxis, but interaction with which could be abolished as well by mutations in the ARD (Lishko et al., 2007). Two ARD binding partners were found to have opposite effects on channel activation: the phosphatidylinositol 4,5-bisphosphate (PIP2) binding to TRPV1 ARD mimicked the action of ATP, while binding of calmodulin had an opposite effect—its binding promoted tachyphylaxis, thus providing a model for TRPV1 desensitization by increased levels of Ca2+ following channel activation. Deletion analyses of either N- or C-termini of TRPV1 indicated that these domains carry additional agonist recognition sites. Mutation of D114 or E761 abolishes capsaicin and RTX sensitivity (Jung et al., 2002; Vlachova et al., 2003). Recent genetic screening for gain-of-function mutations in rat TRPV1 revealed essential roles of pore helix-regulating TRP channel gating (Myers et al., 2008). Several constitutively active point mutations were identified at distinct domains, including replacement of lysine with glutamic acid (K155E and K160E) in the ankyrin repeats, as well as M581T mutation in the S5 domain and F640L in the pore helix domain (Myers et al., 2008). The same positions in the ankyrin domain were previously identified to be regulated by calmodulin and were essential for suppressing TRPV1 activity after repeated activation (Lishko et al., 2007). F640L as well as F640I mutations produced the strongest basal channel activity and altered basal versus proton-evoked currents. Indeed, the basal activity was so strong with these mutations that additional stimulation by low
142
TRPV1 GENETICS
pH did not alter the current. The enhanced basal activity of the F640L mutant resulted in toxicity when expressed in mammalian HEK293 cells. The same mutant also had increased sensitivity to capsaicin and temperature, but it was still sensitive to capsazepine-mediated inhibition, suggesting that this mutation shifted the equilibrium to the open state rather then reflecting an inability of the channel to close (Myers et al., 2008). The same genetic screen identified several mutations with potentiated TRPV1 activity, although not constitutively active: H166R, I352N or T, Q560R, N652D, E684G or V, and L792P (Myers et al., 2008). Comparison of the TM6 sequence in TRPV1 to Na+ channels indicated that there is a highly conserved motif (NML positions 676, 677, 678), which is essential for pore conductivity. Mutations at these three positions (NML676FAP) result in loss of TRPV1 activation by capsaicin and RTX, and the activation by low pH is also severely affected (Kuzhikandathil et al., 2001). Moreover, the TRPV1-NML676FAP variant had a dominant-negative effect, indicating that these amino acids function in pore formation of the multimeric complex. Site-directed mutagenesis studies were performed, using an alanine scan of the entire portion of the TM6 inner helix domain of TRPV1 between Y666 and G683 (Susankova et al., 2007). Mutation of 16 of the 17 residues affected the functionality of the TRPV1 channel with respect to at least one stimulus modality; only mutation of T670 did not affect channel activity. (Susankova et al., 2007). As mentioned above, the posttranslational modification of TRPV1 phosphorylation by PKC and PKA plays a key role in the regulation of channel activity (Cesare and McNaughton, 1996; Cesare et al., 1999; Bhave et al., 2002). Several phosphorylation sites have been identified. S116 (S117 in dog TRPV1) is the phosphorylation site for PKA (Bhave et al., 2002). T704 and S800 have been identified as substrates for PKC phosphorylation; mutation at either position abolished phosphorylation and activation induced by phorbol myristate acetate (PMA). Mutation of S502 to A reduced the PMA-enhanced response to capsaicin (Bhave et al., 2003). Conversely, mutation of T704 to A did not affect enhancement of the response to capsaicin by PMA but dramatically reduced direct activation of TRPV1 by PMA (Bhave et al., 2003). Intriguingly, a later report demonstrated that mutation of T704 to A, but not to I, in conjunction with the S502A mutation, generated a fully functional TRPV1 channel (Novakova-Tousova et al., 2007). R701 may play a key role in the phosphorylation of T507, since it is part of the conserved consensus sequence for CaMKII kinase. In addition, a role of R701 has been proposed for PIP2-TRPV1 ligation. Mutation of R701 strongly affected heat, capsaicin, and pH-evoked currents, but not voltage sensitivity of TRPV1 (Novakova-Tousova et al., 2007). These authors noted that R701A also affected dissociation kinetics for capsaicin, pointing to a potential role of this amino acid in capsaicin binding. TRPV1 sensitization occurs following nerve growth factor (NGF) binding to its receptor (Zhang et al., 2005). TRPV1 phosphorylation by Src kinase was
TRPV1 FUNCTION AND CAUSE DIABETES
143
demonstrated to be a downstream effect of TrkA activation by NGF through activation of PI3 kinase. Phosphorylation of TRPV1 at Y200 (but not of Y195/ Y199/Y383) increased the rate of plasma membrane insertion of TRPV1. TRPV1 activity is modified by reducing agents such as dithiothreitol (DTT) and glutathione, which increase TRPV1 sensitivity to heat. Extracellular C621 has been identified as the residue responsible for the extracellular modulation of TRPV1 by these reducing agents (Susankova et al., 2006). Glycosylation is another form of posttranslational protein modification. Rat TRPV1 was found to be glycosylated at N604, and mutation of this site affected the channel sensitivity to capsaicin. The mutant N604T channel was more sensitive to capsaicin, but it exhibited a decreased maximal capsaicininduced current. The absence of glycosylation also diminished the response to capsazepine, as well as the dependence of the effect of capsaicin on extracellular pH (Wirkner et al., 2005). In summary, the structure–function relationships of TRPV1 from different species and experimental mutagenesis models are extremely complex and remain incompletely understood; a unified theory does not currently exist. The study of the efficacy of novel pharmacological agonists or antagonists targeting TRPV1 would benefit from the use of transgenic mice that exclusively carry fully human TRPV1 protein sequences, but the choice of promoter would still represent a challenge for the generation of a fully humanized TRPV1 system. And, as discussed below, the great polymorphic diversity of human TRPV1 alleles still represents a major challenge toward this goal.
4.6 MISSENSE MUTATIONS IN NON-OBESE DIABETIC (NOD) MICE AFFECT TRPV1 FUNCTION AND CAUSE DIABETES The study of the role of TPRV1 in diabetes (Razavi et al., 2006; Tsui et al., 2007) (see Chapter 16 in this book) revealed that in diabetes-prone NOD mice, TRPV1NOD nociceptive behavioral responses (biting or licking) evoked by intradermal capsaicin were markedly depressed in NOD as compared to non-obese resistant (NOR) mice. Moreover, the maximum Ca2+ response to capsaicin of DRG neurons of NOD mice was dramatically smaller than that of NOR DRG neurons. In addition, there was a shift in the capsaicin concentration–response relationship, with about 10-fold higher capsaicin concentrations required for NOD DRG neurons, compared with NOR DRG neurons. The differences in capsaicin-evoked responses in DRG neurons from NOD mice related to decreased TRPV1 expression and/or decreased function of TRPV1 that could be attributed to the two missense mutations found in the NOD allele. The sequence changes corresponding to those in TRPV1NOD have been engineered into human TRPV1 (P322A, D734E) (Xu et al., 2007). Under defined expression conditions, hTRPV1P322A,D734E showed a markedly abnormal capsaicin concentration–response relationship compared to wild-type
144
TRPV1 GENETICS
human TRPV1. The variant channel was hyporesponsive to capsaicin at low doses (<10 nM) but was hyperresponsive at high doses (>10 nM), with a markedly elevated Hill slope. The genetic changes in the primary sequence of NOD mouse TRPV1 produces changes in TRPV1 function that were directly responsible for the development of diabetes in NOD mice, ultimately, a deficiency of TRPV1-dependent neuropeptides in the endocrine pancreas (Razavi et al., 2006; Tsui et al., 2007).
4.7 FUNCTIONAL POLYMORPHISMS IN THE HUMAN trpv1 GENE Existing evidence emphasizes the key role of TRPV1 in pain, in infla